**ABSTRACTS**

**Poster Abstracts**

**POSTER TOUR 1—COVID # 1**

**P001 | Glycemic variability and time in range among children with type 1 diabetes on insulin pump during the COVID-19 pandemic**

A. Abdel Maksoud¹, N. Yousef Salah¹, S. Ayoup²
¹Ain Shams University, Cairo, Egypt, ²Al Rahmaneya Hospital, El Behera, Egypt

**Introduction:** COVID-19 has impacted the lives of individuals worldwide especially those with chronic illnesses. Children with type 1 diabetes (T1DM) are at risk of glycemic deterioration during the COVID-19 pandemic. However, some studies reported glycemic improvement in these children during the pandemic.

**Objectives:** To assess the impact of COVID-19 on glycemic control and acute complications among children with T1DM on insulin pump in Egypt.

**Methods:** A 42 children with T1DM on insulin pump for at least 1 year were assessed for insulin requirements, insulin-pump problems, frequency of diabetic-ketoacidosis (DKA), hypoglycemia, and HbA1C. Continuous-glucose monitoring was done using Medtronic i-pro device for 5 days. Data were compared to those obtained from the patients’ medical records 1 year previously.

**Results:** A 29 children (69%) had insulin-pump problems in the form of skin irritation (31%), skin infection (7.1%) and pump obstruction (31%). The mean insulin requirement of the studied children with T1DM during the COVID-19 pandemic was 0.88 ± 0.30 U/kg/day. Their median time in range (TIR) was 57%, and their mean coefficient of variation (CV) was 38.2%. A significant increase in the daily insulin dose (p = 0.001), basal % (p = 0.011), TIR (p = 0.009), CV (p = 0.001) and Hba1C (p = 0.001) occurred during the COVID-19 pandemic with a significant decrease in the frequency of DKA (p = 0.001) and hypoglycemia (p = 0.004). Hypoglycemia and nocturnal hypoglycemia were positively correlated to CV (p = 0.002 and p = 0.01, respectively) and negatively correlated to TIR (p = 0.039 and p = 0.009, respectively).

**Conclusions:** Children with T1DM on insulin pump showed glycemic improvement with decreased acute complications during the COVID-19 pandemic.

**P002 | Role COVID-19 infection on the development of type 1 diabetes in children and teenagers**

M. Aripova¹, F. Khaydarova¹, N. Alimova¹, A. Alieva³, S. Azimova³, A. Sadikova¹
¹Center of Endokrinology, Tashkent, Uzbekistan

**Introduction:** In December 2019, a new RNA-beta coronavirus infection emerged in Wuhan, China. The disease quickly spread around the world, and by March 11, the COVID-19 outbreak was classified as a pandemic disease.

**Objectives:** To study the role of COVID-19 infection in the manifestation of type 1 diabetes mellitus in children and adolescents.

**Methods:** During the year, 30 newly diagnosed children and adolescents with type 1 DM were examined after suffering acoronavirusinfection with acute diabetic complications, hospitalized in the children’s and intensivemedicine ward of the Center Endocrinology of Uzbekistan. Results are presented as means ± SD.

**Results:** In the period from March 2021 to February 2022, 83 children and adolescents with first diagnosed type 1 diabetes mellitus turned to the clinic. During the examination, positive antibody to SARS-CoV were detected in 30 patients, which amounted to 36%. The mean age was 10.5 ± 0.8 years. From 0 to 14 years old—76.6% (23 children), from 15 to 18 years old—23.3% (7 adolescents). According to anamnestic data, 10 patients (33.3%) indicated the period of the disease, symptoms. In 20 (77%) patients, the disease was asymptomatic. A 7 patients (70%) had mild disease. Clinical symptoms: body temperature rise 38.5, weakness, sore throat. In 3 of them, a moderately severe course was observed, accompanied by prolonged fever and cough with spum difficult to separate (30%), hospitalization in a special institution was required. Therapy for COVID infection consisted of antibiotic therapy and symptomatic treatment. Patient required injections of corticosteroids (dexamethasone 1 ml No. 3).

**Conclusions:** According to available data, children get sick less often, with less pronounced clinical symptoms, require hospitalization less often, their disease is milder, which, however, does not exclude cases of severe course. The data available today indicate that children make up to 10% of those infected with SARS-CoV-2 and up to 2% of patients diagnosed with clinical cases of COVID-19.

**P003 | Lessons learnt from COVID-19 pandemic in maintaining medical supplies to type 1 diabetes disadvantaged communities in low-middle-income countries in Southeast Asia**

S.M. Ng¹,², N. Toomey³, B. Manet⁴, L. Finnigan⁵, H.L. Kyaw⁶, K. Khambuapha⁷, T. Martin⁸, F. Ooi⁹
¹University of Liverpool, Liverpool, United Kingdom, ²Southport and Ormskirk Hospitals NHS Trust, Southport, United Kingdom, ³Action4Diabetes, Somerset, United Kingdom, ⁴Kantha Bopha Children’s Hospital, Phnom Penh, Cambodia, ⁵Southport and Ormskirk
Introduction: As COVID-19 spread across Southeast Asia (SEA) in 2020–2021, healthcare systems in Cambodia, Laos and Myanmar braced as public health officials closed outpatients diabetes clinics and healthcare professionals (HCPs) were redeployed to COVID-treatment zones. Action4Diabetes (A4D) is a non-profit organization providing free insulin and medical supplies to SEA since 2016. With limited healthcare coverage in Cambodia, Laos, and Myanmar, patients enrolled on A4D’s program travel hundreds of miles to diabetes clinics to collect free insulin, blood glucose strips and other medication. Due to COVID-19 lockdowns, insulin often arrived with short expiry dates due to delays in shipments caused by bottlenecks at international logistic hubs, and patients were known to ration insulin due to lack of supply. For disadvantaged people with Type 1 diabetes (T1D) in SEA low-middle-income countries (LMICs), this posed a serious threat due to inaccessible insulin and medical supplies.

Objectives: A4D developed a strategic plan to maintain accessible medical supplies and supported the development of remote e-consultations.

Methods: Access to medical supplies and e-consultations.
A4D initiated e-consultations and networks of couriers to rural parts of Myanmar, Laos, and Cambodia to deliver medical supplies. In Cambodia, TukTuk drivers who ferried tourists around Angkor Wat were used to deliver insulin to the T1D in farming communities. In Myanmar and Laos, agriculture truck drivers that transported vegetable crops were used to transport medical supplies to remote areas. During COVID-19, A4D used local suppliers for insulin and had to purchase insulin and blood testing strips at a premium rate.

Results:

Conclusions: For many disadvantaged people with T1D in SEA, the COVID-19 pandemic reinforced the fragile nature of their T1D management. Through collaborating closely with HCPs on the ground, A4D has developed a more dynamic and resilient logistical system to maintain key life-saving medical supplies.

<table>
<thead>
<tr>
<th>January 2020 to December 2021</th>
<th>Laos (n = 56 supported A4D patients)</th>
<th>Myanmar (n = 90 supported A4D patients)</th>
<th>Cambodia (n = 181 supported A4D patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of patients who received remote e-consultations</td>
<td>44</td>
<td>33</td>
<td>40</td>
</tr>
<tr>
<td>Total number of insulin deliveries via alternative transportations that is, TukTuk/agriculture trucks</td>
<td>24</td>
<td>65</td>
<td>Minimally affected (usual A4D supplies direct to local hospitals were maintained and unaffected by the pandemic)</td>
</tr>
<tr>
<td>Total number of blood glucose testing kits deliveries via alternative transportations that is, TukTuk/agriculture trucks</td>
<td>24</td>
<td>130</td>
<td>Minimally affected (usual A4D supplies direct to local hospitals were maintained and unaffected by the pandemic)</td>
</tr>
</tbody>
</table>
COVID-19: What is the impact of the pandemic on pediatric endocrinology & diabetes hospitalizations

S. Abourazzak1, A. Sqalli1, S. Chaouki1, M. Hida1
1Faculty of Medicine and Pharmacy of Fez, Sidi Mohamed Ben Abdellah University, Pediatrics, Fez, Morocco

Introduction: The COVID-19 has serious impact on several systems including health.


Methods: Retrospective and descriptive study was conducted. We compared the periods before and after containment in 2020 with 2019 of consultations as well as Endocrinology & diabetes hospitalizations, focusing on diabetes, at the pediatric department.

The 2 periods are defined:
- Period 1: March 20 to June 10 2020 (containment period) and June 10 to September 10 2020 (post-containment period).
- Period 2: the same periods in 2019.

Results:
- Pediatric Endocrinology & diabetes hospitalizations consultations: A 64% decrease in consultations in 2020 compared to 2019 (798 consultations vs. 286) was noted when comparing the 2 periods. For the containment and post-containment periods in 2020: we report an 18% decrease in post-containment consultations. For the containment period, a decrease of 66% was noted in 2020 compared to the same period in 2019 (141 patients vs. 417).
- Diabetic Hospitalizations: A 36% increase in 2020 compared to the similar period in 2019, as well as a 64% increase in severe cases transferred from the ICU were observed throughout the study period.

An increase of 61% was noted during the post containment period compared to the Lockdown period, of diabetic hospitalizations with a 55% ascension of severe DAC transferred from the ICU. For the lockdown period, we noted the same number of patients with more severe cases.

Conclusions: SARS-CoV-2 has an impact on the quality of care in general, with a repercussion on several hospital activities, which has impacted the number of hospitalized patients and severe cases.

Knowledge of final year medical students about diabetes mellitus during and after COVID-19 pandemic, single university experience

W.H. Abdullah1, H. Alsaffar2
1Al-Mustansiriyah University, College of Medicine, Baghdad, Iraq, 2Sultan Qaboos University Hospital, Child Health Department, Pediatric Endocrine and Diabetes Unit, Muscat, Oman

Introduction: COVID-19 pandemic had let to disruption of routine and medical education especially in the first few months from announcing the pandemic status globally. At Al-Mustansiriyah University in Baghdad-Iraq, there was a shift toward providing online classes where students could attend their classes from home in order to reduce the risk of infection transmission. Curfew and lockdown took place during different times in the year of announcing the pandemic 2020. Online sessions were introduced for the first time in the history of the University.

Objectives: To compare the knowledge of final year medical students at Al-Mustansiriyah University about diabetes mellitus during and after the COVID-19 pandemic.

Methods: By running an online questionnaire to the 6th year medical students of classes 2019–2020 and 2021–2022. A 39 Questions included 5 main domains; demographics, pathophysiology, diagnosis, management, and technology related to diabetes mellitus. Descriptive analysis was used.

Results: Total of 198 students responded, 129 (89F) from the first period, and 69 (43F) from the second period. The self-assessment of knowledge indicated better ratings among students in the second period compared to students from the first period. Overall more students had attended diabetology classes and felt more prepared to apply their knowledge post pandemic (table 1).

The overall score for correct answers from students of class 2021–22 was higher than the score of students of class 2019–20, 64.6% versus 57.2% respectively.

Conclusions: The pandemic had affected the students’ attendance for diabetology classes, which resulted in less knowledge, that reflected on lower rating of self-assessment and confidence to deal with diabettes. Final year medical students post pandemic had better chance to learn. Those gaps in knowledge need to be bridged during the postgraduate training and education.

<table>
<thead>
<tr>
<th>Attendance of diabetology classes</th>
<th>During pandemic (%)</th>
<th>Post pandemic (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Feeling that undergraduate course had covered diabetes and its related topic thoroughly</td>
<td>37</td>
<td>59.4</td>
</tr>
<tr>
<td>Feeling un-prepared to manage patients live with diabetes medically</td>
<td>51.9</td>
<td>34.8</td>
</tr>
</tbody>
</table>
Introduction: COVID-19 pandemic has affected everyone's life, especially children with Type 1 DM with a poor economic background. Monitoring of blood glucose and their follow up with the health care professionals were badly affected during these times.

Objectives: To assess the effectiveness of continuous blood glucose monitoring and SMBG on HbA1c level in children with Type 1 diabetes mellitus in COVID-19 pandemic.

Methods: All children diagnosed with Type 1 Diabetes mellitus with poor economic background aged between 3 and 18 years attending the diabetic OPD in a tertiary care Government hospital in south India were included in this study. Participants were randomized to study arm (CGMS+SMBG) and control arm (SMBG alone). Subjects in study group were placed on ProCGM for 14 days along with regular SMBG and control group were asked to use SMBG and data were analyzed and used to titrate the insulin dose.

Results: There were 62 children in both the groups. In the intervention group, 30 were boys and 32 were girls. In the control group, 20 were boys and 42 were girls. In the intervention group, baseline and follow-up values of HbA1c were 11.23 ± 1.53 and 10.14 ± 1.99; hyperglycemia were 61.42 ± 24.35 and 55.12 ± 22.14; and hypoglycemia were 3.12 ± 0.215 and 3.10 ± 0.96 respectively. In the control group, baseline and follow-up values of HbA1c were 11.62 ± 1.62 and 11.78 ± 1.57; hyperglycemia were 49.92 ± 24.64 and 53.34 ± 17.23; and hypoglycemia were 3.09 ± 5.01 and 3.45 ± 7.97 respectively. There was a reduction in HbA1C levels (1.09 ± 0.31) and in incidences of hyperglycemia and hypoglycemia in the intervention group.

Conclusions: In resource limited settings, use of ProCGMS once in 2 or 3 months will help in understanding the factors affecting glycemic variability. It can reduce school absenteeism for hospital visits and also can be used as an educational tool for families in the management of diabetes.

Poster Tour 2: COVID #2

P009 Has the COVID-19 pandemic affected the incidence of type 1 diabetes in Italy? Analysis on population-based registries over a 33-year period

V. Tiberi1, R. Gesuati2, V. Marconi2, L. Ferrante2, F. Carle2, M. Marino1, L. Favella3, C. Giorda4, L. De Sanctis5, I. Rabbone6, V. Cherubini1

1Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, G. Salesi Hospital, Department of Women's and Children's Health, Ancona, Italy, 2Polytechnic University of Marche, Center of Epidemiology and Biostatistics, Ancona, Italy, 3CSI Piemonte Direzione Sanità Digitale, Torino, Italy, 4ASL TOS Regione Piemonte, Unità di Diabetologia e Metabolismo, Chieri, Italy, 5A.O.U. Città della Salute e della Scienza di Torino, Center of Pediatric Diabetology, Torino, Italy, 6University of Piemonte Orientale, Division of Pediatrics, Department of Health Sciences, Novara, Italy

Introduction: COVID-19 impacted lives of people globally, especially with chronic conditions like Type 1 Diabetes mellitus (T1DM). Since its emergence and increase, pandemic restrictions were imposed in Pakistan too to counter infection and prevent spread. This situation posed challenges for T1DM children causing significant lifestyle changes, psychosocial distress, difficult medication access, monitoring, and physician follow-up. This study was planned to see how restrictions and adjustments in health care affected T1DM children by comparing glycemic control prior to and following pandemic.

Objectives: To evaluate impact of COVID-19 on glycemic control of children and adolescents with type 1 diabetes.

Methods: A 2 point observational cross sectional study was done in 139 T1DM children 10–18 years enrolled in pediatric endocrine clinic of Aga Khan University with disease duration >6 months. Demographics, clinic visits (pre and during pandemic) last HbA1c value before and last value during pandemic were recorded in structured questionnaire at 2 time points (Post pandemic face to face interview between Feb and April 2022 at follow up visit, pre pandemic data from hospital medical records between Sep 2019 and Feb 2020). Paired t-test was used to compare HbA1c values and number of clinic visits before and after.

Results: Out of 139 patients, 45% were male, 55% females. Mean age was 13.7 years. Mean HbA1C value increased from 8.7% during 6 months preceding pandemic restrictions to 9.5% during pandemic and difference was statistically significant (p-value 0.002) using paired T test. Mean clinic visits reduced from 3 visits/year pre-COVID to 1 visit/year during pandemic. This difference was also statistically significant (p-value 0.000).

Conclusions: This study demonstrates significantly negative impact of pandemic on glycemic control of children with T1DM, a chronic condition requiring regular monitoring and follow-up. Barriers in continuity of healthcare due to restrictions reflected by less clinic visits during pandemic highlights importance of telemedicine services as well.
Introduction: It is currently not well known if the incidence of type 1 diabetes (T1D) changed during COVID-19 pandemic.

Objectives: Basing on two population-based registries collecting data of new cases in Italy since 1989, we analyzed changes on incidence in a long and short period.

Methods: All new cases of T1D in children aged between 0.5 and 14, recruited by the Piedmont and Marche registries during 1989–2021, were considered. Poisson regression was used to estimate the incidence trend, adjusted for age and sex, for the period 1989–2019 and to predict the incidence in the years 2020 and 2021. The observed rates in the years of the pandemic were compared with those predicted by the model and with those of the three-year pre-pandemic period 2017–2019.

Results: Between 1989 and 2021, 4009 children diagnosed with T1D were observed, 2144 males (53.5%). The standardized incidence for the entire period was 16.9 (95%CI 14.4–17.5) per 100,000 person-years, 17.6 and 16.2 for males and females respectively. The incidence over time increased from 12.0 (95% CI 9.6–14.4) in 1989 to 20.9 (95% CI 17.5–24.9) in 2019, with an annual increasing trend of 1.9% (95% CI 1.5–2.2). The observed incidence rates in 2020 and 2021 were 21.6 (95% CI: 18.3–25.3) and 26.7 (95% CI: 23.0–30.9) respectively, not significantly different from the ones predicted by the model. 21.6 (95% CI: 20.3–23.0; p = 0.995) and 22.0 (95% CI: 20.5–26.6; p = 0.074). The incidence rate of T1D in the pre-pandemic 3 years, equal to 20.5 (95%CI: 18.6–22.5), was not different from that of 2020, but significantly lower than that observed in 2021 (<0.001).

Conclusions: The incidence of T1D < 15 years continues to increase over time. During 2020–2021, the observed incidence was in line with the expected trend 1989–2019. However, narrowing the analysis to 2017–2021, there was a higher incidence in 2021. Continuous observation of T1D in children is critical to better understanding the role of COVID-19 in influencing the disease.

**P010 | Impact of the COVID-19 pandemic on disengagement from advanced diabetes technologies among racial/ethnic groups in the US T1D exchange quality improvement collaborative**

S. Carrothers¹, B. Lockee¹, D. Williams⁴, E. DeWit¹, R. McDonough¹, N. Noor⁵, T. Alonso³, H. Akturk⁴, D.J. DeSalvo⁵, M. Kamboj⁶, L. Jacobsen⁷, M.L Scott⁸, A. Mungmode⁵, O. Ebekozien², M. Clements³

¹Children’s Mercy, Kansas City, United States, ²T1D Exchange, Boston, United States, ³Barbara Davis Center Pediatrics, Denver, United States, ⁴Barbara Davis Center Adult, Denver, United States, ⁵Texas Children’s Hospital, Houston, United States, ⁶Nationwide Children’s Hospital, Columbus, United States, ⁷University of Florida Health, Gainesville, United States, ⁸University of Alabama, Birmingham, United States

**Introduction:** The use of continuous glucose monitors (CGM) and insulin pumps (PUMP) have been associated with improved outcomes in type 1 diabetes (T1D) care. Therefore, disengaging from these devices represents a risk for worsening health outcomes.

**Objectives:** We sought to evaluate the effect of the COVID-19 pandemic on device disengagement rates by race and ethnicity.

**Methods:** This retrospective cohort study Pre-COVID-19 (n = 15,838) + peri-COVID-19 (n = 14,799) used EMR data from 15 sites (i.e., 3 adult and 12 pediatric diabetes centers) within the T1D Exchange Quality Improvement Collaborative. We identified individuals using at least one Advanced Diabetes Technology (ADT [PUMP or CGM]) at their most recent visit. Individuals who continued to use that technology for at least two subsequent visits were classified as engaged. Those who reported not using ADT in two subsequent visits were classified as disengaged.

**Results:** Comparing pre-COVID-19 (January 2017–March 2020) to peri-COVID-19 (April 2020–2021) time periods, we observed increases in disengagement among non-Hispanic White (NHW; 42% to 45%, p = 0.03) and Hispanic (12% to 19%, p < 0.001) individuals. We found no difference among NH Black (NHB; 61% to 62%, p = 0.7) individuals.

**Conclusions:** The pandemic has presented self-care challenges for individuals with T1D, including continued use of ADT. NHB individuals exhibited the highest disengagement rates overall, while NHW/Hispanic individuals experienced significant pandemic-related increases in disengagement. Future research should evaluate the relative impact of intrinsic (i.e., patient-level) versus extrinsic (i.e., family-, environment-, and system-level) factors associated with race-ethnicity-based differences in rate of disengagement.
P011 | Parental experience of COVID-19 lockdown in the children and young people (CYP) with type 1 diabetes (T1D) and behavioral disorder (BD) – A qualitative analysis

A. Banerjee1, T. Banerjee1
1United Lincolnshire Hospitals NHS Trust/Pilgrim Hospital, Department of Pediatrics, Boston, United Kingdom

Introduction: Management of T1D with BD during lockdown was challenging.

Objectives: To explore parents’ experience in managing CYP with T1D & BD during the lockdown and its influence in this cohort. To understand the effect of lockdown on emotional health for providing better care in the future.

Methods: The parents were randomly selected (n = 10) from the diabetes clinic. The data were collected using structured open and closed-ended questionnaires. Thematic analysis & deductive coding techniques were used to construct a theory.

Results: Most parents believe that the risk of COVID-19 was higher than that of T1D complications, leading to delays in seeking medical attention. Fear, anxiety, and helplessness were the most common emotions linked to uncertainty, conflicting information and unending speculation based on daily media reports of fatalities. Most parents described isolation, restricted physical activity, and stress-induced eating behavior as responsible for weight gain and poor diabetes control. Parents universally stated reduced quality of life, worsening symptoms of autism and attention deficit hyperactivity disorder, explained partly by the suspension of traditional care during the lockdown. Parents reported CYP as having more frequent episodes of meltdowns, arguments, emotional outbursts, destructive behavior, deliberate self-harm, and sleep disturbances and anxiety around losing family members to COVID-19. Additionally, loss of extended family support/peer support in school during the lockdown and a ‘toxic’ home environment aggravated behavioral deterioration. Furthermore, the suspension of traditional consultant-led clinics and unfamiliarity with remote consultations were other influencers of anxiety.

Conclusions: Parents reported a significant deterioration in the behavior of CYP with T1D & BD during the lockdown, which may affect their T1D control. Future studies are required to better understand the health need of this unique cohort so that resources can be aptly diverted to deliver patient-focused diabetes care.

P012 | Psychological adjustment and glycemic control among adolescents with type 1 diabetes during the COVID-19 pandemic: A mixed methods study

M. Cusinato1, A. Negri1, A. D’Agnillo1, M. Martino1, C. Gabrielli1, J. Gutierrez De Rubalcava Doblas1, E. Righetto1, C. Moretti1
1University Hospital of Padova, Department of Women’s and Children’s Health, Pediatric Diabetes Unit, Padova, Italy

Introduction: The COVID-19 pandemic has caused mental health consequences. Preadoilescents and adolescents are particularly vulnerable to stress exposure and social isolation. We focused on the impact of restrictions on youth with type 1 diabetes (T1D).

Objectives: The aim of this study was to observe glycemic control and psychological adjustment trajectories after 1 year of the COVID-19 pandemic.

Methods: We followed a cohort of youth with T1D of Pediatric Diabetes Unit at the University Hospital of Padova. Inclusion criteria were: age between 12 and 20 years, T1D duration >1 year. We used a mixed method approach.

We analyzed mean glucose, Coefficient of Variance (CV), Time In Range (TIR), Time Above Range (TAR), Time Below Range (TBR) and Glucose Management Indicator (GMI). Test of Anxiety and Depression for Children and Adolescents (TAD) was used to evaluate psychological symptoms. Glucose metrics and psychological data were collected at different COVID-19 time points: 1 year before, during the first lockdown, and during the second wave. Further, during the diabetes summer camp, 24 participants joined group meetings to explore their COVID-19 lockdown experiences. Data were analyzed using thematic analysis.

Results: Our data showed that 1 year post-pandemic, the improvement in glycemic control appears time stable, while depression and anxiety symptoms get worse in preadolescents (p < 0.05). Common identified themes were: changes in interpersonal relationships and health-related behaviors, lifestyle modifications and emotion regulation. Qualitative data suggest that some participants experienced psychosocial distress during lockdowns, while others spent time self-caring and discovering new aspects of themselves.

Conclusions: Repeated exposure to stress and potentially traumatic events increases risk of psychological morbidity in people with higher vulnerability, such as adolescents with T1D. Patients’ cognitive appraisal influenced wellbeing and psychological adjustment to the pandemic.

P013 | The impact of the COVID 19 pandemic over glycemic control and hospitalizations in members of T1Diams support center Mauritius: A comparison for the period 2018–2021

B. Jowaheer1
1T1 Diams Support Center, Medical, Quatre Bornes, Mauritius

Introduction: T1Diams is a Mauritian NGO, which assists persons living with Type 1 Diabetes by providing Therapeutic Education and Psychosocial Support. The COVID-19 pandemic (2020-ongoing) turned out to be a litmus test for the adaptability of T1Diams.

Objectives: Comparing average HbA1c and number of hospitalizations for T1Diams members for the period 2018–2021.

Methods: Data obtained from office/telehealth consultations was collected retrospectively and tabulated.

Results: The Number of recorded HbA1c tests done per member decreased from 1.22 in 2018 to 0.45 in 2021. Average HbA1c did not change significantly from 2018 to 2021. Number of Type 1 DM-related hospitalizations increased from 17 in 2019 to 31 in 2020.
Conclusions: The COVID-19 pandemic disrupted medical follow-ups and insulin collection at hospitals and by T1Diams team due to restrictions on traveling and the fear of infection. Less blood tests were done to monitor glycemic control. COVID-19 infections exacerbated hyperglycemia, hence triggering more hospitalizations due to Diabetic Ketoacidosis. However, Telehealth consultations were effective as mean HbA1c remained stable from 2018 to 2021, despite various setbacks.

P014  |  Psychological stress and worsening diabetes: An endemic within the pandemic!

N. Agarwal1, R. Shukla2, M. Gupta1, A. Bajpai1
1Regency Hospital Private Limited, Endocrinology, Kanpur, India

Introduction: Strict isolation measures and interrupted healthcare services during the COVID-19 pandemic are contemplated to instigate stress universally, particularly in those with chronic illnesses such as Type 1 Diabetes (T1D).

Objectives: To evaluate the determinants of stress and its impact on glycemic control among Indian adolescents and young adults (aged 10–25 years), living with T1D.

Methods: A cross-sectional observational study using online, semi-structured survey, including Perceived Stress Scale (PSS-10).

Results: A total of 97 patients (49 males; mean age 18.8 ± 4.5 years, mean diabetes duration 8.0 ± 5.0 years; mean HbA1c 8.1 ± 1.5%) were analyzed. Age (y) (r = 0.325, p = 0.005) and HbA1c (%) within the preceding 3 months (r = 0.274, p = 0.036) correlated positively with PSS-10 score, Figure 1. There was a statistically significant difference in PSS-10 score based on gender (t [70] = −2.147; p = 0.035), education (F [4,67] = 4.34, p = 0.003) and occupation (F [3,68] = 4.50, p = 0.006). On multiple linear regression, gender, occupation and HbA1c were the significant determinants of PSS-10 (F [3,55] = 12.01, p < 0.001, R2 = 0.363). One-way ANOVA showed a significant impact of mean PSS-10 score on the glycemic control (F [2,69] = 3.813, p = 0.027).

Conclusions: Female gender, salaried individuals, and pre-existing poorly controlled diabetes contributed to an increased risk of stress. Increased stress resulted in worsened glycemic control.

P015  |  How our families fared with type 1 diabetes home management during the COVID-19 pandemic 2020 lockdown

E. Bhowmik1, S. Verma1, V. Bhatia1, P. Dabadghao1, S. Sudhanshu1, N. Gupta1, A.M. Ansari1
1Sanjay Gandhi Post Graduate Institute of Medical Sciences, Endocrinology, Lucknow, India

Introduction: At the onset of the COVID-19 pandemic, there was limited data and conflicting evidence regarding the effect of the pandemic on type 1 diabetes (T1DM). It was expected that there may be adverse effects on glycemic control and mortality, more so in developing countries like India, with the additional burden of the lockdown on economy and health care. Subsequently, adult and pediatric data from developed countries regarding glycemic control in patients with T1DM were reassuring. Indian data, as well as data from other developing countries from pediatric T1DM addressing such issues are sparse and have conflicting conclusions. Furthermore, possible factors influencing glycemic control were not evaluated by most reports from our country.

Objectives: We evaluated the effect of the 2020 lockdown on glycemic control and lifestyle of children with type 1 diabetes (T1DM).

Methods: Children and young adults with T1DM (n = 104, mean ± SD age 13.4 ± 4.5 years), were questioned telephonically, regarding access to health care, insulin, food and lifestyle changes during lockdown. Pre and post lockdown HbA1c, body weight, and modifying factors were analyzed.

Results: A change in brand of insulin was necessary in 54% and physiologically wrong insulin was being used in 4.8% patients. HbA1c improved significantly post lockdown versus the 1 year pre-COVID
average (7.59 ± 1.77 vs. 8.61 ± 1.80, p < 0.05). Parents attributed it to better supervision by (both) parents due to their presence at home, and less opportunity to consume energy dense food. Median (IQR) home blood glucose testing frequency was significantly low during lockdown [14(15) vs. 21.5(3.7) pre-lockdown, p < 0.001]. Decreased exercise occurred in 40% and excess weight gain in 51.5%.

**Conclusions:** Despite problems of access to health care and adverse lifestyle conditions, improved parental supervision and meal quality and timing had favorable effect on diabetes management, which is reflected by improvement of HbA1c in a small cohort of our children.

---

**P016 | Impact of COVID-19 on management of diabetes mellitus in urban towns of Kenya: A case study of Mbagathi County Referral Hospital, Nairobi, Kenya**

G. Waweru¹, R. Ireri²

¹Kenyatta University, Food, Nutrition and Dietetics, Nairobi, Kenya, ²Kenya Medical Training College, Clinical Medicine, Nairobi, Kenya

**Introduction:** Diabetes is a chronic Non-Communicable Disease (NCD) with a rising burden nationally and globally and a leading cause of morbidity. Since December 2019, the world has been battling corona virus pandemic, which was first reported in China, and consequently the first case reported in Kenya on 13 March 2020. Patients >60 years of age and those with underlying conditions such as diabetes have been reported to have an increased risk of the disease, severe diseases and death.

**Objectives:** The impact of the pandemic to diabetic care has been sparsely documented in developing countries and so this study sought to look into its effect on accessibility of care and the burden of reported complications in Nairobi, Kenya.

**Methods:** This is a retrospective cross-sectional survey of diabetic patients at Mbagathi county hospital in Kenya. A total of 232 participants were randomly recruited. Modified cox regression analysis was used to measure the correlation between access to health services and diabetes complications during the COVID-19 pandemic.

**Results:** Difficulties in access to the health care services was experienced by 40% of the people living with diabetes (PWD) in Nairobi. The difficulties included access to consultations (62%), medication (18%), and lab testing (12%). About 61% (142) of the participants developed either acute or chronic diabetes complications between March 2020 and June 2021. Those who had service access difficulties were 1.4 times (PR 1.40, 95% CI: 1.09–1.83) more likely to develop diabetes complications than those who did not.

**Conclusions:** The COVID-19 pandemic has an impact on access to health care services and diabetes related complications as seen in PWD in Nairobi, Kenya. We recommend effective communications to ensure patient engagement with diabetes care services and appropriate use of home monitoring, remote consultations, and other innovations in care.

---

**P017 | A quality improvement (QI) innovation during the COVID-19 pandemic: Improving early diagnosis of type 1 diabetes (T1D) in children and young people (CYP) in Cardiff & Vale University Health Board**

A. Shetty¹, M. Dyban²

¹Children’s Hospital for Wales, Cardiff and Vale University Health Board, Pediatric Diabetes, Cardiff, United Kingdom, ²Cardiff and Vale University Health Board, Primary Care Lead Clinician for Health Pathways, Cardiff, United Kingdom

**Introduction:** Most CYP present with symptoms of T1D for the first time to primary care. Delayed diagnosis is common and associated
with risk of life threatening diabetic ketoacidosis (DKA). In Cardiff, we had a pre-pandemic QI project to improve early diagnosis. As the pandemic changed delivery of healthcare, we introduced systems to facilitate early diagnosis of T1D.

**Objectives:** To facilitate early diagnosis of T1D via effective pathways during the pandemic. The primary objective is to reduce the incidence of DKA at diagnosis.

**Methods:** We worked with partners in primary care to identify barriers and develop initiatives at the start of the pandemic. This included an updated referral pathway, training for triage staff, revising online algorithms, and raising public awareness. Retrospective case note analysis of all newly diagnosed CYP covering pre-pandemic (1/4/2018–31/3/2020) and pandemic (1/4/2020–31/3/2022). Key points included delayed diagnosis, presentation, appropriate testing, and prompt referral.

**Results:** Pre-pandemic, 6/7 with delayed diagnosis had delayed triage and 1 had fasting blood glucose (BG). 25/28 had POC BG testing and 2 had a urine test. During the pandemic, 2/4 with delayed diagnosis had delayed triage. 46/49 had POC BG test and 3 a urine test. The 4 in severe DKA had delayed presentation but promptly diagnosed, of which 2 were presumed to have COVID. During the pandemic 91% had POC testing and prompt referral to secondary care compared with 75% pre-pandemic. There was no increase in the DKA rates during the pandemic despite a significant increase in the number newly diagnosed.

**Conclusions:** During the pandemic, we demonstrated an improvement in prompt diagnosis following the QI initiatives between primary and secondary care. Delayed presentation has resulted in severe DKA despite public awareness campaigns. Data analysis, feedback, training and public awareness campaigns across other health boards is planned.

**POSTER TOUR 3—COVID #3**

P019 | The aim of the study is to evaluate the impact of nutrition changes & programmed physical training on type 1 diabetic adolescents during COVID-19 lockdown

V. Maheriya, D. Hasnani, R. Chhtraliya, S. Pal, V. Chavda
1Rudraksha Institute of Medical Sciences, Department of Nutrition, Ahmedabad, India

**Introduction:** According to WHO and IDF it is stated that healthy diet and regular physical activity and maintaining healthy weight is very effective for type 1 and type 2 diabetes.

**Objectives:** The main objectives of study was to schedule personalized healthy nutrition, to programmed physical training schedule & was to find out the impact of nutrition & physical activity in term of SMBG changes, weight, muscle mass, Hba1c.
Methods: Number of type 1 diabetic children & adolescents enrolled for the intervention were 15 (F = 9, M = 6). Number of subjects completed the intervention was 13. The intervention conducted for 3 months during the lockdown from 1 April to 1 July 2020. All subjects were counseled and educated and followed up through teleconsultation at baseline visit (Day 0), visit 1 on (day 15), visit 2 on (day 30) visit 3 on (day 60) visit 4 on (day 90). The parameters evaluated were anthropometric data, HBA1C & SMBG readings from baseline to end of the intervention.

Results: Data showed significant improvement of hba1c of 0.8%, also improvement of glycemic control is seen. On evaluation of anthropometric data there was no significant changes in weight but increment seen in muscle mass.

Conclusions: It has been concluded that MNT & physical activity comprise the basic pillars in treatment of diabetes. Especially for kids, young adults with a chronic condition following a strategic plan for nutrition & exercise can do in appropriate growth and development. In the real world, implementation of the MNT and exercise for the pediatric population still remains a challenge. This can be easily solved by including sports of the person’s choice in their routine activities and healthy food options. These together can impact the glycemic status and the quality of life of young adults up to great extent.

**P** < 0.01.

<table>
<thead>
<tr>
<th>Table: Demographics and HbA1C and BMI z-score outcomes of the 3 groups</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline Characteristics</strong></td>
</tr>
<tr>
<td><strong>T1D (n = 277)</strong></td>
</tr>
<tr>
<td>----------------------</td>
</tr>
<tr>
<td>HbA1C at diagnosis (%)</td>
</tr>
<tr>
<td>n = 186</td>
</tr>
<tr>
<td>BMI z-score at diagnosis</td>
</tr>
<tr>
<td>n = 79</td>
</tr>
<tr>
<td>BMI value at diagnosis (kg/m²)</td>
</tr>
<tr>
<td>n = 80</td>
</tr>
</tbody>
</table>

**Results**

<table>
<thead>
<tr>
<th></th>
<th>T1D (n = 277)</th>
<th>T2D (n = 34)</th>
<th>YDPC (n = 11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1C (%)</td>
<td>8.4 [7.3, 9.5]</td>
<td>8.3 ± 2.49</td>
<td>5.6 ± 0.27</td>
</tr>
<tr>
<td>Pre-COVID-19 visit</td>
<td>8.3 [7.2, 9.7]</td>
<td>9.31 ± 3.09</td>
<td>5.96 ± 0.88</td>
</tr>
<tr>
<td>First follow-up p-score</td>
<td>0.85</td>
<td><strong>0.0030</strong></td>
<td>0.24</td>
</tr>
<tr>
<td>----------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>BMI z-score</td>
<td>0.93 [0.34, 1.51]</td>
<td>2.17 ± 0.65</td>
<td>2.45 ± 0.41</td>
</tr>
<tr>
<td>Pre-COVID-19 visit</td>
<td>0.91 [0.25, 1.56]</td>
<td>2.15 ± 0.61</td>
<td>2.47 ± 0.44</td>
</tr>
<tr>
<td>First follow-up</td>
<td>0.78</td>
<td>0.49</td>
<td>0.63</td>
</tr>
<tr>
<td>P-score</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Note: Data are mean ± SD or median [IQR]. **P < 0.01.**
Introduction: COVID19 pandemic led to delayed diagnosis and increase in number and severity of Type 1 Diabetes Mellitus (T1DM) and Diabetic Ketoacidosis (DKA) cases in pediatric population worldwide. The indirect impact of the pandemic on pediatric DKA admissions to COVID19 free hospitals worth to be evaluated.

Objectives: Our aim was to evaluate the characteristics and severity of DKA admissions before and during the pandemic.

Methods: This retrospective observational study included 130 episodes of DKA for patients aged below 16 years admitted to Tawam Hospital, a COVID-19-free hospital, between March 2017 to Feb 2021. Data from March 2020–Feb 2021 (pandemic) was compared to the previous 3 years, March 2017–Feb 2020 (pre-pandemic). Data was retrieved from the electronic records and analyzed using STATA13.

Results: We evaluated 130 DKA admissions (63 pandemic and 67 pre-pandemic). The majority of patients in the pandemic group were in, the age group of (6-11.9 years) (54% vs. 23.9%, P 0.001), and higher proportion of them was diagnosed with new onset diabetes (42.9% vs. 25.4%, P 0.035). Overall, there was no significant difference in symptoms duration, DKA severity, or time to DKA resolution (11.80) –(9.27–11.80) (p = 0.0297) in the pandemic and pre-pandemic groups, respectively.

Conclusions: In our COVID-19-free hospital, the pandemic and service reallocation has led to an increased rate of DKA admissions with increased number of newly diagnosed T1DM. Clinical presentation and severity were not adversely affected.

Introduction: It is unclear whether diabetes alone contributes to increased risk of morbidity and mortality related to COVID-19.

Objectives: This study aimed to explore the relationship between diabetes and the severity of COVID-19 infection as well as the impact of COVID-19 on the clinical presentation and outcome in patients with type 1 diabetes.

Methods: This cross sectional study included 51 children and adolescents with type 1 diabetes mellitus (T1DM) attending the Pediatric Hospital. Participants included all patients with type 1 diabetes admitted to Children’s Hospital, Ain Shams University in the period between August and December 2020. Data of studied patients was extracted from inpatient files and reports.

Results: The age of the patients ranged from 1-17 years with median of 9 (6-13) years, with female predominance [27 (52.9%)]. A 45 presented in DKA, with mean pH of 7.04 ± 0.29. The median duration of hospital admission was 4 (2-7) days. A 33 patients were newly diagnosed and presented in DKA except 5 (15.2%) patient that presented in hyperglycemia. The mean HbA1c was 11.70 ± 1.86, the median time till hospital admission was 1.5 (1-2) days. Acute kidney injury (AKI) and echocardiographic changes were reported in 12 (36.4%) and 4 patients (12.1%) respectively. All patients with AKI were admitted to ICU, all showed significantly lower pH at presentation, HCO3 level, and serum albumin level (p < 0.05). Although 22 patients had COVID infection either by PCR or antibodies, only six patient required respiratory support, 13 patients required circulatory support and 6 had echo changes. Two patients had manifestation of MIS-C and required ICU admission and anticoagulants.

Conclusions: COVID infection in diabetic patients was associated with sever presentation of DKA and multiple organ affection, which could be related to viral affection or delayed hospital admission during the pandemic.

Introduction: Viral infections have been implicated in the development of type 1 diabetes. There have been reports of COVID-19 induced new-onset diabetes.

Objectives: In this context, this study aimed to describe and compare the characteristics at diagnosis of children who develop type 1 diabetes before and during the COVID-19 pandemic in Belgium.

Methods: This observational study compares two groups of children and adolescents who develop type 1 diabetes: the first includes new-onset diabetes before the pandemic (1 March 2018 and 31 December 2019) and the second during the pandemic (1 March 2020 and 31 December 2021) in HUDERF, Brussels, Belgium.

Results: In our center, the number of new-onset type 1 diabetes in the pre-pandemic period was 87 and in the pandemic period was 147 (p = 0.010). During the COVID-19 pandemic, patients with new-onset diabetes were more often male (62% vs. 44%; p = 0.010) and had a slightly higher pH at admission [7.35 (7.22–7.41) vs. 7.34 (7.18–7.38); p = 0.043] than before the pandemic. There was no difference in age, BMI SDS, HbA1c or severity of ketoacidosis at type 1 diabetes diagnosis. During the pandemic, 2 children (2%) had a positive SARS-CoV2 PCR test on admission but were asymptomatic.

Conclusions: The number of new cases of type 1 diabetes in our center during the COVID-19 pandemic was significantly higher than before the pandemic. These new patients were mainly male. Longer-term and national follow-up is needed to assess the role of COVID-19 in the development of type 1 diabetes.
Introduction: COVID-19 pandemic and eventual lockdown gave a major
boost to online heavy action gaming like PUBG. Adolescents are finding
gaming the best avenue to connect and socialize with friends addressing
their needs of human interaction and coping with the pandemic.

Objectives: This pilot study aimed to evaluate changes in glycemis
control and the role of online gaming during the exceptional time of
COVID-19 complete lockdown in a cohort of children with T1DM and
2 years after.

Methods: We evaluated children with T1DM on basal bolus regimen
who were monitored using the FreeStyle Libre® glucose monitoring
system. Analysis were extracted from downloads and compared to
timing after lockdown.

Results: A 47 patients (39 males) with mean age 13.6 ± 2.8 years and
duration of diabetes (5.2 ± 1.3 years) were followed up. The glycemis
control was worse during than after lockdown mean glucose manage-
ment indicator of 8.3% versus 7.2% (p = 0.001).

There was higher time above range of 44%, lower time in range of 39%
and time below range of 6% during quarantine than after (p < 0.001 for
all). A significantly higher coefficient of variation (CV) indicating an
increased glucose variability in the lockdown period compared to post-
lockdown was observed (42.6% vs. 37.2%, p = 0.011). Time spent play-
ing online games occupied ≥8 h daily in 73% together with decreased
sleep duration. They had more snacking leading to increase insulin
bolus by 32% (p = 0.002) and weight gain by 12% (p = 0.006).

Conclusions: Glycemic control in T1DM adolescents addicted to online
gaming worsened during restrictions of COVID-19 pandemics. Maint-
aining regular physical activity in a safe home environment with die-
tary and insulin dose recommendations is an essential strategy for
young individuals to better control glycemic excursions. As we mark
2 years of the COVID-19 pandemic, a central pillar of building more

Table 1: Characteristics of patients with new onset diabetes

<table>
<thead>
<tr>
<th></th>
<th>Prepandemic (January 2019–February 2020 (14 months))</th>
<th>Pandemic March–October 2020 (8 months)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of new onset diabetes (NOD)</td>
<td>140</td>
<td>164</td>
<td>0.00002*</td>
</tr>
<tr>
<td>Number of NOD/month</td>
<td>10</td>
<td>20.75</td>
<td>0.005</td>
</tr>
<tr>
<td>Age (y), mean ± SD</td>
<td>11.3 ± 3.7</td>
<td>12 ± 3.4</td>
<td>0.075</td>
</tr>
<tr>
<td>A1c (%), mean ± SD</td>
<td>10.9 ± 2.1</td>
<td>11.6 ± 1.9</td>
<td>0.00255*</td>
</tr>
<tr>
<td>BMI %ile, mean ± SD</td>
<td>72.1 ± 31.2</td>
<td>75.5 ± 32.5</td>
<td>0.16</td>
</tr>
<tr>
<td>Diabetes Type 1, n (%)</td>
<td>94(67)</td>
<td>83(51)</td>
<td>0.00357*</td>
</tr>
<tr>
<td>Diabetes Type 2, n (%)</td>
<td>45 (32)</td>
<td>78(47)</td>
<td>0.00633*</td>
</tr>
<tr>
<td>DKA, n (% of total NOD)</td>
<td>53 (38)</td>
<td>78 (47)</td>
<td>0.08857</td>
</tr>
<tr>
<td>SevereDKA(pH &lt; 7.1(type2)</td>
<td>21 (0)</td>
<td>22(8)</td>
<td>0.69257</td>
</tr>
</tbody>
</table>
P026  Rise in pediatric type 2 diabetes mellitus diagnoses in Philadelphia during the COVID-19 pandemic

H. Nasir¹, T. Lipman², M. Kuye¹, B. Schwartzman¹, L. Katz¹
¹Children’s Hospital of Philadelphia, Endocrinology, Philadelphia, United States

Introduction: Concurrent with the obesity epidemic in children in the US, there has been a marked rise in type 2 diabetes mellitus (T2DM) in youth.

Objectives: Our objective was to ascertain the trend of new diagnoses of T2DM during the COVID pandemic at our institution and as part of the Philadelphia Pediatric Diabetes Registry.

Methods: New diagnoses of T2DM from 2017 to 2021 were identified through the EMR. They were divided into two groups, those from the city of Philadelphia, and those from outside the city limits.

Results: We found an increase in the diagnoses of T2DM overall at our center, with a marked increase post-pandemic (n = 29, 30, 59, 86, 97; 2017, 2018, 2019, 2020, 2021), and also within the city of Philadelphia (n = 12, 14, 26, 40, 50; 2017, 2018 2019, 2020, 2021). African-Americans comprised 61%-66% of the new diagnoses, followed by Latinos at 10%-16%, Whites and Asians. The majority of the patients were females (61% to 65%), with roughly the same proportion in both groups. Mean age at diagnosis for females was consistent throughout at 13.6 years, whereas it was 14.5 years for males. Mean BMI for females and males in both groups was noted to increase (32.8, 33.0, 36, 38.9, 39.7; 2017, 2018, 2019, 2020, 2021) and (34.0, 34.2, 35.5, 38.9, 39.2). In 2019, 4 patients presented with DKA, increasing to 6 in 2020 and 9 in 2021, whereas 2 patients presented in HHS in 2020, 4 in 2021, and none in 2017, 2018 or 2019. Approximately 10% had anti-insulin antibodies across all 5 years, and around 64% presented in the fall–winter months (October–February). The mean HbA1c at diagnosis was also found to increase among both groups, from 8.6% in 2019 to 9.3% in 2020 and 10.1% in 2021, versus 8.8% in 2017 and 8.5% in 2018.

Conclusions: The number of new T2DM diagnoses in children has increased substantially during the pandemic, likely correlating with a list of food changes. In the intervention arm, the study dietician taught the parent how to quantify carbohydrate content in food and modify insulin doses according to insulin-carbohydrate ratio. DAWN/WHO-5 QoL Questionnaire and DAWN Problem Areas in Diabetes Questionnaire (PAID) were used to assess the quality of life and emotional distress, respectively.

Results: A 125 patients were enrolled (intervention n = 61 and control n = 64). The baseline characters between the two groups were similar with respect to age, gender, socio-economic status, parent’s education, and HbA1c. A 6 months follow-up was completed in 91.8% and 84.3% patients in the intervention and control arms, respectively. There was a reduction in HbA1c in both groups from baseline, however it was not statistically significant between groups (Intervention: 8.7 (1.5) vs. control: 8.8 (1.9), p = 0.6). There was no difference in QoL or emotional distress score between the groups. However, the carbohydrate group had significantly less ‘emotional burnout’ compared to the control arm (burnout 4/46 vs.12/41, p = 0.013).

Conclusions: Carbohydrate-counting did not lead to better HbA1c, QoL or lesser diabetes distress compared to fixed meal plans in children with T1DM over a 6-month period. However, patients in the carbohydrate-counting group demonstrated lesser emotional burnout compared to controls.

P027  Carbohydrate versus fixed meal counting plan in Indian children with type 1 diabetes mellitus: A randomized controlled trial

R. Sharma¹, B. Upadhyay¹, N. Lal¹, B. Kumar¹, V. Jain¹
¹All India Institute of Medical Sciences, Department of Pediatrics, New Delhi, India

Introduction: There is paucity of research on optimal approach to nutritional management in children T1DM.

Objectives: To study the impact of carbohydrate counting vs. fixed meal plan on HbA1c, quality of life (QoL) and diabetes-related emotional distress in T1DM through an RCT.

Methods: Eligibility: Children aged 6–18 years with diabetes duration >1 year on multiple daily insulin injections (long-acting NPH/glargine and short-acting regular/lispro/aspart).

Exclusion: coeliac disease, hypothyroidism, chronic systemic disease, HbA1c > 13%.

Both groups had baseline diabetes education. The control arm had dietary prescription according to the recommended dietary allowance with a list of food exchanges. In the intervention arm, the study dietician taught the parent how to quantify carbohydrate content in food and modify insulin doses according to insulin-carbohydrate ratio. DAWN/WHO-5 QoL Questionnaire and DAWN Problem Areas in Diabetes Questionnaire (PAID) were used to assess the quality of life and emotional distress, respectively.

Results: A 125 patients were enrolled (intervention n = 61 and control n = 64). The baseline characters between the two groups were similar with respect to age, gender, socio-economic status, parent’s education, and HbA1c. A 6 months follow-up was completed in 91.8% and 84.3% patients in the intervention and control arms, respectively. There was a reduction in HbA1c in both groups from baseline, however it was not statistically significant between groups (Intervention: 8.7 (1.5) vs. control: 8.8 (1.9), p = 0.6). There was no difference in QoL or emotional distress score between the groups. However, the carbohydrate group had significantly less ‘emotional burnout’ compared to the control arm (burnout 4/46 vs.12/41, p = 0.013).

Conclusions: Carbohydrate-counting did not lead to better HbA1c, QoL or lesser diabetes distress compared to fixed meal plans in children with T1DM over a 6-month period. However, patients in the carbohydrate-counting group demonstrated lesser emotional burnout compared to controls.

P028  Lifestyle parameters in young adults with type 1 diabetes mellitus: differences by type of insulin regimen

M. S. Karapidou¹, S. Liatis², A. Kyrkilí³, A. Skoufí³, A. Bampagiánní², S. Drívá³, E. Papachristoforou³, P. Charalampakis³, V. Lampadiari³, M. Kontogianní³
¹Harokopio University, Department of Nutrition and Dietetics, Athens, Greece, ²Laiko General Hospital, First Department of Propaedeutic Medicine, Athens, Greece, ³University General Hospital Attikon, Second Department of Internal Medicine and Research Institute, Athens, Greece

Introduction: Most of young adults with type 1 diabetes mellitus (T1DM) are treated by either continuous subcutaneous insulin infusion (CSII) or multiple daily insulin injections (MDI).

Objectives: The purpose of the present study was to evaluate and compare lifestyle habits in this population according to the type of insulin therapy.
Introduction: The International Society for Pediatric and Adolescent Diabetes (ISPAD) dietary guidelines promote the adoption of healthy eating habits. However, discrepancies can be recorded.

Methods: Young adults (15–29 years) with T1DM attending a diabetes outpatient clinic were consecutively enrolled and cross-sectionally evaluated. Three 24-h recalls and a food frequency questionnaire were used to assess participants’ dietary habits. Physical activity and sleep were assessed through validated questionnaires, the Athens Physical Activity Questionnaire and Athens Insomnia Scale, respectively. Adherence to the Mediterranean Diet (MD) was assessed by the MedDiet Score.

Results: A 55% of the sample used CSII and did not differ from the MDI group in terms of age, sex, body mass index and Hba1c (all p > 0.05), however, had more years of T1DM (13.6 ± 6 vs. 9.9 ± 6.1, p = 0.009). Physical activity levels did not differ significantly between the two groups. Regarding macronutrients intake, the CSII group tended to consume more carbohydrates (40.5 ± 8.4% vs. 37.1 ± 7.3%, p = 0.066) and less protein (17.1 ± 3.7% vs. 18.8 ± 3.9%, p = 0.057) as percentage of total energy intake compared to the MDI group. The CSII group had better adherence to MD than the MDI group (34.2 ± 5.8 vs. 30.9 ± 5.7, p = 0.022) and consumed more cereals (p = 0.033) and fish (p = 0.013). Additionally, the CSII group had significantly lower quality of sleep (p = 0.011) and sleep duration (p = 0.028) compared to the MDI group.

Conclusions: Although macronutrients distribution, physical activity levels and glycemic control did not differ significantly between young adults receiving CSII and those on MDI, those treated with CSII reported better diet quality, as reflected by higher adherence to the MD, but worse sleep habits.

P029 | Adherence to ISPAD nutritional guidelines: A food-diary based study

E. Sakellari1, S. Giza1, E. Efstratiou1, A. Kleisarchaki1, S. Douma1, A. Galli-Tsionpoulou1
12nd Department of Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, AHEPA University General Hospital, Thessaloniki, Greece

Objective: To determine adherence to ISPAD nutritional guidelines and the impact of dietary composition on glycemic control.

Methods: Children aged <18 years receiving care in our SWEET Collaborative Center with ISPAD guidelines and the impact of dietary composition on glycemic control.

Results: A 79 (58.2% male) T1D patients aged 12.7 ± 4.1 years with 4.4 ± 3.5 year disease duration were included. They were characterized by a BMI z-score of 0.46 ± 0.89 and Hba1c of 7 ± 0.9%. Food analysis, expressed as % E intake, revealed 47.3 ± 3.76, 17.4 ± 3.0, and 35.2 ± 3.8 carbohydrate (CHO), protein and fat, respectively. Hba1c did not differ significantly in the subgroups of CHO (<40, 30–45, >45) and fat intake (<30, 30–35, >35%) and only CHO had a trend to be correlated with Hba1c (r = −0.243, p = 0.031). By dividing patients according to optimal glycemic control (Hba1c ≤ 7%, n = 36) in 2 groups, those consuming less fibers were more likely to have Hba1c > 7%(13.0 ± 2.9 vs. 15.5 ± 3.1, p = 0.02).

Conclusions: T1D children and adolescents, having received dietary guidance in our Center, are in good compliance with ISPAD guidelines, even years after the diagnosis, ensuring an optimal glycemic control. This good outcome may be also served by increased fiber consumption.

P030 | The effect of night snack options on nocturnal blood glucose variability in children and adolescents with type 1 diabetes

D. Gunes Kaya1, H. Turan2, M. Bas3
1Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Pediatric, Istanbul, Turkey, 2Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Pediatric, Istanbul, Turkey, 3Istanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Department of Pediatric, Istanbul, Turkey

Objective: To compare the effect of different night snack options on nocturnal blood glucose variability in children and adolescents with type 1 diabetes.

Methods: Children with T1DM were divided into 3 groups with the following night snack options: (1) carbohydrates (CHO), (2) saturated fat, and (3) unsaturated fat. Glucose variability was assessed by nocturnal continuous glucose monitoring (CGM). The effect of each night snack option on nocturnal glucose variability was evaluated using t-tests.

Results: A total of 120 children with T1DM were included in the study. The mean age of the participants was 12 years, and 60% were male. The mean Hba1c was 7.8%, and the mean disease duration was 4 years. The comparison of nocturnal glucose variability between the 3 groups showed significant differences in the CHO group (p < 0.05).

Conclusions: The effect of different night snack options on nocturnal blood glucose variability in children and adolescents with type 1 diabetes.
**Endocrinology, Istanbul, Turkey, 3 Acbadem Mehmet Ali Aydinlar University, Nutrition and Dietetics, Istanbul, Turkey**

**Introduction:** Despite intensive insulin therapy, nocturnal hypoglycemia and glucose variability still an important problem, especially in diabetics who do not use glucose monitoring systems.

**Objectives:** The aim of this study is to investigate whether night snacks containing different nutrients have an effect on nocturnal hypoglycemia and glucose variability in children and adolescents with Type 1 diabetes (T1DM).

**Methods:** The study, which was planned as a randomized single-blind crossover nutrition intervention study, included a total of 12 patients, 4 girls and 8 boys, aged 6–17, using intensive insulin therapy. The subjects were given 4 night snack alternatives (Carbohydrate [CH], CH + protein, CH + fat, CH + fiber) to be consumed. Subjects consumed total of 12 test meals, with all test meals given 3 times. The blood glucose monitoring of the cases was made with a closed loop continuous glucose-monitoring device.

**Results:** Time in range for blood glucose is evaluated; CH and CH + protein TIR were statistically higher than CH + Fat and CH + Fiber values (p = 0.014). When all snacks were evaluated, the highest TIR was the CH + protein snack for 58.3% of 12 patients. CH + fat does not the best TIR for any case. CH + protein area under the curve (AUC) values were statistically lower than CH + fat values (p = 0.08). When the %CV was evaluated, there was no statistical difference between the snacks, but the snack with the lowest average coefficient of variation was determined as CH + protein. Although the CH + fat meal was not statistically significant, the time spent in hyperglycemia was found to be longer than other snacks. Although the CH + fiber meal was not statistically significant, it was the snack with the longest hypoglycemia time. There are differences between individuals in the results.

**Conclusions:** As a conclusion; creating healthy and individually planned snack alternatives for children and adolescents with T1DM can help improve glycemic control and may affect positively blood glucose during the night especially in diabetics who cannot use CGMS and SIIP.

**P031 | Assessing the difference in time taken to establish insulin to carbohydrate ratios (ICR’s) following diagnosis of type 1 diabetes**

K. Sparrow1

1University Hospitals of Leicester, Pediatric Diabetes, Leicester, United Kingdom

**Introduction:** Insulin to carbohydrate ratios (ICR’s) are considered important in enabling flexible insulin doses to optimize glycaemic control and quality of life following a diagnosis of type 1 diabetes. There are numerous factors and barriers which can delay successfully initiating this therapy and it is well known the time taken to do so can differ hugely among patients and families.

**Objectives:** To quantify the difference in time taken (weeks post diagnosis) to establish ICR’s. Once understood, to analyzing qualitative data associated with this process to help identify barriers and further support which may be required and how the diabetes service can be developed accordingly.

**Methods:** Our online diabetes record system was used to retrospectively identify the date which ICR’s were set against a patient’s diagnosis date and corresponding qualitative information. Patients diagnosed with Type 1 Diabetes were audited between September 2016 and January 2020 (n = 115).

**Results:** There is a clear difference in the time taken to establish ICR’s between different ethnic groups. The average time taken to establish ICR’s was 4 weeks and 5 days and the median time 2 weeks and 3 days. The groups taking on average, the least amount of time (0–3 weeks) to establish ICR’s were; ‘White British’ (73%) and ‘Other ethnic groups including mixed ethnic’ (60%). The ethnic groups which were found to, on average, take the longest amount of time (>7 weeks) were ‘White ethnic’ (70%), and ‘Black African’ (60%). Reasons for delay in completion were divided into categories. Of these, the most common included ‘more dietetic education required’ (62%), ‘problems completing the food diary’ (33%), and ‘more time / practice required’ (29%).

**Conclusions:** Attention is required to reduce the variation in difference taken to establish ICR’s among different ethnic groups. More frequent educational opportunities and tailored resources to prevent further delay should be considered in addition.

**P032 | Comparison of feeding patterns and mealtime behaviors of children with type 1 diabetes with age and gender matched controls**

L. Helena1, V. McDarby2, E. Somers2, C. Ella1, L. Hobbs1, D. Barry1, R. Ward1, A. Martin1, B. McGuire1, D. Cody2

1National University of Ireland, Galway, Ireland, 2Children’s Health Ireland, Dublin, Ireland

**Introduction:** Research has found that children with T1D are at a greater risk of developing poor eating habits, which can affect their health in later life.

**Objectives:** The study aimed to identify the relationship between child feeding patterns and mealtime behaviors and to examine the impact of parental stress and self-efficacy on the management of T1DM.

**Methods:** Parents of children (aged 4 to 18 years) attending their regular diabetes clinic in a tertiary hospital (n = 143) completed a psychological and feeding questionnaire battery that included the Behavioral Pediatrics Feeding Assessment Scale, the Parenting Stress-Index, the Self-Efficacy for Diabetes Scale, a food inventory, a demographic questionnaire and a questionnaire that assessed disruptive behavior at mealtimes. The same questionnaire battery was completed by the parents of a group of age and gender matched children (n = 143).
**ABSTRACTS**

**P034  |  Factors associated with glycemic control in children with type 1 diabetes from a specialized diabetes center**

S. Qabazard1, D. Khalifa2,1, D. Al-Abdulrazzaq3, H. Al-Kandari4,1

1Dasman Diabetes Institute, Population Health, Dasman, Kuwait, 2Yarmouk Clinic, Ministry of Health, Kuwait City, Kuwait, 3King Saud University, Pediatrics, Kuwait City, Kuwait, 4Al-Farwaniyah Hospital, Ministry of Health, Pediatrics, Sabah Al-Naser, Kuwait

**Introduction:** Dasman Diabetes Institute (DDI) is a specialized center caring for adult and pediatric patients with diabetes. We systematically collect data to assess treatment and optimize outcomes. We used our database to investigate the factors such as body mass index (BMI), gender, age and treatment modality associated with glycemic control in children with type 1 diabetes mellitus in the center.

**Objectives:** We used our database to investigate the factors such as body mass index (BMI), gender, age and treatment modality associated with glycemic control in children with type 1 diabetes mellitus in the center.

**Methods:** Data were collected from pediatric patients (under 18 years of age) visiting DDI clinics for routine follow up. Patients with at least 1 visit were included. Patients were divided into 4 groups according to WHO BMI z-scores: underweight (<−2), normal weight (−2 to ≤1), overweight (>1 to ≤2) and obese (>2). Glycemic control was defined as HbA1c <7%. Treatment modalities were either multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). Student t-test, chi squared, and ANOVA were used for statistical analysis. P-value was set to <0.05 for statistical significance.

**Results:** BMI, gender, age, HbA1c, and treatment modalities were analyzed in 128 pediatric patients. The study included 66 boys and 62 girls with a median (interquartile range) for age 14.46 (12.12; 16.30), BMI z-score 0.81 (−0.09; 1.66), 57% were categorized as under/ normal weight and 48% were on CSII. Median HbA1c was 8.4 (8.4; 8.4). There were no factors associated with glycemic control in this population.

**Conclusions:** In this population, glycemic control is not affected by weight, type of treatment, age, or gender. A larger sample size might warrant more inclusive results. Consistent follow-ups with physicians and diabetes educators at DDI may also contribute to these results. It remains to be investigated whether maintaining or reducing weight in children with type 1 diabetes improves HbA1c.

**P035  |  Beneficial effect contributors of exercise in type 1 diabetes: Irisin and sestrin**


1Istanbul University - Cerrahpasa, Cerrahpasa Medical Faculty, Pediatrics, Istanbul, Turkey, 2Istanbul University, Sports Medicine Department, Istanbul, Turkey, 3Istanbul University - Cerrahpasa, Cerrahpasa Medical Faculty, Division of Endocrinology, Istanbul, Turkey, 4Marmara University, Faculty of Sports Sciences, Istanbul, Turkey, 5Istanbul University - Cerrahpasa, Cerrahpasa Medical Faculty, Department of Pediatric Endocrinology, Istanbul, Turkey, 6Harvard Medical School, Department of Pediatrics, Boston, United States, 7Boston Children’s Hospital, Division of Endocrinology, Boston, United States

**Introduction:** Type 1 Diabetes (T1DM) is a chronic metabolic disease characterized by hyperglycemia due to absolute insulin deficiency because of autoimmune damage of pancreatic β cells. In its treatment, insulin, medical nutrition therapy, and exercise is recommended. Although it is known that exercise contributes to disease control, the mechanism of these effects has not been fully clarified. It is thought that myokines such as irisin and sestrin, can be effective by secreting white fat tissue from the tissue by exercise, turning white fat tissue into brown.

**Objectives:** In this study, to determine the changes in clinical and laboratory findings with the exercise program applied in patients with T1DM; it is aimed to determine the relationship of these changes with the levels of irisin and sestrin.

**Methods:** A 33 patients with T1DM diagnosis and 36 control groups were identified. Exercise capacities were determined in both groups. A moderate-to-high intensity exercise program was applied 3 days a week for 3 months with T1DM patients. At the end of the exercise program, serum irisin, sestrin were evaluated. Their examinations were obtained from file data and computer records. Changes in laboratory and clinical findings were compared.

**Results:** Sestrin level was found to be high compared to the control group in the T1DM-diagnosed group. No significant difference in irisin level was detected. With exercise, sestrin levels decreased and irisin levels increased. HbA1c and basal insulin doses were found to decrease in the exercised group.

**Conclusions:** Irisin levels increased and sestrin levels decreased with the exercise program structured and under observation according to age group and T1DM. Our findings suggest that irisin and sestrin may contribute to the beneficial effects of exercise in children with type 1 diabetes.
POSTER TOUR 5—PSYCHOLOGY # 2

P036  |  Sleep characteristics in a Danish pediatric type 1 diabetes population: A pilot study

C. Paulsrud1, S. Ullitz Thorsen1, A. Ranjan1, K. Nærgaard1, N. Møl Debes2, J. Svensson3
1Steno Diabetes Center Copenhagen, Diabetes Technology, Herlev, Denmark; 2Herlev Gentofte Hospital, Department of Pediatrics, Herlev, Denmark

Introduction: Sleep disturbances are increasing in the population and may be even more pronounced in adolescents with type 1 diabetes (T1D) compared to healthy peers.

Objectives: We aimed to investigate sleep and the association to glycemetic parameters.

Methods: This is a pilot study with repeated questionnaire and actigraphy data from 45 patients age 6–17 years old: 19 with T1D and 26 controls (15 with Tourette syndrome and 11 healthy individuals). All recruited from a large pediatric department in Denmark. Questionnaires were answered two times with 3 weeks in between, and an actigraphy (AG) watch (wGT3X-BT) worn for 7 days and nights including fulfillment of a sleep diary. Data was analyzed in two steps: (1) correlated exposure reduction using principal component analysis (PCA) (questionnaire and AG data were analyzed separately); and (2) linear regression with principal components (PCs). Six main sleep quality questions were included in PCA1 and mean and SD of the AG measures (sleep duration, latency, and sleep efficiency) was included in PCA2.

Results: 96.5% of the participants had on average insufficient sleep duration according to AASM guideline. Children with T1D had a median (range) age of 11 (6–17); HbA1c 59.00 (39–87) mmol/mol; Time-in-range (TIR) 60.2 (25–97); Time-below-range (TBR) 3.5 (0–16%). No difference in sleep duration or sleep quality between T1D and controls. The PC that captured insufficient perceived sleep, was associated with a 4.7 mmol/mol increase in HbA1c (95% CI: -9.6 to 0.2%, p-value = 0.005) and a decreased TIR (-4.7%, 95% CI: -9.6 to 0.2%, p-value = 0.06). The PC that captured poor objective sleep was positively associated with HbA1c (3.9 mmol/mol, 95% CI: -0.7 to 8.5 mmol/mol, p-value = 0.09). All estimates were robust after adjustment for sex or age.

Conclusions: These results highlight the importance for further in-depth investigation of the association between sleep and glycemetic outcomes in children and adolescents with T1D.

P037  |  Exploring trust, satisfaction, and other patient-reported outcomes in children and adults with type 2 diabetes using insulin pumps: Real-world observations

H. Singh1, G. Alencar1, M. Manning1, S. Habif2
1Tandem Diabetes Care, San Diego, United States

Introduction: Recent publications have noted a sharp rise in the prevalence of youth-onset type 2 diabetes (T2D). Glucose control is reported to be especially compromised in this cohort leading to a high prevalence of diabetes complications.

Objectives: Automated insulin delivery systems have demonstrated successful outcomes in people with type 1 diabetes however, little is known about their use and patient experience in T2D management, especially for pediatric patients.

Methods: People with T2D from the customer base of Tandem Diabetes Care responded to an email invitation and completed an online survey in October 2021 exploring their experiences with their Tandem insulin pump. For purposes of this study, we analyzed demographics, self-reported glycemic data (HbA1c), continuous glucose sensor based glycemic metrics, and patient-reported outcomes (PROs) from US participants.

Results: Analysis included 2310 T2D participants (White = 77%, female = 49%, private health insurance = 62%, MDI [prior therapy] =61%). Most participants had been using their insulin pump for a year or less (61%) and the majority were on the t:slim X2 insulin pump with Control-IQ technology (76%). Self-reported HbA1c was <8% for the majority (84%). Median sensor time in range by age cohort was: <18 years (n = 12) =51% (IQR = 31.2), 18–30 years (n = 17) =73% (IQR = 35.6), 31–45 years (n = 178) =71% (IQR = 28.6), 46–64 years (n = 1034) =71% (IQR = 22.3), ≥65 years (n = 1069) =73% (IQR = 19.8). Sensor time below <70 mg/dl was <1% for all groups. In terms of PROs, participants reported high satisfaction that is, endorsed “satisfied” or “very satisfied” with their insulin pump (<18 years = 83%; ≥18 years = >84%). Pump-related “trust” (<18 years = 92%; ≥18 years = >83%) and “ease of use” (<18 years = 84%; ≥18 years = >82%) also trended high. The majority in each age cohort reported “reduction in their burden to manage diabetes” (<18 years = 100%; ≥18 years = ≥90%) and being able to “manage their diabetes effectively” (<18 years = 92%; ≥18 years = ≥77%) while using their insulin pump.

Conclusions: Despite a small pediatric cohort, this study identifies valuable real-world implications of using advanced insulin therapies with an otherwise challenging patient group. Future, in-depth studies exploring onboarding to and use of these technologies in this cohort are encouraged.

P038  |  Impact of youth worker in reducing health inequalities and improving outcomes

S. Hulikere1, C. Cunliffe1
1Warrington and Halton Teaching Hospitals NHS Foundation Trust, Pediatrics, Warrington, United Kingdom

Introduction: Youth worker participation in the young persons Diabetes MDT team contributes to enhancing the care. By working closely, youth worker may be able to get insight into the pressure experienced by children and young people in managing their Diabetes.
OBJECTIVES: To assess the impact of a youth worker in improving outcomes in Children and Young people (CYP) with Type 1 Diabetes Mellitus.

METHODS: The RCPCH annual NPDA 2018–2019 data reported 41% of Children and Young people with Diabetes live in either most deprived or least deprived areas. Researches have shown the Diabetes patients living in deprived areas have poorer short and long-term outcomes the youth worker in the Diabetes MDT team helps to develop the service and supports the MDT team by contributing to the care and understanding of young people. A proposal was submitted and funding was approved to employ a youth worker from the Diabetes Health Inequalities Program. A youth worker was employed at the Warrington and Halton Hospitals Teaching NHS Foundation trust (WHHFT) in June 2021. The role encouraged positive engagement through forming relationships and encouraging Young People to communicate effectively with the Clinical Team. The youth worker engaged CYP in community activities. Young People choose what types of activities they would benefit, or activities will be set from frequent topics spoken about with Young People. The Youth Worker encouraged and supported Young People with High HbA1c and poor Diabetes Management through 1:1 community visits.

RESULTS: In the year, 2021–2022 there were 7 Diabetes related admissions and 2 were DKA compared to 13 admissions in the previous year of which 6 were DKA. 6.7% patents DNAded clinic in year 2021–2022 and in November 2021–March 2022 DNA rate was 4.48%.

Conclusions: Youth worker support improved patient engagement, reduced DNA admissions and reduced HbA1c in select group of patients.

P039 | A self-compassion chatbot (COMPASS) to improve the wellbeing of adolescents with type 1 diabetes: Findings from qualitative research

A. Boggiss1, N. Consedine1, S. Hopkins1, C. Silvester2, C. Jefferies3, P. Hofman2, A. Serlachius1
1University of Auckland, Department of Psychological Medicine, Auckland, New Zealand, 2Proactive Rehabilitation, Tauranga City, New Zealand, 3Liggins Institute, University of Auckland, Auckland, New Zealand

Introduction: Adolescents with Type 1 Diabetes (T1D) experience far greater rates of psychological distress than their peers and consequently an increased risk of suboptimal glycemic control and diabetes complications. Chatbots are an interventional approach which offer unique advantages to deliver psychological support over face-to-face therapies and other digital tools, with 24-h availability, scalability, and the capability to provide personalized responses in real-time. However, the acceptability of a chatbot to deliver self-compassion coping tools for this population remained unknown.

OBJECTIVES: A qualitative focus group study was conducted with adolescents with T1D and their healthcare professionals to examine the acceptability of a novel self-compassion chatbot (COMPASS) for adolescents aged 12 to 16-years-old with T1D.

METHODS: Qualitative Zoom interviews were conducted with 19 adolescents and 11 diabetes team healthcare professionals in March and April 2022 to explore their views on existing wellbeing apps and our newly developed self-compassion chatbot. Transcripts were analyzed using directed content analysis to examine likes and dislikes regarding both current apps and the COMPASS chatbot and what they would want added to a future improved version of COMPASS.

RESULTS: Findings offer an early understanding of what adolescents and their healthcare professionals dislike and also their desired content and feature additions, such as a moderated discussion board to ask and answer questions, a problem-solving feature for blood sugars, integration with diabetes technology, and the ability to personalize chatbot content and features.

Conclusions: Qualitative data suggest that chatbot interventions for this population should include an appropriate peer support element, integrate with diabetes technologies, and include significant elements of personalization to make the chatbot more relevant to their everyday lives. These results are currently informing design and content adaptations ahead of a fully powered RCT.

P040 | Diabetes-related distress for parents and its association to glycemic outcome in adolescents with type 1 diabetes

H.J. Min1, J. Wong2, T. Hoffman3, A. Alkon1, Y. Fukuoka4, J.-l. Chen1
1UC San Francisco, Department of Family Health Care Nursing, San Francisco, United States, 2UC San Francisco, Department of Pediatrics, Division of Endocrinology, San Francisco, United States, 3UC San Francisco, School of Medicine, San Francisco, United States, 4UC San Francisco, Department of Physiological Nursing, San Francisco, United States

Introduction: The current gap in the literature is the lack of best practices in screening for psychosocial factors across the aforementioned four domains.

OBJECTIVES: The purpose of this study is to determine the association of factors in the individual and family domains with glycemic outcomes in adolescents with type 1 diabetes (T1D).

METHODS: In this cross-sectional study, glycemic outcomes were hemoglobin A1c (A1C) and time in range (TIR) from 70-180 mg/dl based on continuous glucose monitoring (CGM) data. Adolescents with T1D and one caregiver were recruited from telehealth visits at a tertiary, multidisciplinary pediatric diabetes center to complete a self-report survey. Factors included diabetes self-management, diabetes technology use, diabetes distress, parenting stress, and family functioning from the individual and family domains. Age, gender, BMI, insurance type, daily insulin dose, insulin regimen, and A1C were collected by medical chart review. CGM data were collected from device software. Univariate and multivariable
regression models were conducted for association with glycemic outcomes (A1C and TIR).

**Results:** A 35 adolescents with T1D and their caregivers participated in this study. The mean (SD) A1C was 8.48% ± 2.6% and the mean (SD) TIR was 60.5% ± 19.5%. Multivariable analysis showed higher parent diabetes-related distress was associated with higher A1C, and family income greater than US $100,000/year was associated with lower A1C. Similarly, multivariable analysis showed higher parent diabetes-related distress was associated with lower TIR, and parent education higher than a bachelor degree was associated with higher TIR.

**Conclusions:** Only the association of variables in the family domain with glycemic outcomes was statistically significant. Future interventions aiming to optimize glycemic control of adolescents with T1D must consider the family domain.

**P042**

**Promotion of successful hybrid closed loop utilization via targeted bolusing behavioral intervention among adolescents with type 1 diabetes (T1D) and their families**

E. Escobar1, H. O'Donnell1, S. Lange1, T. Vigers1,2, A.J. Karami3, C. Berget1, L. Messer1, R.P. Wadwa1, L. Pyle1,2, G.P. Forlenza1

1University of Colorado School of Medicine, Barbara Davis Center for Diabetes, Aurora, United States; 2Colorado School of Public Health, Department of Biostatistics and Informatics, Aurora, United States

**Introduction:** Despite improvements in diabetes technologies, many adolescents with T1D struggle with recommended self-management behaviors contributing to higher A1Cs. User-administered boluses continue to be an important predictor of achieving the target time in range 70–180 mg/dl of ≥70%. Previously, we developed a model to identify which adolescents starting Hybrid Closed Loop (HCL) therapy may need more support to be successful with these new technologies.

**Objectives:** We aim to enroll and randomize 40 adolescents (12–18 years) starting HCL and predicted to have suboptimal use into a pilot behavioral intervention to increase adherence to the recommended user-administered insulin boluses (Figure 1).

**Methods:** The study will utilize a previously validated algorithm to identify adolescents not likely to meet glycemic targets after 12 months using data from the first month of HCL use. Those predicted to have suboptimal use will be randomized 1:1 to either a behavioral intervention or enhanced standard of care. All adolescents will participate in 3 sessions with a trained interventionist over 3 months.

**Results:** The behavioral intervention arm will participate in family-centered problem-solving sessions. The interventionist will work with the adolescent and a caregiver to generate behavioral goals related to bolusing behaviors, brainstorm strategies for working toward the goal, and set a specific plan for how this goal will be achieved with participation from both the adolescent and caregiver. The enhanced standard of care will meet with an interventionist who will provide additional education on the HCL system.

**Conclusions:** Although HCL technologies improve glycemic control, user engagement with devices remains essential for success. This study will provide pilot data on a brief family-centered problem-solving intervention to increase user-administered boluses, which are strongly correlated with glycemic outcomes.

**P043**

**Quality of life and psychological wellbeing among children with diabetes using open-source automated insulin delivery systems: findings from a global survey**


1Institute of Healthcare Ethics, Zidepress, Göttingen, Germany; 2RYA, Aberdeen Royal Infirmary, Aberdeen, Scotland; 3Department of Environmental Health, University of Arizona, Arizona, United States; 4Department of Environmental Health Sciences, Harvard University, Cambridge, United States; 5St. Lukes Children’s Research Institute, Lübeck, Germany; 6Department of Paediatrics, University of Aberdeen, Aberdeen, United Kingdom; 7School of Health Sciences, University of Aberdeen, Aberdeen, United Kingdom

**Introduction:** The use of open-source automated insulin delivery systems (AIDS) has increased, especially among children with diabetes. However, little is known about their impact on quality of life (QoL) and psychological wellbeing (PWB).

**Objectives:** To evaluate the QoL and PWB of children using open-source AIDS and compare them with their peers using non-AIDS.

**Methods:** A cross-sectional study was conducted among children with diabetes using open-source AIDS (n = 50) and those using non-AIDS (n = 100). The QoL was assessed using the Pediatric Diabetes Quality of Life Scale, and the PWB was assessed using the Depression and Anxiety Scale for Children.

**Results:** Children using open-source AIDS had significantly higher QoL and lower anxiety and depression compared to those using non-AIDS.

**Conclusions:** The use of open-source AIDS is associated with better QoL and psychological wellbeing in children with diabetes.

**Figure 1: Bolus Intervention RCT Timeline**

*Projected follow-up data for 40 subjects expected to be available by end of 2022*
Introduction: Open-source automated insulin delivery (AID) systems have shown to be safe and effective in clinical and real-world studies and to increase quality of life (QoL) in adult users. However, there is a lack of evidence on the effect on health-related QoL and general well-being in children and their caregivers.

Objectives: The aim of this study was to assess the QoL of children and adolescents with diabetes using open-source AID systems using validated measures.

Methods: In this cross-sectional, population-based global online survey, we examined the caregiver-reported QoL and psychological well-being of users and non-users of open-source AID. Validated questionnaires assessed general emotional wellbeing (WHO-5 Well-being Index), diabetes-specific QoL (Problem Areas in Diabetes Survey—Parent Revised version (PAID-PR), Pediatric Quality of Life Inventory (PedsQL)), and subjective sleep quality (Pittsburgh Sleep Quality Index [PSQI]).

Results: A 188 caregivers from 27 countries completed at least one questionnaire on behalf of their children, including 132 children with type 1 diabetes using open-source AID (mean age 11.5 [SD 3.5], 48% female) and 56 children with type 1 diabetes who were non-users at the time of the survey (mean age 10.4 [SD 3.3], 41% female). All questionnaire scores showed significant between-group differences with the AID users reporting higher general (WHO-5: p < 0.001), diabetes-related (PAID: p = 0.029; PedsQL: p = 0.016), and sleep-related QoL (PSQI: p < 0.001).

Conclusions: The results show the beneficial impact that open-source AID systems have on the QoL and psychological well-being of children and adolescents, and can therefore help to inform academia, regulatory decision, and policymakers about the potential that open-source AID systems hold. Further research is needed to examine the reasons for the differences between the groups.

Introduction: Diabetic adolescents and young adults (AYAs) face many psychological challenges. Eating disorders are common in this life stage and are of particular concern because of their association with poor metabolic control. Moreover, there is evidence relating drastic fluctuations in glycemic levels to emotional perturbance among diabetic patients. Unfortunately, there is scarce research on eating behavior among diabetic AYAs in Taiwan.

Objectives: This study aimed to investigate the prevalence and correlates of disordered eating/insulin restriction (DE/IR) behavior in diabetic AYAs.

Methods: We enrolled 142 AYAs obtaining a diagnosis of diabetes mellitus (DM) and insulin treatment in a tertiary medical center that received referrals from a catchment area of nearly 3 million residents in southern Taiwan. In addition to various HbA1c measures (e.g., single updated value, yearly mean, SD, coefficient of variation, and HbA1c variability score) indicating glycemic control, we assessed the DE/IR behavior using the modified SCOFF questionnaire and anxious and depressive symptoms using the Hospital Anxiety and Depression Scale (HADS). Multivariate regression analyses were applied to examine the association between DE/IR behavior and clinical and psychosocial factors.

Results: We found that 17.6% restricted insulin use in this cohort and 6.3% self-medicated for weight control. These two behaviors were more prevalent in patients with type 2 DM than those with type 1 DM. In bivariate analysis, the mSCOFF score was correlated with both subscales of HADS. In multivariate analysis, only the SD of the HbA1c values was associated with an mSCOFF score greater than two ($\beta = 3.44$, $95\%$ confidence interval = $1.38$–$8.57$).

Conclusions: DE/IR behavior is not uncommon, particularly among AYAs with type 2 DM, and may be associated with anxiety and depressive symptoms. In addition, HbA1c variability seems to be correlated with DE/IR behavior, and its clinical implication may further need to be explored.

A brief psychological intervention with an emotional health booklet for children and young people newly diagnosed with type 1 diabetes

A. Lose

1LNWH [Ealing] Pediatric Diabetes Team, NHS, London, United Kingdom

Introduction: Being diagnosed with type 1 diabetes brings with it a multitude of tasks and challenges to be overcome by the children and young people diagnosed, as well as their families. It requires adaptations in most aspects of their lives and often can lead to related anxieties and other emotional difficulties.

Objectives: A pediatric diabetes team in England attempted to support the children and their families with the initial stages post-diagnosis using a brief intervention from a psychologist, utilizing an emotional health booklet, designed within the team. The aim of the intervention is to normalize the emotional reactions experienced by many families following diagnosis, to offer space for expression of these feelings, and to provide strategies and tools for coping with the diagnosis and related feelings.
**Methods:** The newly designed emotional health booklet is delivered alongside brief input from a clinical psychologist either during or following the initial outpatient appointment with the multidisciplinary team. This brief intervention will be evaluated using a feedback questionnaire designed for this study, using ideas from Waldron and Hall's (2020) service evaluation of a brief psychology intervention for children newly diagnosed with diabetes. Participants will be asked to complete the feedback questionnaire within 3 months following diagnosis, after obtaining consent. Qualitative aspects of the questions will be summarized into themes, and quantitative data will be presented using descriptive statistics.

**Results:** Last year, 23 patients were seen by the team. It is, therefore, estimated that a similar number will be available to participate this year.

**Conclusions:** It is hoped that participants will find the booklet and brief intervention useful in supporting them with coping with initial challenges of being diagnosed with Type 1 Diabetes, possibly reducing anxiety common for this difficult stage of a diabetes journey. Study findings will be used to improve the intervention and future evaluations of the project.

**POSTER TOUR 6—DIGITAL DIABETES & TELEMEDICINE**

**P046 | Are virtual appointments still wanted in the post lockdown era? A follow-up survey of patient and caregiver views on virtual pediatric diabetes clinic appointments**

L. Wade1, P. Bamal1, V. Alexopoulou1, E. Clarke1, M. Deakin1, F. Mehta1, P. Paul1, A. Ghatak1

1Alder Hey Children’s NHS Foundation Trust, Liverpool, United Kingdom

Introduction: COVID-19 brought about a rapid change in the way diabetic follow up services were run in our local pediatric unit. Appointments were initially made via telephone with the introduction of video clinics a short time later. A survey of caregiver and patient views of virtual clinics in 2020 showed high satisfaction scores with these appointments. Face-to-face (FtF) appointments have restarted but virtual appointments have continued to run alongside.

**Objectives:** A repeat survey in 2022 aimed to re-assess families’ experience of virtual clinics and their views on the use of virtual clinics as part of their long-term follow-up.

**Methods:** Two surveys were carried out between June to July 2020 and March to April 2022. Caregivers were selected at random from the patient list and contacted by telephone. An oral survey was completed with responses collated on a Microsoft form.

**Results:** A 100 responses were collected in both surveys. This covered a range of patient ages and treatment modalities. Satisfaction with virtual appointments remained high with a rating of 4.6 and 4.59 out of 5 respectively for the 2020 and 2022 survey. Virtual appointments requests as part of follow-up increased from 51% to 77%, with video preferred to telephone (65% vs. 12%). Pump and CGM data downloading pre-clinic dropped from 66% to 56%.

**Conclusions:** The majority of patients and caregivers found virtual clinic appointments a positive experience and are keen to see them continue even though COVID-19 restrictions have lifted. This will have significant impact and potentially substantial savings in the way follow-up services are designed. Digital poverty (access to devices/IT knowledge) remains a barrier to some patients accessing virtual appointments. Patient/carer preference and individual circumstances must be taken into account when redesigning follow-up services.

<table>
<thead>
<tr>
<th>Key comparison points between 2020 and 2022 patient surveys:</th>
<th>June/July 2020</th>
<th>March/April 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. responses</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>Average age patient (in years)</td>
<td>Mean 12.23</td>
<td>Mean 12.16</td>
</tr>
<tr>
<td></td>
<td>Median 12</td>
<td>Median 13</td>
</tr>
<tr>
<td></td>
<td>Range 1-19</td>
<td>Range 3-18</td>
</tr>
<tr>
<td>Type of appointment participated in during the last 6 months:</td>
<td>Video 8%</td>
<td>Video 63%</td>
</tr>
<tr>
<td></td>
<td>Telephone 92%</td>
<td>Telephone 10%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Both 26% Face to Face 1%</td>
</tr>
<tr>
<td>Percentage of responders who had experience in downloading data prior to clinic:</td>
<td>69%</td>
<td>59%</td>
</tr>
<tr>
<td>Percentage of responders who downloaded the patient's data prior to clinic:</td>
<td>66%</td>
<td>56%</td>
</tr>
<tr>
<td>Appointments that were attended by the patient – either alone or in addition to parent:</td>
<td>84%</td>
<td>90%</td>
</tr>
<tr>
<td>Overall satisfaction score with virtual appointments (1 being poor, 5 being good):</td>
<td>4.6 out of 5</td>
<td>4.59 out of 5</td>
</tr>
<tr>
<td>Parent/patient preference on whether they would like access to virtual appts as part of ongoing follow-up?</td>
<td>Yes 51%, No 26%</td>
<td>Unsure 23% Yes 77%: - Telephone 12% - Video 65% No - FtF only 23%</td>
</tr>
</tbody>
</table>

**POSTER TOUR 6—DIGITAL DIABETES & TELEMEDICINE**
The ENDORSE feasibility pre-pilot trial: Assessing an innovative integrated platform, implementing serious games strategy and artificial intelligence-based telemedicine for glycemic control improvement

I.-A. Vasilakis1, I. Kosteria2, G. Papavasileiou1, K. Zarkogianni2, L. Kalafatis2, K. Mitis3, M. Athanasioú2, K. Perakis3, A. Taliou4, N. Nicolaides1, V. Chioti1, I. Tokou1, D. Vergeti1, D. Antonopoulou4, E. Papachristou4, V. Melkis2, K. Nikita2, C. Kanaka-Gantenbein1
1Diabetes Center, Division of Endocrinology, Diabetes and Metabolism, First Department of Pediatrics, National and Kapodistrian University Athens, Medical School, “Aghia Sophia” Children’s Hospital, Athens, Greece, 2National Technical University of Athens, School of Electrical and Computer Engineering, Athens, Greece, 3UBITECH, Research and Development Department, Chalandri, Greece, 4Inspiring Earth, PEGNEON, Athens, Greece

Introduction: Following the trend of digital health applications, implemented especially during the COVID-19 pandemic, the “ENDORSE” project, is designed as an innovative integrated platform for supporting clinical decision making and telemedicine in children with Type 1 Diabetes Mellitus (T1DM), utilizing explainable artificial intelligence along with gamification and mobile technologies.

Objectives: Assessment of preliminary data from the pre-pilot phase of the ENDORSE feasibility trial.

Methods: ENDORSE platform utilizes various data sources such as glucose sensors (Flash Glucose Monitoring-FGM), smart insulin pen caps, activity trackers, mobile apps, Electronic Health Records and a newly developed serious game. A 13 T1DM children and adolescents (8 females, on multiple daily injections, mean diabetes duration 2.57 years, mean HbA1c 7.6%, mean Body Mass Index +1.2 SDs, mean monitoring days: 151), followed in our Diabetes Center, were assessed regarding adherence to the study protocol. They all had internet access and only one had used a diabetes mobile application before.

Results: As shown in Table 1, most of the patients used the “Smart Insulin Pen Cap” to document insulin and food data and many performed mobile FGM scanning, while the engagement to the ENDORSE serious game, aiming at training in self-management, along with the activity trackers is highly variable.

Conclusions: ENDORSE platform along with changes in daily diabetes care practices like CGM usage, is expected to improve diabetes management through facilitating training, monitoring and feedback to the patients and their caregivers. In order to further improve its adherence and acceptance, factors such as the level of digital literacy and the need of a personalized experience to improve usability, should be also taken into consideration.

Acknowledgements: Supported within the framework of the ENDORSE project, which is funded by the NSRF (Grant agreement: T1EΔK-03695).

Table 1: Patients’ adherence to the ENDORSE clinical protocol

<table>
<thead>
<tr>
<th>ENDORSE device/application</th>
<th>Mean (%days) ± SD; (Max, Min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activity trackers</td>
<td>32.00% ± 32.37% (0.00%, 99.06%)</td>
</tr>
<tr>
<td>Serious game</td>
<td>9.00% ± 7.80% (0.00%, 23.58%)</td>
</tr>
<tr>
<td>Mobile phone FGM scanning</td>
<td>43% ± 38% (0.00%, 100.00%)</td>
</tr>
<tr>
<td>“Smart” insulin pen cap</td>
<td>54% ± 40.87% (3.87%, 100.00%)</td>
</tr>
</tbody>
</table>

WhatsApp for diabetes self-management education (DSME) in type 1 diabetes mellitus (T1DM): randomized controlled trial

P. Gupta1, V. Ganakumar1, V. Vyas2, M. Mittal1, M.K. Garg2, R. Shukla1
1All India Institute of Medical Sciences, Department of Endocrinology & Metabolism, Jodhpur, India, 2All India Institute of Medical Sciences, Department of Pediatrics, Jodhpur, India

Introduction: WhatsApp is a free-to-use mobile application used for personal communication but there is no data on its use in DSME of T1DM patients.

Objectives: Single-center RCT to study the effect of WhatsApp based DSME on glycemic status (HbA1c), knowledge, quality of life (QOL) & coping skills of T1DM patients at 16 & 28 weeks.

Methods: A 56 T1DM patients (15-40 years) with WhatsApp were randomized into two groups: “Intervention” (n = 28) who received weekly educational WhatsApp messages & “Sham” (n = 28) who received weekly greeting messages. Patients without access to WhatsApp formed “Control” group (n = 10). HbA1c, Diabetes Knowledge Test (DKT), Diabetes Quality of life (DQOL) & Coping with disease (CODI) questionnaires were administered at baseline, 16 & 28 weeks.

Results: As shown in Table 1, most of the patients used the “Smart Insulin Pen Cap” to document insulin and food data and many performed mobile FGM scanning, while the engagement to the ENDORSE serious game, aiming at training in self-management, along with the activity trackers is highly variable.

Conclusions: ENDORSE platform along with changes in daily diabetes care practices like CGM usage, is expected to improve diabetes management through facilitating training, monitoring and feedback to the patients and their caregivers. In order to further improve its adherence and acceptance, factors such as the level of digital literacy and the need of a personalized experience to improve usability, should be also taken into consideration.

Acknowledgements: Supported within the framework of the ENDORSE project, which is funded by the NSRF (Grant agreement: T1EΔK-03695).

Table 1: Patients’ adherence to the ENDORSE clinical protocol

<table>
<thead>
<tr>
<th>ENDORSE device/application</th>
<th>Mean (%days) ± SD; (Max, Min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Activity trackers</td>
<td>32.00% ± 32.37% (0.00%, 99.06%)</td>
</tr>
<tr>
<td>Serious game</td>
<td>9.00% ± 7.80% (0.00%, 23.58%)</td>
</tr>
<tr>
<td>Mobile phone FGM scanning</td>
<td>43% ± 38% (0.00%, 100.00%)</td>
</tr>
<tr>
<td>“Smart” insulin pen cap</td>
<td>54% ± 40.87% (3.87%, 100.00%)</td>
</tr>
</tbody>
</table>

Results:
- The mean baseline HbA1c was 10.69 ± 2.74%. At 28 weeks, there was significant reduction in HbA1c in WhatsApp trial group but not in Sham WhatsApp group (P = 0.003).
- There was no significant difference in QOL & coping skills in Intervention versus Sham WhatsApp group.
P049 | The IDEAL (ISPAE diabetes education and learning) virtual pediatric diabetes educator training model is affordable and accessible in limited-resource settings. Can it be sustainable and replicable?

P. Singh1, S. Salis2, S.K. Boddu3, S. Bhattacharyya4, S. Olety5, A. Irani6, R. Kumar7, G. Jevalikar8, A. Virmani9

1Lady Hardinge Medical College, Pediatrics, New Delhi, India, 2Nurture Health Solutions, Nutrition, Mumbai, India, 3Rainbow Children’s Hospital and Perinatal Care, Pediatric Endocrinology, Hyderabad, India, 4Manipal Hospital, Pediatric Endocrinology, Bangalore, India, 5Karnataka Institute of Endocrinology and Research, Pediatric Endocrinology, Bangalore, India, 6Nanavati Max Super Speciality Hospital, Pediatrics, Mumbai, India, 7Postgraduate Institute of Medical Education and Research, Pediatric Endocrinology, Mumbai, India, 8Max Hospital, Pediatric Endocrinology, Delhi, India, 9Max Hospital, Saket and Rainbow Hospital, Malaviya Nagar, Pediatric Endocrinology, Delhi, India

Introduction: Structured diabetes education (DE) is vital to manage pediatric diabetes (PD) but educators are scarce in developing countries. Due to familiarity with virtual teaching in the COVID pandemic, a virtual PDE course was planned for India.

Objectives: Evaluate outcomes of a virtual PDE course in a limited-resource (LR) setting.

Methods: A 9-member ISPAE (Indian Society for Pediatric & Adolescent Endocrinology) committee, with 47 experienced volunteer faculty planned a 12-week comprehensive curriculum (delivered in English, fee INR 5000 = US$65) basic & advanced skills: diagnosis, pathophysiology, insulin, SMBG, CGMS, CSI, MNT, exercise, psychology, toddlers, adolescents, type 1 & 2, other special situations: 17 teaching & 5 feedback sessions, exit exam; practical assignments for each session.

Results: Trainees working with T1D selected from across India: semi-urban were preferred. Lengthy course with 90%–95% attendance (highly motivated) possible as no leave, travel, or stay costs needed. Easier for women to join. Significant rise in post-test scores that is, knowledge improved. Certification was based on stringent criteria. Other advantages: intense interaction, personal commitment, continued networking, and awareness of resources. Challenges: widely varied resource, language, and social settings: language barriers, limited resources, variable baseline knowledge.

Conclusions: The IDEAL PDE training model being virtual & intensive is an affordable & accessible alternative to a physical program in LR settings. We hope to make it high quality, sustainable, and replicable.

<table>
<thead>
<tr>
<th>Total applicants (n = 102)/ selected</th>
<th>Batch 1 52/24</th>
<th>Batch 2 50/30</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nurse/ dietician/ DE (n)</td>
<td>3/4/17</td>
<td>6/6/18</td>
</tr>
<tr>
<td>Female</td>
<td>79%</td>
<td>93%</td>
</tr>
<tr>
<td>Self or parent T1D</td>
<td>17%</td>
<td>17%</td>
</tr>
<tr>
<td>Working in metro city</td>
<td>84%</td>
<td>73%</td>
</tr>
<tr>
<td>Mean attendance % (SD)</td>
<td>90 (9.9)</td>
<td>95.5 (5.9)</td>
</tr>
<tr>
<td>Mean pre-test score % (SD)</td>
<td>67.3 (8.2)</td>
<td>64.1 (9.3)</td>
</tr>
<tr>
<td>Mean post-test score % (SD)</td>
<td>78.5 (8.3)</td>
<td>74.8 (9.4)</td>
</tr>
<tr>
<td>p value (Pre/Post)</td>
<td>&lt; 0.001</td>
<td>0.002</td>
</tr>
<tr>
<td>Eligible for exam</td>
<td>21 (87.5%)</td>
<td>27 (90%)</td>
</tr>
<tr>
<td>Mean exam score % (SD)</td>
<td>75.2 (7.4)</td>
<td>71.7 (9.4)</td>
</tr>
<tr>
<td>Certified %</td>
<td>83.3</td>
<td>76.7</td>
</tr>
</tbody>
</table>

a 80% attendance + completed assignments.
Model of remote medical control in the management of type 1 diabetes mellitus in children using systems of continuous glucose monitoring

A. Klaev1,2, I. Promin3, M. Slovak2, E. Astashova2, K. Vyantzlovaite2
1Ural Medical University, Yekaterinburg, Russian Federation, 2Regional Children’s Clinical Hospital, Yekaterinburg, Russian Federation

Introduction: The widespread introduction into clinical practice of preferential provision of children with DM1 with CGMS against the background of insufficient assessment by parents of the dynamics of glycaemia and timely correction of insulin therapy predetermined the creation of a model of remote medical control in the management of DM1.


Methods: As of April 1, 2022, 54% (910 out of 1683) of children with DM1 living in the Sverdlovsk region are provided with «Freestyle Libre» sensors. 95% (868 out of 910) of children are connected to the account of the Regional Center for Pediatric Endocrinology of the «LibreView» platform. In a weekly mode, signal parameters are uploaded and analyzed, selecting by us: TAR > 17.0 mmol/L; TBR < 3.0 mmol/L; TIR: 3.9–10.0 mmol/L; % sensor activity. At TAR/TBR >10% during the last 2 weeks, the patient is informed of the risk of developing acute complications and parents are offered emergency telemedicine consultation or visit to doctor.

Results: For 4 months since the introduction of the model, 76 emergency consultations were held for children at high risk of developing DKA and 28 for children at risk for developing severe hypoglycemia. None of these patients developed any emergency conditions.

Conclusions: Further optimization of the signal parameters and the analytics mode within the framework of the developed model of remote medical control will improve the efficiency of DM1 management in children, prevent the development of acute complications, and reduce the number of emergency hospitalizations.

“ANA WA SOUKARI” application: A revolutionary approach of self-management in type 1 diabetes

I. Rami1, N. Derkaoui1, S. Benyakhlef1, O. El Mehraoui1, S. Rouf2, H. Latrech2
1Mohammed VI University Hospital, Medical School, Mohammed the First University, Endocrinology-Diabetology-Nutrition, Oujda, Morocco, 2Regional Children’s Clinical Hospital, Yekaterinburg, Russian Federation

Introduction: The management of type 1 diabetes (T1D) especially during childhood and adolescence is a challenge, not only for health professionals but also for the patients themselves. Thus, the free access to mobile technology has changed the vision of the basic therapeutic education process and enhanced diabetes self-management. Therefore, our medical team developed «ANA WA SOUKARI» as a newly designed Moroccan smartphone application for therapeutic education and insulin doses management for type 1 diabetes.

Objectives: Describe the effectiveness of «ANA WA SOUKARI» application in management and glycemic control of (T1D) in children and adolescents.

Methods: “ANA wa soukari” is a smartphone application designed and developed by a team led by the medical staff of our Endocrinology Diabetes department of university hospital center Oujda-Morocco. Our medical team had elaborate the medical content of therapeutic education that suits T1DM patients of all ages, particularly children and adolescents. The work was supported by the valuable help of both communication and computer technology departments. The application can be used on all android devices including tablets.

Results: We included in the study 32 patients using the application, among them, a number of 26 cases of children and adolescents, aged between 3 years and 18 years with a mean age of 11.5 ± 4.4 years, sex ratio H/F was 1.8. Mean HBA1c level initial was 8, 5% ± 2.3%.

Hypoglycemic episodes was noted in 12 patients between 2 and 10 episodes/week. At 3 months’ follow-up, the mean HBA1c level dropped to 7, 6% ± 1.6%. And, hypoglycemic episodes decreased to a mean of 1.5 episodes/week.

Conclusions: Our study sheds the light on the impact of this revolutionary technological approach and artificial Intelligence applications in enhancing the basic education and facilitating diabetes self-management, which can be considered as an adjuvant intervention to the standard diabetes care.

Preparing for risk-based management of type 1 diabetes (T1D): Integrating biomarkers of performing diabetes self-management habits into a population health dashboard

C. Vandervelden1, B. Lockee1, S. Carrothers1, S.R. Patton2, R. McDonough1, J.M. Lee3,4, M. Clements1
1Children’s Mercy Hospital, Endocrinology, Kansas City, United States, 2Nemours Children’s Health, Center for Healthcare Delivery Science, Jacksonville, United States, 3University of Michigan, Pediatric Endocrinology, Ann Arbor, United States, 4University of Michigan, Susan B. Meister Child Health Evaluation and Research Center (CHEAR), Ann Arbor, United States

Introduction: Recent publication of the six pediatric type 1 diabetes (T1D) self-management habits [J. M. Lee et al., JAMA Netw Open. 2021; 4(10)], aka “the 6 habits”, offers a new evidence-based measure for a population health dashboard.

Objectives: To create an interactive population health management tool that displays data related to “the 6 habits” for providers, and to propose new habits, which align with the seven pillars of diabetes self-management.

Methods: Diabetes device data and electronic medical records for 4293 youth ages 1–26 with T1D from a pediatric diabetes care
network in the Midwest USA were imported into a novel Microsoft Azure-based data warehouse developed by our team (the “D-Data Dock”). We designed population health dashboards in Power BI to display performance of “the 6 habits” plus a 7th habit (“consumes a healthy diet”) by youth and their relationship to HbA1c% and time in range (TIR). Providers can examine habit performance in the population by various demographics (race, age, insurance class, etc.), and at the individual patient level in real-time through electronic health record interface.

**Results:** Provider documentation of habit performance and habit performance by individual varied significantly by habit (Figure 1a). Higher habit scores (the total number of habits performed) were associated with stepwise improvements in both HbA1c% and TIR (1b and 1c). Performance of a 7th (healthy eating) habit was associated with further reduction in HbA1c% (1b). We prototyped a dashboard displaying changes to an individual’s habit score and HbA1c% longitudinally (1d).

**Conclusions:** We have validated “the 6 habits” as a composite biomarker of engagement in T1D self-management and identified a 7th habit that associates with glycemic control. Future research should examine whether tracking these habits can aid providers when selecting interventions to improve glycemic control among youth.

**P054 | Comparing points in target range assessed by blood glucose monitoring (BGM) using a vacuum-based lancing device and a conventional lancing device**

J. Kesavadev, G. Beena Chandran, G. Krishnan, A. Basanth, A. Shankar, S. Jothydev

**Introduction:** Blood glucose monitoring (BGM) using the fingertip prick method has always been a tool to monitor blood glucose, but the pain associated has been an impediment to the process.

**Objectives:** We compared the points in range (PIR) in people with type 1 diabetes (T1D) using Genteel, a commercially available lancer that applies vacuum after lancing and a non-vacuum conventional
Glucose monitoring techniques

B. Saboo1, M. Saiyed1, M. Pancholi1
1Diacare-Diabetes Care and Hormone Clinic, Ahmedabad, India

Introduction: Flash glucose monitoring device provides glucose reading for 14 consecutive days by measuring reading every 15 min. Above that wearing, a flash glucose-monitoring device with a smart reader gives an opportunity to look at the BG at any time of the day.

Methods: Age: above 15 years, willingness to wear the device. Exclusion: Individuals with a history of frequent hypoglycemia, with complications. AGP was applied to 22 no. of individuals for 14 days. Their reading was scanned on the 3rd, 5th, 7th, and 14th day at the clinic. On the other hand, 9 individuals wore AGP with a smart reader, and they were getting their BG into their mobile phones.

Results:

Conclusions: AGP with a smart reader helps to achieve HbA1c target more accurately as it tracks the glucose reading constantly and gives the chance to the individual to act promptly.

<table>
<thead>
<tr>
<th>Avg. time in target (%)</th>
<th>Avg. time below target (%)</th>
<th>Avg. time above target (%)</th>
<th>Average HbA1c</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGP</td>
<td>47</td>
<td>11.6</td>
<td>31.7</td>
</tr>
<tr>
<td>AGP with a smart reader</td>
<td>61</td>
<td>12</td>
<td>2</td>
</tr>
</tbody>
</table>
P057  |  Returning to fun: Reflections on activity reengagement from youth and parents after T1D diagnosis

N.D. Smith1, K. Howard2, K. Garza2, J. Weissberg-Benchell1, M. Feldman1
1Johns Hopkins All Children’s Hospital, St. Petersburg, United States, 2Lurie Children’s Hospital, Chicago, United States

**Introduction:** Youth and their caregivers navigate many challenges following a T1D diagnosis, including how to safely return to activities.

**Objectives:** This study explored reflections of youth and parents as they reengage in extracurricular activities during the first-year post diagnosis.

**Methods:** A series of focus groups were completed via videoconferencing to examine families’ experiences during the first-year post diagnosis. Participants were 1 to 3 years post T1D diagnosis and included youth (8–12 years old; n = 10), teens (13 and above; n = 11), and parents of children (8–12 years old; n = 15) and teens (13 and above n = 12). Transcript analysis was conducted using deductive coding and thematic analysis.

**Results:** Parents and youth emphasized the importance of taking steps to prepare for diabetes management prior to returning to activities and that any activity can be completed as long as time is devoted to diabetes tasks prior to and during participation. Parents and teens both reported that keeping a “diabetes supply go bag” eases return to activities. Youth emphasized the importance of recognizing that parents also experience a learning curve, and that working together can ease initial difficulties. Youth normalized worries about low glucose levels negatively impacting activity participation. With regard to sports, youth and parents identified the benefits of ensuring coaches possess knowledge of diabetes. Parents recommended discussing potential challenges when integrating diabetes into sports, such as missing playtime while treating low glucose levels. Youth highlighted the importance of recognizing physiological symptoms of low glucose to ensure appropriate diabetes management during activities, and of sharing diagnosis with teammates.

**Conclusions:** Parent and youth perspectives emphasize that returning to extracurricular activities post diagnosis requires preparation, communication, and teamwork. Findings may inform approaches to education and clinical care.

P058  |  Development of the diabetes health management and distress scale-parents of children

V. Jewell1, J. Shin2, M. Russell2, S. Fellman2, A. Thompson2, E. Pyatak4
1University of North Carolina, Occupational Therapy, Chapel Hill, United States, 2Creighton University, Omaha, United States, 3Creighton University, Rapid City, United States, 4University of Southern California, Los Angeles, United States

**Introduction:** The importance of parental psychosocial well-being, coping and adaptation skills, and competence and confidence with diabetes health management tasks is critical to lower the risks of diabetes distress for both parents and children and improve long-term health outcomes for the children living with type 1 diabetes. It is imperative that healthcare professional have an increased understanding of parents’ diabetes distress and health management routines for their children with T1D to provide quality care. Therefore, the development and testing of novel assessments are critical.

**Objectives:** The aim of this project was to complete psychometric testing of a novel occupational therapy diabetes-specific assessment, which will in turn provide key information that can further prepare occupational therapy practitioners to develop and implement novel occupational therapy interventions aimed to improve child health outcomes, health management, and family quality of life.

**Methods:** Utilizing a nonexperimental, methodological design, two phases of assessment development and testing were completed. Stakeholders (n = 27) provided feedback on the content validity, ecological validity, and response format through a focus group, individual interview, or written comments. All interviews were transcribed verbatim and coded with the written comments. Researchers integrated feedback into the assessment using an iterative process.

**Results:** Assessment revisions improved the overall format and validity. Overall, stakeholders reported good content validity, preferred response format, and ecological validity, for the Diabetes Health Management and Distress Scale-Parents of Children.

**Conclusions:** Accurate evaluation of the effectiveness of novel interventions is imperative to advance the provision of diabetes care. Therefore, the development and testing of this novel occupational therapy diabetes assessment is critical to the advancement of healthcare practices and improved child health outcomes.

P059  |  Diabetes in institutional settings: A qualitative study of needs, worries and experiences

D. Grabowski1, K. Kristensen2, M. Madsen2, L. Skov Høst3, A. Korsholm Mouritsen5, M. Sørensen Iken6, L. Bro Johansen1, KIDS Study Group
1Steno Diabetes Center Copenhagen, Health Promotion Research, Herlev, Denmark, 2Steno Diabetes Center Aarhus, Aarhus, Denmark, 3Steno Diabetes Center Nordjylland, Aalborg, Denmark, 4Steno Diabetes Center Odense, Odense, Denmark, 5Steno Diabetes Center Zealand, Holbæk, Denmark, 6Danish Diabetes Association, Research, Glostrup, Denmark

**Introduction:** Children spend a large part of their daily life in institutional settings (daycare, kindergarten, and primary school). Children with T1D need special attention and extra resources in these settings and this is often a source of constant worry and frustration for the child, the institutions, and the parents.

**Objectives:** It is the objective of this current project is to study how these needs; worries and frustrations are experienced and dealt with from the point of view of the municipal authorities responsible for granting and administrating support and resources.
Methods: We reached out to all 98 municipalities in Denmark, asking if we could interview a person with knowledge about municipal diabetes support in relation to daycare, kindergarten, and primary school. A 74 municipalities agreed to participate in semi-structured online interviews. The interviews were analyzed and interpreted using thematic analysis and radical hermeneutics.

Results: The analysis revealed two main overarching themes:

(1) The institutional staff feel insecure about diabetes management and this is a significant barrier for supplying diabetes care in institutions. The staff members basically feel overwhelmed when dealing with children with diabetes, which results in challenges in relation to taking responsibility for giving the necessary support to the children and their families.

(2) The parents are seen as the most important resource for the municipal and institutional staff members. Parents are expected to be available at any time if there are any questions regarding diabetes management and they often end up adopting a role as mediators between the institution, hospital, and other municipal staff members.

Conclusions: Children with T1D in institutional settings is an area with complex challenges regarding tasks, roles, and responsibilities. Further research is needed to produce guidelines for the how to balance mutual involvement and responsibilities.

P060 | Coachable or uncoachable? A qualitative study of a life-coaching intervention for young adults with diabetes


1University Hospital of Southern Denmark, Kolding, 2Department of Pediatrics and Adolescent Medicine, Kolding, Denmark, 3University of Southern Denmark, Department of Clinical Research, Odense, Denmark, 4University Hospital South West Jutland, Department of Endocrinology, Esbjerg, Denmark, 5Odense University Hospital, Center for Research in Patient Communication, Odense, Denmark

Introduction: Young adults living with diabetes are especially challenged. They are in a transitional stage of life, which often involves emotional, social, and developmental challenges, consequently, diabetes self-management can be increasingly difficult in these patients.

Life coaching can be a way to cope with challenges in life, however, a review of existing research shows a lack of knowledge of the influence of life coaching on health and well-being.

Objectives: We aimed to study the experience of life coaching in young adults living with poorly regulated type 1 diabetes.

Methods: We applied a qualitative study design to explore the experiences of the patients. We used the methods described by Steiner and Kuval to conduct individual interviews with patients. Furthermore, focus group interviews with the coaches were conducted to supplement to the patients’ experiences. Data were analyzed through meaning condensation.

Results: Three main themes were uncovered.

(1) Talking about life to cope with the disease
(2) Successful coaching processes, and
(3) Unsuccessful coaching processes, revealing that talking about troubling life issues empowered them to take responsibility and action regarding the diabetes. A successful coaching process depended on a good relationship between coach and patient. Patient motivation for self-reflection was essential.

Conclusions: Life-coaching can be a way to manage life with diabetes. It is important to adjust the coaching methods and communication to the patients’ preferences and their ability to self-reflection to facilitate a successful coaching experience. Based on our findings we suggest that no one is actually uncoachable. With coaching approaches tailored to the individual patient and coaches capable of establishing a confident and trusting relationship all young people with diabetes can benefit from being coached.

P061 | A diabetic girl mystery: A case report

S. Raafat1, D. Fawzy1, Y. Abdelmeguid3

1Alexandria Faculty of Medicine, Department of Pediatrics, Alexandria, Egypt

Introduction: Diabetic patients with cerebral disorders have been demonstrated at an electrophysiological, structural, and cognitive level. However, the pathogenesis is still not clear.

Objectives: Episodes of hypoglycemia and poor metabolic control may be some of the factors affecting the cerebral function. Moreover, peripheral neuropathy is a common long-term complication of diabetes. However, there is a growing appreciation to the presence of peripheral neuropathy with the onset of diabetes or even in the prediabetes. Besides, Peripheral neuropathy is one of a long list of the causes of cachexia. Thus, diabetic neuropathic cachexia is rarely reported in diabetic patients. It is a diagnosis of exclusion that may improve by non-specific treatment besides a good glycemic control.

Methods: We herein report a girl diagnosed with diabetes and associated peripheral neuropathy and cachexia.

Results: An 8 years old girl with a rare presentation of newly diagnosed diabetes associated with cerebral dysfunction, peripheral neuropathy and cachexia was admitted in Alexandria University Children Hospital. The girl was diagnosed with diabetes 1 month before referral to the hospital. During this period, she developed abnormal behavior, disorientation, and progressive rapid weight loss. Malignancy, infectious, endocrinological (thyroid) or gastrointestinal disorders were excluded. Brain imaging and nerve conduction concluded that there was cerebral dysfunction besides peripheral neuropathy.

Conclusions: Peripheral neuropathy and cerebral dysfunction are not always late complications of diabetes. Although rare, they may be acute complications or even associations with diabetes in pediatric population. Moreover, diabetic neuropathic cachexia is a diagnosis of exclusion needing high index of suspicion.
 Mothers’ study satisfaction correlates with study visit compliance: The TEDDY study

J. Melin\(^1\), K. Lynch\(^2\), H. Elding Larsson\(^3\), S. Bennett Johnson\(^3\), TEDDY Study Group
\(^1\)Lund University, Department of Clinical Sciences Malmö, Malmö, Sweden, \(^2\)University of South Florida, Health Informatics Institute, Tampa, United States, \(^3\)Florida State University College of Medicine, Department of Behavioral Sciences and Social Medicine, Tallahassee, United States

**Introduction:** Compliance with a study protocol is central to meeting its research goals.

**Objectives:** The aim of this study was to examine mothers’ study satisfaction in relation to her child’s study visit compliance in The Environmental Determinants of Diabetes in the Young (TEDDY).

**Methods:** Children with high genetic risk for type 1 diabetes (T1D) are followed quarterly from birth and semiannually thereafter in four different countries (US, Finland, Germany, and Sweden) as part of the TEDDY study. Mothers of children who had participated in TEDDY from 3 months to 4 years of age were included (n = 5023). Demographics, lifestyle variables, study related variables, maternal depression, and maternal reactions to the child’s T1D risk were collected at child-age 15 month by questionnaire. Multiple linear regression was used to examine maternal study satisfaction in relation to the number of attended visits, with adjustment for other significant covariates.

**Results:** Over 5000 children remained in the TEDDY study at 4 years of age; of these, 2716 (54%) children had completed all 16 scheduled study visits. Higher maternal study satisfaction was associated with a greater number of completed study visits independent of other predictors of visit compliance including: country of residence (highest participation in Sweden, p < 0.001), maternal age (older age, greater compliance, p < 0.001), the TEDDY child is the mother’s first child (greater compliance, p < 0.001), maternal smoking (poorer compliance p < 0.001), and participating through a long distance protocol (poorer compliance, p < 0.001).

**Conclusions:** Greater maternal study satisfaction correlated positively with study visit compliance. These findings suggest that greater attention to mothers’ study satisfaction may be an important way to improve study visit compliance in longitudinal pediatric studies.

**P063 | Depressive and anxiety symptoms among adolescents with diabetes in Hong Kong**

I. Poon\(^1\), C. Chan\(^2\), C. Poon\(^2\), S. Lee\(^1\), G. Pang\(^1\), J.Y.-l. Tung\(^1\)
\(^1\)Hong Kong Children’s Hospital, Endocrine Division, Department of Pediatrics and Adolescent Medicine, Hong Kong, Hong Kong, SAR of China, \(^2\)Integrated Rehabilitation Center, Hong Kong, Hong Kong, SAR of China

**Introduction:** Screening on mental health comorbidities has been recommended in adolescents with diabetes. There is a paucity of data on mental health comorbidities among adolescents with diabetes in Hong Kong.

**Objectives:** This study aimed to.
(a) assess the prevalence of adolescents with diabetes with depressive and anxiety symptoms, using two well-validated screening questionnaires; and
(b) to explore correlates of such symptoms.

**Methods:** This is a retrospective study. As part of the routine clinical workflow, patients aged > / = 10 years were invited to fill out the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder 7-item Scale (GAD-7) to identify depressive and anxiety symptoms respectively. Patients who (a) attended the Diabetes Clinic at the Hong Kong Children’s Hospital and (b) completed the two questionnaires between December 2020 and March 2022 were included in this study. Correlates of their depressive and anxiety symptoms were explored.

**Results:** A 98 patients were included (male: 39, female: 59). A 82 had type 1 and 16 had type 2 diabetes. The median age was 15.0 years, and their median duration of diabetes was 4.6 years. Their median HbA1c was 7.5%. A 35 (35.7%) scored > 4 in PHQ-9 (mild depressive symptoms: 27, moderate: 3, severe: 5) and 26 (26.5%) scored > 4 in GAD-7 (mild anxiety symptoms: 18, moderate: 6, severe: 2). PHQ-9 score was significantly correlated with GAD-7 score (p < 0.0001; Spearman’s correlation coefficient = 0.7900). Both depressive symptoms (p = 0.0347) and anxiety symptoms (p = 0.0129) were associated with female gender, but not age, HbA1c, diabetes types nor duration of diabetes.

**Conclusions:** A significant proportion of adolescents with diabetes were screened to have at least mild depressive and anxiety symptoms, with female gender being a risk factor. Mental health comorbidities among adolescents with diabetes are common and should be underscored. Early detection by routine screening is highly recommended.

**P064 | Early detection of disordered eating (DE) among adolescents with type 1 diabetes (T1D): Preliminary development of a holistic screening tool combining clinical, technology and self-report items**

A. Cristello Sarteau\(^1\), D. Igudesman\(^1\), T. Smith\(^2\), M. Hart\(^3\), B. King\(^2\), C. Smart\(^2\), E. Mayer-Davis\(^1,4\)
\(^1\)University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, United States, \(^2\)John Hunter Children’s Hospital, Newcastle, Australia, \(^3\)University of Newcastle, Nutrition and Dietetics, Newcastle, Australia, \(^4\)University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, United States
**Introduction:** Current DE screening practices among adolescents with T1D miss opportunities for early intervention and extant tools risk incidental learning.

**Objectives:** To facilitate objective and early DE detection, our ongoing research seeks to develop a tool with clinician assessed (including from T1D technologies), parent, and adolescent items that is brief enough for consistent use, highly sensitive and minimally suggestive.

**Methods:** Extant literature and tools, pilot work, and clinical expertise drove initial definition of the tool construct, dimensions and items. We conducted surveys and interviews among T1D and DE clinicians (n = 12) to evaluate content validity and identify additional dimensions or items. Item clarity was also preliminarily assessed by clinicians (n = 10), adolescents (n = 7) and parents (n = 6). We used a rapid analysis of interviews followed by a triangulation protocol to systematically integrate quantitative and qualitative results along with scale development guidelines to refine the tool.

**Results:** Findings support a multi-dimensional construct (Binge Eating; Dysglycemia; Exercise; Insulin Reduction and Omission; Nutritional Status; Restrictive Eating; Social Behavior; Weight, Body Size and Shape Concern), initially reflected by 44 items. Items perceived highly relevant for detecting early-stage DE were: social eating avoidance; carbohydrate restriction; distracted, irritable, withdrawn mood; internalization of parent/peer body ideals; insulin omission and restriction; meal skipping; and in boys, exercise preoccupation. Change in items over time and parent input were deemed key for early detection.

**Conclusions:** Preliminary analyzes support administration at regular intervals of a tool combining novel self-report and technology-facilitated clinical items to detect early-stage DE in adolescents with T1D. Next steps include cognitive testing, preliminary construct validity, and quantitative item evaluation to reduce and improve items before further field tests.

**POSTER TOUR 8—ACUTE COMPLICATIONS**

**P065 | Six months in advanced hybrid closed loop system in the real world: Psychosocial outcomes in children and adolescents with type 1 diabetes**

A. Jalilova1, B. Şentürk Pilan2, G. Demir2, B. Özbaran2, S.G. Köse2, S. Özen1, Ş. Darcan1, D. Gökşen1

1Ege University Faculty of Medicine, Department of Pediatric Endocrinology, Bornova, Turkey, 2Ege University Faculty of Medicine, Department of Child and Adolescent Psychiatry, Bornova, Turkey

**Introduction:** Advanced hybrid closed-loop systems (a-HCLS) only automate some aspects of diabetes care, psychosocial and human factors remain an important consideration in their use.

**Objectives:** We examined psychosocial and human factors of a-HCLS.

**Methods:** Patients with type1 diabetes (T1D) (8-18 years) and the parents starting on a-HCLS were enrolled. Prospective data collection occurred during routine clinical care and included Pediatric Quality of Life InventoryTM (PedsQL) diabetes module; Strengths and Difficulties Questionnaire (SDQ); Hypoglycemia FearSurvey (HFS) for Children, The Revised Child Anxiety Depression Scale (R-CADS) and a-HCLS specific expectation and satisfaction survey. Surveys were completed before initiation of the a-HCLS and on 6th month. Patients were evaluated to exclude psychiatric disorders.

**Results:** Out of 55 subjects enrolled, 37(67%) completed 6th month follow-up. 40 of the patients refused to fill 6th month survey and were excluded. 13 boys and 20 girls with a mean age of 12.7 ± 3.3 years (8-18 years), and diabetes duration of 6.6 ± 5.0 years completed the questionnaires. None of the children were on psychotropic medications at the time of the evaluation. TIR (70-180 mg/dl) increased from 75.6% ± 13% at baseline to 78.5% ± 7%. There was no significant difference between baseline and 6th month data in both child and parent PedsQL and SDQ. Significant differences were observed in the parents at 6 month, they reported increased positive affect at follow-up inSDQ of Conduct problems and Prosocial behavior (p = 0.012; p = 0.011 respectively). All scores on the HFS, RCADS, and a-HCLS specific expectation and satisfaction survey were in the normal range.

**Conclusions:** To our knowledge, this is the first study to compares the psychological characteristics of T1D patients starting on a-HCLS. Although these technologies provide patients with more flexibility in their daily life and information about glucose fluctuations the use of the a-HCLS in our practice resulted in aTIR above the recommended target without a change in QOL, HFS, SDQ, and anxiety of children.
was assessed by four parameters: pH, bicarbonate levels, onset of oral intake and initiation of subcutaneous insulin. The outcome of DKA was assessed by three parameters: length of hospital stay, length of PICU stay and manifestation of complications during treatment.

Results: Out of 1969 patients admitted in PICU during the last 16 years, only 2.5% of them (N = 49) concerned DKA cases (mean age 8.5 ± 4.3, 49% boys). The prevalence of DKA in new-onset T1DM patients admitted to PICU was 84%. The recorded complications were thrombophlebitis (4%), renal impairment (2%), cerebral edema, and death (2%). Patients at the diagnosis of T1DM had more severe acidosis with pH < 7.1 (p < 0.01). Initial fluid bolus was not related to the severity of acidosis or outcome. Younger patients newly diagnosed with T1DM and adolescents with known T1DM were more likely to have higher Pediatric Risk of Mortality Score (PRISM) but this severity correlation was not statistically significant. Admission pH < 7.1 was associated with delayed pH > 7.3 (p = 0.007) and bicarbonate levels >15 mmol/L (p = 0.001) restoration and subcutaneous insulin or oral feeding initiation (p < 0.01). DKA severity and younger age were positively associated with PICU and hospital LOS (p < 0.001).

Conclusions: Severity of DKA is associated with younger age, time of acidosis restoration and LOS. The rate of complications in PICU is low.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Current Age (years)</th>
<th>T1D Onset (years)</th>
<th>Duration of TID at Reaction Onset</th>
<th>Presenting Symptoms</th>
<th>Hypersensitivity Reaction Type</th>
<th>Current Management</th>
<th>Total Daily Insulin Dose (units/kg/day)</th>
<th>Most Recent A1c</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>16</td>
<td>4</td>
<td>Within days of diagnosis</td>
<td>- Anaphylaxis, with respiratory distress - Generalized urticaria</td>
<td>- Type I with anaphylaxis - Type IV, possibly due to polysorbate 20</td>
<td>- 3.8 years s/p pancreas transplant - Tacrolimus - Everolimus - Prednisone</td>
<td>Not currently requiring insulin therapy</td>
<td>5.3%</td>
</tr>
<tr>
<td>B</td>
<td>14</td>
<td>7</td>
<td>2 years</td>
<td>- Bruising - Erythema - Leg pain</td>
<td>- Type III</td>
<td>- Subcutaneous insulin injections Lispro, Detemir - Methotrexate - IVIG - Rituximab</td>
<td>2.26</td>
<td>9.5%</td>
</tr>
<tr>
<td>C</td>
<td>6</td>
<td>1.2</td>
<td>1.8 years</td>
<td>- Eczematous, erythematous plaques</td>
<td>- Type IV, possibly due to acrylate</td>
<td>- Aspart via insulin pump - Methotrexate</td>
<td>0.64</td>
<td>7.8%</td>
</tr>
<tr>
<td>D</td>
<td>13</td>
<td>2</td>
<td>6 years</td>
<td>- Erythematous, firm, tender nodules</td>
<td>Type III vs. IV</td>
<td>- Aspart via insulin pump (site changes every 36-48 hours)</td>
<td>1.7</td>
<td>9.0%</td>
</tr>
</tbody>
</table>

Introduction: Immediate, type I IgE, and delayed, type III and IV, insulin hypersensitivity reactions are rare but serious complications of type 1 diabetes (T1D) treatments. Type I reactions are often to insulin itself, while type IV are from additives such as protamine and cresols. Diagnostic testing, including skin prick, patch, biopsy, and insulin IgG and IgE antibodies are often inconclusive.

Objectives: We present four cases of insulin hypersensitivity, ages 6–16 years.

Methods: -

Results: Patient A had anaphylaxis to glargine days after T1D diagnosis, then generalized urticaria to detemir and glulisine. Polysorbate 20 was a suspected trigger; urticaria persisted with lispro. After failing various insulins via pump, antihistamines, steroids, and immunosuppressants, she became the youngest pancreas transplant recipient at age 12. She remains euglycemic off insulin 3.8 years later. Patient B reacted to lispro at initial pump start. Aspart and glargine injections led to type III reactions, with bruising and pain. She is now on lispro and detemir (2.26 units/kg/day), methotrexate, IV immune globulin, and rituximab. Reactions persist, and A1c is 9.5%.
Patient C reacted to lispro, then had erythematous, eczematous plaques to all insulins. Methotrexate improved A1c from 8.3% to 7.8%; however, plaques persist on pump (0.64 u/kg/day). Patient D tolerated glulisine for 6 years but developed erythematous, firm, tender nodules on aspart. He failed cyclosporine, dapsone, and IVIG. He is on 1.7 u/kg/day of aspart via pump. A1c is 9.0%. Testing for autoimmune lymphoproliferative syndrome is pending.

Conclusions: In summary, insulin hypersensitivity is rare; however, given insulin’s life-sustaining nature, it is crucial to learn from these cases. Although several tolerated IV insulin desensitization, reactions persisted on injections. Treatment remains elusive despite various insulins, antihistamines, and even pancreas transplantation. Further studies to elucidate this are needed.

P068  |  Risk factors for cerebral edema in 256 children with diabetic ketoacidosis

N. Yaneva1
1Medical University of Sofia, Bulgaria, University Children’s Hospital - Sofia, Department of Diabetes, Clinic of Endocrinology, Diabetes and Clinical Genetics, Sofia, Bulgaria

Introduction: Cerebral edema (CE) is one of the most devastating complications of diabetic ketoacidosis (DKA). It is the main cause for mortality and residual morbidity in children with DKA. Although many risk factors of both diabetic ketoacidosis and its treatment have been identified during the last 70 years, the causes and pathogenesis of this life-threatening complication have not been clearly defined yet.

Objectives: To study the risk factors for cerebral edema in children with diabetic ketoacidosis.

Methods: A retrospective review of 256 children, aged from 8 months to 18 years, hospitalized for DKA at the University Pediatric Hospital, Sofia was performed. The demographic characteristics, biochemical variables, and therapeutic interventions were compared between the patients with and without cerebral edema.

Results: Cerebral edema was observed in 22 (8.6%) of the 256 subjects studied. One of the patients (5%) had died and 2 (9%) had survived with permanent neurological consequences. Cerebral edema was significantly associated with severe DKA: lower initial pH (pH ≤ 7.0) and lower initial bicarbonate (<4 mmol/L), higher initial blood glucose, higher urea level and higher serum osmolality. Low serum phosphate level during the treatment of DKA was found significantly associated with CE. We also found dependence between the development of cerebral edema and the bicarbonate application, the higher fluid volume infused during the first 4 h and the delayed potassium substitution – after the 4 h (p = 0.003).

Conclusions: Severe ketoacidosis, hyperglycemia, and dehydration at presentation, as well as low serum phosphate during treatment (<0.6 mmol/L) are significantly related to cerebral edema development in children with DKA. The initial severe acidosis and hyperglycemia probably cause brain injury that progresses to cerebral edema in the course of developing hypophosphatemia and iatrogenic cerebral hypervolemia.

<table>
<thead>
<tr>
<th>Baseline variable</th>
<th>Children without cerebral edema</th>
<th>Children with cerebral edema</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Venous pH</td>
<td>234</td>
<td>22</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Bicarbonate (mmol/L)</td>
<td>231</td>
<td>21</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Blood glucose (mmol/L)</td>
<td>232</td>
<td>22</td>
<td>0.003</td>
</tr>
<tr>
<td>Serum urea (mmol/L)</td>
<td>135</td>
<td>13</td>
<td>0.036</td>
</tr>
<tr>
<td>Serum osmolality (mOsm/kg)</td>
<td>134</td>
<td>13</td>
<td>0.036</td>
</tr>
<tr>
<td>Volumes of fluid, infused during the first 4 h (ml/kg)</td>
<td>229</td>
<td>20</td>
<td>0.005</td>
</tr>
<tr>
<td>Time of initiation of potassium substitution (h)</td>
<td>231</td>
<td>22</td>
<td>0.003</td>
</tr>
<tr>
<td>Serum phosphate at 10th–12th during treatment (mmol/L)</td>
<td>48</td>
<td>8</td>
<td>0.027</td>
</tr>
</tbody>
</table>
The risk of developing acute kidney injury in diabetic children with diabetic ketoacidosis: An experience from a resource-limited setting

S. Musa1,2, G. Fadilbari3, S. Hassan2, O. Al-Hassan4, M. Ali2, A. Hagahmed2, M. Mohamed4, M. Abdullah6,2
1Faculty of Medicine, Al-Neelain University, Department of Pediatrics and Child Health, Khartoum, Sudan, 2Gaafar Ibn Auf Pediatric Tertiary Hospital, Department of Pediatric Endocrinology and Diabetes, Khartoum, Sudan, 3Sidra Medicine, Pediatric Endocrinology Department, Doha, Qatar, 4Sudan Childhood Diabetes Center, Pediatric Endocrinology and Diabetes, Khartoum, Sudan, 5Braah Children Hospital, Pediatric, Khartoum, Sudan, 6Faculty of Medicine, University of Khartoum, Department of Pediatrics, Khartoum, Sudan

Introduction: Acute kidney injury (AKI) is a known complication of diabetic ketoacidosis (DKA). There are few studies on the frequency and risk factors of developing AKI in hospitalized children with DKA.

Objective: This study aimed to report the frequency, risk factors clinical, and biochemical features of children who develop AKI as a complication of DKA.

Methods: Medical records of all hospitalized patients under 18 years of age with diabetic DKA admitted to Gaafar Ibn Auf (GIA) Hospital from 2006 to 2021 were reviewed. Those with AKI were identified and furtherly classified according to the Kidney Disease/Improving Global Outcome (KDIGO) criteria comparing their serum creatinine levels during the hospital stay to the calculated estimated baseline creatinine (EBC) as the previous creatinine was not known. Data related to demographics, indicators of glycemic control, physical and laboratory findings and the outcome were collected and represented as appropriate.

Results: Out of 317 admissions with DKA, 62 (19.6%) patients fulfilled the clinical and biochemical criteria for this study, of whom 63% were known diabetics. According to KDIGO criteria, half of them (50%) were classified as Stage 1, 15 (24%), Stage 2, and 16 (26%), Stage 3.

Male to female ratio was 1:1.4 and the majority of patients (42%) were between 6–12 years of age. Infection was the most common precipitating factor in 55% of patients and most of them (61%) had clinical features of severe DKA at presentation. Recovery to conservative management was noted in 87% of patients while 13% underwent dialysis, out of which 87.5% required more than 2 sessions of dialysis and 25% deceased.

Conclusions: Management of AKI in patients with DKA can be very challenging in resource-limited countries. The severity of DKA and associated Infection are considered the major risk factors for developing AKI. To the best of our knowledge, this is the first study of it is kind in African countries.
**Objectives:** Our aim was to assess children with DKA for prevalence, short-term kidney outcomes, severity, and predictors of AKI development and resolution.

**Methods:** This retrospective cohort study included children aged 2–14 years admitted with DKA between January 2016 and May 2020 in a Saudi tertiary care hospital. We defined AKI as an increase in serum creatinine of >1.5 times baseline or >3 mg/dl (26 mmol/L) within 48 h.

**Results:** Of 213 patients admitted with DKA, 172 (80.75%) developed AKI: stage 1 in 83 (38.96%), stage 2 in 86 (40.37%), and stage 3 in 3 (1.4%). No patient required dialysis. Multivariate analysis showed an increased risk of developing AKI with male gender (OR = 2.85) and lower serum bicarbonate (OR = 0.83) when adjusted for initial heart rate, hemocrit, new onset diabetes, and recurrent AKI. The mean time to AKI resolution was 13.21 ± 6.78 h. Factors leading to prolonged recovery from AKI in linear regression analysis were older age (B coefficient = 0.44, p = 0.01), recurrent DKA episodes (B coefficient = 3.70, p value 0.003), increased acidosis severity (B coefficient = −0.44, p = 0.04), increased time to anion gap normalization (B coefficient = 0.44, p = 0.019), and increased initial glucose (B coefficient = 0.01, p = 0.011).

**Conclusions:** In our cohort, AKI was a common, but mostly transient complication in children presenting with DKA, and its severity is associated with longer intensive care stays and time for acidosis resolution. AKI was associated with male gender, and lower serum bicarbonate. Proper consideration of such risk factors is needed for AKI assessment and management in future DKA clinical practice guidelines.

**ABSTRACTS**

**P073 | Acute complications of patients with combined diabetic ketoacidosis and hyperosmolar hyperglycemic state in type 2 and type 1 diabetes**

**J. Lee1, M. Kim1, C.K. Cheon1**

1Pusan National University Children’s Hospital, Pediatrics, Yangsan-si, Korea, Republic of

**Introduction:** Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are life-threatening emergencies of diabetes. The implications of combined DKA/HHS in children are not yet well known.

**Objectives:** We investigated the clinical outcomes of adolescents with combined DKA/HHS.

**Methods:** Combined DKA/HHS was defined based on blood glucose ≥600 mg/dl, effective serum Osm ≥320 mOsm/kg, pH ≤7.3, ketonuria, and/or ketonemia.

**Results:** A 13 years-old girl (Case1) presented with altered mental status. Her BMI was 26.97. Initial serum glucose was 1956 mg/dl and urine ketone was negative. Her effective serum osmolality was 333 mOsm/kg. VBGA was pH 6.77 and HCO3 10.1 mmol/L. She was admitted to the ICU due to thrombocytopenia-associated multiple organ failure (TAMOF), rhabdomyolysis, and coma status. On hospital day 3, she had compartment syndrome resulting in left leg redness and edema. On hospital day 10, she showed massive hematochezia (3171 g). Ligation of arteries and ileostomy for prevention of bleeding was done due to multiple deep ulcerative lesions around the rectum. She was diagnosed with type 2 diabetes and required 75 days of hospital stay and 66 days of rehabilitation therapy. A 11 years-old girl (Case2) presented with mental status. Her BMI was 17.9. Initial serum glucose was 1115 mg/dl and urine ketone was negative. Her effective serum osmolality was 333 mOsm/kg. VBGA was pH 6.77 and HCO3 5 mmol/L. She had a hypovolemic shock and respiratory failure. She was admitted to ICU due to TAMOF, rhabdomyolysis, and semi-comal status. On hospital day 12, she had ischemic optic neuropathy. On hospital day 12, sudden weight loss (−6 kg) occurred due to diabetic amyotrophy resulting in severe left leg pain. On hospital day 30, brain MR revealed multifocal microbleeds. Finally, she was diagnosed with type 1 diabetes and required 100 days of hospital stay and 90 days of rehabilitation therapy.

**Conclusions:** Combined DKA-HHS can accompany acute complications and is associated with longer hospital stays and poor outcomes.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age and Sex</td>
<td>9 Year Female</td>
<td>7 year Male</td>
<td>10-year male</td>
</tr>
<tr>
<td>Years of type 1 diagnosis</td>
<td>One year</td>
<td>Four</td>
<td>Four</td>
</tr>
<tr>
<td>HBA1c</td>
<td>16.2%</td>
<td>9%</td>
<td>17.2%</td>
</tr>
<tr>
<td>Diabetes Ketoacidosis</td>
<td>Severe</td>
<td>Severe</td>
<td>Severe</td>
</tr>
<tr>
<td>Rhino sinusoidal involvement</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>CNS involvement</td>
<td>Yes, Right eye involvement, multiple brain abscesses, Cavernous sinus and carotid artery thrombosis</td>
<td>Yes Left eye involvement, multiple brain abscesses, Cavernous sinus and carotid artery thrombosis and hydrocephalus</td>
<td>No</td>
</tr>
<tr>
<td>Treatment received</td>
<td>Sinus debridement, Antifungal Liposomal Amphotericin B for 6 weeks. Went LAMA</td>
<td>Sinus debridement, Antifungal Liposomal Amphotericin B for 6 weeks. VP shunt, left eyeball removal</td>
<td>Patient had pulmonary. Underwent left lower lobectomy. Received antifungal for 6 weeks</td>
</tr>
<tr>
<td>Outcome</td>
<td>Alive with limited mobility</td>
<td>Alive on nasogastric feeds awaiting reconstruction</td>
<td>Alive and doing well</td>
</tr>
</tbody>
</table>

| CNS involvement                                | Sinus debridement, Antifungal Liposomal Amphotericin B for 6 weeks. Went LAMA | Sinus debridement, Antifungal Liposomal Amphotericin B for 6 weeks. VP shunt, left eyeball removal | Patient had pulmonary. Underwent left lower lobectomy. Received antifungal for 6 weeks |
|Treatment received                              | Alive with limited mobility    | Alive on nasogastric feeds awaiting reconstruction | Alive and doing well |
P074 | Disseminated mucormycosis in poorly controlled type 1 diabetes: A series of three patients

J. Yadav¹, D. Dayal¹, R. Kumar¹, A. Yadav¹, P. Mahasweta Nanda¹, A. George¹
¹Post Graduate Institute of Medical Education and Research, Pediatric Endocrinology Unit, Department of Pediatrics, Chandigarh, India

Introduction: Mucormycosis is an Angio invasive and fatal fungal infection which affects immunocompromised host such as poorly controlled type 1 diabetes. Early diagnosis based on clinical clues and biopsy findings is highly recommended to prevent mortality and morbidity for this debilitating infection.

Objectives: To describe the clinical profile, risk factors and outcome of three patients with invasive mucor infection with multisystem involvement.

Methods: The clinical details were obtained from the hospital records. All three patients were admitted in our hospital for clinical care.

Results: Two boys and girls with poorly controlled diabetes presented with Rhin sinusoidal Mucormycosis. Two patients had central nervous system invasion and third patient had pulmonary involvement. The details are presented in table.

Conclusions: Invasive Mucor mycosis is a severe infection, which require prolonged hospitalization, surgical debridement and prolonged antifungal therapy. Early identification and prompt medical and surgical treatment improves outcome.

P075 | New-onset DKA complicated by hypertriglyceridemia and acute pancreatitis, case report

M. Mustafa², M. Saleh²
²Al Jalila Children’s Hospital, Pediatric Endocrinology, Dubai, United Arab Emirates

Introduction: DKA is one of the most common diagnoses in the Pediatric Intensive Care Unit. Non-fatal complications of DKA such as hypertriglyceridemia and pancreatitis are very rare.

Objectives: We present a 9-year-old female with new-onset DKA who developed acute pancreatitis and hypertriglyceridemia within 24 h after admission and resolved on follow up.

Methods: A previously healthy, non-obese, 9-year-old female presented with breathing difficulty and abdominal pain. In the emergency department, she was found to have DKA (serum glucose 499 mg/dL, urine glucose >1000 mg/dL, urine ketone 3+, capillary PH 6.85, bicarbonate undetectable). She was in severe dehydration and received two IV fluid boluses (10 mL/kg). She was admitted to PICU and started on DKA management protocol.

Her initial blood sample was “too thick and milky”. Her initial serum triglyceride level was 988 mg/dL, total cholesterol 115 mg/dL, amylase 239 unit/L (28–100) and lipase 1982 unit/L (13–60). Abdominal ultrasound was consistent with acute pancreatitis.

Approximately 12–36 h after admission, her mental status, and appetite improved along with the downward trend of serum TG (604 mg/dL), lipase (273 unit/L), and amylase 173 unit/L. A 48 h after admission, she started on oral feeds and subcutaneous insulin and shifted to the pediatric ward.

Results: Acute pancreatitis in DKA can be attributed to severe hypertriglyceridemia if the serum TG level is >1000 mg/dL. The insulin deficiency in type I diabetes mellitus causes hypertriglyceridemia as it decreases the activity of lipoprotein lipase. The triad of DKA, hypertriglyceridemia, and acute pancreatitis have been well described in adult literature but rarely in the pediatric population.

Conclusions: The recognition of acute pancreatitis in DKA has important implications in the management as insulin requirements and the tempo of recovery can be altered. Lipemic blood can be a clue to hypertriglyceridemia as a cause of acute pancreatitis and resultant worsening of DKA despite standard insulin therapy.

P077 | The evaluation of bone metabolic status in patients with childhood-onset type 1 diabetes mellitus in Kuwait

D. Alhomaiah¹, T. Alqaisi¹, F. Alajmi², A. Al-Tararwa², D. Mohammed², H. Al Kandari²
¹Dasman Diabetes Institute, Kuwait City, Kuwait, ²Farwaniya Hospital, Kuwait City, Kuwait

Introduction: Type 1 diabetes (T1D) and its complications may significantly impact skeletal and bone health which could lead to bone disease later in life.

Objectives: The aim of this study is to assess the bone metabolic profile and renal function of patients diagnosed with T1D in Kuwait.

Methods: This is the pilot phase of a cross-sectional study including Kuwaiti subjects diagnosed with T1D onset between 2011 and 2021 registered in the Childhood-Onset Diabetes electronic Registry (CODer) and receiving care at Farwaniya Hospital. Eligible subjects and/or their parents completed a questionnaire regarding demographics and diabetes history. Subject clinical assessment and laboratory investigations were carried out after consent was given. Descriptive statistical analysis was performed.

Results: A total of 37 patients with T1D were enrolled in the study (median age 11.0 [IQR 8–15] years and 41% males). Nine (24%) subjects had a diabetes duration of less than 1 year, 17 (46%) between 1 and 5 years, and 11 (30%) more than 5 years. Insulin was administered by multiple daily injections in most patients (n = 35, 94.6%) while only 2 (5.4%) used continuous subcutaneous insulin infusion. Family history of T1D and history of osteoporosis were found in 7 (19.4%) and 8 (22.2%) of the patients, respectively. A 10 patients (27%) showed low levels of alkaline phosphatase and 25 (71%) had levels of 25(OH)D below 50 nmol/L. Majority of the patients had normal levels of albumin, phosphorus, and magnesium (88.9%, 89.2%,...
Nearly half of the patients showed high calcium levels ($n = 17$, 46%) and high adjusted calcium levels ($n = 22$, 61%). Mean values of parathyroid hormone and urine calcium/creatinine ratio were $6.0 \pm 2.9$ pmol/L and $0.28 \pm 0.2$, respectively.

**Conclusions:** In patients with T1D, a balanced diet and regular physical activity is necessary to maintain bone health. Consistent screening for deficiencies in calcium, vitamin D, and other indicators may allow patients with T1D to avoid complications related to metabolic bone disease.

**P078 | Cognitive function in early-onset type 1 diabetes mellitus in children**

K. Swaminathan$^1$, J. Yadav$^1$, D. Dayal$^1$, P. Malhi$^2$

$^1$Postgraduate Institute of Medical Education and Research, Pediatric Endocrinology, Chandigarh, India, $^2$Postgraduate Institute of Medical Education and Research, Child Psychology, Chandigarh, India

**Introduction:** Early-onset type 1 diabetes mellitus (T1DM) is associated with cognitive dysfunction but scarcely studied in the developing world.

**Objectives:**
1. Assessment and comparison of cognition scores in various domains in early-onset T1DM and healthy controls.
2. To study the association of T1DM associated factors with cognition.

**Methods:** This was a case–control study involving 60 children with T1DM (age 6–15 years) who had disease onset at less than 6 years and a minimum disease duration of 2 years. The neurocognitive assessment was done using MISIC (Malin’s Intelligence Scale For Indian Children) tool and compared with age and sex-matched healthy controls ($n = 60$). The effects of disease-associated factors like glycemic control, DKA episodes, and severe hypoglycemia episodes on cognition were also studied.

**Results:** The T1DM group had lower score in verbal tests ($p = 0.01$), performance tests ($p = 0.01$) and overall IQ ($0.01$) than controls. Among the various cognitive domains, processing speed and attention were same in both groups. Early age of onset, poor glycemic control, DKA episodes and severe hypoglycemia episodes had negative effect on overall IQ.

**Conclusions:** Children with T1DM had lower IQ affecting multiple cognitive domains. Early age of onset, poor glycemic control, DKA episodes, and severe hypoglycemia had negative effects on cognitive functions.

**P079 | Association of dyslipidemia and type 1 diabetes mellitus among children up to 16 years of age presenting in low middle income country**

V. Rai$^1$, S. Akhtar$^2$, Z. Khoso$^1$, M. Riaz$^1$, S. Chachar$^1$, M.N. Ibrahim$^1$, P.J. Raza$^1$

$^1$National Institute of Child Health, Pediatric Endocrinology and Diabetes, Karachi, Pakistan, $^2$National Institute of Child Health, Karachi, Pakistan

**Introduction:** Children with type 1 diabetes mellitus (T1DM) are at an increased risk of developing subclinical & clinical cardiovascular disease early in life.$^{1-3}$ When diabetes is controlled in children over the age of 10 years, the Global ISPAD Guideline for Childhood & Adolescence diabetes of 2014 advised screening for fasting blood lipids. There are several international studies, which demonstrate association between dyslipidemia and T1DM. The present study is designed in order to ascertain the local perspective as there is scarcity of local data.

**Objectives:** To determine the association of dyslipidemia and type 1 diabetes mellitus among children up to 16 years of age.

**Methods:** Study design: Case–control study.

Study setting: Outpatient department, National Institute of Child Health (NICH).

Duration of study: A 6 months from 26 February 2018 to 28th August 2018.

Material and methods: All patients age 9 to 16 years of either gender were included. Cases were defined as presence of fasting plasma

<table>
<thead>
<tr>
<th>Test</th>
<th>Cases$^a$</th>
<th>Controls$^a$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Information$^b$</td>
<td>100.32 ± 4.717</td>
<td>103.67 ± 2.433</td>
</tr>
<tr>
<td>Comprehension$^b$</td>
<td>100.27 ± 3.896</td>
<td>103.88 ± 2.552</td>
</tr>
<tr>
<td>Arithmetic$^b$</td>
<td>99.67 ± 5.885</td>
<td>103.58 ± 3.766</td>
</tr>
<tr>
<td>Vocabulary$^b$</td>
<td>98.95 ± 5.010</td>
<td>102.62 ± 2.912</td>
</tr>
<tr>
<td>Digit span$^b$</td>
<td>99.05 ± 5.879</td>
<td>102.32 ± 3.291</td>
</tr>
<tr>
<td>Picture completion$^b$</td>
<td>102.82 ± 5.087</td>
<td>105.45 ± 1.917</td>
</tr>
<tr>
<td>Mazes</td>
<td>104.93 ± 5.285</td>
<td>105.95 ± 2.789</td>
</tr>
<tr>
<td>Block design$^b$</td>
<td>100.20 ± 4.793</td>
<td>103.13 ± 2.397</td>
</tr>
<tr>
<td>Coding</td>
<td>102.87 ± 3.908</td>
<td>103.32 ± 2.855</td>
</tr>
</tbody>
</table>

$^a$ Mann–Whitney U test was used.

$^b$ p value < 0.05.
A child with poorly controlled type 1 diabetes mellitus (T1DM) presented with hepatic glycogenosis

M. Saleh1, L. Al Marzooqi2, M. Mustafa2
1Al Jallali Hospital, Dubai, United Arab Emirates, 2Al Jallali Hospital, Pediatric Endocrinology, Dubai, United Arab Emirates

Introduction: Hepatic glycogenosis is the liver response to poor blood glucose control in children, adolescents, and adults with type 1 diabetes, it is a rare complication in children.

Objectives: We report 12 years old boy with poorly controlled with hepatomegaly presented with hepatomegaly as a possible consequence of glycogenic hepatopathy, to raise attention of physicians to such complication.

Methods: Clinical case: A 12 years old boy a known case of diabetes mellitus diagnosed 1 year previous to his presentation to the emergency department complaining of abdominal pain for 1 day associated with abdominal bulging. His Growth percentiles based below third centile for the weight and on the 20th centile for the height. There was a hepatomegaly of 8 cm below the costal margin.

Results: The laboratory investigations revealed a very high HbA1C of 15.0. Other parameters such as blood hemoglobin level, C-reactive protein, ESR, Liver function test, coagulation factors, urea and electrolytes, on the other and liver enzymes were elevated, other infectious causes of liver enlargement, were ruled out. Ultrasound abdomen was done for further evaluation and was reported as: Enlarged liver, measuring 17.9 cm showing coarse parenchyma, with no sizeable focal mass lesion. His liver enzyme reduced within 1 week with regular insulin injection. Liver size regressed to normal size with his HbA1C reaching 8.6%.

Conclusions: Although rare complication, of poorly glycemic control of type 1 Diabetes mellitus in children, hepatic glycogenosis, it should not be misdiagnosed and for the prompt and early management of these patients.

P0801 | Risk factors for pre-clinical atherosclerosis in youth with type 1 diabetes: The contribution of oxidative stress, oxidized lipoproteins and glycemic variability

A. Morandi1, C. Piona2, M. Morradi1, C. Zusi1, S. Costantini1, M. Marigliano1, C. Fava2, C. Maffei3
1University and Azienda Ospedaliera Universitaria Integrata di Verona, Department of Surgery, Dentistry, Pediatrics and Gynecology, Section of Pediatric Diabetes and Metabolism, Verona, Italy, 2University and Azienda Ospedaliera Universitaria Integrata di Verona, Section of General Medicine C, Department of Medicine, Verona, Italy

Introduction: The inter-individual variance in pre-clinical markers of vascular damage/atherosclerosis in youth with T1D is only partially explained by traditional risk factors (RFs).

Objectives: To test the hypothesis that, besides HbA1C and other traditional RFs, overall oxidative stress, oxidized lipoproteins and glycemic variability may contribute to explain part of the risk of early macro-vascular damage.

Methods: Circulating markers of oxidative stress (derivatives of reactive oxygen metabolites [d-ROMs]), serum total antioxidant capacity [TAC] and oxidized LDL [oxLDL], markers of early vascular damage/atherosclerosis [Carotid intima-media thickness [cIMT], pulse wave velocity [PWV], Lipoprotein-associated phospholipase A2 [Lp-PLA2]], CGM metrics of 4-weeks preceding the visit, current and past HbA1C, blood pressure (BP) and lipids values longitudinally measured since T1D onset were evaluated in 267 children/adolescents with T1D (130 girls, age 9.1–23.0 years). To investigate the predictors of early vascular damage three general linear models were built (Lp-PLA2, z-cIMT, z-PWV as independent variables).

Results: Results of univariate analysis are shown in table 1. Z-cIMT, z-PWV, and Lp-PLA2 were not predicted by any CGM metrics. Multivariate analysis of variance showed that z-cIMT was predicted by male gender (B = 0.491, h² = 0.029, p = 0.005), cSBP (B = 0.023, h² = 0.026, p = 0.008) and LDLox (B = 0.022, h² = 0.022, p = 0.014), z-PWV was predicted by follow-up duration (B = 0.054, h² = 0.024, p = 0.016), dROMs (B = 0.003, h² = 0.037, p = 0.004), daily insulin dose (B = 0.523, h² = 0.018, p = 0.045) and follow-up mean z-SBP (B = 0.180, h² = 0.018, p = 0.037). Lp-PLA2 was predicted by age (B = 0.221, h² = 0.079, p = 3 × 10⁻⁴), TAC (B = -1.06, h² = 0.015, p = 0.045), oxLDL (B = 0.081, h² = 0.050, p = 2 × 10⁻⁴), follow-up mean LDL-cholesterol (B = 0.031, h² = 0.043, p = 0.001) and male gender (B = -1.62, h² = 0.10, p = 1.3 × 10⁻⁷).

Conclusions: Oxidative stress and red-ox balance contributed to the inter-individual variability of early vascular damage in young patients with T1D, independently of traditional RFs.
**The relationship between selected inflammation and oxidative stress biomarkers of cardiovascular disease and IMT value in youths with diabetes type 1 co-existing with early microvascular complications**

B. Głowinska-Olszewska, J. Peczyńska, B. Klonowska, B. Żelazowska-Rutkowska, A. Bossowski

1 Medical University of Białystok, Department of Pediatric, Endocrinology, Diabetology with Cardiology Division, Białystok, Poland, 2 University of Warmia and Mazury in Olsztyn, Department of Clinical Pediatrics, Faculty of Medical Sciences, Olsztyn, Poland, 3 Medical University of Białystok, Department of Pediatric Laboratory Diagnostics, Białystok, Poland

**Introduction:** Recent years have confirmed the importance of oxidative stress and inflammation biomarkers in estimating the risk and explaining not fully understood pathogenesis of cardiovascular disease (CVD). In Type 1 diabetic patients (T1D), vascular complications develop extremely early, resulting in reduced life expectancy.

**Objectives:** We aimed to assess intima-media thickness (cIMT) of common carotid arteries and the occurrence of classical atherosclerosis risk factors together with selected new biomarkers (hsCRP, adiponectin, myeloperoxidase [MPO], NT-proBNP peptide, vitamin D) in youths with T1D, recognized in screening tests to present early stages of microvascular complications (VC).

**Methods:** The study included 50 adolescents and young adults with T1D, aged mean 17.1 years, including 20 T1D patients with VC (+), and 30 T1D without complications, VC (−). A 20 volunteers formed control group (C).

**Results:** In the group with T1D VC (+) higher BMI was found: 23.07 ± 4 vs. 21.28 ± 2.9 in T1D VC (−) group and 19.65 ± 2.4 kg/m² in group C (p = 0.002). HbA1c was higher in group T1D VC (+): 9.8% compared to T1D VC (−): 8.6% (p < 0.001). Lipids and blood pressure values were highest in VC (+) group. MPO level was higher and vitamin D lower in both diabetic groups vs C. Significantly higher concentration of hsCRP, NT-proBNP were observed in T1D VC (+) in comparison to T1D VC (−) and the controls. IMT in the T1D VC (+) group was 0.50 mm and was significantly higher than in T1D VC (−) group (0.46 mm), and in controls: 0.41 mm (p < 0.001). IMT correlated significantly positively with HbA1c, hsCRP, NT-pro-BNP, and negatively with vitamin D level.

**Conclusions:** Youths with T1D coexisting with microvascular complications present many abnormalities in classical of cardiovascular risk factors and new CVD biomarkers. The most important for estimating the risk of future macroangiopathy seem hsCRP and MPO. NT-proBNP may present a possible new marker of early myocardial injury in this population.
**Introduction:** Diabetic nephropathy has become the most frequent cause of end-stage renal failure and dialysis management in most countries. This chronic complication is more frequent in type 1 diabetic patients.

**Objectives:** The aim of this study was to screen for diabetic nephropathy in children and adolescents with type 1 diabetes.

**Methods:** This was a prospective cross-sectional study with a survey of type 1 diabetic patients under 18 years of age followed in the Internal Medicine Department of the Sourou Sanou University Hospital (CHU-SS) in Bobo-Dioulasso. Albuminuria and creatinuria were measured on the first morning sample of the patients followed by the calculation of the albuminuria/creatinuria ratio on sample. Albuminuria on sample was considered pathological if it was higher than 200 mg/L and an A/C ratio higher than 25 mg/mmol of creatinine in men and 35 mg/mmol of creatinine in women. A 24-h proteinuria was performed when the microalbuminuria/creatinine ratio was pathological.

**Results:** A total of 21 patients were included in the study. The mean age of the patients was 15.5 ± 3 years with extremes of 11 and 17 years. The sex ratio was 2. The mean age of onset of diabetes was 13 ± 3.2 years with extremes of 6 and 17 years. The duration of diabetes was 3.4 years. Diabetes was unbalanced in 19 patients. The mean microalbuminuria was 40.1 mg/L. One patient had positive microalbuminuria. The microalbuminuria/creatinuria ratio was pathological in 4 patients. Renal failure was noted in one patient. Diabetic retinopathy was present in one patient.

**Conclusions:** Screening for diabetic nephropathy in diabetic children is of paramount importance as this is a potentially long-lasting form of diabetes.

**P084** | Early cataract in children and adolescents living with type 1 diabetes: An insight from a single center in North India

**Introduction:** Cataract is the leading cause of visual impairment in adults living with type 1 diabetes (T1D). Unfortunately, data on early diabetic cataract among children and adolescents is limited. Further, majority of this data is available from the developed countries, which cannot be generalized.

**Objectives:** To report the characteristics and surgical outcome of early cataract in Indian children and adolescents living with T1D.

**Methods:** It is a retrospective observational study (January 2005–December 2020). The medical records of children and adolescents diagnosed with T1D over the last 15 years were retrieved and analyzed.

**Results:** Of 150 T1D patients, a total of 10 patients (five boys; 19 eyes) were diagnosed with cataract. The mean age at diagnosis of T1D was 8.6 ± 3.2 years (range, 3–12 years) and cataract was 13.2 ± 4.1 years (range, 6–18 years). Mean HbA1c at the time of cataract diagnosis was 7.99 ± 0.98%. History of DKA was documented in six patients (60%). Nearly 70% (n = 7) patients belonged to the lower socio-economic strata. Cortical cataract (12/19 eyes; 63%) was the most common morphology identified. These patients were operated after a mean duration of 0.5 ± 0.7 years. Phacoemulsification (PE) was done in 5 patients (10 eyes), small-incision cataract surgery in 4 patients (seven eyes), and micro-incision cataract surgery in 1 patient (two eyes). The best corrected visual acuity remained good after a mean follow-up duration of 3.2 ± 2.7 years (range 0–8 years). Four patients developed non-proliferative retinopathy after a mean diabetes duration of 8.9 ± 1.3 years (7–10 years). PCO was not observed in patients who underwent hydrophobic, heparin-coated, and multi-focal IOL implantation. It was observed in eight eyes that were treated by Nd-YAG capsulotomy.

**Conclusions:** Our study reinforce the need for early cataract screening in the pediatric diabetes population, especially in those, belonging to lower socio-economic strata, and/or with history of DKA. Age of the patient and diabetes duration do not predict the risk of cataract formation.

**P085** | Investigating the role of inflammation on early CVD development in youth with type 1 diabetes: The CARDEA study

**Introduction:** Cardiovascular disease (CVD) is one of the leading causes of death in young adults, with type 1 diabetes (T1D) as a major risk factor. The CARDEA (Cardiovascular Risk in Diabetes in Early Adolescence) study aims to explore early CVD development in youth with T1D.

**Objectives:** To investigate the role of inflammation on early CVD development in youth with T1D.

**Methods:** The CARDEA study is a prospective, longitudinal, observational study of youth with T1D aged 12–20 years. Blood samples and medical records are collected at baseline and annually. Inflammatory markers, including C-reactive protein (CRP) and interleukin-6 (IL-6), are measured. Cardiovascular outcomes are assessed using ultrasound imaging and electrocardiography.

**Results:** Preliminary data analysis revealed a significant association between higher CRP levels and increased carotid intima-media thickness (CIMT), a marker of early atherosclerosis. Elevated IL-6 levels were also associated with an increased risk of cardiovascular events.

**Conclusions:** The CARDEA study highlights the importance of early intervention to prevent CVD in youth with T1D, especially targeting inflammatory markers as potential modifiable risk factors.
Introduction: Youth with type 1 diabetes (T1D) display early signs of cardiovascular disease (CVD), but underlying mechanisms remain poorly understood.

Objectives: We examined the association between markers of inflammation and early CVD markers in youth with and without T1D.

Methods: Cross-sectional study of 100 adolescents and 97 age- and sex-matched healthy controls from Sainte-Justine Hospital Diabetes Clinic. Cardiac MRI measured left ventricular mass indexed by height (LVMH), papillary mass, wall thickness, and ejection fraction. We measured aortic stiffness with pulse-wave velocity (PWV) and brachial artery endothelial function with a flow-mediated dilation test (velocity time integral [VTI] and acceleration). Leptin, adiponectin, tumor necrosis factor α (TNF-α), TNF receptor 1 (TNFR1), TNF receptor 2 (TNFR2), interleukin-6 (IL-6) and C-reactive protein were measured by ELISA. Multivariable regression models were estimated adjusting for age, sex, BMI z-score, Tanner stage, physical activity (accelerometer), ethnicity, and heart rate in stratified analyzes.

Results: In youth with T1D: Higher TNFR1 was associated with a greater papillary mass ([95%CI]: 0.16% [0.02, 0.29]) and higher TNFR2 with a decreased wall thickness (−6 × 10⁻⁴ mm [−11.7 × 10⁻⁴, −0.3 × 10⁻⁴]).

In healthy controls: Higher levels of IL-6 and adiponectin were associated with unfavorable markers: higher PWV (0.26 m/s [0.04, 0.48]) and lower VTI (−0.57 cm/s [−1.07, −0.09]), respectively. Lower leptin and higher TNFR2 were associated with a greater LVMH (−0.48 g/m² [−0.73, −0.24]) and 0.004 g/m² [0.0002, 0.007], respectively and higher TNFR2 was associated with greater wall thickness (6.2 × 10⁻⁴ mm [0.3 × 10⁻⁴, 12.3 × 10⁻⁴]).

Conclusions: Results suggest that inflammation contributes to early CVD, with marked effects on vascular function and cardiac structure differing based on T1D presence. The paradoxical association between adiponectin and endothelial function calls for further exploration.

POSTER TOUR 10—CHRONIC COMPLICATIONS # 2

P086 | Oxidative stress and early cardiovascular disease in youth with type 1 diabetes: The CARDEA study

N. Silva Navarro1, M. Masse1, V. McNealis1,2, S. Harnois-Leblanc1,3,4, J.-C. Lavoie1,3, M.G. Friedrich5,6, A. Van Huls6,7, A.M. Nuyt1,9, J.-L. Bigras1,9, T.A. Barnett1,10, A. Benedetti1, M.-È. Mathieu1,11, V. Drapeau12, M. Henderson13,9

1Research Center of CHU Sainte-Justine, Montréal, Canada, 2McGill University, Department of Epidemiology, Biostatistics and Occupational Health, Montréal, Canada, 3Université de Montréal, School of Public Health, Montréal, Canada, 4Research Center of Center Hospitalier Universitaire de Montréal, Montréal, Canada, 5Université de Montréal, School of Nursing, Montréal, Canada, 6Université de Montréal, Department of Pediatrics, Montréal, Canada, 7McGill University, Department of Family Medicine, Montréal, Canada, 8McGill University, School of Kinesiology and Physical Activity Sciences, Montréal, Canada, 9Research Center of Center Hospitalier Universitaire de Montréal, Montréal, Canada, 10McGill University, Department of Physical Activity, Québec, Canada

Introduction: Cardiopulmonary disease (CVD) is evident as early as adolescence among individuals with type 1 diabetes (T1D). Oxidative stress plays a crucial role in the pathophysiology of CVD, but little is known about mechanisms in youth.

Objectives: We examined associations between oxidative stress and early markers of CVD in youth with and without T1D.

Methods: Cross-sectional study of 100 adolescents and 97 age- and sex-matched healthy controls from Sainte-Justine Hospital Diabetes Clinic (Montréal, Canada). Oxidized glutathione (GSSG), reduced glutathione (GSH), total glutathione (GST) measured by capillary electrophoresis and represent hydrogen peroxide metabolism. We measured aortic stiffness with pulse-wave velocity (PWV) and endothelial function with a brachial artery flow-mediated dilation test (velocity time integral [VTI] and acceleration). Left ventricular mass indexed by height (LVMH), papillary mass, wall thickness, and ejection fraction were determined by cardiac magnetic resonance. Multivariable regression models were estimated adjusting for age, sex, BMI z-score, Tanner stage, physical activity (accelerometer), ethnicity, and heart rate. Interaction terms for the presence of T1D were tested and results stratified by groups.

Results: Youth with T1D had lower GSSG, GSH, and GST compared with controls (previously reported). Greater levels of GSSG were associated with higher PWV ([95%CI]: 1.12 m/s [0.18, 2.04]) in the T1D group, but not in controls (−0.11 m/s [−0.91, 0.62]). GSSG levels were positively associated with wall thickness in the T1D group (2.38 mm [−0.21, 5.07]), without reaching statistical significance. No other associations between oxidative stress markers and CVD markers were noted.

Conclusions: Our findings suggest that the dysregulation in hydrogen peroxide metabolism in youth with T1D could accelerate arterial stiffness development and alter cardiac structure, making oxidative stress a potential target for CVD prevention in this population.

P087 | Prevalence and associated factors of chronic complications among outpatients with type 2 diabetes mellitus: A case of Nyeri County Referral Hospital, Kenya

R. Ireri1, G. Waweru2

1Kenya Medical Training College, Clinical Medicine, Embu, Kenya, 2Kenya University, Food Nutrition and Dietetics, Nairobi, Kenya

Introduction: Diabetes mellitus and its associated complications is a public health concern globally, imposing heavy burden to the healthcare system.
**Prevalence and management of diabetic nephropathy in Libyan type 1 diabetic patients**

O. Fathalla1, I. Hadeed1, N. Algazir1, M. Ghai1, S. Abusrew1
1Tripoli University Libya, Pediatric Endocrine and Diabetes, Tripoli, Libya

**Introduction:** Diabetic nephropathy (DN) is the leading cause of end-stage renal disease worldwide. Chronic hyperglycemia and high blood pressure are the main risk factors for the development of DN. Poor glycemic control, hyperlipidemia, oxidative stress, environmental, genetic and epigenetic factors play an important role in the pathophysiological development of DN.

**Objectives:** The objectives of this study were to estimate the risk for nephropathy in its various phases and to assess the variable related to the onset and progression in patients who have had type 1 diabetes and the identification of these factors may have therapeutic implications in the follow up of these patients.

**Methods:** This retrospective study for 10 years (1990–2000). It was conducted in pediatric endocrine department, Tripoli University Hospital, Libya. A clinic-based cross-sectional study of 1209 patients with T1DM aged 10–18 years and mean duration of diabetes 12 years (8–18 years).

All patients screened by 24 h urine collections to detect microalbumin and it was considered positive, if it is more than 30 mg/day.

**Results:** The frequency of microalbuminuria 31% (374 patients), 52% were females and 48% were males. The major part of patients with microalbuminuria those with more than 8 years diabetic duration. Furthermore, most of them was with mean HbA1c 10% over last 3 years prior to develop microalbuminuria. In treatment of patient with microalbuminuria, we used angiotensin converting enzyme inhibitor drugs and only 52 (4.3%) patients with overt proteinuria were treated with combination of ACEI and angiotensin receptor blocker drugs.

**Conclusions:** High prevalence of incipient DN. Longer diabetes duration and higher HbA1c were associated with the presence of diabetic nephropathy. The therapeutic regimen of DN is usually multifactorial, which includes tight glycemic control, blood pressure control, lipid-lowering agents, weight loss, protein restriction, and smoking cessation.
P090 | Vascular complications of type 1 diabetes in children, adolescents and young adults: Preliminary results from a global survey to assess screening, prevention and management practices across the world

C. Piona1, T.J. dos Santos2, A. Chobot3, E. Giani4, L. Mavecchia5, C. Maffei5, C. de Beaufort6

1University and Azienda Ospedaliera Universitaria Integrata of Verona, Department of Surgery, Dentistry, Pediatrics and Gynecology, Section of Pediatric Diabetes and Metabolism, Verona, Italy, 2Hospital Vithas Almeria, Instituto Hispalense de Pediatría, Almeria, Spain, 3Institute of Medical Sciences, University of Opole, Poland Department of Pediatrics, University Clinical Hospital, Department of Pediatrics, Opole, Poland, 4University of Cambridg, Department of Pediatrics, Cambridge, United Kingdom, 5Center Hospitalier, Department of Pediatric Diabetes and Endocrinology, Clinique Pédiatrique, Luxembourg, Luxembourg

Introduction: Skin autofluorescence (sAF) is a non-invasive measure of tissue advanced glycation end products accumulation.

Objectives: To evaluate worldwide physicians’ practices regarding screening, prevention and treatment of micro- and macro-vascular complications of Type 1 Diabetes according to ISPAD guidelines.

Methods: Between March and April 2022, we collected responses from pediatric diabetologist through a web-based survey to assess practices related to screening, prevention and treatment of nephropathy, retinopathy, neuropathy, and risk factors (RFs) for macrovascular diseases.

Results: A total of 115 physicians from 48 countries responded to date. The prevalence of screening for complications, according to the ISPAD guidelines, was 87% for nephropathy and 74% for retinopathy (74%), but lower for neuropathy (19%) and RFs for macrovascular disease (52%). Frequency of lack of screening was 19% for neuropathy, 11% for macrovascular disease and 4.3% for nephropathy and retinopathy, and this was mainly due to lack of access to screening methods. Patient’s financial contribution for screening was requested for nephropathy (30%), retinopathy (28%), neuropathy (28%) and RFs for macrovascular diseases (31%). Between 30% and 40% physicians started screened from the age of 10–11 years and 20% from puberty. Half of the survey respondents was very familiar with the guideline content and reported sufficient knowledge for nephropathy (80%), RFs for macrovascular disease (80%), retinopathy (50%) and neuropathy (50%) treatments. First-line treatment recommended by ISPAD guidelines, initiated by physicians, was 55% for persistently elevated albuminuria/proteinuria, 60% for retinopathy, 63% for neuropathy, 83% for LDL-c > 100 mg/dl, 75% for elevated blood pressure, 85% for hypertension.

Conclusions: These preliminary results suggest that there is wide variation across the word in the adoption and implementation of the ISPAD guidelines on vascular complications. Further data collection and analysis are needed for a more comprehensive analysis of the issues limiting the implementation of the ISPAD guideline for vascular complications.

P091 | Assessment of skin autofluorescence association with glycated hemoglobin, cardiovascular risk markers and concomitant chronic diseases in children with type 1 diabetes

M. Jankowska1, B. Mianowska2, I. Pietrzak2, J. Chrzanowski3, J. Sołek3, A. Szadkowska2

1Polish Mothers’ Memorial Institute Research Hospital, Department of Developmental Neurology and Epileptology, Łódź, Poland, 2Medical University of Lodz, Department of Pediatrics Diabetology Endocrinology and Nephrology, Łódź, Poland, 3Medical University of Lodz, Department of Biostatistics and Translational Medicine, Łódź, Poland

Introduction: Skin autofluorescence (sAF) is a non-invasive measure of tissue advanced glycation end products accumulation.

Objectives: Our aim was to assess sAF association with glycated hemoglobin (HbA1c) values, cardio-vascular risk markers, and comorbidity of autoimmune thyroiditis or celiac disease in children with type 1 diabetes (T1D).

Methods: Patients aged 3–18 years with ≥6 months T1D duration participated. sAF was measured with AGE Reader (Diagnoptics BV, Netherlands). Cholesterol fractions, triglycerides, HbA1c, C-reactive protein (CRP), ambulatory blood pressure monitoring records, body mass index Z-score and body composition parameters were analyzed.

Results: 348 patients were included (182 boys; median age 14.3 years [IQR 11.2–17.1] with median T1D duration 5.5 years [3.1–8.8]). Median HbA1c was 7.3% [6.7%–8.1%]. Median sAF was 1.40 AU [1.27–1.53] and positively correlated with current HbA1c, mean of historical average HbA1c, and negatively correlated with age, BMI, and RFs. sAF positively correlated with percentage of body fat, body impedance and CRP, and negatively correlated with baseline metabolic rate (BMR) in kcal (respectively r: 0.27, 0.22, 0.15, 0.14, all p < 0.01). sAF positively correlated with percentage of body fat, body impedance and CRP, and negatively correlated with basic metabolic rate (BMR) in kcal (respectively r: 0.12, 0.14, 0.17 and 0.24, all p < 0.001). In the multiple regression model parameters that remained positively correlated with sAF were: age (β = 0.40, p = 0.0001), historical HbA1c (β = 0.24, p < 0.0001), CRP (β = 0.15, p = 0.014), female sex (β = 0.26, p = 0.034) and presence of celiac disease (β = 0.11, p = 0.062); while BMI (β = −0.51, p < 0.0001) remained negatively correlated.

Conclusions: in young T1D patients with relatively short diabetes duration sAF reflects well previous glycemic control represented by historical average HbA1c, however its associations with classic CV-risk markers are not evident. sAF correlations with BMR and celiac disease deserve further research.

P092 | Early markers of atherosclerosis in children and adolescents with type 1 diabetes mellitus

C.G. Delhikumar1, P. Bharathy1, M. Rajappa2, A. Anantharaj3, J. Sahoo1

1Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Pediatrics, Pondicherry, India, 2Jawaharlal Institute of
Introduction: Type 1 Diabetes mellitus (T1DM) children with uncontrolled hyperglycemia develop endothelial damage that triggers inflammatory processes resulting in early-onset atherosclerosis.

Objectives: To study the early atherosclerosis changes using Flow-mediated dilation (FMD) of the brachial artery, carotid intima-media thickness (CIMT), inflammatory markers (hsCRP, IL-6), and endothelial markers (sICAM and sVCAM).

Methods: We recruited 4 to 18-year-old children with T 1DM and age and sex-matched normal children, excluding those with familial hypercholesterolemia, syndromic disorders, and cardiovascular disease. We measured CIMT and FMD in both groups. Biomarkers hsCRP, IL-6, sICAM, and sVCAM, were analyzed in T1DM.

Results: We enrolled 40 T1DM children and 40 controls with 27(67.5%) girls in each group. The mean age was 9.68 years. T1DM group had 4(10%) obese and 4(10%) overweight children. Among cases, 9(22.5%) had diabetes for > 5 years, 24(60%) required daily insulin between 0.8 to 1.2 IU/kg/day and 26(65%) had HbA1c >10gm/dl. The children with uncontrolled HbA1c had higher BMI (r = 0.40, p = 0.01). A 6(15%) had autoimmune thyroiditis. The CIMT values were significantly higher in cases (0.69 mm) than controls (0.59 mm). A 29(72.5%) cases had abnormal combined CIMT values. FMD was lesser in cases than controls but not significant. The median values of hs-CRP, IL-6, sICAM, sVCAM were 0.81 mg/L, 6.27 pg/ml, 46.33 ng/ml and 66.81 ng/ml respectively. CIMT correlated positively with hip (r = 0.335, p < 0.001) and waist circumference (r = 0.371, p = 0.018).

We had significant correlation of IL-6 with CIMT (r = 0.543, p = <0.001) and sICAM with FMD (r = −0.397, p = 0.011). VCAM was low in obese and overweight children.

Conclusions: Children with type 1 diabetes had higher CIMT than normal children, whereas FMD did not differ. The association between elevated inflammatory markers with high CIMT and low FMD indicates inflammation plays an essential role in endothelial dysfunction.

P093 | The impact of tight versus less tight glycemic control on the course of type 1 diabetes in children

A. Ochocinska, J. Šviderska, M. Wysocka-Mincewicz

Children’s Memorial Health Institute, Department of Biochemistry, Radioimmunology and Experimental Medicine, Warsaw, Poland.

Introduction: Recent studies show that maintaining normal blood glucose levels is not sufficient to reduce the incidence of chronic type 1 diabetes (T1D) complications. Biochemical disturbances accompanying hyperglycemia in the asymptomatic period may induce the formation/activation of various biologically active substances, which may influence the treatment process.

Objectives: The aim of our study is to assess the effect of strict adherence to normoglycemia on blood levels of: amylin, catestatin, chromogranin A (ChgA), nerve growth factor (NGF), platelet activating factor (PAF), proamylin, and uromodulin.

Methods: The study included 156 patients with T1D aged 6–18 (mean age: 12 ± 4)–patients of The Children’s Memorial Health Institute. The control group (n = 30) consisted of age-matched children (mean age: 9 ± 4), with no metabolic disorders and no diagnosis of T1D. The tight glycemic control group was defined as having a glycated hemoglobin concentration of ≤7.5%.

Results: Concentration of all parameters assessed in the study group differed statistically significantly from those obtained in the control group. NGF, ChgA, uromodulin and PAF, concentration levels differed between patients with a disease duration >3 years and newly diagnosed patients (11.2 ± 4.22 pg/ml, 57.6 ± 18.5 ng/ml, 164.3 ± 175 ng/ml, 0.41 ± 0.64 ng/ml vs. 20.2 ± 86.0 pg/ml, 74.2 ± 15.6 ng/ml, 304.0 ± 126.5 ng/ml, 0.21 ± 0.08 ng/ml respectively).

In the group of children whose the disease has lasted more than 3 years, peptide levels did not differ statistically (p > 0.05) between patients, regardless of whether or not they adhered to the strict glycemic regime.

Conclusions: Blood concentration of the tested proteins did not change depending on the glycemic control. There is no relationship between the risk of developing and/or severity of diabetic complications and the concentration of the studied markers in children with T1D, regardless of whether they achieve the goal of normoglycemia or not.

P094 | Genetic based risk prediction for the development of diabetic nephropathy in children and adolescents with type 1 diabetes

F. Evin, T. Atik, G. Ak, T. Köse, C. Kabasakal, S. Özen, Ş. Darcan, D. Gökşen

1Ege University, Pediatric Endocrinology, Izmir, Turkey, 2Ege University, Izmir, Turkey

Introduction: The pathogenesis of diabetic nephropathy (DN) is multifactorial, however most of its development mechanisms are remain unknown.

Objectives: We aimed to create genetic-based clinical risk scoring.

Methods: Polymorphisms in AFF3, CARS, CERS2, ERBB4, GLRA3, RAET1L, TMPO, ZMIZ1 genes were investigated and the DN and non-DN(WDN) groups were compared in terms of clinical findings and biochemical laboratory data.

Results: Of the 43 DN cases (Girl/Boy: 22/21) included in the study, 36(6.9%) had a family history of consanguineous marriage between their parents, and 9(20.9%) had a family history of T1DM. Of the cases, 23(53.5%) were diagnosed with diabetic ketoacidosis, 14(32.6%) with diabetic ketosis, and 6(14%) with incidental T1DM.

The mean age of detection of microalbuminuria (MA) in patients with diabetic nephropathy was 13.33 ± 3.20, and the duration of diabetes...
was 4.95 ± 3.99 years. MA was present at the time of diagnosis of 
T1DM in 5 cases (11.6%). The duration of diabetes in the WDN group 
was matched with the age at which diabetic nephropathy developed 
in the DN group. Table 1 summarizes a number of clinical and labora-
tory data in DN and WDN groups at the time of detection of MA. 
In the cases in the DN and T1DM groups; 13 polymorphisms were inves-
tigated in AFF3, CARS, CERS2, ERBB4, GLRA3, RAET1L, TMPO, ZMIZ1, 
FRMD3 genes. The determined results were compared with randomly 
assigned healthy controls. There was no difference in the frequency of 
polymorphism between DN, WDN, and healthy control groups. 

**Conclusions:** This study is a comprehensive study revealing the 
clinical and molecular features of diabetic nephropathy, and clinically the 
risk factors previously shown in the literature were confirmed. How-
ever, in this study, no difference was found between type diabetes 
and healthy control groups in polymorphisms known to be associated 
with diabetic nephropathy.

**ABSTRACTS**

**P095 | Plasma levels of vitamin B12 and Neurofilament light 
chain in adolescents with type 1 diabetes with and without 
neuropathy**

M.T. Jespersen1, T. Parkner2, H. Tankisi3, A.J. Terkelsen1,4, 
J.R. Nyengaard5,6, E.T. Vestergaard7,8, K. Kristensen8, 
V.F. Rasmussen4,7 
1Aarhus University Hospital, Department of Neurology, Aarhus, 
Denmark, 2Aarhus University, Department of Clinical Biochemistry, 
Department of Clinical Medicine, Aarhus, Denmark, 3Aarhus University, 
Department of Neuropathology, Department of Clinical Medicine, 
Aarhus, Denmark, 4Aarhus University, Danish Pain Research Center, 
Department of Clinical Medicine, Aarhus, Denmark, 5Aarhus University, 
Core Center for Molecular Morphology, Section for Stereology and 
Microscopy, Department of Clinical Medicine, Aarhus, Denmark, 6Aarhus 
University Hospital, Department of Pathology, Aarhus, 
Denmark, 7Randers Regional Hospital, Department of Pediatrics, Randers, 
Denmark, 8Aarhus University Hospital, Steno Diabetes Center Aarhus, 
Aarhus, Denmark

**Introduction:** Neuropathy is a well-known complication to diabetes. 
However, still little is known about biochemical markers to detect early 
signs of neuropathy in younger patients.

**Objectives:** To investigate plasma levels of vitamin B12 and the nerve 
damage marker, Neurofilament light chain (NFL) in adolescents with 
type 1 diabetes (T1D) with or without neuropathy. We hypothesize 
that patients with neuropathy have signs of B12 deficiency and 
increased levels of NFL.

**Methods:** A 60 adolescents (15–18 years, diabetes duration >5 years) 
with T1D and 23 control subjects were included. Based on results 
from nerve conduction studies, the patients were divided into two 
groups: with (DN+) and without (DN-) diabetic neuropathy. Plasma 
levels of vitamin B12 (B12), vitamin B12-TC-bound (holoTC) and NFL 
were determined by immunoassays, while plasma methylmalonate 
(MMA) was analyzed by mass spectrometry.

**Results:** A 23 of the adolescents with T1D had abnormal NCS (DN+, 
n = 23), and 37 had normal results (DN-, n = 37). There were no sig-
nificant differences in B12 parameters between DN- and DN+ (B12 
p = 0.1; holoTC p = 0.2; MMA p = 0.4). Comparing DN+ with control 
subjects showed no significant differences in MMA- and holoTC-
levels (MMA median: DN+: 0.12 vs. control subjects: 0.15 μmol/L, 
p = 0.6; holoTC median: DN+: 121.75 vs. control subjects: 
77.40 pmol/L, P = 0.06), but revealed significantly higher B12-levels 
in DN+ (B12 median: DN+: 438.29 vs. control subjects: 
309.95 pmol/L, P = 0.02).

No significant differences in NFL levels between the groups were 
found (NFL median (range): DN+: 5.16 (2.12–13.24) ng/l; DN+: 5.85 
(2.35–14.31) ng/l; control subjects: 5.24 (3.07–8.00) ng/l), p = 0.5).

**Conclusions:** This study found similar plasma levels of B12 parameters 
and NFL in adolescents with and without diabetic neuropathy, sug-
gest that reduced B12 level is not contributing as cause of occur-
rence of neuropathy in adolescents with T1D. Furthermore, NFL is not 
a relevant biomarker of large nerve fiber damage in this T1D 
subpopulation.

**POSTER TOUR 11—OBESITY & TYPE 2 DIABETES**

**P096 | Non-alcoholic liver disease in overweight and obese 
children detected by Fibroscan and its determinants**

M. Fajrudheen1, A.K. Satapathy2, S. Mahapatro3, M.K. Panigrahi2, 
1AIIMS Bhubaneswar, Pediatrics, Bhubaneswar, India, 2AIIMS 
Bhubaneswar, Gastroenterology, Bhubaneswar, India
**Introduction**: Childhood obesity and NAFLD are upcoming major health issues in developing and developed nations. Early detection of NAFLD and NASH in the reversible stage and appropriate measures can prevent progression to severe disease. Even though liver biopsy is the gold standard for diagnosis, an alternate non-invasive technique to detect early fibrosis is the need of hour. Fibroscan with Controlled attenuation parameter (CAP) is a novel noninvasive modality to detect both fatty changes as well as fibrotic changes early in these children.

**Objectives**: To detect the prevalence of NAFLD and NASH in overweight and obese children. And to compare it with the existing imaging modality that is ultrasonography.

**Methods**: A cross-sectional study was done from January 2020 to October 2021 in overweight and obese children attending a tertiary care hospital. Relevant history, physical examination, anthropometric measurements, and laboratory investigations were done. NAFLD and NASH changes in the liver were assessed using USG and Fibroscan.

**Results**: Among 178 children studied, 116 were boys and 62 were girls. In these, 31% were overweight and the rest were obese. Fatty liver and fibrotic changes were observed in 46% and 33.1% children respectively using Fibroscan. A good correlation was observed between Fibroscan, ultrasound, and PNFI scores in detecting fatty liver and fibrotic changes in the liver. Age, BMI, waist circumference, ALT, AST were high in children with NAFLD. There was also higher prevalence of increased fasting blood sugars in children with NAFLD. ALT value of more than 29.5 U/L was found to have a sensitivity of 78% and specificity of 81% in detecting NAFLD in children with obesity and overweight.

**Conclusions**: A high prevalence NAFLD was found in overweight and obese children. Fibroscan is a useful modality to detect early fibrotic changes in these children. Alanine transferase (ALT) and skinfold thickness were found to be significantly associated with NAFLD in overweight and obese children.

**P097** | **Dyslipidemia in young patients with type 2 diabetes and maturity onset diabetes of the young: an observational study**

M. Bhat1, J. Bhat2

1Government Medical College, Medicine, Srinagar, India. 2Government Medical College, Endocrinology, Srinagar, India

**Introduction**: Youth onset type 2 diabetes (T2D) is increasing. In addition more of the patients are diagnosed with maturity onset diabetes of the young (MODY). Dyslipidemia is an important modifiable cardiovascular (CVD) risk factor and most of the times untreated in youth with diabetes.

**Objectives**: To evaluate the prevalence of dyslipidemia and compare the lipid concentrations in youth with T2DM to MODY at a tertiary care institute.

**Methods**: A cross sectional study performed over 1 year period, evaluating patients with T2D or MODY, seen at least once in clinic over a period of 1 year, with age of onset of diabetes <25 years, not on the statins were included. Serum total cholesterol (TC), low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL) and triglyceride concentration (TG) was measured. Independent and
multivariable linear regressions of LDL-C and HDL-C concentrations were performed.

Results: A total of 167 T2D and 44 MODY patients were included. Serum TC (169.58 ± 30.17 mg/dl vs. 157.54 ± 48.89 mg/dl) and LDL levels (105.22 ± 22.82 mg/dl vs. 97.60 ± 19.23 mg/dl) were significantly higher and HDL levels (33.64 ± 6.89 vs. 43.37 ± 7.95) were significantly lower in T2D as compared to the MODY patients. Serum triglyceride levels were similar between the two groups. About 53.3% with T2D (n = 89) and 36.4% with MODY (n = 16) had LDL-C above ≥100 mg/dl. In addition 24% T2D patients and 19% with MODY had LDL ≥130 mg/dl, who likely met criteria for starting statin therapy. Higher LDL and/or lower HDL were associated with increased age, diabetes duration, higher HbA1C, obesity, and T2D.

Conclusions: This highlights the need for more aggressive dyslipidemia screening and treatment in youth with diabetes. The prevalence of dyslipidemia is more in youth T2D as compared to MODY.

P098 | Dulaglutide in youth with type 2 diabetes (T2D): Results of the AWARD-PEDS randomized, placebo-controlled trial

S. Arslanian1, T. Hannon2, P. Zeitler3, L. Chao4, C. Boucher-Berry5, M. Barrientos-Pérez6, E. Bismuth7, S. Dib8, J.J. Cho9, D. Cox9

1UPMC Children's Hospital of Pittsburgh, Pittsburgh, United States, 2Riley Hospital for Children, Indianapolis, United States, 3Children's Hospital Colorado, Colorado, United States, 4Children's Hospital of Los Angeles, Los Angeles, United States, 5Children's Hospital of the University of Illinois, Illinois, United States, 6Angeles Hospital of Puebla, Puebla, Mexico, 7University Robert Debré Hospital, Paris, France, 8Federal University of São Paulo State, São Paulo State, Brazil, 9Eli Lilly and Company, Indianapolis, United States

Introduction: AWARD-PEDS was a Phase 3 trial to assess the efficacy and safety of dulaglutide (DU), a once-weekly GLP-1 receptor agonist, in youth (10 to <18 years old) with T2D treated with lifestyle alone or on stable metformin with or without basal insulin.

Objectives: The primary aim was to demonstrate superiority of DU (pooled doses) vs placebo for change in HbA1c at 26 weeks.

Methods: Participants (mean age, 14.5 yrs; mean BMI, 34.1 kg/m²) were randomized to placebo (N = 51), DU 0.75 mg (N = 51), or DU 1.5 mg (N = 52). Analyses included all patients with ≥1 dose of study drug, excluding data after initiation of rescue therapy.

Results: DU was superior to placebo (figure) in improving glycemic control measured by change in HbA1c, percent of patients with HbA1c <7%, and change in fasting glucose at Week 26. No effect of DU was observed on BMI change (p = 0.776). Fewer patients assigned to DU compared to placebo required rescue therapy (2.9% vs. 17.6% respectively, p = 0.003).

Conclusions: In conclusion, in youth with inadequately controlled T2D treated with or without metformin and/or basal insulin, once weekly DU 0.75 mg or 1.5 mg was superior to placebo in improving glycemic control without an effect on BMI through 26 weeks, with a safety profile consistent with that established in adults.

P099 | Course and predictors of pre-diabetes in Indian children and adolescents

M. Agrawal1, N. R1, S. Benerjee1, P. Sen1, V. Yadav1, A. Bajpai1

1Center of Diabetes - Endocrine Research, Regency Hospital, Pediatric Endocrinology, Kanpur, India

Introduction: There has been a substantial global rise in the prevalence of pre-diabetes commensurate with the obesity epidemic. There is limited information about the course and its predictors of progression/remission of pre-diabetes in Indian children.

Objectives: To determine the outcome and predictors of pre-diabetes in Indian children and adolescents.

Methods: Clinical course was followed in 58 children and adolescents (37 boys; 13 ± 3.6 years of age) for 1.9 ± 1.2 years. Management included lifestyle measures in all and metformin in 36. Clinical, auxological, and biochemical parameters (Glucose status, lipid profile, alanine amino transaminase) were assessed at baseline and after two, six, and 12 months and then annually. The predictors of worsening of disease and changes in fasting and glucose tolerance were assessed on univariate analysis.

Results: The study showed that remission from pre-diabetes was observed in 36 (62.1%). The disease continued in 15 (25.9%) with frank Type 2 diabetes progression in seven (12.1%). The increase in BMI SDS
was the most important predictor of disease progression \((p = 0.034)\). The mean change in BMI SDS was \(0.17 \pm 0.82\) in diabetic children.

**Conclusions:** A substantial proportion of Indian children and adolescents with prediabetes persist to have persistent disease or progress to Type 2 Diabetes. Weight gain was the main predictor of the progression of the disease.

**P100** | The correlation between consumption of simple carbohydrate and waist measurement in Budya Wacana Elementary School Yogyakarta students

N. Susanto

1Duta Wacana Christian University, Faculty of Medicine, Yogyakarta, Indonesia

**Introduction:** The excessive simple carbohydrate consumption is able to increase the amount of glucose savings in the blood. The unused glucose savings in the body then synthesized into fatty acids. The fatty acids changed into fat tissue under the skin layers, one of the place to store the fatty acids is the abdomen area. Central obesity is a condition where there is an excessive amount of fat tissue in the abdomen area. Central obesity can occur both on adult and young kids.

**Objectives:** To find the correlation between simple carbohydrate consumption and waist measurement in Budya Wacana Elementary School Yogyakarta Students.

**Methods:** This study uses the Semi Quantitative Food Frequency Questionnaire (SQFFQ) to see the frequency of the food intake for every respondent. Every respondent of this study fill the questionnaire and having a waist measurement.

**Results:** This study has 161 students as the respondent from the 4th, 5th, and 6th graders. There are 88 (54, 7%) respondents that consumed normal amount of simple carbohydrate with normal waist measurement. There are 8 (5%) respondents that consumed normal amount of simple carbohydrate with high waist measurement. There are 28 (17, 4%) respondent who have high simple carbohydrate consumption and normal waist measurement. The rest of the respondent, 37 students (23%) have high consumption of simple carbohydrate with high waist measurement result. The correlation between the consumption of simple carbohydrate and waist measurement is intermediate correlation.

**Conclusions:** There is an intermediate correlation between simple carbohydrate consumption and waist measurement in Budya Wacana Elementary School Yogyakarta Students.

**P101** | Rapid progression of type 2 diabetes in Indian adolescents: A cause of concern

P. Sen, C. Dave, R. Narayanan, S. Banerjee, M. Agarwal, R. Shukla, A. Bajpai

1Regency Center For Diabetes and Endocrinology Research, Pediatric and Adolescent Endocrinology, Kanpur, India

**Introduction:** Adolescent type 2 Diabetes is associated with rapid beta-cell exhaustion and the need for multiple medications. There is a lack of data about the course of Type 2 Diabetes in Indian adolescents and its predictors.

**Objectives:** To study the course of Type 2 Diabetes in Indian adolescents and its predictors.

**Methods:** A 26 adolescents with Type 2 Diabetes (19 boys, age 15.6 \(\pm\) 2.3 years) were followed up for 2.8 \(\pm\) 2.0 years till an age of 19.05 \(\pm\) 3.11 years regarding anthropometric measures, glycemic control, treatment required, and comorbidities. Predictors for disease course were ascertained.

**Results:** The initial treatment included metformin alone \((n = 16)\), insulin alone \((n = 1)\), in combination with insulin \((n = 7)\), and in combination with other drugs \((n = 2)\). Seven patients achieved remission 0.61 \(\pm\) 0.593 years after diagnosis and four of these patients relapsed 1.15 \(\pm\) 0.2 years later. Treatment at last follow-up included metformin alone \((n = 7)\) or in combination with additional agents (Insulin in 2, GLP1 receptor analog in 5, and SGLT2 Inhibitor in 8, DPP4 in 6). Three patients are in remission and off medication. A decrease in BMI SDS showed a trend of persistent metformin responsiveness (a decrease of \(-0.0383 \pm 0.41\) in those responsive to metformin as against an decrease of 0.11 \(\pm\) 0.43 in those needing combination therapy). Complications at last follow-up included microalbuminuria in 3 (11%) and steatohepatitis in 17 (65%).

**Conclusions:** Indian adolescents with Type 2 diabetes have an aggressive course with rapid progression to metformin failure and a high prevalence of comorbidities. Timely initiation of management and weight loss is essential to retard the progression of the disease.

**P102** | A review of type 2 diabetes mellitus (T2DM) in children and youth in Gulf Cooperation Council (GCC) countries

I. Al Alwan, A. Babiker

1King Saud Bin Abdulaziz University for Health Sciences, Pediatrics, Riyadh, Saudi Arabia

**Introduction:** Traditional T2DM is an adult-onset disease. Over the last two decades, the global rise in obesity in children and youth (CY) coincided with a dramatic increase in the incidence of T2DM
Predictive ability of Triglyceride-glucose (TyG) index and related parameters for metabolic syndrome (MetS) and insulin resistance in Greek pediatric population

E. Dikaiaisou, E.-A. Vlachopapadopoulou, F. Athanasouli, I. Kosteria, C. Kafeti, S. Fakiolas, S. Michalacos

Introduction: TyG index has emerged as a simple, cost-effective surrogate marker for predicting insulin resistance in children. Objectives: To investigate the ability of TyG Index to identify MetS, as well as the ability of TyG-related parameters to improve prediction of MetS and Insulin Resistance (IR) in Greek children and adolescents.

Methods: TyG index, HOMA-IR and the TyG products were calculated in a sample of 145 children (46.9% boys) with mean age 10.2 ± 3.2 years, with overweight or obesity. TyG index was calculated as ln(triglycerides (mg/dl) × fasting glucose (mg/dl))/2. TyG-BMI was calculated as TyG index × BMI z-score and TyG-WHR (Waist to Height Ratio) as TyG index × WHtR. The predictive ability of TyG index and products was determined by using receiver operating characteristic (ROC) curves. The overall performance of the ROC analysis was quantified by computing area under the curve (AUC).

Results: Insulin resistance, defined as HOMA-IR ≥ 2.5, was present at 54.5% of the participants, while 18.6% had MetS, defined according to Cook et al. 2003. TyG Index was significantly higher in children with MetS (p < 0.001). ROC curve analysis for TyG Index showed that the optimal cut-off value for the prediction of MetS was 8.36 with sensitivity 85% and specificity 89%, whereas for the prediction of IR was 8.13, with sensitivity 59% and specificity 71%. The AUC was 0.908 and 0.674, respectively (p < 0.001). Moreover, the optimal cut-off value for the prediction of MetS with TyG-BMI was 18.3 with sensitivity 74% and specificity 57% and for IR 18.6, with sensitivity 52% and specificity 68%. The AUC was 0.675 for MetS and 0.605 for IR. Similarly, the optimal cut-off value of TyG-WHR for the prediction of MetS was 5.32, with sensitivity 70% and specificity 84%, while for IR it was 5.02, with sensitivity 66% and specificity 68%. The AUC for MetS was 0.830 and for IR 0.686.

Conclusions: TyG Index is a stronger predictor for MetS, however TyG-WHR is superior for the prediction of IR of all the other parameters studied.

The association between depressive symptoms and overweight or obesity in prepubertal children: Findings from the QUALITY cohort


1Université de Montréal, Montreal, Canada, 2McGill University, Montreal, Canada, 3University of Toronto, Toronto, Canada

Introduction: Although recent meta-analyzes suggest a positive association between obesity and depressive symptoms in adults and adolescents, the nature of this association in prepubertal children remains unclear.

Objectives: This study aimed to examine the bidirectional associations between levels of depressive symptoms and weight status in 8-10 year-old children followed for 2 years, and whether these associations differed by sex.

Methods: We used data from the QUebec Adipose and Lifestyle InvesTigation in Youth Cohort Study’s baseline and first follow-up evaluations (n = 558). Depressive symptoms were assessed using the 12-item Center for Epidemiological Studies Depression scale. Weight status was determined using body mass index z-scores (WHO). Univariable and multivariable linear and logistic regression models were used to test the association between depressive symptoms and weight status, adjusted for age, sex, physical activity, screen time, parental education, alcohol and cigarette use and baseline outcome measure.

Results: Depressive symptoms in children did not differ by weight status. Furthermore, children with higher levels of depressive symptoms at baseline were not more likely to have overweight or obesity 2 years later (odds ratio [95% CI] = 0.95 [0.88; 1.02] per scale unit increment).
Likewise, baseline overweight/obesity was not associated with higher levels of depressive symptoms at follow-up (beta coefficient [95% CI] = 0.20 [−0.47; 0.87]). No meaningful associations emerged in sex-specific analyzes.

Conclusions: Contrary to the literature in adults and adolescents, our study did not detect an association between weight status and depressive symptoms in childhood over a two-year period. Potential underlying mechanisms linking weight status and depression in adults might not apply as early as prepubertal childhood. Further longitudinal studies in more diverse samples are needed to confirm these findings.

P105 | Diagnosis and management of type 2 diabetes in a pediatric diabetology clinic in Annaba, Algeria

N. Selim¹, F. Abdelaziz², D. Belamri¹, L. Bousti¹, H. Sehab¹, N. Bouchair¹
¹University of Annaba, Department of Pediatrics, Saint Therese Clinic, Annaba, Algeria, ²Medical Practice, Annaba, Algeria

Introduction: Type 2 diabetes (T2D) is defined as an insulin resistance associated with a progressive insulin-secretory defect, its incidence in the pediatric population has grown in parallel with the worldwide rise in obesity.

Objectives: The objectives of our study is to determine the frequency of T2D in our clinic and to identify the diagnostic circumstances as well as the therapeutic modalities.

Methods: In our pediatric diabetology clinic, we collected 17 cases of T2D between 2015 and 2020. A 14 patients presented with overweight or obesity, and 3 had a normal weight, the diagnosis was based on history, clinical and biological data and the good response to oral hypoglycemic agents.

Results: The age at diagnosis was between 12.3 and 16.5 years, with 12 girls and 5 boys, the BMI was between 20.5 and 51 kg/m², the history of T2D is found in all patients, acanthosis nigricans was present in 11 patients, HbA1c at diagnosis was from 6.4 to 13%, c-peptide was normal in 15 patients, insulinenaemia was variable, T1D antibodies were negative in 16 patients and only one positive in a patient, the lipid balance was disturbed in only 2 teenagers, one of whom had the Polycystic ovary syndrome.

the screening for microangiopathic complications carried out in all patients came back without abnormalities. All patients received insulin therapy initially and then were put on oral hypoglycemic agents with a good response.

Conclusions: It is necessary to know how to think about T2D in children with particular circumstances of onset of their diabetes; such as puberty, obesity and a history of T2DM. The treatment consists in the administration of oral hypoglycemic agents with a good follow-up of the patients to know how to reintroduce the insulin if necessary.

P107 | A comparison between the FreeStyle Libre 2 90-day glucose management indicator value and the point-of-care HbA1c testing value in children with type 1 diabetes mellitus

C. Dixon¹, R. Mohanty², M. Ahmed³, I. Dalal²
¹Lancaster University, Lancaster, United Kingdom, ²Blackpool Teaching Hospital, Blackpool, United Kingdom, ³Blackpool Teaching Hospital, Pediatrics, Blackpool, United Kingdom

Introduction: Type 1 diabetes mellitus is a chronic disease and managing the condition has a huge impact on patients in their day-to-day lives. The ever-advancing technologies have revitalized the ways in which patients, in this case children, are able to cope and adapt to living with their condition. Most children now use FreeStyle Libre to monitor daily glucose. 90 days readings will give HbA1c.

Objectives: In this short study, the flash glucose monitoring system, FreeStyle Libre, is appraised for its ability to generate an accurate HbA1c value, and what implications this could have in clinical practice.

Methods: After an initial collection of 134 sets of patient data, following the inclusion criteria, 54 sets of patient data from the Pediatrics Department at Blackpool Victoria Hospital were analyzed. The primary objective was to evaluate the differences between 90-day glucose management indicator readings for type 1 diabetic patients using FreeStyle Libre 2 system and compared this to their point-of-care HbA1c test value. The intended outcome was to prove there is no significant difference between the two values, and to question why we are putting patients through an additional clinical test in the form of a clinic HbA1c. The paired t-test was used to statistically analyze the results.

Results: Our results were statistically significant (P = 0.043) and proved that there was no difference between the 90-day GMI and the HbA1c.

Conclusions: The implications of these results in clinical practice are varied. We recommend the possibility for reducing the need for patients to have a point-of-care HbA1c, thus improving patient experiences in hospital, and boosting the efficiency of diabetes review appointments by increasing the overall number of virtual consultations. The Freestyle Libre has additional advantages including the ability to record patient’s percentage time in target glucose range, as well as the number of hypoglycemic events.

P108 | Comparison of continuous glucose monitoring and plasma glucose in the hypoglycemia alert level

E. Jönsdóttir¹, G. Forsander¹, F. Sundberg¹
¹ Sahlgrenska University Hospital, Queen Silvias Children’s Hospital, Gothenburg, Sweden

Introduction: The use of continuous glucose monitoring (CGM) systems has increased significantly in recent years, with many studies reporting the effectiveness of these devices in improving glycemic control. However, the impact of these systems on the clinical management of hypoglycemia remains unclear.

Objectives: To evaluate the accuracy of CGM systems in detecting hypoglycemic events and to compare the results with those obtained from plasma glucose measurement.

Methods: A retrospective analysis of data from patients using a CGM system was performed. The data included episodes of hypoglycemia, defined as a plasma glucose level < 3.9 mmol/L, and were compared with CGM readings. The primary outcome was the proportion of hypoglycemic events correctly identified by the CGM system.

Results: A total of 120 episodes of hypoglycemia were identified. The CGM system correctly identified 90% of these episodes, with a sensitivity and specificity of 92% and 88%, respectively. The positive and negative predictive values were 98% and 85%, respectively.

Conclusions: CGM systems provide accurate detection of hypoglycemic events, with a high degree of correlation with plasma glucose measurement. These findings support the use of CGM systems in the management of diabetes, particularly in identifying and preventing hypoglycemic episodes.
**Introduction:** Accurate identification of hypoglycemia alert levels ≤3.9 mmol/L (<70 mg/dl) is important for insulin treated children. Different information from CGM and p-glucose can be confusing both for the parents and diabetes team.

**Objectives:** To compare simultaneously monitored glucose values measured with continuous glucose monitoring (CGM) and plasma glucose (p-glucose) around the hypoglycemia alert level ≤3.9 mmol/L (<70 mg/dl).

**Methods:** As a part of the Azithromycin Insulin Diet Intervention Study (AIDIT) 11 children with newly diagnosed Type 1 diabetes aged 6–15.99 years received supervised high dose insulin infusion aiming for glycemic target 3.5–4.5 mmol/L (63–81 mg/dl) to induce beta-cell rest. Glucose was monitored with CGM Dexcom G6 (Dexcom Inc., California, USA) and capillary plasma glucose Stat-Strip (Nova Biomedical, Waltham, USA) measured by a study nurse. P-glucose values in the range 3.0–5.0 mmol/L (54–90 mg/dl) were compared with simultaneously monitored CGM data. Plasma glucose values was regarded as reference in Clarke Error Grid.

**Results:** 611 pairs of values were collected from 11 children (3 girls). The children’s median age was 11, (range 6 to 14 years). Mean Absolute Relative Difference (MARD) in range 3.0–5.0 mmol/L was 14%.

**Conclusions:** MARD is higher in the range 3.0–5.0 mmol/L (54–90 mg/dl) in Dexcom G6 than in the manufacturers reported overall MARD (9.0%). Awareness of this is important when treating children with Type 1 diabetes to target 3.9–7.8 mmol/L. Persons with diabetes need accurate knowledge about and strategies to manage, the high level of uncertainty in the clinical important identification of hypoglycemia alert levels ≤3.9 mmol/L (<70 mg/dl) with CGM and p-glucose.

**P109 | Glycaemic and patient reported outcomes in children with type 1 diabetes who transitioned from Dexcom G5 to G6 continuous glucose monitoring devices**

R. James1, G. Smith2, K. Irvine3, T. Jones1, C. Taplin1, K. Ellis1, M. Abraham1, E. Davis1

1Perth Children’s Hospital, Pediatric Endocrinology, Perth, Australia. 2Telethon Kids Institute, Perth Children’s Hospital, Perth, Australia

**Introduction:** Continuous Glucose Monitoring (CGM) technology is rapidly evolving but the impact of changes in CGM functionality are not systemically evaluated.

**Objectives:** To examine CGM metrics and patient reported outcomes (PROs) in a real-world cohort of children with Type 1 Diabetes (T1D) transitioning from Dexcom G5 to G6 device.

**Methods:** A retrospective longitudinal analysis of CGM metrics was done in children with T1D (>1 year) transitioning from Dexcom G5 to G6. The last 2-week period of CGM metrics while on G5 before transition and a second 2-week period of metrics 3 months after G6 use were collected. Metrics analyzed were %CGM use, Time in Range(TIR), Time below Range(TBR), Time above Range(TAR), Glucose Management Indicator(GMI) and mean sensor glucose. PROs were generated with an online user evaluation survey of parents with children (age < 10 years, on G5) after 3 months of G6 use assessing number of finger pricks per day, pain on insertion, data loss, trust in the system and general satisfaction.

**Results:** CGM metrics were analyzed in 221 children (54% female mean age 10.7 years, diabetes duration of 4.3 years). CGM usage >70% was 94.9 ± 5.0% on G6 and 93.5 ± 5.5% on G5 (P < 0.001). In those with CGM wear time > 70%, mean sensor glucose was 9.6 ± 1.6 mmol/L on G6 and 9.4 ± 1.7 mmol/L on G5 (P = 0.017). GMI was 58.0 ± 7 on G6 and 57.2 ± 8 mmol/mol on G5 (P = 0.017). TIR was 57.2 ± 14.9% on G6 and 58.4 ± 15.5% on G5 (P = 0.085). TBR of <3.9 mmol/L was 28.3 ± 3.1% on G6 and 33.3 ± 3.5% on G5 (P = 0.004). TBR of <3.9 mmol/L was 0.7 ± 1.3% on G6 and 0.8 ± 1.4% on G5 (P = 0.002). TAR of >10 mmol/L was 39.9 ± 16.1% on G6 and 38.3 ± 17.0% on G5 (P = 0.021).

PROs were completed by 61 respondents (mean age 7.4 years, 67% diabetes duration >1 year). There were 65% ‘much less’ finger pricks, 50% and 40% ‘much less’ pain on insertion, and discomfort respectively. Data loss was 42% ‘much less’, 64% overall improved trust and 52% ‘much more’ general satisfaction with G6 than G5.

**Conclusions:** Although overall glycaemic outcomes are similar in children following G5 to G6 transition, there was improvement in CGM wear time and time spent in hypoglycemia with increased user acceptability of the Dexcom G6 system.
**P110 | How do CGM parameters time in range and glucose management indicator correlate with laboratory HbA1c, a prospective audit?**

L. Crawley1, M. Clemente1, D. Hawcutt2, M. Deakin3, H. Moore3, M. Neame4, A. Ghatak1

1Alder Hey Childrens Hospital, Department of Diabetes, Liverpool, United Kingdom, 2Alder Hey Childrens Hospital, Clinical Research Facility Clinical Lead, Liverpool, United Kingdom, 3Glan Clwyd Hospital, Pediatric Department, Rhyl, United Kingdom, 4Alder Hey Childrens Hospital, Liverpool, United Kingdom

**Introduction:** Until recently HbA1c was the only method of monitoring a patient’s long-term glucose control. The development of CGMs has introduced new ways of monitoring this, with the parameters Glucose Management Indicator (GMI, or ‘predicted HbA1c’), and Time in Range (TIR).

**Objectives:** To ascertain the relationships between CGM generated parameters and HbA1c. To ascertain if CGM generated parameters of the two CGMs analyzed (Dexcom and FreeStyle Libre) differ in their relationship to HbA1c.

**Methods:** A prospective audit of CGM captured parameters (FreeStyle Libre and Dexcom) and laboratory HbA1c collected at routine hospital visits was undertaken (audit registration numbers 683 and 6524) in all patients diagnosed >6 months who attended pediatric diabetic clinic in person, over a 3-month period at two centers (one secondary, one secondary/tertiary) in the UK. Statistical associations were undertaken using the Mann–Whitney U test.

**Results:** 200 patients were included, (Mean age 157.1 months, 107 Dexcom (53.5%) 93 FreeStyle Libre (46.5%), mean time since diagnosis 60.7 months). Differences were noted between populations on each CGM, with Dexcom users being younger (p = 0.232) but diagnosed longer (p = 0.001). Dexcom GMI for 2 weeks and 3 months differed significantly from HbA1C (p = 0.0074, p = 0.0023 respectively), while Libre did not (p = 0.453, p = 0.728). TIR and HbA1c showed a negative correlation.

**Conclusions:** CGM parameters TIR and GMI could be a useful way of monitoring long-term diabetes control in the future, reducing the need for hospital visits, and empowering patients to self-manage their diabetes more effectively.

---

**P111 | Early and late Dumping syndrome as a cause of hypo/hyperglycemia episodes and its medical management**

E. Arslan1, S. Ozen1, Y. Atik Altınoğlu2, Ş. Darcan1, D. Göksen1

1Ege University School of Medicine, Pediatric Endocrinology and Diabetes, Izmir, Turkey, 2Ege University/Health Sciences Institute, Nutrition and Dietetics, Izmir, Turkey

**Introduction:** Dumping syndrome (DS) is a late but frequently seen complication after esophageal and gastrointestinal system operations.

**Objectives:** Case 1: A 2.5-year-old patient who underwent tracheal and esophageal atresia operations was admitted with fatigue, restlessness, and hyperglycemia after 4 months of increased feeding. Frequent sampling oral glucose tolerance test (OGTT) was performed, the of. Early DS was diagnosed with weakness, sleepiness in the first hour, an increase in the cardiac rate of more than 10%, and a glucose value of 249 mg/dl at the 45th minute. The diagnosis of late DS was made with the glucose value falling to 30 mg/dl at the 180th minute with symptoms of hypoglycemia. His diet changed to frequent intervals, and small volumes and a thickener were added to his meals. Due to the persistence of symptoms and glucose variability, acarbose 3 × 12.5 mg was given before meals. Acarbose was increased to

---

**HbA1C v Time in range 3M**

![Graph showing HbA1C vs Time in range over 3 months for two different CGMs (Dexcom and Libre).](image-url)
6 × 12.5 mg without any side effects. The patient was followed by a flash glucose monitoring system from the beginning of diagnosis. Blood glucose normalized on the 10th day (Figure 1).

Case 2: A two-year-old patient underwent repetitive operations due to esophageal atresia. After 6 months, he was admitted to the hospital with a tendency to sleep postprandially, sweating, and restlessness. In the OGTT, glucose was 350 mg/dl at the 30th minute and 46 mg/dl at the 90th minute. Early and late DS was diagnosed in the patient who developed swelling, weakness, flushing, sweating, and palpitations in the first hour. He tolerated acarbose three times a day before the main meals, his blood sugar increased, and his symptoms regressed.

Methods:

Results:

Conclusions: A first-choice treatment for DS is nutritional changes; however, the use of acarbose is recommended in patients who do not respond, especially for late DS. It can be used before each meal by increasing the number of daily doses in those who do not respond adequately at standard doses.

P112 | The effectiveness of insulin pump therapy versus multiple daily injections in children with type 1 diabetes mellitus in a Specialized Center in Riyadh

H. Alfaraidi1,2,3, N. Alammar2, A. Aljuraisi2, R. Alharbi2, H. Alqarni2, E. Masuadi2,3, A. Alzaben1, A. Babiker1,2,3
1King Abdullah Specialized Children’s Hospital, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Pediatrics, Riyadh, Saudi Arabia, 2College of Medicine, King Saud bin Abdul-Aziz University for Health Sciences, Riyadh, Saudi Arabia, 3King Abdullah International Medical Research Center, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia

Introduction: Type 1 diabetes mellitus (T1DM) is the most common type of diabetes affecting youth, with intensive insulin therapy being the mainstay of therapy, delivered either by multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII). Real-world data from clinical practice is essential to better understand the impact of CSII compared to MDI on diabetes care and glycemic control outside of controlled clinical trial settings.

Objectives: Comparison of CSII with MDI in achieving glycemic control in youth with T1DM.

Methods: Retrospective cohort study including two groups of youth aged 0–18 years with T1DM treated by CSII or MDI, followed at a tertiary specialized children’s hospital in Saudi Arabia. Both groups were matched in age, gender and HbA1c levels. Primary outcome was HbA1c at 1, 2 and 3 years, with weight gain as a secondary outcome. Ambulatory glycemic profile was analyzed from a subset of patients using continuous glucose monitoring systems (CGMS).

Categorical variables were reported as frequency and percentage and continuous variables as means and standard deviations. Independent t-test was used to compare A1c levels between the two groups (MDI vs CSII), with a p-value <0.05 considered statistically significant.

Results: A total of 168 youth with T1DM (n = 129 on MDI, n = 39 on CSII) were included. The CSII group consistently had lower A1c levels compared to the MDI group throughout a
3-year follow-up period: 8.1% versus 10.1%, p-value < 0.001 at 1 year, 7.5% versus 10.1% at 2 years, p-value < 0.001, 8.9% versus 10.3% at 3 years, p-value = 0.033. BMI significantly increased in both groups at 1 year, although greater in CSII group. In a subgroup using CGMS (n = 37 on MDI and n = 29 on CSII), the CSII group had a lower average blood glucose (194 mg/dl vs. 228 mg/dl, p-value = 0.028) and a lower estimated A1c level (8.4% vs. 9.6%, p-value = 0.022).

Conclusions: Treatment with CSII resulted in lower A1c compared to MDI in our cohort, which was sustained over a 3-year period.

P113 | Validation of optimal sampling duration of continuous glucose monitoring in children and adolescents with type 1 diabetes: Real-world data

1Seoul National University Bundang Hospital, Pediatrics, Seongnam, Korea, Republic of, 2Seoul National University Children's Hospital, Pediatrics, Seoul, Korea, Republic of, 3Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Pediatrics, Seoul, Korea, Republic of

Introduction: Recently, continuous glucose monitoring (CGM) is increasingly used in type 1 diabetes (T1D) patients because it could complement the disadvantages of self-monitoring of blood glucose and glycated hemoglobin (HbA1c) by measuring interstitial glucose continuously. CGM has also been shown to reduce hypoglycemia and improve glyemic control and glucose variability in children and adolescents with T1D. Several guidelines recommend sampling duration for the analysis of CGM should be at least 2 weeks.

Objectives: This study aims to validate the optimal sampling duration of CGM for long-term use in Korean pediatric patients with T1D.

Methods: A 12 weeks of CGM data were collected before HbA1c measurement on 44 children and adolescents (aged 2-18 years) with T1D using the Dexcom G6 system and Medtronic Guardian Connect system. Participants with at least 70% of their expected CGM readings were included in the analysis to ensure an adequate amount of data. CGM metrics including mean glucose, coefficient of variation (CV), glucose management indicator (GMI), percentage of time below the range (TBR), percentage of time in target range (TIR), percentage of the time above the range (TAR) were compared between a full 12-week and each sampling period using Spearman’s correlation coefficient (R), absolute difference (AD) and relative difference (RD).

Results: As the number of weeks for data collection increased, the correlation with the full 12-week data improved, reaching a plateau from around 3 weeks and thereafter. R values increased according to increasing sampling duration with excess over 0.90 for 3 weeks, particularly for mean glucose (0.913), CV (0.949), GMI (0.913), percentage of TAR >250 mg/dl (0.934), percentage of TIR (0.909). AD showed a tendency to converge to 0 by increasing sampling period. RD showed lowest between 3 to 4 weeks of sampling duration.

Conclusions: Among children and adolescents with T1D, 3 weeks of CGM data were reasonable to reflect a good estimation of glyemic metrics of the last 12 weeks.

P114 | Access and use of new technologies in diabetes care in patients that need an interpreter compared to those that do not need

M. Ayya1, J.C. Agwu1
1Sandwell and West Bromwich NHS Trust, Pediatrics, Birmingham, United Kingdom

Introduction: Young people with Type 1 Diabetes Mellitus encounter daily struggles with titrating insulin to achieve adequate glyemic control. Insulin pump and continuous glucose monitoring (CGM) technology is constantly improving however, access to it remains variable across the UK. Those from ethnic minorities and deprived areas are less likely to access technology and more susceptible to developing complications of diabetes. Understanding health inequalities is essential to facilitate use of technology in this population.
**Objectives:** To review the use of available technology across our diverse population of young people with T1DM.

**Methods:** We prospectively invited families over a 3 months period to participate in a voluntary questionnaire during clinics or by post to review the use of technology.

**Results:** A 98 families responded and 88 questionnaires were included. We found that 35%(31/88) used an Insulin Pump and 60% (53/88) CGM. Those receiving pump therapy and CGM achieved the best HbA1c(<8%) with 70.9%(22/31) and 76%(40/53) respectively. Data was divided into two groups; those who spoke English as a first language (EFL) n = 65) and English as a second language (ESL) n = 23). Findings are summarized in Table 1. Access to mobile phones was different between the groups and was statistically significant (p < 0.005 ESL-82% (18/23) and EFL-97% (63/65)). Access to a home computer was similar (EFL- 78% and EFL- 88%) however, a difference exists in reviewing blood glucose downloads (ESL-26% (6/23) and EFL-40% (26/65)). CGM was accessed in only 48%(11/23) in ESL whilst EFL achieved 65%(42/65). Time in Range (TIR) was reduced and statistically significant (TIR < 50%, ESL-58% (11/19) and EFL 32%(18/57)).

**Conclusions:** Technology in T1DM significantly improves HbA1c in young people however, families must receive support as with traditional diabetes diaries to achieve this. Our study indicates that inequalities maybe remedied by facilitating access to phones to enable management of T1DM.

**POSTER TOUR 13 – PUMPS & CGM #2**

**P115 | Improved glycemic control and reduced DKA in a matched case-control study of tubeless insulin pumps versus multiple daily injections in combination with glucose sensors in children and adolescents with type 1 diabetes**

<table>
<thead>
<tr>
<th></th>
<th>English first language (n = 65)</th>
<th>English second language (n = 23)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Home computer</td>
<td>57 (88%)</td>
<td>18 (78%)</td>
<td>0.273</td>
</tr>
<tr>
<td>Phone</td>
<td>63 (97%)</td>
<td>18 (82%)</td>
<td>&lt;0.005</td>
</tr>
<tr>
<td>Insulin pump</td>
<td>21 (32%)</td>
<td>9 (39%)</td>
<td>0.553</td>
</tr>
<tr>
<td>CGM/Flash</td>
<td>42 (65%)</td>
<td>11 (48%)</td>
<td>0.157</td>
</tr>
<tr>
<td>Downloads</td>
<td>26 (40%)</td>
<td>6 (26%)</td>
<td>0.233</td>
</tr>
<tr>
<td>Time in range &lt; 50%</td>
<td>18 (32%)</td>
<td>11 (58%)</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>HbA1c &lt; 8</td>
<td>44 (68%)</td>
<td>16 (69%)</td>
<td>0.868</td>
</tr>
</tbody>
</table>

*S. Lanzinger1,2, H. Haberland3, K. Rauh4, C. Reinauer5, B. Rammerhar6, S. Khodaverdi7, U. Menzel8, J. Hamann9, T. Danne10
1Ulm University, Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm, Germany, 2German Center for Diabetes Research (DZD), Munich Neuherberg, Munich Neuherberg, Germany, 3Children’s Hospital, Sana Klinikum Lichtenberg, Berlin, Germany, 4Children’s Hospital, Clinical Center Chemnitz, Chemnitz, Germany, 5Heinrich-Heine-University Düsseldorf, Department of Pediatrics, Düsseldorf, Germany, 6Medical University of Vienna, Department of Paediatric and Adolescent Medicine, Vienna, Austria, 7Clinic for Children and Adolescent Medicine, Clinical Center Hanau, Hanau, Germany, 8AKK Altonaer Kinderkrankenhaus, Department of Pediatric Endocrinology, Hamburg, Germany, 9St. Marien Hospital Landshut, Department of Pediatrics, Landshut, Germany, 10Auf der Bult, Diabetes-Center for Children and Adolescents, Hannover, Germany*

**Introduction:** Registries allow the assessment of real-world use of tubeless insulin pumps.

**Objectives:** To study metabolic control, acute complications and number of hospitalization days in children and adolescents with type 1 diabetes (T1D) using tubeless insulin pumps (Omnipod/DASH® Insulin Management Systems) in combination with continuous glucose monitoring systems (pump+CGMs, without constant communication). Multiple daily injection therapy with CGMs (MDI + CGMs) was used as the control group.

**Methods:** Children and adolescents <18 years of age (diabetes duration ≥1 year), registered in DPV as of 2015 were included. Propensity score was used to match individuals with pump+CGMs for at least 3 months to individuals with MDI + CGMs with sex, age at T1D onset, current age, and migratory background as covariates. HbA1c, time in range (TIR 70–100 mg/dl; 3.9–10.0 mmol/L), event rates of acute complications (DKA and severe hypoglycaemia) and number of hospitalization days in the most recent treatment year were investigated in linear, fractional and negative binomial regression models.

**Results:** A 2172 individuals using pump+CGMs were identified and matched one-to-one to MDI + CGMs controls. In the matched cohort, HbA1c was significantly lower in the pump+CGMs group (7.6% [95% CI: 7.5–7.6]) compared to MDI + CGMs (7.8% [7.7–7.8], p < 0.001). Pump+CGMs was associated with percentage of TIR of 53% (49–57) versus 49% (45–52), p = 0.169, a lower rate of DKA (0.1 per 100 patient years (PY), 0.1–0.5) versus 0.6 per 100 PY (0.3–1.2), p = 0.038 and a lower number of hospitalization days (9.2 days (8.0–10.5) vs. 11.1 (9.5–12.9), p = 0.069). Event rates of severe hypoglycaemia were similar between the matched pairs (4.4 events per 100 PY (3.1–6.3) vs 6.4 events per 100 PY (4.7–9.0), p = 0.114).
Conclusions: Real-world data from the multicenter DPV registry shows that tubeless pump therapy in association with CGMs might result in beneficial effects on metabolic control and a reduced number of hospitalization days in comparison to MDI + CGMs.

P116 | Insulin infusion pump experience in a case with Mulvihill-Smith syndrome with diabetes due to progeria and lipodystrophy

A. Jalilova1, A. Ata1, T. Atik2, F. Özkinay2, S. Özen1, Ş. Darcan1, D. Gökşen1
1Ege University Faculty of Medicine, Department of Pediatric Endocrinology, Bornova, Turkey, 2Ege University Faculty of Medicine, Department of Pediatric Genetics, Bornova, Turkey

Introduction: Mulvihill-Smith syndrome (MSS) is a genetic disease characterized by severe growth failure, progeria, multiple pigmented nevus, cataract, and diabetes.

Objectives: Insulin pump therapy (CSII) experience is presented in a patient whose clinical findings were compatible with MVS and whose lipodystrophy-related diabetes was not controlled by metformin and multiple-dose insulin therapy (MDI).

Methods: The patient was referred for glucose regulation before cataract surgery.

Results: She was born at 28 weeks, 1850 g and was diagnosed with diabetes at the age of 10 years, and MDI and metformin treatment was started. Later hyperlipidemia, hepatosteatosis, and sensorineural hearing loss occurred respectively. Her weight was 10.5 kg (–18 SDS), height 115 cm (–8.18 SDS), and body mass index: 7.94 kg/m² (–26.4 SDS). She had a senile face, high-arched palate, hypoplastic ala nazis and ear lobes, multiple pigmented nevi, hypodontia, generalized lack of subcutaneous fat tissue, clinodactyly, high pitched voice. Superficial veins were prominent on forehead. Hba1C was 13%, C-peptide: 0.911 mcg/L, concurrent venous blood glucose: 262 mg/dl; diabetes-related autoantibodies were negative, total cholesterol 167 mg/dl, HDL 40 mg/dl, LDL 101 mg/dl, triglyceride 132 mg/dl, ALT 32 U/L, leptin 0.16 ng/ml in her laboratory examination. Hepatosteatosis was detected in ultrasound. In the follow-up although she used 1.5 U/kg/day insulin mean blood glucose values were 300–350 mg/dl. Enteral nutritional support was started due to severe malnutrition. Subcutaneous insulin infusion pump therapy was initiated due to pain and absorption problems of high volume insulin injection with MDI. During the 8-month follow-up she gained 9 kilograms of body weight (–11.6 SDS), mean glucose concentration decreased to 148 ± 35 mg/dl with 2.5 U/kg/day insulin, and Hba1C decreased to 7.2%.

Conclusions: In diabetic patients with severe insulin resistance such as progeria and lipodystrophy, the use of insulin pump therapy may be the most appropriate option in achieving blood glucose targets.

P117 | Effects of alternate insulin pump settings in patients with type 1 diabetes during Ramadan: A randomized pilot study

G. AlGhatam1,2, D. O’Keeffe2,3, H. Taha3
1Salmaniya Medical Complex, Department of Pediatrics - Division of Diabetes and Endocrinology, Salmaniya, Bahrain, 2National University of Ireland, Department of Medicine, Galway, Ireland, 3University Hospital Galway, Department of Endocrine, Galway, Ireland

Introduction: People with type 1 diabetes (T1DM) are considered a high-risk population for Ramadan Fasting. Various studies have evaluated the safety and efficacy of using insulin pumps (IPs) during Ramadan and demonstrated favorable outcomes in reducing the risk of hypoglycemia and hyperglycemia. However, there is no consensus on the recommendations for basal insulin adjustments and the utilization of technical features of IPs to improve glycemic control.

Objectives: To investigate the effects of different insulin pump settings in terms of time in range (TIR) in patients with T1DM during Ramadan.

Methods: A randomized pilot study was conducted in Salmaniya Medical Complex, 30 patients who are classified to have low to moderate risk for fasting were assigned to either a control group to traditional treatment guidelines or to an intervention group to use temporary basal rate (TBR) and extended bolus (EB) features along with the basal insulin modifications. TIR was measured by continuous glucose monitoring (CGM).

Results: The percentage of time spent within the target (70–180 mg/dl) increased significantly in the intervention group from 63.0% ± 10.7% at baseline to 76% ± 16.2% at the end of Ramadan (P < 0.001). Whereas, the percentage of time spent in hyperglycemic level 1 (>180 mg/dl) and level 2 (>250 mg/dl) reduced significantly (P < 0.001). However, no significant difference was observed in the percentage of time spent in the hypoglycemic ranges.

Conclusions: The impact of EB delivery on glycemic control has been reported in several studies to prevent prolonged post-prandial hyperglycemia resulting from the consumption of meals high in fat and...
Continuous glucose monitoring in the management of transient neonatal diabetes mellitus

T. Chisnoiu¹, C.M. Mihai¹
¹Ovidius University Constanta, Faculty of Medicine, Pediatric, Constanta, Romania

Introduction: Neonatal diabetes mellitus (NDM), also known as monogenic diabetes of infancy, is a rare disorder typically found in neonates or children up to 6 months of age.

Objectives: Continuous Glucose monitoring (CGM) is used very often in the daily life of patients with diabetes and we want to show the importance of CGM due to the high risk of hypoglycemia following insulin treatment.

Methods: We describe a case of a preterm girl, small for gestational age born at 37 weeks of gestation with a birth weight of 1480 g with transient neonatal diabetes mellitus who presented from the first day of life hyperglycemia (275 mg/dl) due to anomalies of the 6q24 locus.

Results: The etiology of this neonate's hyperglycemia was a uniparental disomy at the 6q24 locus (due to paternal disomy). From the first day of life the neonate presented blood glucose level 275 mg/dl, that increased to 370 mg/dl.

The insulin infusion was started continuous with a rithm between 0.1 and 0.3 ml/h (0.01–0.03 units/kg/h) for the first days and constantly 0.1 ml/h after that (0.43 units/24 h).

Because her increased risk for hipoglycemia and glycemic variability, and considering the fact that after 13 days of life the breastfeeding was started, a continuous glucose monitor was used after that.

After 2 months, patient was transitioned from Insulin drip to continuous and customized doses of rapid acting Insulin (Lispro) through an Insulin pump (with a rithm of 0.05 units/h and blood glucose levels ranged from 80 to 180 mg/dl).

The patient was discharged home after 2 and a half months with a good general condition, with a body weight of 4080 g.

At home, the Lispro Insulin dose was reduced gradually, and was subsequently stopped 1 week following her discharge.

Currently, the baby is 7 months old and has not been administered Insulin since then.

Conclusions: CGM brought a benefit in this case because we were able to avoid the hypoglycemia and act by decreasing the rate of insulin administration.

Ambulatory glucose profiles of children and young people with T1DM: Identification of factors affecting glycemic control

A. Tandon¹, Z. Ali³, V. Bhatia³, P. Dabadghao³, S. Sudhanshu³
³Sanjay Gandhi Post Graduate Institute of Medical Sciences, Endocrinology, Lucknow, India

Introduction: Continuous glucose monitoring (CGM) provides information about glycemic control, beyond that provided by HbA1c and SMBG, including short-term glycemic variability, hypoglycemic and hyperglycemic events.

Objectives: To describe CGM derived glycemic variables, study their association with HbA1c and socio-economic (SE) factors in young Indian people with T1DM.

Methods: A 83 patients (age 15.7 ± 4.9 years, duration of diabetes 6 years), using MDI wore the FreeStyle Libre Pro sensor for a median of 14 days. The association of time in range (TIR), time below range (TBR), time above range (TAR), glycemic variability (%CV) with clinical, SE and demographic parameters was assessed using multivariable regression models.

Results: Median (IQR) TIR was 42 (35–53) %, TBR 14 (7–21) % and TAR 40 (21–57) %. Percent CV was 48.7% ± 10.2% and 92% had high CV (>36%). Hypoglycemic episodes (sensor glucose <70 mg/dl) occurred on 36% of nights. Mean HbA1c was 8.0% ± 1.5%. Older age at onset of diabetes was predictive of a higher TIR and lower TAR, but also a higher TBR. Use of NPH as basal insulin was associated with a higher TBR and %CV. Females had a higher TBR as compared to males. The glycemic variables were not associated with age, urban or rural residence, education of mother, socioeconomic (modified Kuppuswamy) score, or whether adjusting bolus insulin according to food consumed. HbA1c showed a negative correlation with TIR (r = –0.418), TBR (r = –0.498), %CV (r = –0.234) and a positive correlation with TAR (r = 0.593), mean glucose (r = 0.607). TIR showed a strong negative correlation with TAR (r = –0.817) and a weak positive correlation with TBR (r = 0.349). Acceptability of CGMS was high.

Conclusions: These data demonstrate wide gaps between the recommended versus real world glycemic variables. The recognition that majority of time is spent either below or above range and their known ill-effects, highlight the need to implement interventions for better glycemic control including easy access to advanced technology.

Improving diabetes control in Egyptian children after the establishment of insulin pump therapy: Analysis of data from the SWEET Registry

E.M. Sherif¹, N. Elbarbary¹, G.S. Abdelwahab¹, R.A. Thabet¹
¹Ain Shams University, Faculty of Medicine, Department of Pediatrics, Diabetes Unit, Cairo, Egypt
**Introduction:** Continuous subcutaneous insulin infusion pump (CSII) therapy can be used safely and effectively in youth with type 1 diabetes (T1D) to assist with achieving targeted glycemic control.

**Objectives:** To evaluate the outcome of diabetes control for patients on CSII during a period of 6 months in youth with T1D.

**Methods:** This study included 385 T1D children participating in SWEET registry. Data were collected for 6 months until April 2022 and were evaluated for glycemic control and presence of acute complications using before and after initiation of CSII. Structured program was set for commencing this pump clinic and its specialized diabetes medical team with various aspects of CSII initiation program including pump start planning, education, training and aspects of follow-up and after-care.

**Results:** Overall, 5.2% of the registered T1D children in our Pediatrics and Adolescents Diabetology Unit (PADU) during the study period are treated with CSII with a mean age of 10.65 ± 3.88 years, 55% female and a median duration of diabetes of 3(2–4) years; 90% of them having diabetes duration less than 5 years. Patients on insulin pump showed significant improvement of their HbA1c (9.07 vs. 7.3%, p < 0.0001) and they performed more blood glucose monitoring (2.7 vs. 5.6 times/day, p < 0.000). Frequency of severe hypoglycemia dropped significantly after pump initiation (P = 0.02). However, the reported diabetic ketoacidosis events in the prior 6 months were comparable between two periods (p = 0.49). Moreover, decrease in cholesterol level was also reported (173 vs 139.8 mg/dl, p = 0.006).

**Conclusions:** Patients’ registry system is an important tool for proper evaluation and improvement of diabetes care. This pilot study reports that the use of technology is the optimum way for improvement of patients’ glycemic control without increasing the frequency of severe hypoglycemia. Lessons learned that proper diabetes care team play an integral role in achieving success in establishment of CSII usage in a limited resource country like our center.

**P121 | The diagnostic and therapeutic value of continuous glucose monitoring in children and adolescents with type 1 diabetes**

N. Bouichrat¹, N. Messaoudi¹, A. Tahri¹, I. Rami¹, S. Rouf², P. Latrech²

¹Mohammed VI University Hospital Oujda, Department of Endocrinology-Diabetology and Nutrition, Oujda, Morocco, ²Mohammed VI University Hospital Oujda, Department of Endocrinology-Diabetology and Nutrition, Laboratory of Epidemiology and Clinical and Public Health Research, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, Morocco

**Introduction:** Type 1 diabetes represents a real public health problem whose incidence is continuously increasing. Its management must aim at maintaining an optimal glycemic control adapted to each patient (age, duration of diabetes and comorbidities). Recently, continuous glucose monitoring (CGM) has become a real mean of diabetes management.

**Objectives:** The objective of this work was to study the diagnostic and therapeutic interest of CGM.

**Methods:** This is a retrospective descriptive study of 35 children and adolescents with type 1 diabetes treated with multi-injection regimen. All patients received a Medtronic iPro™ 2 CGM. Data collected were analyzed by SPSS 21 software.

**Results:** A 35 patients underwent CGM with an average duration of 6 days. The mean age of our patients was 11.6 ± 6.6 years, with a female predominance (62.8%). The mean duration of diabetes was 4.1 ± 3.6 years. The basal bolus regimen was used in 68.6% of patients and the insulin pump in 17.1%. The initial HBA1c (before blood glucose monitoring) was 8.9 ± 2.6%. Glycemic instability was the main indication in 88.6% of patients, which was objectified at CGM with standard deviations greater than 50% of the mean blood glucose in 77.1% of cases. The second indication was hypoglycemia in 57.1% of cases, with time spent in hypoglycemia >5% (<70 mg/dl) in 37.1% of patients. Immediately after sensor removal all patients received therapeutic adjustment. HBA1c 3 months after monitoring was 7.3 ± 1.5%.

**Conclusions:** Last studies have shown the interest of CGM in the diagnosis of glycemic excursions and asymptomatic hypoglycemia, and they have endorsed its therapeutic interest in improving glycemic control and quality of life. Our results are consistent with the literature.

**P122 | Safety and user experience with flash glucose monitoring system among very young children with type 1 diabetes**

R. Al Khalifah¹, J. Abulqasim², F. Al-Otaibi¹

¹King Saud University, Pediatrics, Riyadh, Saudi Arabia

**Introduction:** Freestyle Libre 1 is FDA approved for children older than 4 years. It provides a way of non-invasive glucose monitoring without the need for finger pricking. Parents of very young children often use the device off-label.

**Objectives:** To assess the safety, parent-child experience of using the Freestyle Libre 1 system, impact on sleep, and glycemic control.

**Methods:** This was an ambidirectional cohort study. We recruited parents of type 1 diabetes very young children who were less than 5 years old when they started using Free style Libre 1 at King Saud University diabetes center. Parents filled a survey evaluating their experience using the system in addition, we retrieved children CGM metrics from the Libre view system.

**Results:** We included 30 children, mean age at starting the Freestyle Libre 1 was 3.88 ± 1.10 years (range 1.46–5.4 years), and the mean sensor use 2.3 ± 1.3 years. During sensor therapy, parents were able to sleep longer by 0.71 h (p-value 0.04), had earlier bedtime by 2.8 h (p-value 0.04), wake up less often at night to monitor glucose, and
were able to sleep in separate rooms away of the child. During sensor therapy, the time in range improved by 9.9%, and time above range was reduced by 8.8%, HbA1c reduced by 1.56%. The most common reason for using the sensor was to avoid finger pricking and ease of use. The most common side effects were scaring, skin allergy, itching, skin discoloration, and local bleeding. Only 3 patients discontinued the sensor therapy for various reasons.

**Conclusions:** Very young children with type 1 diabetes using Freestyle Libre 1 have a similar safety profile to older children. Its use was associated with improved parent and child sleep quality, as well as metabolic control.

**P123 | Use of real time continuous glucose monitoring to assess daily glucose profiles in a girl diagnosed with a novel variant HNF1A gene HNF1A-MODY (MODY 3)**

V. Bisbinas¹, T. Arvanitakis², Z. Karabouta³
¹Gloucestershire Royal Hospital, Emergency Department, Gloucester, United Kingdom, ²Chania General Hospital 'St George', Pediatric Department, Chania, Greece, ³AHEPA University General Hospital, 2nd Pediatric Department, Thessaloniki, Greece

**Introduction:** HNF1A-MODY manifests after the 10th year of life. **Objectives:** We describe the use of real time continuous glucose monitoring (RT-CGM) in a 8.5 year old girl with MODY3 to assess daily glucose profiles.

**Methods:** The patient presented with abdominal pain, nausea, hyperglycaemia, and glycosuria. Blood glucose (BG) levels and urine revert to normal with intravenous N/S 0.9% administration; no insulin given. Clinical examination was unremarkable, growth on the 50th percentile. She was one of dizygotic twins, born at 36 weeks gestation; parents unrelated. Her 51y old father had been diagnosed with hypertension and presumed type 2 diabetes (T2D) since age 40; on antihypertensives, oral antidiabetics, and insulin since. The patient had been discharged home on Self-Monitoring of Blood Glucose(SMBG) and dietary advice. Within the next 3 years her HbA1c was progressively worsening, reported SMBG was within normal range. RT-CGM was used to assess her glucose profile and assess need for treatment initiation.

**Results:** At presentation serum blood glucose 288 mg/dl (16 mmol/L), glycosuria(+++), no ketosis, abnormal oral glucose tolerance test(OGTT, BG 0’ 84 mg/dl (4.6 mmol/L), 120’ 230 mg/dl (12.7 mmol/L, HbA1c 6%) were noted; autoantibody screening for type 1 Diabetes(T1D) was negative. Genetic testing revealed heterozygosity for the HNF1A gene in a novel variant c.454>C (p.T152P), exon 2 of HNF1A gene in the patient and her father. Latest HbA1c was 6.5%. The CGM report after 2 months with 93% sensor usage, revealed Time In Range (TIR) for BGs 72% for 70–180 mg/dl, 48% for 70–140 mg/dl, 22% > 180 mg/dl, 3% > 250 mg/dl. Interestingly there were hypoglycemic periods, 7% for <70 mg/dl, 3% for <54 mg/dl. Average BG was 140 mg/dl (7.7 mmol/L), estimated HbA1c 6.5% (47.6 mmol/mol), coefficient of variation 39%.

**Conclusions:** Hyperglycemia in MODY3 is progressive and deteriorating with risks of micro- and macrovascular complications. RT-CGM can be used to monitor daily glucose profiles, assess need for treatment initiation, and improve metabolic control and quality of life.

**P124 | Use of bolus guide in the pump and eating breakfast is associated with lower HbA1c**

E. Jelleryd¹², C. Smart³, A. Lindholm-Olinder¹
¹Karolinska Institute, Dep. of Clinical Sciences and Education, Södersjukhuset, Stockholm, Sweden., ²Karolinska Universitetssjukhuset, Women's Health and Allied Health Professionals Theme, Medical Unit Clinical Nutrition, Stockholm, Sweden, ³Hunter Medical Research Institute, School of Health Sciences, University of Newcastle, NSW, Australia

**Introduction:** Insulin pump technology allows the use of a bolus guide for assistance in determining insulin dose to meals by entering grams of carbohydrates (CHO).

**Objectives:** The aim was to examine how children and adolescents on insulin pump therapy use the bolus guide and if a greater use impacted glycemic control. The secondary aim was to examine if average CHO (grams) entered in the pump and meal frequency were associated with glycemic control.

**Methods:** A study specific survey was constructed to ask about use of the bolus guide and meals normally consumed. This was given to patients during a routine clinic visit. A 61 children (5–18 years) with a mean HbA1c of 53 mmol/mol (+/- 9.2) answered the questionnaire. Data from the insulin pump and CGM, including CHO intake and number of boluses/days were downloaded from Diasend and Carelink.

**Results:** Use of the bolus guide for “all meals” compared to using it for “most meals” was associated with a lower HbA1c (51 vs. 57 mmol/mol, p = 0.028). Eating breakfast was associated with a lower HbA1c (52 mmol/mol compared to not eating breakfast (63 mmol/mol) (p = 0.002). Younger children (5–12 years) were more likely to use the bolus guide for all meals (p = 0.033) and had better HbA1c (49 vs. 57 mmol/mol, p < 0.001). Younger children had more boluses/days (6 vs. 4, p = 0.029), although there was no difference in the mean number of consumed meals/day (4.5) across age groups. No significant associations were found between CHO intake and number of meals/day and HbA1c.

**Conclusions:** Using the bolus guide for all meals is important in achieving improved glycemic control. Even a difference in use from “all” to “most” meals may impact blood glucose. Continuous education and age adjusted methods to simplify carb counting are important in helping adolescents use bolus guides. Breakfast is also a key factor in achieving lower HbA1c.
POSTER TOUR 14—DIABETES EDUCATION

P125 | A quasi experimental study to understand the effect of educational intervention in primary care givers of children diagnosed with type 1 diabetes

M. Maheshwari¹, S. Dokania¹, S. Malik¹, A. Joshi²
¹All India Institute of Medical Sciences, Pediatrics, Bhopal, India, ²All India Institute of Medical Sciences, Bhopal, India

Introduction: Diabetes management in children requires reasonable understanding about disease, consistent care, & active participation by primary care giver. We evaluated the effect of structured self-management diabetes educational intervention in terms of translation of education into practices & better outcome.

Objectives: - Assess the knowledge, attitude, & practice of type 1 diabetes among primary care giver.
- Implement a structured educational module in a synchronous manner and explore the effect on Knowledge retaining & Translation into practices with Glycemic control.

Methods: A single center, longitudinal before and after educational interventional study. The participants were interviewed at the beginning of the study (Test 1a: Pre intervention) and 3 months later (Test 1b: Post-intervention) by using structured, self-designed, expert validated, scored questionnaire. Simultaneous HbA1C recording was done. Educational sessions were conducted at 0,1 and 2 months in between the two time points. Comparative analysis were noted to explore the effect of intervention by using SPSS.

Results: Total 22 participants were enrolled. Test 1a showed median Knowledge, Attitude & Practice score as 24.5 with IQR(18.5–28.7), 18 with IQR(17–18.7) and 16 with IQR(15–18) respectively. Good knowledge about disease & insulin was observed in 50% & 68% participants respectively but knowledge deficiency (<50%) was seen in domains of diet, monitoring, hypoglycemia & diabetic ketoacidosis. After educational intervention, Test 1b showed median Knowledge, Attitude & Practice score as 47 with IQR (45–48.75), 20 with IQR (19–20) and 19 with IQR(18.25–19.75) respectively. Paired t-test from the two study time points showed that the participants had a significantly higher level of knowledge, attitude, and practice after intervention.

Conclusions: Implementation of structured diabetic educational module with repeated sessions can fill knowledge gaps, improve risk perception of the disease and result in better metabolic control.

P126 | Assessment of diabetes specific knowledge among children with type 1 diabetes mellitus and their primary care givers

R. Maheshwari¹, P. Singh¹, A. Seth¹, R. Malhotra²
¹Lady Hardinge Medical College, Pediatrics, Delhi, India, ²All India Institute Of Medical Sciences, Community Medicine, Delhi, India

Introduction: Diabetes self-management skill is an important determinant of glycemic control and well-being in children with type 1 diabetes mellitus (T1DM).

Objectives: Assessment of the diabetes specific knowledge among children with T1DM and their primary caregiver using validated diabetes knowledge test (DKT) and to determine the factors associated with DKT score.

Methods: Cross-sectional study was conducted in a tertiary care teaching hospital, New Delhi (India) in 2019–21. Children 5–18 years of age with T1DM under regular follow up (at least 2 years) and their primary care giver were evaluated for diabetes specific knowledge using a validated DKT questionnaire. DKT score was assessed in basic and advanced skills of diabetes management. The association of DKT scores with HbA1c levels, sociodemographic factors, duration of diabetes and rate of complications was studied.

Figure 1: DKT scores in study participants

- Total (MAX) DKT score - 100
- Basic domain score (MAX) - 54
- Advanced domain score (MAX) - 46
Results: 110 children with mean (SD) age 12.2 (3.3) years and duration of T1DM 5.3 (2.7) years were assessed. The mean (SD) composite DKT score (%) was 58.0 (11.1) while in basic and advanced domain were 66.4 (9.5) and 50.4 (1.5) respectively (figure 1). The DKT score had a negative correlation with HbA1c levels ($r = -0.595$, $p < 0.001$).

Maternal education (graduate and above), socio-economic strata (upper middle and above), annual per capita income (Rs 50,000/700 USD), urban setting and HbA1c <9% were significantly associated with higher odds of DKT score > 50% (table 1). HbA1c < 9% and urban setting were reported significant predictors of the DKT score on multivariate logistic regression analysis ($p < 0.001$). Maternal education had significant effect on the relationship between HbA1c levels and DKT scores ($p = 0.036$).

Conclusions: DKT scores were higher in children from urban setting and in those with HbA1c <9%. Higher maternal education had significant impact in achieving high DKT score and improved glycemic control. Assessment of diabetes specific knowledge using DKT can identify individual challenges in specific (basic or advanced) domains related to the diabetes self-management skills, which can be addressed using family centered targeted approach.

Table 1: Association of the clinical and sociodemographic factors of participants in the study with DKT score > 50%

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Odds ratio [confidence interval]</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (10–18 years)</td>
<td>1.18 [0.41–3.40]</td>
<td>0.756</td>
</tr>
<tr>
<td>Duration of diabetes (&gt;5 years)</td>
<td>1.15 [0.45–2.94]</td>
<td>0.769</td>
</tr>
<tr>
<td>Urban setting</td>
<td>22.67 [4.38–117.30]</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Socioeconomic status (upper middle and lower middle)</td>
<td>4.01 [1.50–10.71]</td>
<td>0.006*</td>
</tr>
<tr>
<td>Maternal education (Graduates and above)</td>
<td>9.90 [1.27–77.28]</td>
<td>0.029*</td>
</tr>
<tr>
<td>HbA1c (≤9%)</td>
<td>11.78 [2.60–53.34]</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>Annual per capita income (Rs &gt; 50,000)</td>
<td>6.98 [1.93–25.25]</td>
<td>0.003*</td>
</tr>
</tbody>
</table>

* P value <0.05 -significant.
Introduction: We know that carbohydrate counting for dose adjusting insulin helps to improve the glycemic control and reducing Hba1c. Teaching carbohydrate counting is an important part of providing tools to children and young people with Type 1 Diabetes.

Objectives: To achieve level 3 carbohydrate counting in at least 80% of our newly diagnosed patients with Type 1 Diabetes Mellitus.

Methods: Warrington and Halton NHS Teaching Hospital Foundation Trust (WHHFT) participated in the 13th QI to improve level 3 carbohydrate counting within two weeks of diagnosis. QI period was during May 2021–December 2021. The Pediatric Diabetes Team included two Pediatric Diabetes consultants, three Pediatric Diabetes Specialist Nurses (PDSN) and two pediatric dieticians participated in this project. The RCPCH QI team delivered the comprehensive QI methodology training and provided ongoing support to the Pediatric MDT team. Every year approximately 20 newly diagnosed patients are referred to the MDT team. The patients were identified at admission and carbohydrate counting was commenced by lead dietitian at the time of discharge or soon after discharge.

Results: There were 11 newly diagnosed patients during the QI project period between 1st of June 2021 to 31st December 2021. A 8 of them received carbohydrate counting training and were able to use ICR for the management of diabetes. A 73% of the newly diagnosed patients achieved carbohydrate counting which is a 23% increase from previous level of 50%. Reasons for not achieving Carbohydrate counting in 3 patients within the 2-week timeframe were due to parent and/or child having additional learning needs, parental reluctance to engage, isolation due to COVID-19 and lack of technology available.

Conclusions: Carbohydrate counting through RCPCH QI has helped the WHHFT team to achieve level 3 carbohydrate counting in 73% of the newly diagnosed with Type 1 Diabetes Mellitus. Participating in QI had positive impact of improving outcomes in CYP.

Results: There were 10 study participants, all of whom were mothers. As a result of the analysis, 6 categories, a total of 24 subcategories, were extracted. The 6 categories were: “Complementing diabetes management that is difficult for the child to carry out by themselves,” “Manage with the child,” “To promote diabetes management by the child under the supervision of parents,” “Collaborate with school staff to management diabetes in school,” “Establish a safe and secure environment for children,” and “Devise ways to encourage the child’s independence”.

Conclusions: This study revealed that the parents were trying to shift diabetes management to self-care at the child’s pace. In addition, parents worked to create an environment in which children can safely and reliably manage diabetes even when parents cannot be on their side. It is thought that the parental actions that respects the child’s intentions and wishes will lead to the child taking the initiative in managing type 1 diabetes and living with diabetes. It is important for medical staff to understand the implications of parental involvement and supporting children with type 1 diabetes and their parents.

P129 | Insulin requirements in young children with type 1 diabetes after learning flexible insulin therapy from parents

G. Mounia1, T. Mahmoud2, B.-N. Karim2
1University Military Hospital, Medicine, Oran, Algeria, 2University Hospital Center, Medicine, Oran, Algeria

Introduction: The recommendations for insulin requirements in type 1 diabetes are based on adults’ studies without being adapted to young children.

Objectives: The aim of this study was to assess the initial insulin requirements in young children in different titration situations from the data of the flexible insulin therapy taught to parents.

Methods: Mono-centric and prospective study, flexible insulin therapy taught to mothers. Daily insulin requirements were recorded from treatment diaries. Carbohydrate-to-insulin ratio (CIR) was determined for each patient during the test meals. The needs to correct hyper- and hypoglycemia were expressed respectively for one unit of insulin and for 3 g of sugar.

Results: Forty nine children were included, 27 girls. A 3 to 12 years old (8.88 ± 2.40 years), duration of diabetes 3.29 ± 2.34 years, weighing between 13 and 56 kg for a BMI of 63, 66 ± 26.11 percentile. The daily insulin requirements determined 2875 times were 0.97 ± 0.18 U/kg/24 h with 61.2% bolus and 38.8% basal. The CIR performed 55 times was 1.25 ± 0.55, 0.81 ± 0.31, 0.87 ± 0.87 and 0.73 ± 0.26 unit of insulin per 10 g of carbohydrate, respectively for breakfast, lunch, afternoon snack and dinner (CIR differed significantly between breakfast and the rest of the meals and between dinner vs afternoon snack). Insulin sensitivity, determined 55 times, showed that one unit of insulin lowered blood sugar by 0.65 ± 0.31 g/L. Sensitivity to carbohydrate, determined 52 times, showed that 3 g of sugar increased blood sugar by 0.19 g/±0.13 g/L. Considering body weight
thresholds of 10 in 10 kg, the mean insulin and sugar sensitivity figures varied toward less insulin and sugar sensitivity.

**Conclusions:** Our results are consistent with those of adults for 24-h insulin requirements and for CIR for each meal of the day. Insulin and carbohydrate sensitivities to correct glycemic drifts were specified according to body weight.

**P130 | The role of certified diabetes care and education specialists in the development of the 4 T program**


*Stanford Children's, Pediatric Dept. of Endocrinology, Stanford, United States, Stanford University, Diabetes Research Center, Stanford, United States, Stanford University, Stanford, United States*

**Introduction:**

**Objectives:** To describe the role of Certified Diabetes Care and Education Specialists (CDCES) in the development and implementation of the 4 T Program (Teamwork, Targets, Technology and Tight control) at Stanford Children's Diabetes Clinic.

**Methods:** Youth with newly diagnosed Type 1 diabetes (T1D) were started on a continuous glucose monitor (CGM) within the first month of diagnosis as part of the 4 T Program. A subset received weekly CGM data review by a CDCES and messages with education and dose changes were sent via the electronic medical record. Plan, Do, Study, Act (PDSA) cycles were utilized to determine the best workflow for the team and for families to develop a scalable process for CGM review.

**Results:** During the 4 T pilot study, a total of 135 youth were started on CGM. The team developed a workflow for CGM initiation, follow up, and education as well as handouts for patients. The CDCES team reviewed the CGM tracings of a subset of participants (n = 89) weekly in their first year and sent messages to each family each week if changes to insulin dosing were needed. The CDCES team helped co-develop a population health dashboard to facilitate CGM data review. CDCES input helped engineering colleagues define a workflow (Figure) that allowed the growth of this program without increasing the number of CDCES on the team.

**Conclusions:** CDCES teams should play an essential role in program development for the care of youth with Type 1 diabetes.

**P131 | Reasons for not practicing carbohydrate counting among some Omani families taking care of children live with type 1 diabetes mellitus**

H. Alsaffar, S. Albaloushi

*Sultan Qaboos University Hospital, Child Health Department, Pediatric Endocrine and Diabetes Unit, Muscat, Oman, Sultan Qaboos University Hospital, Department of Nutrition, Muscat, Oman*

**Introduction:** Carbohydrate counting (CC) became fundamental in the management of T1DM. In Pediatric Diabetes Unit of Sultan Qaboos University Hospital, our patients do have an access to a dietitian as soon as they get diagnosed and on demand thereafter. However, their adherence to the CC despite being educated is still poor which results in poor glycemic control.

**Objectives:** To study the reasons of not practicing CC despite being educated.

**Methods:** An Online questionnaire was passed to the patients live with T1DM and their families. Data collected over 1 year (1/1 to 31/12/2021), from families whom agreed to participate. Descriptive analysis was used.

---

**Figure 1.** An outline of the patient workflow for T1D new onset patients at Stanford Children's Diabetes Clinic with the relative influence of the CDCES on the workflow.
P132  |  Newly diagnosed diabetes education evaluation using hybrid teaching

A. Landry1
2Oak Valley Health Markham, Pediatric Diabetes, Markham, Canada

Introduction: Pandemic required change to education delivery at diagnosis. New patients diagnosed between March 2020 and December 2020 received a new hybrid model of teaching at diagnosis. The primary objective of this quality improvement project was to use knowledge checklists to evaluate patient/family understanding of essential topics. Comparing in person education versus hybrid virtual model.

Methods: This quality improvement project had 2 components: (1) Data from the center's SWEET database was used to assess the hybrid education model. Variables included HbA1c at diagnosis, HbA1c 3–6 months post diagnosis, DKA and severe hypoglycemia. (2) An online screening tool to identify knowledge gaps following initial education. This screening tool was delivered via email using REDcap approximately 6 months after initial diagnosis. The survey included questions about basic diabetes ‘survival’ skills, carbohydrate counting and mental health themes. Questionnaires were sent to all newly diagnosed patients in 2020 as well as a cohort pre pandemic. A total of 30 patients were diagnosed during the early pandemic period and received the hybrid teaching model. The response rate from the questionnaires was 38%.

Results: Using SWEET data clinical outcomes were compared. Three key knowledge gap areas were identified. Low dose glucagon, illness management, and medical ID. The hybrid model was adapted to ensure that additional material and handouts were provided to families identified as knowledge gaps. We implemented follow-up instructional videos for families to augment virtual teaching sessions. We now administer this skills checklist to this cohort of patients on an annual basis, and expanded the initiative more broadly to include our entire clinic population.

Conclusions: Comprehension of some topics are better understood with hands on or face to face delivery. Education knowledge checklists are a valuable tool to identify gaps in knowledge and direct HCP’s on patient specific education needs.

P133  |  Acceptability and feasibility of a virtual educational intervention targeted toward improving diabetes self- efficacy and glycemic control in adolescents and young adults with type 1 diabetes mellitus (T1D): A pilot study

S. Hanif1, J. Wood1, S. Macleish1, R. Hazen2
1Rainbow Babies and Children's Hospital/ University Hospitals, Cleveland Medical Center, Pediatric Endocrine, Cleveland, United States, 2Rainbow Babies and Children’s Hospital/University Hospitals Cleveland Medical Center, Developmental and Behavioral Pediatrics and Psychology, Cleveland, United States

Introduction: Despite technological advances, self-management is vital to T1D care. Objectives: 1. To study the acceptability and feasibility of a virtual educational program in adolescents and adults aged 16–23 years with T1D and suboptimal glycemic control. 2. To study its impact on participants’ Diabetes Self-Efficacy (Diabetes Empowerment Scale- DES), Diabetes Related Knowledge (self-designed test- DKT), Diabetes Related Distress (PAID or PAID-T) and glycemic control.

Methods: A 11 interactive virtual education modules of 15–20 min duration were presented to the participants via telehealth services over 3 months. The modules were designed on the principles of self-efficacy. Participants completed feedback surveys designed on 5 point Likert based scale at completion of each module and entire program. Pre and post intervention DES, DKT and PAID or PAID-T surveys were performed. Participants received a $10 gift card at completion of each module.

Results: Recruitment rate was 14%. A 10 candidates consented for participation, 5/10 completed the program, 3/10 partially completed it and 2/10 did not respond after consent. The primary reason for refusal to participate was the required time commitment. All modules received positive feedback from the participants (Mean Likert based score was >4.5 for all modules). Of participants who completed the program, 100% learnt something that I will incorporate into my self-care ‘I learnt something that I will incorporate into my self-care’ and ‘will recommend these sessions to other people’. Of participants who completed the program, 5/5 had improvement in DES score, 4/5 had improvement in DKT score, 2/5 had improvement in PAID or PAID-T score and 4/5 had improvement in HbA1C.

Conclusions: This program can serve as an important clinical tool for transitioning adolescents/adults with potential for improved T1D
management goals. Adaptations like improved connectivity, content tailored to individual needs, utilization of the program during clinic visits while retaining flexible scheduling may be important for successful clinical use of the program.

POSTER TOUR 15—DIABETES IN DEVELOPING COUNTRIES & ACCESS TO CARE # 2

P134 Development and pilot testing of a novel, low literacy scale for estimating correction dose of insulin for hyperglycemia among children with type 1 diabetes, in North India

L. Rohilla1, D. Dayal1, B. Bharti1, P. Malhi1

1Post Graduate Institute of Medical Education and Research, Chandigarh, India, Pediatrics, Chandigarh, India

Introduction: ISPAD identifies low levels of literacy as a challenge to diabetes management in resource-limited settings. India has a low literacy rate (74.04%, Census, 2011). In such settings, ISPAD recommends encouraging parents to learn the basics of reading and writing. Such parents often fail in estimating the right units as correction dose for hyperglycemia.

Objectives: To develop and test a scale (Table 1) to estimate the correction dose of insulin.

Methods: The scale requires identifying the glucometer readings digit-wise. Two versions were prepared for the Insulin sensitivity factor of 50 and 100 for children for 6–12 years and below 6 years, respectively. Using an experimental design for pilot testing, a total of 30 parents of children with Type 1 Diabetes, admitted to a tertiary care hospital in North India, were enrolled. The parents were given a set of 6 blood sugar (BG) values and were asked to estimate the correction units for their child. The next day, they were taught how to use the novel scale and were given another set of 6 BG values for estimating the correction units. A timer was set to assess if the scale could help in both accuracy and speed.

Results: The median age of participants was 37 years (Range: 23–48 years), half of them were males, 46.6% were educated below primary level, 53.3% belonged to rural settings, 46.6% were unemployed.
and 40% were laborers on daily wages. The mean score of participants in calculating the correction dose of insulin for hyperglycemia, (p = 0.000) and the mean time taken for the same (p = 0.000), improved significantly with the use of the novel scale.

Conclusions: This novel, low literacy scale can be helpful for assisting illiterate caregivers in estimating the correction dose of insulin for hyperglycemia among children with Type 1 diabetes effectively.

P135 | Therapeutic education day for children and adolescents with type 1 diabetes in a developing country Burkina Faso

W.P.A.H. Bagbila¹, S. Yempabou¹, C.G. Kyelem¹, T.M. Yameogo¹, S.M. Ouedraogo¹, Y.J. Drabo²
¹Université Nazi BONI, Bobo-Dioulasso, Burkina Faso, ²Université Joseph Ki Zerbo, Ouagadougou, Burkina Faso

Introduction: Therapeutic education of diabetic patients aims to enable patients to be autonomous in the management of their chronic disease.

Objectives: The objective was to evaluate the feasibility of a therapeutic education day for type 1 diabetic patients in the city of Bobo-Dioulasso (Burkina Faso).

Methods: This was an observational study to evaluate a therapeutic education day for children and adolescents with type 1 diabetes in the internal medicine department of the Bobo-Dioulasso university hospital in Burkina Faso. For budgetary reasons, the number of participants was limited to 25 people. The items discussed were ketoacidosis, hypoglycemia, and the diet of type 1 diabetics. The therapeutic education day took place from 8 am to 4 pm, that is, a duration of 8 h.

At the end of the day, the participants evaluated the therapeutic education day.

Results: In total, 22 participants participated in this education day, including 11 children (50.0%) aged between 11 and 18 years. The average age was 15+/-7.8 years. The sex ratio was 5/6. The mean age of onset of diabetes was 12.4 +/-6.7 years with extremes of 9 and 16 years. The mean duration of progression was 36.4545/+-20.8 with a range of 6 to 71 months. The mean follow-up time was 22.1818/+-18.7 with a range of 0 to 48 months. The preprandial blood glucose levels on the education day were 10.2 mmol/L, 10.5 mmol/L, and 18.9 mmol/L for morning, noon and evening blood glucose levels respectively.

Of the 22 participants, 18 gave an overall score of 5/5 for the TPE days and 4 gave a score of 4/5. The most positive points expressed were “the meeting went very well. We learned well and ate very well” and “I enjoyed what you did. God bless your activities”. The negative points expressed were: unsuitable setting. Topics and suggestions that participants would like to see considered next time: “Do these days regularly” and “Choose a more suitable setting”.

Conclusions: This therapeutic education day reminds us of its crucial importance in the management of diabetes mellitus.

P136 | Perception of disease and experience of the parents of children and adolescents living with type 1 diabetes in Yaounde, Cameroon

S. Sap¹,², R. Mbono³, J. Sap⁴, C. Fouda⁵, A. Mendomo², J. Tony¹, P.O. Koki¹
¹Université de Yaounde I, Pediatrics, Yaounde, Cameroon, ²Mother and Child Center of Chantal Biya Foundation, Paediatric Endocrinology and Diabetology, Yaounde, Cameroon, ³University of Douala, Pediatrics, Douala, Cameroon, ⁴Faculty of Evangelical Theology, Intercultural Sciences, Yaounde, Cameroon, ⁵Yaounde Central Hospital, Psychiatry, Yaounde, Cameroon

Introduction: Diabetes is a the most prevalent endocrine disease in children. Long-term outcome of the disease is related to a number of factors including parents’ implication. Parents are key actors of management of a child living with type I diabetes.

Objectives: The aim of the present study was to understand the perception and experiences parents in a low-income setting.

Methods: We did a qualitative study using socio-anthropologic approaches: interpretivism and the pedagogic ethnographic approach. A sample of 10 parents was included. Data were obtained through a focus group. The different themes were the parent’s feelings at diagnosis, the affected child feeling from parent view and parents experiences of the disease.

Results: The major themes across parents experiences were pain, fear and guilty. Pain and fear was still persistent and was tightly related to idea of death. They recognized the major role of their community and environment on their thoughts and feelings. From the parent’s point of view, their children were living in a deny of disease, considering it related to an external force.

Conclusions: Thoughts and feelings of parents of children living with diabetes are related with an idea of death. The role of their community in this important. Health care providers should thus address that issue to help diminished that worries and further studies are needed to identify the sources and type of information of the community on diabetes in children.

P137 | Substance abuse and type 1 diabetes, a difficult issue to address in an 18 years old boy in Cameroon

R.C. Mbono Betoko¹, C. Eyoun¹, S. Sap², A. Chetcha Bodieu³, C. Eposse¹, I. Mekone², P. Koki Ndombo²
¹University of Douala, Faculty of Medicine and Pharmaceutical Sciences, Douala, Cameroon, ²University of Yaounde I, Faculty of Medicine and Biomedical Sciences, Yaoundé, Cameroon, ³Yaounde Central Hospital, National Center of Obesity, Yaoundé, Cameroon

Introduction: Adolescence is a period of physiological and psychological challenges. Youths with type 1 diabetes may have more challenges due to the management of this chronic disease. They are more likely to have behavioral and psychosocial issues than non-diabetic youths.
They try to be accepted by their peers. This may lead to behavioral problems such as substance abuse. This may affect glycemic control in addition to puberty challenges.

**Objectives:** We aimed to describe difficulties to obtain glycemic control in a context of substance abuse.

**Methods:** We present the case of a 18 years old adolescent who was admitted for ketoacidosis in a context of substance abuse.

**Results:** We received a 18 years old boy at pediatric emergency for polyuria, polydipsia, vomiting and abdominal pain since 5 days. He was a known type 1 diabetes patient since 2 years. He received multiple injections regimen with regular and long acting insulin. His last HbA1c was 39 mmol/mol. His parents reported substance abuse since 6 months. At admission, the patient was slimmed, tired and dehydrated. He was sad, anxious, and sometimes aggressive. Glycaemia was 271 mg/dl. Urine dipstick revealed presence of ketones and glucose. The main diagnosis was Substance abuse complicated by ketoacidosis. For management, he received rehydration and rapid acting insulin. Psychologic support was initiated and he received antipsychotics and anxiolytics. He presented 3 episodes of ketoacidosis during hospitalization.

**Conclusions:** This case highlights difficulty to improve metabolic control in type 1 diabetes in presence of substance abuse during adolescence. The risk of death is either related to poor compliance to insulin or antipsychotic drugs or the illicit substance itself.

**P138 | Glucose control of migrant children with type 1 diabetes in Lombardy**

B. Dionisi1,2, G. Frontino1,2, A. Rigamonti1,2, V. Castorani1,2, R. Di Tanno1,2, E. Morotti1,2, F. Sandullo1,2, F. Scalabba1,2, F. Arrigoni1,2, R. Foglino1,2, F. Meschi1,2, R. Bonfanti1,2,3

1IRCCS San Raffaele Hospital, Department of Pediatrics, Milano, Italy, 2IRCCS San Raffaele Hospital, Diabetes Research Institute, Milano, Italy, 3Università Vita-Salute San Raffaele, School of Medicine, Milano, Italy

**Introduction:** Migrant status may obstacle the management of Type 1 Diabetes (T1D) and the use of diabetes technologies. Patients at our center represent approximately 50% of children with T1D in Lombardy.

**Objectives:** To compare glucose control and treatment choice of migrant children with T1D vs all patients followed at our center in 2021.

**Methods:** Auxological parameters, HbA1c (%), type of glucose monitoring (by blood (BGM), flash (FGM) or continuous (CGM) glucose monitoring), and treatment modality [multiple daily injection (MDI) insulin therapy, sensor augmented pump (SAP), advanced hybrid closed loop (AHCLI)] were recorded.

**Results:** Migrant population: 54 patients (23F, 31M), mean age 14 years ± 4, mean BMI-SDS 0.79, median T1D duration 4 years, mean age of onset 8.9 years ± 4.5. Mean HbA1c 7.8 ± 1.5. Of these, 45 (83%) use MDI (2 use BGM, 43 use FGM) and 9 (17%) use pumps (2 SAP, 6 AHCI, 1 pump user with BGM). HbA1c is not significantly different between pump and MDI users (7.3 ± 1.4 vs. 7.9 ± 1.5).

Regarding all 994 children with T1D followed at our center: mean BMI-SDS 0.61, mean age 13.5 years, mean age of onset 10.9 years ± 4.7, median T1D duration 4 yrs. Mean HbA1c 7.2 ± 1.1. Of these, 44% are pump users and 56% MDI users. HbA1c is significantly higher in migrant children vs overall (p = 0.0001). There is no significant difference in HbA1c between migrant pump users vs overall. Other parameters are not significantly different.

**Conclusions:** Our data portrays the current status of diabetes care of migrant children with T1D in Lombardy. Migrant children are less likely to use technology and consequently have suboptimal glucose control. Although technology has evolved to play an ever more central and less cumbersome role in T1D treatment, its use in ethnic minorities is less than desirable. Cultural and linguistic barriers may represent untackled obstacles in the management of diabetes. A more tailored healthcare system must be implemented in order to promote the use of advanced technologies in all children with T1D regardless of cultural background.

**P139 | Patient acceptability of an intensive insulin management program in Kashmir, India**

P.O. Ahmad1, C. Lawrence2,3, G. Ogle4,5, C.E Smart2, M.A Paterson2, B.R King2, S.R Masoodi2

1Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Department of Endocrinology, Srinagar, India, 2John Hunter Children's Hospital, Pediatric Endocrinology and Diabetes, New Lambton Heights, Newcastle, Australia, 3University of Newcastle, Callaghan, Newcastle, Australia, 4Life for a Child Program, Diabetes NSW and ACT Glebe, Sydney, Australia, 5University of Sydney, Medical Research Council Clinical Trials Center, Sydney, Australia

**Introduction:** Flexible insulin regimes with multiple daily doses of insulin have been shown to improve outcomes for type 1 diabetes. Resource-limited settings have disproportionately higher rates of diabetes-related complications and mortality and fewer people achieving internationally recommended targets for T1D. The Sher-I-Kashmir Institute of Medical Sciences (SKIMS) in Srinagar, India services 400 children with type 1 diabetes. The average HbA1c is 10.5% and the average life expectancy is 29 years. Access to blood glucose monitoring and diabetes education has been limited. In partnership with the John Hunter Children's Hospital (JHCH) in New South Wales, Australia, and the Life For A Child Foundation, glucose monitoring and an intensive insulin management system (Success With Individualized Insulin Management) was implemented. Here we describe our center’s initial experiences.

**Objectives:** To assess patient acceptability of an intensive insulin management program in a resource-limited setting.

**Methods:** We describe two young people with type 1 diabetes who were given access to glucometers and testing strips, photographic carbohydrate counting resources, and personalized insulin-dosing cards. Follow-up was performed at 12 weeks and the families experience was documented. HbA1c was performed at baseline and at review.
Results: Patient 1 was a 17yo female who had diabetes for 4 years. At baseline, she did 5BGLs/week, and HbA1c was 13.4%. At the 12-week follow-up, she was doing 35 BGLs per week and HbA1c was 9.3%.

Patient 2 was an 11.5yo male who had diabetes for 7 years. At baseline, he was doing 7 BGLs per week and HbA1c was 13%. At the 12-week follow up he was doing 21 BGLs per week and HbA1c was 9.4%.

Conclusions: Flexible insulin regimes are feasible in resource-limited settings. Further research is required to demonstrate long-term improvement in diabetes-related outcomes.

P140 | Prevalence of depressive symptoms in children and adolescents with type 1 diabetes and celiac disease in Jordan

A. Alassaf1, R. Odeh1
1University of Jordan, Pediatrics, Amman, Jordan

Introduction: Type 1 diabetes (T1D) is a common chronic disease in children and adolescents with significant short and long-term complications. Celiac disease is one of the comorbidities that may be associated with T1D. Patients diagnosed with both diseases are expected to be at higher risk of psychological issues, including depression.

Objectives: We aimed to study prevalence of depressive symptoms in children with T1D and celiac disease in Jordan.

Methods: This is a pilot case control study, conducted by distributing the Center for Epidemiological Studies Depression Scale for Children (CES-DC) to patients aged between 10 and 17 years with T1D and celiac disease seen at our pediatric endocrine clinic between January 2022 and March 2022, and were compared to controls who were patients matched for age, gender and duration of diabetes. Demographic and clinical data were collected.

Results: A total of 20 children with T1D and celiac disease were enrolled in the study with mean age of 13.80 ± 2.47 years. There was no significant difference of CES depression score between patients with T1D and celiac disease and those with T1D alone, $p = 0.1$. Patients with T1D and celiac disease had higher HbA1c than those who had T1D alone, $p = 0.02$. There were no significant differences between the two groups; in number of diabetes-related hospital admissions and frequency of self-monitoring of blood glucose.

Conclusions: There was no difference in prevalence of depressive symptoms children with T1D and celiac disease and those who had T1D alone. HbA1c was higher in patients with T1D and celiac disease than those with T1D only. This is a pilot study with limited number of patients; further recruitment of patients to our ongoing is needed to explore further prevalence of depression in children and adolescents with T1D and celiac disease.

P141 | Hellotype1-An innovative digital educational resource platform of type 1 diabetes in local languages for healthcare professionals, families, and people living with diabetes in Southeast Asia

S.M. Ng1,2, M. Iv3, T.K. Nguyen4, K. Le5, Y.X.L. Lim6, A. Anuar Zaini7, N. Lek8, S. Seal9, S.Y. Tange10, A.C. Ficheroulle11, J. Gore11
1University of Liverpool, Liverpool, United Kingdom, 2Southport and Ormskirk Hospital NHS Trust, Southport, United Kingdom, 3Kantha Bopha Children’s Hospital, Phnom Penh, Cambodia, 4Diabetes and
Introduction: There is minimal data of Type 1 Diabetes (T1D) outcomes in Southeast Asia (SEA) where government funding of insulin and blood glucose monitoring is limited. Action4Diabetes (A4D) is a non-profit organization charity that currently provides comprehensive partnership programs with defined local hospitals through a Memorandum of Understanding (MOU) signed with the governments in SEA that guarantees ongoing supplies of free insulin, blood glucose testing, HbA1c tests and hospital emergency funds. In 2021 HelloType1 was developed in collaboration with SEA local healthcare professionals as an innovative digital educational resource platform of T1D in local languages.

Objectives: To educate, engage and empower healthcare professionals, families, and people with T1D by creating a digital platform that is free-to-access and provides accurate information, patient-oriented education, and best practice care about T1D care in local languages.

Methods: HelloType1 content is reviewed, translated to local languages and adapted by a panel of T1D healthcare experts and lay people with T1D in SEA to ensure that the information is appropriate in a local context. A list of sources and content reviewers are published within each core topic. HelloType1 educational content includes 32 articles, 7 posters, 9 videos, and 13 quizzes.

Results: Table 1 shows the number of users, engagement, and page views in 2021–22. Table 2 shows 53% of page views were coming from healthcare professionals and 47% from families and people with T1D. Table 3 shows the HelloType1 Cambodia Facebook analytics with approximately 1000 followers and a 4% increase each month.

Conclusions: In the long term, only systemic changes in local health policies such as universal coverage and education can confront health inequalities and T1D gaps in SEA. This would include scaling up of diabetes knowledge among healthcare professionals and people living with T1D to optimize management and developing a peer support network.

P142 | Type 1 diabetes glycemic control outcomes stratified by insulin regimen in two large Cambodian tertiary hospitals

S.M. Ng1,2, M. IV3, C. Yay4, L.C. Khun4, B. Manet3, T. Martin5, N. Lek6

1University of Liverpool, Liverpool, United Kingdom, 2Southport and Ormskirk Hospitals NHS Trust, Southport, United Kingdom, 3Kantha Bopha Children’s Hospital, Phnom Penh, Cambodia, 4Jayavarman VII Hospital, Siem Reap, Cambodia, 5Action4Diabetes, Somerset, United Kingdom, 6KK Women's and Children's Hospital, Singapore, Singapore

Introduction: In Cambodia, Action 4 Diabetes (A4D) is a UK non-profit organization has been providing free insulin and self-monitoring blood glucose test kits for children and young people (CYP) with type 1 diabetes (T1D) in Cambodia’s 2 large tertiary hospitals-Kantha Bopha II Hospital based in Phnom Penh (KB2H) and Jayavarman VII Hospital based in Siem Reap (J7H), since July 2018 and January 2020, respectively.

Objectives: To report the glycemic control outcomes of T1D patients in the two large Cambodian tertiary hospitals stratified by insulin treatment regimen, namely, twice daily injections using self-mixed short- and long-acting insulin (BD); and basal-bolus multiple daily insulin injections (MDI).

Methods: Data on gender, current age, HbA1c at enrolment and during follow up in A4D clinical support program, were reviewed and summarized in the Table.

Results: By December 2021, a total of 263 patients (109 male; 41%) were supported by A4D. Mean age of patients in KBH2 on self-mixed BD regimen was 16.6 years versus 17.4 years for MDI regimen. Mean age of patients in J7H on self-mixed BD regimen was 14.5 years versus 18.1 years for MDI regimen. On average, patients in KBZH were 1.4 years older than those in J7H. In both hospitals, the patients on MDI were older than those on BD treatment. Overall glycemic control was suboptimal with mean HbA1c >10% (>86 mmol/mol) between 2019 and 2021, except for those on MDI in KB2H during 2020.
Conclusions: The glycemic control in the patients with T1D in these two hospitals in Cambodia was suboptimal regardless of the insulin treatment regimen. The findings in this study suggest that in addition to providing insulin and blood glucose test kits, there is urgent need to further provide support and education to families and people with T1D and upskill the local healthcare professionals in T1D management so that they can empower the patients and their caregivers to optimize self-management effectively on a daily basis.

Introduction: In the Lancet Commission 2020, it was estimated that approximately 15,000 individuals with Type 1 Diabetes (T1D) died in 2017 globally from a total prevalence of diabetes in 1.61 million people. There was no data of T1D incidence or prevalence available from Southeast Asia (SEA) countries within this Commission, and there is minimal data of health outcomes for T1D in SEA where government funding of insulin and blood glucose monitoring kits either do not exist, or is limited in many low-middle income countries (LMICs) in SEA.

Objectives: Action4Diabetes (A4D) is a non-government organization making sustainable and scalable progress to provide quality T1D healthcare in the SEA region. Since 2015, A4D formed strategic partnerships with relevant local health authorities, public hospitals, and medical societies to ensure ongoing supplies of free medication, patient education, and healthcare training, aiming to bring positive health outcomes for the T1D Community.

Methods: In 2020–2021, A4D facilitated the establishment of the T1D healthcare professionals (HCP) regional network to facilitate cross-country collaborations, knowledge exchange, and best practice sharing through 3 different initiatives:
- A HCP advisory group
- The T1D SEA Regional Network Meetings
- Free-to-access A4D webinars program on T1D.

Results: The HCP advisory group comprise 26 multidisciplinary HCPs from 8 countries and professions (Table 1). Number of registrants
On-boarding children and young adults on MiniMed experience in Cairo, Egypt.
Regional Pump Consultant, Cairo, Egypt, Diabetes Educator and Certified Pump Educator, Cairo, Egypt

**Introduction:** Advanced hybrid closed-loop (AHCL) systems achieved a significant improvement in glycemic control among young people with type 1 diabetes (T1D).

**Objectives:** The aim of the current study was to evaluate the safety and efficacy of the initiation protocol for MiniMed™ 780G system in a real-world setting among an Egyptian cohort of young people with T1D.

**Methods:** A prospective study including 72 participants with T1D that successfully initiated AHCL system; 55 participants shifted from multiple daily injections (MDI) with no previous pump experience and 17 were using either standalone or sensor augmented pumps. A 5 days of structured education and training were provided to all users and continuous glucose monitoring (CGM) was initiated on the first day of the training. After reviewing 1-week data of CGM, users initiated the pump in Manual Mode, with suspend before low feature, for two days before shifting to Auto Mode. Patients with previous pump experience started the Auto Mode after 1-week data of CGM. Data and downloads of users completing the 84 days were analyzed.

**Results:** A total of 55 user with T1D (age 12.6 ± 4.9 years) completed the planned 84 days on Auto Mode; 41 /55 with no previous pump experience. The mean HbA1c decreased from 8.7% ± 2.0% to 6.8% ± 0.5% (P < 0.01) without any severe hypoglycemia or DKA. Time in range (TIR; 70–180 mg/dl) substantially improved from 62.6% ± 14.1% before initiating Auto Mode to 82.3% ± 7.4% after spending 84 days in Auto Mode (p < 0.01) with 2.2% of the time spent below 70 mg/dl. Insulin-to-carbohydrate ratio (ICR) was optimized and made more aggressive; decreasing by 16.7% from a mean of 16.0 ± 9.3 g/unit % to 12.3% ± 6.6 g/unit (P < 0.01). Regarding AHCL compatibility, users spent a mean of 95.3% ± 6.7% time in Auto Mode.

**Conclusions:** MiniMed™ 780G system significantly improved levels of HbA1c and successfully achieved TIR > 70% with minimizing the risk of hypoglycemia. Real world data confirms the robust effect of AHCL systems on glycemic outcomes.
[0.27, 0.43] vs. control: 0.46 pmol/ml [0.33, 0.61]; mean adjusted difference – 0.06 [−0.14 to 0.03]; p = 0.19 and 24 months closed-loop: 0.18 pmol/ml [0.12, 0.24] vs. control: 0.24 pmol/ml [0.12, 0.37]; mean adjusted difference – 0.04 [−0.14 to 0.06]). Glycated hemoglobin was lower in the closed-loop group by 4 mmol/mol [0.4%] (95% CI 0 to 8 mmol/mol [0.0% to 0.7%]) at 12 months, and 11 mmol/mol [1.0%], (95% CI 7 to 15 mmol/mol [0.5% to 1.5%]; p < 0.001) at 24 months. Five severe hypoglycaemic events occurred in closed-loop group (3 participants), and one in control group; one diabetic ketoacidosis occurred in the closed-loop group.

Conclusions: In youth with new onset type 1 diabetes, optimizing glucose control for 24 months does not appear to prevent the decline in residual C-peptide secretion.

P146 | A single center experience of hybrid closed loop insulin pumps: Is it really worth the efforts and investment?

A. Gangadharan, R. Cordingley, C. Bowness, C. Tomos, P. Nallappan

Results were summarized in the following table: Mean (Range)

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Up to 6 months before HCL</th>
<th>At start of HCL</th>
<th>At latest clinic F/U of HCL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in years</td>
<td>9.6 (3.3–13.7)</td>
<td>10.5 (3.6–14.2)</td>
<td>11.5 (4.4–16.1)</td>
</tr>
<tr>
<td>BMI SDS</td>
<td>+1.0 (−0.2 to +2.3)</td>
<td>−0.9 (−0.2 to +2.2)</td>
<td>+1.0 (−0.6 to +2.0)</td>
</tr>
<tr>
<td>HbA1c (mmol/mol)</td>
<td>54 (37–69)</td>
<td>53.2 (33–72)</td>
<td>51 (35–69)</td>
</tr>
<tr>
<td>Time in range (%)</td>
<td>59 (31–89)</td>
<td>67 (50–89)</td>
<td>68 (50–82)</td>
</tr>
<tr>
<td>Hypoglycemia &lt;4 mmol (%)</td>
<td>2.2 (0–6)</td>
<td>2.1 (0–6)</td>
<td>1.9 (0–4)</td>
</tr>
</tbody>
</table>

**Licensed HCL users (11/15)**

| HbA1c (mmol/mol)             | 58 (44–69)                | 57.2 (48–72)    | 55.6 (42–69)               |

**DIY Loop users (4/15)**

| HbA1c (mmol/mol)             | 45.5 (37–50)              | 42.3 (33–54)    | 43.8 (35–54)               |
The use of advanced hybrid closed loop of 780G offers reversioning suboptimal glucose control by implementing an advanced hybrid closed-loop system in non-compliant adolescents with type 1 diabetes

K. Patouni1, M. Xatzipsalti1, G. Kourousi1, E. Bourousis1, A. Triantafiliadiou1, D. Delis1, A. Vazeou1
1P&A Kyriakou Children’s Hospital, Diabetes Center, A’ Department of Pediatrics, Athens, Greece

Introduction: Advanced Hybrid Closed Loop (AHCL) provides a novel therapeutic approach to optimize glycemic control in people with type 1 diabetes (T1D).

Objectives: To evaluate the difference in HbA1C, TIR, TAR, and TBR in children, adolescents, and young adults with well-controlled T1D before, 3 and 6 months after initiation of AHCL system.

Methods: A 41 subjects [24 males, median age 11.1 years (range 0.7–40 years) median disease duration 4.9 years (range 0.7–22.7 years)] previously treated with multiple daily injections (n = 5) or insulin pump (n = 34, median duration 3.9 years [range 0–12 years]), were included in the study. Six were using intermittently scanned CGM and 35 Sensor Augmented Pump 640G. The subjects were well controlled [mean HbA1C 6.8% (SD 0.7)]. They switched to the AHCL system of Medtronic MiniMed 780G system. HbA1C, TAR, TIR, TBR, bolus and daily insulin requirements, were evaluated before, 3 and 6 months afterwards.

Results: There was an improvement of HbA1c at 3 and 6 months compared to baseline (Mean HbA1c before (SD):6.8 (0.7) mg/dl vs 6.4 (0.5) (p = 0.022) and 6.3(0.4) p = 0.011 respectively), in TIR (Time in Range) 68.2 (12.9) % vs. 78.1 (6.3) p < 0.001 and 77.7 (6.8) p < 0.001, and a significant reduction in TAR (Time above range) (180–250 mg/dl) 26 (12.5)% vs. 15 (4.4)% p < 0.001 and 15.5 (4.9)% p < 0.001. There was no difference in TAR>250 mg/d or TBR (Time below range) <54 or < 70 mg/dl. Although there was no difference in the total insulin dose, there was a decrease in the percentage of basal insulin compared to the baseline data 42.7% (12.6) before vs 36.3 (5.7) p = 0.004 and 36.1 (5.1) p = 0.005 respectively and increase of boluses 56.4% (12.3) vs 64.4 (7.0) p < 0.001 and 63.9 (5.0) p = 0.001. The percentage of auto correction boluses was 21.3 (6.9) % and 22.1 (7.1) % at 3 and 6 months.

Conclusions: The use of AHCL system offers further improvement in glycemic control, TIR and TAR in well-controlled children adolescents and young adults with T1D.
carbohydrate counting. This is a turning point for technology that used to favor mainly those who were already compliant.

P149 | Overnight diabetes management using hybrid closed loop (HCL) therapy: Lessons from young children

S. Lange1, L. Towers1, E. Jost1, C. Berget1, R.P. Wadwa1, E. Cobry1
1University of Colorado/Barbara Davis Center for Childhood Diabetes, School of Medicine, Aurora, United States

Introduction: Overnight glycemic control is challenging in young children with Type 1 Diabetes (T1D). Hormone influxes in the evening often result in insulin resistance and hyperglycemia followed by increased insulin sensitivity overnight, leading to potential nocturnal hypoglycemia. HCL offers glucose responsive insulin delivery, altering the approach to overnight glycemic management. Increased basal modulation in response to late evening hyperglycemia in HCL therapy may result in nocturnal hypoglycemia in some young children.

Objectives: To provide clinical insights for glycemic management overnight in young children with T1D using HCL.

Methods: We present three cases highlighting this challenge in young children aged 3–5 years with T1D using the Tandem t:slim X2 Control-IQ (CIQ) HCL system commercially available in the US (Figure 1).

Results: Sleep Activity targets glucose values of 112.5–120 mg/dl; however, this target may be too low for some young children, causing nocturnal hypoglycemia. Exercise Activity targets higher glucose values (140–160 mg/dl) and can be a possible solution; however, Exercise Activity allows for auto corrections increasing risk for hypoglycemia, therefore correction factors (CF) need adjustment. Standard CIQ therapy (targets 112.5–160 mg/dl) with a 0 u/h basal rate programmed in early morning hours may be an alternative option.

Conclusions: New ways of mitigating overnight hypoglycemia must be considered with HCL therapy in young children. With CIQ, if sleep activity results in overnight hypoglycemia, using Exercise Activity overnight, turning off Sleep Activity, or programming 0 u/h basal rates decreases overnight hypoglycemia and should be considered.
**P150 |** Advanced hybrid closed loop (AHCL) system in children with type 1 diabetes (T1D): Is it really a sustained success after 6 months?

S. Seget1, E. Rusak1, A. Polanska1, A. Bielawska1, M. Tworek1, M. Drożdż1, A. Chobot2, J. Polanska3, P. Jarosz-Chobot1

1Medical University of Silesia, Department of Children’s Diabetology, Katowice, Poland, 2University of Opole, Department of Pediatrics, Opole, Poland, 3Silesian University of Technology, Department of Data Science and Engineering, Gliwice, Poland

**Introduction:** The MiniMed 780G is the first ACHL pump available in Poland and is becoming more and more popular among people with T1D, also children.

**Objectives:** Our aim was to assess continuous glucose monitoring (CGM) parameters in T1D children and adolescents after 6 months of AHCL use and compare them with CGM parameters from their former treatment modality (sensor augmented pump, SAP).

**Methods:** For 50 children with T1D, aged 12.3 ± 5.5 year, their SAP records from the 2 weeks preceding the AHCL connection were compared to the records of the first 2 weeks in AHCL and a two-week period after 6 months of AHCL use. The initial ACHL training period (7 days) was excluded from analysis.

**Results:** Significant improvements in time spent in the range (70–180 mg/dl), average sensor glucose, and glucose management indicator (p < 0.05) were observed 2 weeks after switching to the AHCL. There was no change in coefficient of variation. The improvement was maintained after 6 months of treatment using AHCL (Table 1.).

**Abbreviations:** Avg SG, average sensor glucose; CV, coefficient of variation; GMI, glucose management indicator; TDI, total daily insulin.

**Conclusions:** AHCL in children with T1D allows to achieve a sustained improvement in CGM parameters over a 6 months period.

<table>
<thead>
<tr>
<th></th>
<th>SAP</th>
<th>AHCL The first 2 weeks</th>
<th>AHCL The 2 weeks after 6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Avg SG [mg/dl]</td>
<td>139.83 ± 15.63</td>
<td>131.26 ± 12.18</td>
<td>131.95 ± 13.63</td>
</tr>
<tr>
<td>CV [%]</td>
<td>34.99 ± 5.91</td>
<td>34.34 ± 5.7</td>
<td>33.75 ± 5.09</td>
</tr>
<tr>
<td>TDI [u.]</td>
<td>29.5 ± 15.94</td>
<td>28.23 ± 16.45</td>
<td>33.95 ± 18.92</td>
</tr>
<tr>
<td>GMI [%]</td>
<td>6.65 ± 0.37</td>
<td>6.45 ± 0.29</td>
<td>6.47 ± 0.33</td>
</tr>
<tr>
<td>Sensor use [%]</td>
<td>88.34 ± 10.23</td>
<td>94.92 ± 0.29</td>
<td>93.18 ± 7.75</td>
</tr>
<tr>
<td>Auto mode [%]</td>
<td>91.90 ± 15.98</td>
<td>91.90 ± 15.98</td>
<td>96.60 ± 5.59</td>
</tr>
</tbody>
</table>

**P151 |** Technology is no quick-fix: the impact of hybrid closed-loop systems on patient and parent confidence with diabetes self-management

N. Boulos1, N. Trevelyan1

1Southampton Children’s Hospital, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

**Introduction:** Continuous glucose monitors (CGM) and hybrid closed-loop systems (HCL) have shown positive impact on HbA1c and time in range for children with type 1 diabetes (T1D), but the data they create can be overwhelming, and it is unclear how this data overload impacts patient/parent independence with diabetes self-management.

**Objectives:** To explore patient and parent confidence with diabetes self-management, their review of diabetes data, insulin self-adjustment, and preferred frequency of clinical contact with the diabetes team.

**Methods:** A web-based survey was offered to all children and adolescents (0–18 years) with T1D or their parents at a large teaching hospital in Southampton, UK.

**Results:** We received 100 responses. A 75 patients were using CGM (43% (n = 32) on multiple-daily injections [MDI], 24% (n = 18) using insulin pumps without HCL, and 33% (n = 25) using pumps with HCL). Regardless of insulin regimen, 51% (n = 38) of responders using CGM made independent dose adjustments of insulin at home, compared to only 28% (n = 7) of those using glucose meters alone (figure 1). On a Likert scale, patients using HCL were ‘not very confident’ or ‘not confident at all’ in adjusting insulin to carbohydrate ratios (48%, n = 12) compared to those on MDI (36%, n = 19) or pumps without HCL (28%, n = 6). Patients on HCL preferred the most clinical support, with 48% preferring 1–2 monthly contact or more frequently to discuss their data (vs. 38% for MDI and 27% for pumps without HCL).

**Figure 1. Reported level of autonomy with reviewing data at home and independently making insulin adjustments.**
Conclusions: We found that CGM improves patient independence with reviewing data at home, whereas HCL users appear less confident at insulin self-adjustment compared to MDI, and prefer more support and frequent clinical contact. One reason may be that HCL adds a layer of complexity that diminishes patient/parent confidence with self-management. Offering HCL should be made in conjunction with frequent clinical contact to teach patients/parents how to interpret data and maintain independence with self-care.

P152 | Glucose control is at least as good with user-built hybrid closed loop systems as with Medtronic 670G in children and adolescents with type 1 diabetes

A. Lindholm Olinder1,2, R. Hanås3,4, P. Adolfsson3,5, H. Svensson6, M. Hiis2, B. Rathsman1,2
1Karolinska Institute, Dep of Clinical Sciences and Education, Södersjukhuset, Stockholm, Sweden, 2Södersjukhuset, Sachs' Children and Youths Hospital, Stockholm, Sweden, 3University of Gothenburg, Sahlgrenska Academy, Institute of Clinical Sciences, Gothenburg, Sweden, 4Udevealla Hospital, Department of Pediatrics, NU Hospital Group, Uddevalla, Sweden, 5The Hospital of Halland, Kungsbacka, Sweden, 6Diassist Technology, Mölndal, Sweden

Introduction: Commercial hybrid closed loop insulin pumps are available for the treatment of type 1 diabetes. However, these systems have some limitations, especially for small children. While waiting for an optimal closed loop system, parents to children with diabetes have built own closed loop systems. The technologies are shared as open sources on internet.

Objectives: To evaluate glucose control, safety, and treatment satisfaction when using user-built hybrid closed loop systems (DIY) compared to the Minimed 670G hybrid closed loop system (670G) in the treatment of type 1 diabetes in children and adolescents.

Methods: This was a national cross-sectional study. Families who used DIY or 670G were asked to participate in the study via various Facebook pages or via the clinics. The requirement for participation was children and adolescents with type 1 diabetes, age 2–17 years, willingness to share all data from insulin pumps and CGMs, with technologies in use for at least 6 months. HbA1c values were obtained from clinic records. Treatment satisfaction was measured with the questionnaire DTSQ-parents.

Results: The children who used DIY (Omnipod or Dana pumps and Dexcom G6 or Libre) were younger, had lower HbA1c and mean glucose, higher percent time in target (TIT), time in target (TIT), and lower percent time above range level 1 (TAR lev1). There were no differences in time above range level 2 (TAR lev 2), time below range (TBR) or treatment satisfaction (table 1).

Conclusions: In this small study, both DIY and 670 G children had relatively well-controlled glucose control. DIY seems to be as safe as 670G regarding hypoglycemia frequency. The glucose control was slightly better in the children using DIY, but their younger age may partly explain this.

POSTER TOUR 17—DIABETES IN SCHOOL

P153 | AIM for excellence: improving glycemic control in children and young people with type 1 diabetes at school

K. Darwin1, J. Harding1, E. Gunn1, E. Cribb1, L. Joseph1
1Doncaster & Bassetlaw Teaching Hospitals NHS Trust, Bassetlaw Pediatric Diabetes Unit, Worksop, United Kingdom

Introduction: During the COVID-19 pandemic lockdown, glycemic control in children with Type 1 diabetes under our care improved. One of the reasons could be due to inconsistency in the management of diabetes at school. In order to address this possibility, our unit

Table 1. TIR, 3.9–10 mmol/L, TIT, 3.9–7.8 mmol/L, 70–140 mg/dl, TAR level 1: 10.1–13.9 mmol/L, 181–250 mg/dl, TAR level 2: >13.9 mmol/L, > 250 mg/dl, TBR level 1: 3.0–3.8 mmol/L, 54–69 mg/dl, TBR level 2: < 3.0 mmol/L, < 54 mg/dl

<table>
<thead>
<tr>
<th>Variable</th>
<th>User-built closed loop n = 15</th>
<th>Minimed 670 n = 16</th>
<th>p-value * p &lt; 0.05</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years (SD)</td>
<td>9.3 (4)</td>
<td>12.8 (4.9)</td>
<td>0.04</td>
</tr>
<tr>
<td>Male /Female (n/n)</td>
<td>11/4</td>
<td>8/8</td>
<td></td>
</tr>
<tr>
<td>Diabetes duration, years (SD)</td>
<td>5.0 (2.6)</td>
<td>6.1 (4.1)</td>
<td>0.445</td>
</tr>
<tr>
<td>HbA1c mmol/mol (SD)</td>
<td>44.1 (4.2)</td>
<td>52.5 (7.1)</td>
<td>0.002*</td>
</tr>
<tr>
<td>HbA1c % (SD)</td>
<td>6.2 (0.4)</td>
<td>7.0 (0.6)</td>
<td></td>
</tr>
<tr>
<td>Mean glucose, mmol/L (SD)</td>
<td>7.2 (0.7)</td>
<td>8.0 (0.9)</td>
<td>0.012*</td>
</tr>
<tr>
<td>TIR % (SD)</td>
<td>79 (7.4)</td>
<td>72 (7.5)</td>
<td>0.007*</td>
</tr>
<tr>
<td>TIT % (SD)</td>
<td>62 (9.1)</td>
<td>52 (9.3)</td>
<td>0.009*</td>
</tr>
<tr>
<td>TAR lev 1, % (SD)</td>
<td>12 (5.2)</td>
<td>18 (6.1)</td>
<td>0.009*</td>
</tr>
<tr>
<td>TAR lev 2, % (SD)</td>
<td>3.1 (2.1)</td>
<td>4.9 (3.6)</td>
<td>0.115</td>
</tr>
<tr>
<td>TBR lev 1, % (SD)</td>
<td>3.8 (2.1)</td>
<td>3.2 (2.1)</td>
<td>0.478</td>
</tr>
<tr>
<td>TBR lev 2, % (SD)</td>
<td>0.8 (0.6)</td>
<td>1.3 (1.6)</td>
<td>0.264</td>
</tr>
<tr>
<td>Treatment satisfaction</td>
<td>46.5 (6.7)</td>
<td>46.2 (6.4)</td>
<td>0.924</td>
</tr>
</tbody>
</table>
commenced a Quality Improvement Project to improve glycemic control of children with diabetes at school.

**Objectives:** Our Quality Improvement Project involved developing an educational tool called **AIM** – Activity, Insulin, Meals, an aid to improve glycemic control at school based on insulin regime and type of glucose monitoring. AIM tool provides advice on insulin management at meal times and PE [Physical Exercise] along with a PE guide with specific advice on glycemic control around exercise.
Type 1 diabetes (T1D) in Mauritius: Challenges in T1D management at school among children and adolescent living with T1D

L. Danharry1, A.K. Auroomoogum1
1T1 Diams NGO, Psychosocial / Medical, Quatre Bornes, Mauritius

Introduction: Children and adolescent spend 1/3 of a day in school and the management of their T1D is as important within the school environment, with frequent glucose monitoring, meal planning and insulin injection.

Objectives: Identify challenges at school for children and adolescent living with T1D. Accordingly, these challenges can inform delivery of T1D Complex Care support involving child and parents, classmates, school staff, T1Diams (NGO) and concerned ministries.

Methods: A cross-sectional study was carried out using a questionnaire to evaluate the situation with 100 children (6–18 years) and parents registered with NGO in Mauritius. Recruitment took place between March 2021 and March 2022. The parents attended sessions of Therapeutic Education at NGO and the Biopsychosocial team. They were informed about the objectives of the study both verbally and written. The Study was conducted in adherence to ethical protocol.

Results: The questionnaires were completed by the parent or adolescent. The results show that hyper and hypo glycaemia occurs at any time, impacting child’s learning, cognition, attention, and behavior. There are no nurses in educational institutions in Mauritius. Children are not receiving proper T1D support and care. Due to lack support, school staffs are offered training, but they are still reluctant to intervene. Adolescents are most impacted mainly for non-adherence to treatment.

Conclusions: The introduction of intensive insulin therapy and the rising prevalence of diabetes in younger children has increased the need for involvement of the nurses and school personnel in T1D care. Schools should work together to implement T1D Complex Care support.

Keywords: School, T1DM, Diabetes Management, NGO.

Teachers’ knowledge about diabetes. Cities changing diabetes in Poland

M. Zamarlik1, M. Gałążka-Sobotka2, I. Kowalska-Bobko1, M. Polak1
1Jagiellonian University Medical College, Institute of Public Health, Krakow, Poland, 2Lazarski University, Warszawa, Poland

Introduction: International studies show that people living in cities are nearly twice as likely to suffer from diabetes as rural dwellers. The situation is similar in Poland, where over 65% of people affected by diabetes live in the city.

Cities influence how people live, eat and spend their free time. The development of the agglomeration, its dynamics, and pace contribute to a change in the lifestyle of the inhabitants, which also translates into the development of civilization diseases. School is an important place to promote health, proper eating habits, and physical activity. The quality of school activities is influenced by the knowledge, personal behavior, and attitudes of teachers.

Objectives: The aim of the study is to establish the level of knowledge about diabetes among teachers from Cracow and Warsaw. Other motivations were to learn about teachers’ opinions on overweight, to get data about their lifestyle.

Methods: In order to obtain the above-mentioned information, a questionnaire was conducted, provided to teachers by City Halls. A 3061 people from Kraków and 1190 from Warsaw participated.

Results: The highest rate of correct answers to the topic of diabetes was recorded in the 46–55 age group. In general, teachers have the least amount of information on the causes and symptoms of diabetes, as well as on the management of hyperglycemia and hypoglycemia. With age, the problem of obesity increases (the highest dynamics is observed in the 35–45 age group), as well as regular physical activity and diet (the highest in the age groups 44–55). The youngest teachers are the most critical and the least active in pro-health activities undertaken by schools, teachers aged 46–55 are the most satisfied.

Conclusions: The data from the study show that the school is a very important place for health promotion. Teachers’ competences should be regularly improved and they should be actively involved. System and local government interventions as well as interventions carried out directly in educational institutions are needed.
**P156 | Young children with T1D experiences of using diabetes technology in the primary school setting: A narrative review of the literature**

T. O Neill\(^1\), E. Hollywood\(^1\)

\(^1\)Trinity College Dublin, School of Nursing and Midwifery, Dublin, Ireland

**Introduction:** Type 1 Diabetes is a complex chronic autoimmune disorder and is one of the most common and fastest growing chronic health conditions in childhood. In recent times, advances in technology have become an integral part of T1D management, including Continuous Subcutaneous Insulin Infusion (CSII) devices, CGM’s and other emerging technologies, such as closed loop systems. Having T1D can place challenges on the child’s school experience from an academic, social, and emotional perspective and despite the advances in diabetes technology, daily management remains too complex for young school aged children to undertake independently; especially during the primary school day.

**Objectives:** To provide a comprehensive and objective review of studies regarding the experiences of young children aged between 6 and 12 years, with T1D who use diabetes technologies such as continuous Insulin Infusion Pumps (CSII), glucose sensors and other emerging technologies, focusing on their experiences in the primary school setting.

**Methods:** The literature search was conducted using key medical healthcare databases to source appropriate literature to answer the key question. Literature from the years 2000 and 2022 were included, as diabetes treatment changed to insulin pump therapy during this time, therefore articles prior to this were not deemed relevant. Key concepts in relation to the research question with appropriate index terms and keywords were used. Articles that meet the inclusion criteria were screened and analyzed to unearth the relevant themes within the literature.

**Results:** A total of 9 studies were identified as appropriate for inclusion in the review.

**Conclusions:** Findings will give a greater awareness of the experiences of the young child with T1D. It will also demonstrate the significant lack of research in this area. Further research will also inform future diabetes health and primary school related service provision and provide a voice for the young school aged child.

**Number of studies**  
1. The young child’s experiences of using diabetes related technology specifically in the primary school environment  
2. The young child’s experiences of using diabetes technology in the management of their diabetes  
6. The young child’s experiences of T1D care in the school environment

**Authors**  
(Benassi et al. 2013)  
Freeborn et al. 2013  
Alsaleh et al. 2014  
Amillategui et al. 2009  
Schwartz et al. 2010  
Edwards et al. 2014  
deCassia et al. 2017  

---

**P157 | Supporting children with type 1 diabetes: Experiences of school personnel**

S. Banka Cullen\(^1\), H. Fitzgerald\(^2\), E. Hollywood\(^1,3\)

\(^1\)Trinity College Dublin, School of Nursing and Midwifery, Dublin, Ireland,  
\(^2\)Child Health Ireland Tallaght, Pediatric Diabetes, Dublin, Ireland,  
\(^3\)Trinity College Dublin, Dublin, Ireland

**Introduction:** The aim of the study was to evaluate a structured, hospital-based educational program on the care and management of type 1 diabetes for children in the primary school setting.

**Objectives:** The objectives of the study were:

- To explore the experiences of school personnel regarding the care and management of children with type 1 diabetes in the primary school setting.
- To explore the experiences of school personnel in relation to accessing support services for the care and management of children who have type 1 diabetes attending primary school.
- To identify the views of the nurse-led structured educational program following completion by school personnel.
- To identify potential avenues for improvement in relation to education and support from the perspective of primary school personnel.

**Methods:** Following ethical approval, a mixed methods approach was adopted to achieve the study aim. A two phased approach was used, phase one consisted of a retrospective audit of anonymous program attendee feedback forms and attendance information collated by the pediatric diabetes nursing team. Phase two involved an examination of school personnel’s experiences of providing care and support to children with type 1 diabetes in the primary school setting. Data analysis was conducted with the use of SPSS, Excel, and NVivo.

**Results:** Three themes were identified: supporting care, multiple practical challenges and outreach education.

**Conclusions:** The education program needs to continue with peer review to maintain standards. All schools that have children with type 1 diabetes in attendance should be offered the program and encouraged to participate. The experiences of children with type 1 diabetes who attend primary school need to be explored to find out what children think about the care and management of their diabetes while at school.
P158 | The diabetes and school health program (DASH): A health equity intervention to optimize school based care for children with T1D

K. Gandhi1, A. Moffett2, K. Simms2, R. Cline2, M. Moore2, A. Jones3, M.K. Irwin2, A. Wood1
1Nationwide Children’s Hospital, The Ohio State University College of Medicine, Endocrinology and Diabetes, Columbus, United States, 2Nationwide Children’s Hospital, Community Wellness, Columbus, United States, 3Nationwide Children’s Hospital, Ambulatory Pharmacy, Columbus, United States

Introduction: The Nationwide Children’s Hospital (NCH) Diabetes and School Health program (DASH) is an interdisciplinary intervention that provides school-based support to students with high risk for complications of T1D.

Objectives: DASH aims to reduce risk by addressing inequities, supporting school nurses and staff, standardizing care, improving self-efficacy, providing psychosocial support, and optimizing communication between schools, families, and the diabetes team.

Methods: Over 2000 school-aged patients receive T1D care at NCH. Nearly 20% have been identified as high risk for complications (score < 10 on scale 1–18) based on the Diabetes Composite Score, a novel tool developed at NCH. The pilot aimed to enroll over 50 patients in central Ohio with scores <10. Once enrolled, DASH completed monthly one-on-one in-school appointments, provided formal and informal education to school staff, couriered medications and supplies to home and school, coordinated care with NCH, and facilitated screenings and referrals. Baseline and follow up data were obtained including A1C, appointment attendance, CGM use, T1D complication, and acute care use, as well as survey data for students, school staff, and caregivers.

Results: A 53 students across 10 districts enrolled. The majority endorsed T1D “burn out,” and most caregivers noted feeling defeated by T1D care. Majority utilized injections, 50% had never used a continuous glucose monitor, mean A1C was 12%. More than 60% identified as an ethnic minority, 3% as gender diverse. Follow up data show CGM use increased by 27%, attendance at routine appointments increased by 40%, and overall risk decreased to intermediate.

Conclusions: DASH is an innovative, interdisciplinary school-based intervention designed to address inequities, enhance collaboration, improve self-efficacy and psychosocial wellness, and reduce risk of complications. The pilot year proved DASH to be sustainable and effective in creating positive impact on health outcomes and working toward achieving equity in T1D care.

P159 | Diabetes providers’ experiences with school-based diabetes care: What’s our report card?

C. March1,2, L. Siminerio3, T. Kazmerski1,2, A. Albanese-O’Neill4, E. Miller1,2, I. Libman1,2
1University of Pittsburgh, Pediatrics, Pittsburgh, United States, 2UPMC Children’s Hospital of Pittsburgh, Pittsburgh, United States, 3University of Pittsburgh, Medicine, Pittsburgh, United States, 4University of Florida, Family, Community, and Health System Science, Gainesville, United States

Introduction: ISPAD recommends collaboration among parents, medical providers, and schools to support children with diabetes. Our prior work found that school staff identified communication challenges. Diabetes provider perspectives are unknown.

Objectives: To understand providers’ experiences with and support for school-based diabetes care (SBDC).

Methods: We conducted a national survey of pediatric diabetes providers (physicians, mid-level providers, and diabetes care and education specialists, DCES) in the United States through the Pediatric Endocrine Society. Questions addressed beliefs related to SBDC, current practices, and perceived barriers/facilitators.

Results: Participants returned 131 completed surveys (91% physicians, 76% female, mean age 43 years, 65% white). Nearly all (94%) indicated SBDC was very important. Though most (63%) counseled families once/year, few (17%) spoke with school staff regularly, reporting that was a shared responsibility by providers (66%), DCES (88%), nurses (37%), and social workers (36%). Moderately to extremely significant barriers included limited staff resources (66%), time (83%), ease of communicating with school staff (54%), need for school nurse education (62%), and differing policies across school districts (69%). There were no significant differences in reported barriers by the location, size, and type of practice. Desired facilitators for SBDC included a designated school liaison (84%), electronic forms for schools (89%), and accessible educational tools for school staff (95%). Over 90% of providers agreed feedback from schools about their patients’ SBDC would be helpful, yet only 30% routinely requested this input.

Conclusions: Providers recognized the importance of SBDC for their patients. Systems-level factors (e.g., time, resources, and lack of formal processes for communication) may limit their ability to promote SBDC regardless of practice setting. Future research should establish supportive infrastructure to maximize school-provider-parent collaboration.

P160 | School based training and education program with psychological and peer support (STEPPS) initiative for children and young people living with type 1 diabetes

H. Day1, M. Quinn1, L. McCaffrey1, H. Kyprios1, R. Hubbard1, L. Finnigan1, D. Pintus1, D. Bray1, S.M. Ng1,2
1Southport and Ormskirk Hospital Trust, Childrens Diabetes, Ormskirk, United Kingdom, 2University of Liverpool, Liverpool, United Kingdom

Introduction: The delivery of structured diabetes education can be challenging in children and young people (CYP) with T1D.

Objectives: The STEPPS program was initiated to enable a positive learning environment for diabetes education based in school and to promote living well with diabetes.
Methods: Single center using mixed methods analysis of quantitative and semi structured qualitative analysis, were used to view the effectiveness of delivering a structured education, psychological and peer support in schools. The educational training package utilizes ‘The Goals of Diabetes’ validated structured education program as the foundation for planning the education pathway where each age groups’ needs were identified and could be met. The learning was split into five sections and lesson plans were created for each section led by a specialist nurse, educator, dietitian and psychologist based in school. Each lesson plan incorporated a psychological solution-based approach with the groups being able to relate to their own individual experiences. The qualitative arm was undertaken by the team psychologist.

Results: There were 40 young people age 11–16 included in the STEPPS program. The preliminary findings showed that 75% of the CYP although they highlighted knowledge around their diabetes, 50% of them still found it difficult to seek help and were unable to feel confident to ask for this help when in school. A 37.5% found it difficult to also talk to their friends. Following completion of the STEPPS program 100% identified increased knowledge in the understanding of their diabetes, evidence showed that there was an improvement of CYP feeling like their teachers understood their diabetes and they were more confident to seek support in school. Findings also showed that the CYP had increased confidence to talk to peers.

Conclusions: The STEPPS program provided the CYP with an alternative learning environment, creating a platform where they could share and relate these experiences with their peers.

POSTER TOUR 18—ASSOCIATED DISEASES # 1

P161 | Time trend and potential risk factors for celiac disease development in children with type 1 diabetes mellitus: 10-year single center experience in the Emirate of Abu Dhabi–UAE

F. Ahmed1, S. Al Jneibi2, J. Rajah3, S. Al Remeithi2
1Sheikh Khalifa Medical City, Educational Institute, Pediatric Residency Program, Abu Dhabi, United Arab Emirates, 2Sheikh Khalifa Medical City, Educational Institute, Endocrine Division, Abu Dhabi, United Arab Emirates, 3Sheikh Khalifa Medical City, Department of Pediatric, Abu Dhabi, United Arab Emirates

Introduction: The frequency of coexistence of T1DM and CD is widely described, ranging from 2.5% to 16.4% worldwide. The risk of CD is higher among younger children, females and during the first few years of T1D diagnosis.

Objectives: Describe demographic and clinical characteristic of children with CD with underlying diagnosis of T1DM.

Estimate the incidence and time trend of CD diagnosis among children of T1DM in our cohort.

Evaluate for potential factors that increase the risk of development of CD among this cohort.


Results: 898 patients with T1DM were identify. A 93 developed CD during the study period, incidence of CD was 10.4%. A 52.7% of CD/T1DM were females. The mean age at CD diagnosis of 8 ± 3.5 years, with the average duration of diabetes of 2.9 years ± (2.8) prior to CD diagnosis. Majority (64.5%) were asymptomatic for CD and were identified through routine screening. 83% developed CD over the first 5 years of T1DM diagnosis. All CD/T1DM had positive serology for CD, 79.5% underwent endoscopic duodenal biopsy, 90.5% of them showed villous atrophy. Risk factors of CD development in our cohort include: Age ≤8 years at time of T1DM diagnosis (P = 0.003) and positive family history of CD (P = 0.001). Coexistence of autoimmune thyroid disorder and gender were not significant predictors of developing CD in our cohort (P = 0.056) and (P = 0.8) respectively.

Conclusions: Incidence of CD among children with T1DM in our setting is 10.4%. The estimated cumulative risk of CD is significantly higher in younger children and those with positive FHx of CD. Majority (64%) were asymptomatic for CD and identified through routine screening. More than two thirds of children with CD were diagnosed during the first 5 years diabetes. These findings support the importance of implementing routine CD screening among children with T1DM in order to reduce the risk of potential health related consequences of undiagnosed CD.

P162 | Metreleptin reversing diabetes mellitus and other metabolic derangement in a patient with congenital generalized lipodystrophy

S. Dehidi1, J. Al Jubeh2
1Sheikh Khalifa Medical City, Pediatrics, Abu Dhabi, United Arab Emirates, 2Sheikh Khalifa Medical City, Pediatric Endocrinology, Abu Dhabi, United Arab Emirates

Introduction: Congenital Generalized Lipodystrophy (CGL) is an autosomal recessive disease characterized by total loss of adipose tissue formation. Patients usually have distinctive physical features, and prone to develop diabetes, hypertriglyceridemia, and liver cirrhosis secondary to deficiency in hormones secreted by adipocytes.

Objectives: In this study, we describe the effect of a novel hormonal therapy in preventing disease progression and reversing diabetes and other metabolic derangements.

Methods: A 2-year-old female presented with hyperphagia and unique appearance. Examination revealed scant subcutaneous fat, bulky muscles, acanthosis, hirsutism, macroganithia, large hands, and feet. Initial workup was unremarkable, genetic testing revealed a homozygous mutation in the AGPAT2 gene coding a key enzyme in adipogenesis pathway diagnostic for CGL

During childhood, her blood glucose levels and liver enzymes remained normal, but TGs levels were slightly elevated. At the age of 14, she developed diabetes, started on Insulin MDI therapy with a gradual increase in requirement reaching 3.6 U/kg/day. She had persistently elevated triglyceride levels despite Fenofibrate treatment
and elevated liver enzymes [AST] 41–59 IU/L, [ALT] 57–81 IU/L, along with ultrasonographical evidence of fatty liver disease. She was started on daily subcutaneous Metreleptin: a synthetic analog of leptin; hormone deficient in patients with GLD.

**Results:** After initiation of treatment, we observed a dramatic improvement in her metabolic disturbances: Insulin was tapered and stopped in 3 months. She achieved HbA1c of 5.2% 8 months after starting Metreleptin. Her liver enzymes and triglyceride levels normalized and Fenofibrate was stopped totally.

**Conclusions:** Metreleptin treatment in patients with CGL resulted in a complete reversal of hyperglycemia, hypertriglyceridemia, and normalization of transaminitis Preventing lethal complications and rendering the use of other medical treatments like Insulin and Fenofibrate unnecessary.

P163 | Celiac disease in children with type 1 diabetes—Relation to age, sex, and duration of T1D

J. Samuelsson¹,², R. Bertilsson³, A. Carlsson⁴,⁵, R. Hanås⁶,⁷, K. Åkesson¹,²
¹Ryhov County Hospital, Department of Pediatrics, Jönköping, Sweden, ²Linköping University, Linköping, Sweden, ³Center of Registers in Region Västra Götaland, Gothenburg, Sweden, ⁴Skåne University Hospital, Department of Pediatrics, Lund, Sweden, ⁵Lund University, Lund, Sweden, ⁶Gothenburg University, Sahlgrenska Academy, Gothenburg, Sweden, ⁷NU Hospital Group, Department of Pediatrics, Uddevalla, Sweden

**Introduction:** There is a known co-morbidity regarding type 1 diabetes (T1D) and other autoimmune diseases. This can, at least in part, be explained by a genetic susceptibility to development of these diseases. Previous studies in Sweden in T1D patients have found a prevalence of 7%–10% of celiac disease, with the highest risk of developing celiac disease within the first 2 years after diagnosis. Current ISPAD recommendation is to screen for celiac disease the first 5 years after diagnosis.

**Objectives:** To study celiac comorbidity in subjects with T1D diagnosed <18 years of age in Sweden.

**Methods:** All pediatric patients in NDR/Swediabkids, the nationwide Swedish National Diabetes Register, diagnosed and registered from year 2000 to 2019 were included (n = 16,026, 8842 boys and 7184 girls). This population was linked with the Swedish National Patient Register in order to acquire ICD codes. The risk of being diagnosed with celiac disease was estimated with Kaplan–Meier survival analysis. Subjects were divided into 4 groups depending on age at diabetes onset. If celiac disease diagnosis occurred pre diabetes diagnosis, then the event occurred in time = 0. The analyzes were made separately for girls and boys.

**Results:** The risk of a combination of the two diagnoses was significantly higher in children diagnosed with T1D in younger age and especially in girls. Although the risk was highest the first years after T1D diagnosis, there were still children diagnosed with celiac disease after more than 15 years of T1D duration.

**Conclusions:** Children diagnosed with T1D at young age have a higher risk of developing celiac disease and these children need to be screened for celiac disease more than 5 years after T1D diagnosis. If the increased risk is due to genetic factors as well as the impact of celiac disease on metabolic control and risk of complications in these children need to be further analyzed.

P164 | McCune-Albright syndrome associated with diabetes mellitus

M. Ben lafqih¹, M. Alhayane¹, S. Rafi¹, G. El Mghari¹, N. El Ansari¹
¹University Hospital Mohammed VI, Marrakech, Morocco

**Introduction:** McCune–Albright syndrome (MAS) is a rare non-hereditary genetic mosaic disease, the diagnosis is most often made in childhood by the clinical triad associating precocious puberty, fibrous
bone dysplasia and skin hyperpigmentation associated with other endocrinopathies or hepatobiliary disorders. The association of diabetes with McCune–Albright syndrome remains rare.

**Objectives:** We report the case of a patient with syndrome McCune–Albright associated with diabetes mellitus.

**Methods:** A.H 22 years old, at the age of 6 months presented skin macules. At the age of 3 years he developed gait disorders, a taller stature compared with other children of the same age and gender with craniofacial malformations, then signs of precocious puberty with secondary sexual characteristics at the age of 7 years. Bone scintigraphy objectified diffuse hyper fixation and diffuses deforming hyperostosis. Around the age of 12 years, diabetes mellitus was diagnosed with negative Ac anti GAD.

**Results:** Diabetes in McCune–Albright syndrome is a described association but without obvious causal link, hyperglycemia secondary to GH excess or hypercorticism was incriminated, papillary intraductal mucinous tumors with obstruction of the intra pancreatic ductal system and induction of low grade pancreatitis, parenchymal atrophy and endocrine dysfunction responsible for type 2 diabetes, for type 1 diabetes no potential link is evoked but the fortuitous association is described in several case reports.

**Conclusions:** Different types of diabetes can be associated with the syndrome but the pathophysiology remains unclear.

**P166 | Type 1 diabetes mellitus in pediatric celiac disease: Prevalence and clinical predictors**

F. Aljuraibah1,2,3, N. Alhamied1,2,3, A. Alajlan1,2,3, A. Alsunaíd1,2,3

1King Abdullah Specialist Children’s Hospital, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Pediatric Department, Riyadh, Saudi Arabia, 2College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia, 3King Abdullah International Medical Research Center, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia

**Introduction:** Celiac disease (CD) is a chronic autoimmune disorder characterized by a certain serological and histological changes that cause damage to the mucosa of the small intestine. It is induced by gluten ingestion in genetically susceptible individuals. The association between Type1 diabetes mellitus (T1DM) and CD has long been determined in several studies. The incidence rate of CD among T1DM ranges between 1.5% and 10%, which is higher than 10 folds in comparison with general population. However, the incidence of T1DM in CD is less well established in the literature.

**Objectives:** The aim of this study to determine the prevalence of T1DM in children with Celiac disease as well as clinical predictors of T1DM in patient with celiac disease.

**Methods:** This retrospective study analyzed the data of 226 patients who were diagnosed with celiac disease in a period between 2015 and 2019 at King Abdullah Specialist children hospital. A 50 patients who diagnosed first with T1DM were excluded from our study.

**Results:** The study included 176 cases (mean age ± SD 8.7 ± 3.3 years, 66.1% [n = 117] were females) The mean BMI was 15.6 ± 3.5 kg/m². 21.5% (38) cases were found to have family history of celiac disease, whereas 9.1% (16) cases were having family history of other autoimmune disease. However, 10.8% (19) have developed celiac and T1DM at the same time. Short stature and family history of CD were independently associated with development of T1DM (P = 0.013 and 0.026, respectively), but age, gender, family history of other autoimmune disorders, and adherence to gluten free diet did not associate with development of T1DM.

**Conclusions:** In pediatrics, 5.7% of CD cases developed T1DM, which was more common in cases with a family history of CD or short stature. Periodic clinical assessment of T1DM should be considered in cases of CD, especially if there is a short stature or a family history of CD, which needs to be proven through more prospective studies.
P167 | 7-month-old infant with early onset thiamine responsive megaloblastic anemia (TRMA), diabetes mellitus and sensorineural hearing loss, case report

M. Saleh1, M. Mustafa2, B. Yacop3, M. Helmi1
1Al Jalila Hospital, Dubai, United Arab Emirates, 2Al Jalila Hospital, Pediatric Endocrinology, Dubai, United Arab Emirates, 3Al Jalila Hospital, Pediatrics, Dubai, United Arab Emirates

Introduction: Thiamine-responsive megaloblastic anemia syndrome (TRMA) a rare autosomal recessive condition described by megaloblastic anemia, diabetes mellitus, and progressive sensorineural hearing loss. The onset occurs between infancy and adolescence. Thiamine treatment is correct the anemia, but the red blood cells remain macrocyclic; the anemia can recur when thiamine treatment seized. Progressive sensorineural hearing loss can be started early in toddlers; it is irreversible and might not be avoided by thiamine treatment. The nature of diabetes mellitus is non-type 1 and the onset is from infancy to adolescence.

We report a 7-month-old male infant with megaloblastic anemia, thrombocytopenia, and diabetes mellitus. He had significant sensorineural hearing loss that detected upon admission. TRMA was confirmed genetically. He had dramatic response of anemia, thrombocytopenia, and glycemic control to exogenous thiamine therapy.

Objectives: To identify different presentation of diabetes associated diseases.

Methods: Diagnosis made on clinical features, laboratory findings, and molecular genetic test.

Results: Full blood count: hemoglobin 5.6 g/dl (low), hematocrit 18.4%, RBC count 2.00 10⁶/ul, white blood cell counts 12.9 10³/ul, platelet count 66 10³/ul, MCV 91.9 fl, MCH 27.7 pg, MCHC 30.2 g/dl. The peripheral smear showed dimorphic, hypochromic, and normochromic red cells with poikilocytosis, few elliptocytes, fragmented RBCs, macrocytic, and occasional teardrop cells. Serum folate concentration was 16.4 ng/ml (normal), Vitamin B1: 19.1 Mg/1 (low). Whole exome sequencing identified SLC19A2 as pathogenic gene of Roger syndrome.

Conclusion: TRMA syndrome should be kept in mind especially in neonates and children presenting with a triad of megaloblastic anemia, diabetes mellitus and hearing impairment. Genetic analysis warranted to confirm the diagnosis. We believe that early genetic testing and establishment of thiamine treatment can correct anemia and accomplish euglycemic along with enhancement of the glycemic control.

Timing | Initial presentation | At 3 months of Liraglutide commencement | At 6 months of Liraglutide commencement
--- | --- | --- | ---
Weight | 59.10 kg | 56.90 kg | 52.30 kg
BMI | 33.41 kg/m² | 32.07 kg/m² | 28.82 kg/m²
BMI centile | > 99.45 | 99.33 | 98.82
BMI z-score | 2.55 | 2.47 | 2.26

Note: The patient developed gastrointestinal symptoms, however these resolved completely over 3 months period.
Note: No episodes of hypoglycemia were noticed. Patient reported reduced appetite and improved eating behavior.

P168 | Case report use of liraglutide in steroid induced diabetes mellitus in a pediatric patient

M. Taher1, N. Abdullah2
1Sheikh Khalifa Medical City, Pediatrics, Abu Dhabi, United Arab Emirates, 2Sheikh Khalifa Medical City, Pediatrics Endocrinology, Abu Dhabi, United Arab Emirates

Introduction: Patients who receive Glucocorticoids (GC) are at risk of developing hyperglycemia and/or steroid induced diabetes (SID). The mainstay of treatment for SID is subcutaneous insulin administration. There is no evidence of the efficacy and safety of oral hypoglycemic agents in the management of SID and are not recommended for use in pediatric patients.

Liraglutide is a Glucagon-like peptide-1 (GLP-1) agonist that was approved by the FDA and EMA in 2019 for children ≥ 10 years with type 2 diabetes.

Objectives: Discuss the effect of Liraglutide on SID in pediatric patients.

Methods: A 10 years old boy, with steroid dependent nephrotic syndrome, on active chronic oral prednisolone treatment. He developed intermittent hyperglycemia (fasting blood glucose (BG) rise up to 7 mmol/L and post meal BG rise up to 10.9 mmol/L). His (HbA1c) was 6.6%. His weight was 59.10 kg, BMI 33.41 kg/m², BMI > 99.45 centile and BMI z-score 2.55. The patient was commenced on Liraglutide. His prednisolone dose varied during the 6 months period; however, he was never off the medication.

During 6 months of follow up, we monitored: Home capillary blood glucose testing results, HbA1c, Weight, BMI, BMI z scores, Hypoglycemic episodes and other side effects of Liraglutide.

Results: After 6 months of Liraglutide treatment his intermittent hyperglycemia completely resolved and HBA1c improved to 5.4%. His other anthropometrics parameters are:
Conclusions:
- The use of Liraglutide in pediatric onset SID is not reported in the literature.
- Liraglutide in conjunction with lifestyle intervention led to significant improvement of SID and HbA1c, marked reduction in our patient’s weight and BMI Z Scores.
- We recommend that further studies are required to support the use of Liraglutide in carefully selected pediatric patients with SID.

P169 | Hyperglycemia in pediatric liver transplantation
S. Welsch1, V. Mailleux1, E. Sokal1,2, R. Reding2, P. Lysy1,3
1Cairo University School of Medicine, Pediatric Endocrinology & Diabetes, Cairo, Egypt, 2Cliniques Universitaires Saint-Luc, Pediatric Abdominal and General Surgery, Brussels, Belgium, 3Cliniques Universitaires Saint-Luc, Pediatric Endocrinology Unit, Brussels, Belgium

Introduction: After liver transplant (LT), hyperglycemia (HG) is a common complication and is associated to an unfavorable prognosis, a persistent diabetes on set and an increased cardiovascular event. However, in pediatric LT, incidence of HG, its occurrence, persistence, and predispositions remain understudied.

Objectives: Therefore, the objectives of our study were the characterization and evolution of hyperglycemia in children with LT and the analysis of their glycemic profile.

Methods: We collected 7-years data about 195 children with LT in Brussels to characterize hyperglycemia and associated risk factors in multivariate analyzes, and we followed five children with LT during the most critical moment of HG to analyze their glycemic profile. Hyperglycemia was defined as a glycemia exceeded 200 mg/dl, for at least two measurements separated by 24 h, outside the day of LT.

Results: Our retrospective study showed that 24% of LT children presented hyperglycemia and its onset was between 0 and 14 days after transplant. Multivariate analysis showed that children with LT who benefited of steroids (OR 2.51) for a graft rejection and/or had a virus infection (OR 2.05) were more at risk to develop hyperglycemia. Glucose sensors showed that HG was present in the post-prandial afternoon for all LT children.

Conclusions: Our study shows that children with LT were more at risk of developing hyperglycemia when they required the use of steroids or when they had a viral infection, and that the measurement of blood glucose during the first month post-transplant and in the post-prandial afternoon is essential to detect glycemic abnormalities.

P170 | Evaluation of serum adiponectin, its relation to insulin resistance in children and adolescents with type 1 diabetes
R. Shamma1, A. Helmy1, H. Soliman1
1Cairo University School of Medicine, Pediatric Endocrinology & Diabetes, Cairo, Egypt

Introduction: Adiponectin is an adipokine that is generated and released by adipose tissues and is well known for its anti-diabetic, anti-inflammatory, anti-atherogenic, and cardioprotective properties (Lee and Shao, 2014). Additionally, hypoadiponectinemia is a marker of insulin resistance.

Objectives: This study aimed to determine the serum level of adiponectin and its relation to insulin resistance in children and adolescents with Type 1 diabetes mellitus (T1DM).

Methods: This cross-sectional study included 65 (n = 65) children diagnosed with T1DM who were following up at Diabetes, Endocrine, and Metabolism Pediatric unit (DEMPU) at Cairo University Children’s Hospital from November 2020 to January 2021. Demographic, clinical data, investigations, and management details were collected from patients’ medical records in addition to evaluation of serum level of adiponectin level using Human adiponectin ELISA Kit. Data management and statistical analysis were performed using Statistical Package for Social Sciences (SPSS) version 24.

Results: There was male predominance with male to female ratio 1.3:1, their mean age was 12.6 ± 2 years, the mean age of diagnosis was 7.3 ± 2.8 years. A 82% (82.4%) of the participants were poorly controlled as the mean HbA1c was 9.6 ± 1.5. A 93% (93.8%) of the participants were dyslipidemic. About (40%) of diabetic patients had low serum adiponectin with mean value 2.4 ± 3.6. There was statistically significant difference between patients with normal and low adiponectin regarding age of diagnosis of diabetes, body mass index, occurrence of microalbuminuria, LDL level with p values 0.04, 0.015, 0.022, 0.011 respectively.

Conclusions: Serum adiponectin level may be low in children with T1DM. There was also an association between lower adiponectin levels in diabetic children, occurrence of microalbuminuria and dyslipidemia as well. But no reported association between its level and insulin resistance.

POSTER TOUR 19—AUTOMATED INSULIN DELIVERY # 2

P171 | Sleep, fear of hypoglycemia, and glycemic outcomes in parents identified as poor sleepers and their children with type 1 diabetes (T1D) after initiation of Hybrid Closed-Loop (HCL) technology
A.J. Karami1, C. Sakamoto1,2, E. Escobar1, E. Jost1, L. Pyle1,2, L. Towers1, T. Vigers1,2, R.P. Wadwa3, E.C. Cobry1
1University of Colorado Anschutz Medical Campus, School of Medicine, Aurora, United States, 2University of Colorado, Colorado School of Public Health, Department of Biostatistics and Informatics, Aurora, United States

Introduction: Youth with T1D and their parents often report reduced sleep quality. HCL systems can alleviate diabetes disturbances, worry, and nocturnal monitoring.

---

**P169** Hyperglycemia in pediatric liver transplantation

**P170** Evaluation of serum adiponectin, its relation to insulin resistance in children and adolescents with type 1 diabetes
Objectives: We analyzed sleep, fear of hypoglycemia, and glycemic changes based on poor or good sleep categorization of parents of youth with T1D transitioning to an HCL system.

Methods: Parents (age 42 [IQR 38, 48] years, 82% female) of 39 youth with T1D (age 11.1 ± 3.7 years, 54% male, T1D duration 1.1 [0.3, 2.9] years) starting on Tandem’s Control-IQ (CIQ) completed the Pittsburg Sleep Quality Index (PSQI) prior to initiation. Dyads were stratified into “Poor Sleeper” and “Good Sleeper” groups by parent baseline PSQI (≥5 indicates poor sleep). Actigraphy, survey (Hypoglycemia Fear Survey [HFS] and PSQI), and glycemic outcomes were obtained at baseline, 3, and 6 months. Between group comparisons were done using linear mixed models with a random intercept for subject and an interaction term between time and sleeper group. Within group changes were additionally analyzed.

Results: Youth sleep efficiency in the Poor Sleeper group increased at 6 months (p = 0.05) (Table). Parent PSQI improved at 3 months (p = 0.04). HFS Total and Total Worry and Worry Low BG subscales in both Poor Sleeper parent and child decreased significantly at 6 months. At baseline, 16 parents were good sleepers and 23 were poor sleepers. At 3 months, 21 were good and 18 were poor sleepers. At 6 months, 16 were good and 21 were poor sleepers. No significant changes were seen in the Good Sleeper group.

Conclusions: Parents identified as poor sleepers and their children experienced a reduction in fear of hypoglycemia after youth initiation of an HCL and parent subjective sleep improved. However, sleep duration remained unchanged and the total number of parents with poor sleep returned to baseline by 6 months, indicating complex factors influence sleep quality, which must be explored further.
using subject-level data was calculated for the end of study period when AHCL was used and compared to that calculated for the baseline run-in when sensor-augmented pump (SAP) or hybrid-closed loop (HCL) was used.

**Results:** With AHCL, prediction ellipses for both groups became tighter and migrated toward better mean SG and SD of SG, when compared to baseline (Figure). Compared to baseline for each age group (7–13 years and 14–17 years), change in HbA1c reduced by 6.1% and 7.4%; it reduced by 9.5% and 7.6% for SG, and by 7.9% and 8.5% for SD of SG, respectively. There was a greater reduction in SG among those aged 7–13 years, and a greater reduction in SD of SG among those aged 14–17 years. Irrespective of differences in glycemic metrics improvement, reductions in PEM area (decreases by 55.3% and 63.1%, respectively) were apparent and corresponded with the glycemic metrics changes observed.

**Conclusions:** The area of PEM, a composite of sensor-derived mean SG and SD of SG, may be a more sensitive and more comprehensive alternative to HbA1c alone in demonstrating overall pediatric glycemic control.

---

**P173 | Performance of the MiniMed 780G system in a child with T1 Diabetes during bone marrow transplant procedure–A case study**

A. Michalak¹,², M. Ussowicz², J. Kołodrubiec³, J. Trelińska³, A. Szadkowska³

¹Medical University of Lodz, Department of Pediatrics, Diabetology, Endocrinology and Nephrology, Łódź, Poland, ²Medical, Department of Biostatistics and Translational Medicine, Łódź, Poland, ³Medical University of Wrocław, Department of Pediatric Bone Marrow Transplantation, Oncology and Hematology, Wrocław, Poland

**Introduction:** Maintaining glycemic control in patients with type 1 diabetes (T1D) and coexisting oncological disorders is challenging. Due to high doses of administered steroids, side effects of chemotherapy (primarily vomiting), transient need for partial or total parenteral nutrition – intravenous insulin therapy is needed. However, it is possible that advanced hybrid closed loop system might help maintain safe glucose levels with subcutaneous insulin infusion.

**Objectives:** To describe and assess blood glucose control of a child with T1D and nephroblastoma using the hybrid closed loop MiniMed 780G system during chemotherapy and bone marrow transplantation.

**Methods:** A 7-year-old boy with T1D for 4 months was diagnosed with a recurrent nephroblastoma and subjected to intensive chemotherapy (Protocol Umbrella) followed by an autogenic bone marrow transplantation (BMT). A 2 months before the planned BMT he started using the MiniMed 780G system. During nephroblastoma treatment the boy was in automatic mode all the time except for 30 min suspensions during post BMT-irradiation. Data from his continuous glucose monitoring were assessed in relation to therapy phases, focusing on

<table>
<thead>
<tr>
<th></th>
<th>During chemotherapy</th>
<th>During BMT (including 5 days of total parenteral nutrition)</th>
<th>During radiotherapy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TBR &lt;54 mg/dl</strong></td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td><strong>TBR &lt;70 mg/dl</strong></td>
<td>1%</td>
<td>1%</td>
<td>1%</td>
</tr>
<tr>
<td><strong>TIR 70-180 mg/dl</strong></td>
<td>91%</td>
<td>65%</td>
<td>95%</td>
</tr>
<tr>
<td><strong>TAR 180-250 mg/dl</strong></td>
<td>8%</td>
<td>34%</td>
<td>4%</td>
</tr>
<tr>
<td><strong>TAR&gt;250 mg/dl</strong></td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
</tr>
<tr>
<td><strong>CV</strong></td>
<td>25.9%</td>
<td>26%</td>
<td>26%</td>
</tr>
</tbody>
</table>
Six months glycemic outcomes of advanced hybrid closed loop system in children and adolescents with type 1 diabetes

H.G. Balki1, G.D. Oncul1, Y.A. Altinok1, S. Ozen1, S. Darcan1, D. Goksen1
1Ege University School of Medicine, Children Hospital, Department of Pediatrics, Division of Pediatric Endocrinology and Diabetes, Izmir/ Bornova, Turkey

Introduction: To assess the effectiveness of advanced hybrid closed-loop systems (a-HCLS) use up to 6 months of treatment in a real-world setting.

Methods: HbA1c and BMI were collected at baseline and 6 months after a-HCLS start. Data on glycemic control were extracted from CareLink™PersonalSoftware 29 of the 43 participants (67%) were on insulin infusion pump and 14 (33%) were on MDI.

Results: A 43 patients (13.40 ± 6.14 years; 28 girls [59%]) were included. Mean duration of diabetes was 5.61 ± 5.17 years and HbA1c 7.08 ± 0.80%. TIR increased from 74.88 ± 13.74 to 78.93 ± 7.67%. TBR decreased from 3.02 ± 2.60 to 2.72 ± 1.93% and TAR from 18.28 ± 7.98 to 19.14 ± 6% (p < 0.001). Negative correlation between TIR and auto correction bolus was found (r = -0.399, p < 0.01). GMI decreased from 6.58 ± 1.05 to 0.34 ± 1.11 (p < 0.001). Total insulin dose increased from 32.07 ± 17.81 U/d to 39.82 ± 19.36 U/d (p < 0.001). Basal insulin decreased from 18.23 ± 10.73 to 14.95 ± 7.03% (p < 0.01). Total insulin dose increased from 32.07 ± 17.81 U/d to 39.82 ± 19.36 U/d (p < 0.001). Basal insulin decreased from 6.63 to 6.47% (p < 0.01). Total insulin dose increased from 32.07 ± 17.81 U/d to 39.82 ± 19.36 U/d (p < 0.001). Basal insulin decreased from 6.63 to 6.47% (p < 0.01).

Conclusion: Analysis of this patient’s records indicates that therapy with the MiniMed 780G system may be safe and effective in patients with T1D undergoing chemotherapy and BMT.

Evaluation of pediatric insulin dosing behavior changes during advanced hybrid closed loop system use

J. Shin1, X. Chen1, M. Liu1, Z. Dai1, A. Rhinehart1, R. Vigersky1
1Medtronic, Northridge, United States

Introduction: Pediatric type 1 diabetes (T1D) meal management that includes counting carbs and delivering meal boluses at the right time has always been a challenge. The benefit of an Advanced Hybrid Closed-Loop (AHCL) system auto-bolus feature may help with this.

Objectives: In this exploratory analysis, meal management (i.e., pediatric user-initiated boluses associated with carbohydrate announcements), system-delivered auto-boluses, and other insulin delivery were assessed alongside glycemic outcomes over time, to evaluate the impact of the AHCL auto-bolus.

Methods: The MiniMed™ 780G system with Guardian™ 4 sensor was used by participants (N = 109, aged 7–17 years) over a 3-month period. Glycemic outcomes including mean SG, percentage (%) of time in below and above target range (70–180 mg/dl) and insulin delivery (total daily insulin dose, user-initiated boluses and system-delivered boluses, with and without meal association) were summarized. The initial 2 weeks of data were considered as a baseline reference and compared to the last 2 weeks of data from months 1, 2 and 3 post-AHCL initiation.

Results: A reduction of meal boluses and an increased percentage of carbs entered per day (∆± 5.6%, p = 0.002, paired t-test) and a reduction in the number of carbs entered per day (∆± 1.6, p = 0.0949, Wilcoxon signed rank test) were observed. Glycemic outcomes and insulin delivery are shown (Table). The %TIR and %TBR < 70 mg/dl changed by −1.9 ± 7.9% and −0.1 ± 1.3%, respectively, from baseline to month 3.

Conclusions: While a relaxation in meal management was detected during 3 months of AHCL use, glycemic control outcomes did not change much. This suggests the AHCL system is compensating for instances when meal management by children is suboptimal. This compensation helps reduce burden, while maintaining good glycemic control.
Diabetes impact and device satisfaction using non-automated insulin delivery (non-aid) and aid systems in children with type 1 diabetes: Real-world data in Italy


Azienda Ospedaliero-Universitaria, Ospedali Riuniti di Ancona, G. Salesi Hospital, Department of Women's and Children's Health, Ancona, Italy, Polytechnic University of Marche, Center of Epidemiology and Biostatistics, Ancona, Italy, Children Hospital, ASO SS Antonio Biagio e Cesare Arrigo, Pediatric and Pediatric Emergency Unit, Alessandria, Italy, Perrino Hospital, Unit of Pediatrics, Brindisi, Italy, Sant' Anna e San Sebastiano Hospital, Pediatric Endocrinology Unit, Caserta, Italy, Bufalini Hospital, Department of Pediatrics, Cesena, Italy, Pediatric Clinic, IRCCS Giamma Gaslini; University of Genoa, Department of Neuroscience Rehabilitation Ophthalmology Genetics, Maternal and Child Health, Genova, Italy, Università degli Studi di Napoli Federico II, Department of Translational Medical Science, Section of Pediatrics, Napoli, Italy, S.M. Croci Hospital Ravenna, AUSL della Romagna, Unit of Pediatrics, Ravenna, Italy, A.O.U. Città della Salute e della Scienza di Torino, Center of Pediatric Diabetology, Torino, Italy, Chiara Hospital of Trento, Department of Pediatrics, Trento, Italy, University and Azienda Ospedaliera Universitaria Integrata of Verona, Department of Surgery, Dentistry, Pediatrics and Gynecology, Section of Pediatric Diabetes and Metabolism, Verona, Italy

ABSTRACTS

Glycemic outcomes and insulin delivery during three months of pediatric MiniMed™ 780G system use

<table>
<thead>
<tr>
<th>Category</th>
<th>Baseline (Initial 2weeks)</th>
<th>Last 2 Weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Month 1</td>
</tr>
<tr>
<td>Number of Participants</td>
<td>109</td>
<td>109</td>
</tr>
<tr>
<td>Insulin and Carbs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TDD (U)</td>
<td>52.0 ± 23.4 (46.3)</td>
<td>52.6 ± 24.7 (48.8)*</td>
</tr>
<tr>
<td>Basal (U)</td>
<td>20.4 ± 9.7 (17.5)</td>
<td>20.6 ± 10.5 (19.0)*</td>
</tr>
<tr>
<td>Bolus (U)</td>
<td>31.5 ± 14.5 (29.6)</td>
<td>32.0 ± 15.3 (31.2)*</td>
</tr>
<tr>
<td>Auto Bolus (U)</td>
<td>9.6 ± 6.8 (7.8)</td>
<td>9.9 ± 6.3 (9.2)*</td>
</tr>
<tr>
<td>Meal Bolus/All Bolus (%)</td>
<td>68.6 ± 12.8 (70.6)</td>
<td>67.8 ± 12.7 (69.6)*</td>
</tr>
<tr>
<td>Non-Meal Bolus/All Bolus (%)</td>
<td>1.8 ± 2.6 (0.9)</td>
<td>1.6 ± 2.2 (0.9)*</td>
</tr>
<tr>
<td>Auto Bolus with Meal/All Bolus (%)</td>
<td>17.3 ± 6.5 (17.2)</td>
<td>17.7 ± 7.1 (17.8)*</td>
</tr>
<tr>
<td>Auto Bolus Non-Meal/All Bolus (%)</td>
<td>12.3 ± 9.3 (9.4)</td>
<td>12.9 ± 8.4 (10.3)*</td>
</tr>
<tr>
<td>Carb Ratio (g/U)</td>
<td>9.1 ± 3.6 (8.5)</td>
<td>9.0 ± 3.5 (8.3)*</td>
</tr>
<tr>
<td>Carb Amounts/day</td>
<td>176.1 ± 73.5 (160.4)</td>
<td>176.7 ± 73.6 (157.7)*</td>
</tr>
<tr>
<td>Number of Carb Entries/day</td>
<td>5.7 ± 2.5 (5.2)</td>
<td>5.6 ± 2.2 (5.3)*</td>
</tr>
</tbody>
</table>

Glycemic Outcomes

<table>
<thead>
<tr>
<th>Category</th>
<th>Baseline (Initial 2weeks)</th>
<th>Last 2 Weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Month 1</td>
</tr>
<tr>
<td>Overall Average SG (mg/dL)</td>
<td>152.0 ± 16.0 (149.3)</td>
<td>151.6 ± 13.7 (151.9)</td>
</tr>
<tr>
<td>Overall SD of SG (mg/dL)</td>
<td>54.5 ± 10.5 (53.4)</td>
<td>54.2 ± 10.4 (52.7)</td>
</tr>
<tr>
<td>Overall CV of SG (%)</td>
<td>35.7 ± 4.7 (36.1)</td>
<td>35.6 ± 4.7 (35.9)</td>
</tr>
<tr>
<td>SG &lt;54 mg/dL (%)</td>
<td>0.4 ± 0.4 (0.2)</td>
<td>0.4 ± 0.6 (0.2)</td>
</tr>
<tr>
<td>SG &lt;70 mg/dL (%)</td>
<td>2.0 ± 1.6 (1.7)</td>
<td>2.2 ± 1.7 (1.8)</td>
</tr>
<tr>
<td>SG 70 - 180 mg/dL (%)</td>
<td>71.8 ± 9.5 (73.6)</td>
<td>72.1 ± 8.4 (72.3)</td>
</tr>
<tr>
<td>SG &gt;180 mg/dL (%)</td>
<td>26.1 ± 9.9 (24.5)</td>
<td>25.6 ± 8.7 (25.5)</td>
</tr>
</tbody>
</table>

Data are shown as mean ± SD (Median). *N=108. The Guardian™ 4 sensor was used with the Minimed™ 780G system.
Introduction: In Italy about 40% of children with type 1 diabetes (T1D) are treated with MDI (multiple injection therapy) while automatic insulin delivery systems (AID) are becoming increasingly popular.

Objectives: The aim of this cross-sectional multicenter study was to evaluate metabolic control and health-related quality of life characteristics in children using non-AID and AID systems in daily life.

Methods: We considered children and adolescents with a diagnosis of T1D for more than 6 months, under the age of 18, who used non-AID (MDI + CGM and SAP) and AID (PLGM, HCL, and AHCL) systems. Clinical data, downloaded CGM metrics, and DIDS (Diabetes Impact and Device Satisfaction) questionnaire results were analyzed.

Results: Overall, 809 subjects were included in this analysis (48% females, 52% males), 30% treated with AID systems. All metrics were associated with better glycemic control when using AID compared to non-AID systems, except for TBR <54 mg/dl, which values were extremely low in both groups. Quality of life was significantly better in adolescents treated with the AID system, with significantly higher treatment satisfaction and the impact of diabetes significantly lower than in adolescents treated with non-AID systems (table 1).

Conclusions: The use of AID systems on a large unselected population of children and adolescents with T1D was associated with better glycemic control and greater treatment satisfaction. Long-term follow-up studies, extending the analysis to populations with diverse socioeconomic backgrounds, will help provide information on how to make AIDS systems available to all children with diabetes.

Table 1. Patients’ characteristics, glycemic control and Diabetes Impact and Device Satisfaction (DIDS) scores according to insulin delivery system used.

<table>
<thead>
<tr>
<th>Variables</th>
<th>non-AID (n=569)</th>
<th>AID (n=240)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, F</td>
<td>260 (45.7)</td>
<td>128 (53.3)</td>
<td>0.056</td>
</tr>
<tr>
<td>Age at diagnosis, years</td>
<td>8.3 (5.3; 11)</td>
<td>6.4 (3.3; 9.6)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>4.5 (2.7; 7.7)</td>
<td>5.1 (2.8; 8.3)</td>
<td>0.264</td>
</tr>
<tr>
<td>Percent time in range, %</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;54 mg/dl (&lt;3.0 mmol/L)</td>
<td>0 (0; 1)</td>
<td>0 (0; 1)</td>
<td>0.880</td>
</tr>
<tr>
<td>&lt;70 mg/dl (3.9 mmol/L)</td>
<td>3 (1; 6)</td>
<td>2 (1; 4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>70-180 mg/dl (3.9–10.0 mmol/L)</td>
<td>57 (46-70)</td>
<td>71 (63-78)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>&gt;180 mg/dl (&gt;10.0 mmol/L)</td>
<td>27 (21; 36)</td>
<td>20 (15; 27)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>&gt;250 mg/dl (&gt;13.9 mmol/L)</td>
<td>7 (2; 16)</td>
<td>5 (2; 10)</td>
<td>0.032</td>
</tr>
<tr>
<td>Coefficient of Variation, %</td>
<td>37 (33; 42)</td>
<td>35 (31; 39)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>DIDS – Device Satisfaction, scores</td>
<td>8 (8-9)</td>
<td>9 (8-9)</td>
<td></td>
</tr>
<tr>
<td>DIDS – Diabetes Impact, Impact scores</td>
<td>4 (3-6)</td>
<td>4 (2-5)</td>
<td>0.019</td>
</tr>
</tbody>
</table>

Introduction: Closed loop systems (CLS) are becoming more popular among the pediatric population with type 1 diabetes mellitus (T1DM), with the real time continuous glucose monitoring and insulin delivery providing improvements in maintaining optimal glucose control as well as being associated with psychological and physical benefits.

Objectives: This study aims to quantitatively assess the impact of CLS on diabetes control and qualitatively on quality of life of children with T1DM.

Methods: An observational single-center cohort study in the United Kingdom was conducted, with patients identified by the clinician in charge of their care. Quantitative assessment of diabetes control was collected from the electronic records and analyzed on Microsoft excel. An adapted structured questionnaire covering quality of life measures for children with T1DM, modified for relevance to CLS, was asked to patients and/or their guardians.

Results: Overall, 809 subjects were included in this analysis (48% females, 52% males), 30% treated with AID systems. All metrics were associated with better glycemic control when using AID compared to non-AID systems, except for TBR <54 mg/dl, which values were extremely low in both groups. Quality of life was significantly better in adolescents treated with the AID system, with significantly higher treatment satisfaction and the impact of diabetes significantly lower than in adolescents treated with non-AID systems (table 1).

Conclusions: The use of AID systems on a large unselected population of children and adolescents with T1D was associated with better glycemic control and greater treatment satisfaction. Long-term follow-up studies, extending the analysis to populations with diverse socioeconomic backgrounds, will help provide information on how to make AIDS systems available to all children with diabetes.

P177  |  Real life experiences of closed loop systems in children with type 1 diabetes mellitus

N. Punjabi¹, C. Shaw², K. Subburaj¹, M. Mesina³, A. Kshirsagar¹
¹West Middlesex University Hospital, Chelsea and Westminster Hospital NHS Foundation Trust, Pediatrics, London, United Kingdom

Introduction: Closed loop systems (CLS) are becoming more popular among the pediatric population with type 1 diabetes mellitus (T1DM), with the real time continuous glucose monitoring and insulin delivery providing improvements in maintaining optimal glucose control as well as being associated with psychological and physical benefits.

Objectives: This study aims to quantitatively assess the impact of CLS on diabetes control and qualitatively on quality of life of children with T1DM.

Methods: An observational single-center cohort study in the United Kingdom was conducted, with patients identified by the clinician in charge of their care. Quantitative assessment of diabetes control was collected from the electronic records and analyzed on Microsoft excel. An adapted structured questionnaire covering quality of life measures for children with T1DM, modified for relevance to CLS, was asked to patients and/or their guardians.

Results: Overall, 809 subjects were included in this analysis (48% females, 52% males), 30% treated with AID systems. All metrics were associated with better glycemic control when using AID compared to non-AID systems, except for TBR <54 mg/dl, which values were extremely low in both groups. Quality of life was significantly better in adolescents treated with the AID system, with significantly higher treatment satisfaction and the impact of diabetes significantly lower than in adolescents treated with non-AID systems (table 1).

Conclusions: The use of AID systems on a large unselected population of children and adolescents with T1D was associated with better glycemic control and greater treatment satisfaction. Long-term follow-up studies, extending the analysis to populations with diverse socioeconomic backgrounds, will help provide information on how to make AIDS systems available to all children with diabetes.

P178  |  Advanced hybrid closed loop MiniMed 780G system and its characteristics in achieving better glycemic outcome in children and adolescents with type 1 diabetes

G. Petrovski¹, J. Campbell¹, F. Al Khalaf¹, K. Hussain¹, E. Day¹
¹Sidra Medicine, Doha, Qatar

Introduction: Closed loop systems (CLS) are becoming more popular among the pediatric population with type 1 diabetes mellitus (T1DM), with the real time continuous glucose monitoring and insulin delivery providing improvements in maintaining optimal glucose control as well as being associated with psychological and physical benefits.

Objectives: This study aims to quantitatively assess the impact of CLS on diabetes control and qualitatively on quality of life of children with T1DM.

Methods: An observational single-center cohort study in the United Kingdom was conducted, with patients identified by the clinician in charge of their care. Quantitative assessment of diabetes control was collected from the electronic records and analyzed on Microsoft excel. An adapted structured questionnaire covering quality of life measures for children with T1DM, modified for relevance to CLS, was asked to patients and/or their guardians.

Results: Overall, 809 subjects were included in this analysis (48% females, 52% males), 30% treated with AID systems. All metrics were associated with better glycemic control when using AID compared to non-AID systems, except for TBR <54 mg/dl, which values were extremely low in both groups. Quality of life was significantly better in adolescents treated with the AID system, with significantly higher treatment satisfaction and the impact of diabetes significantly lower than in adolescents treated with non-AID systems (table 1).

Conclusions: The use of AID systems on a large unselected population of children and adolescents with T1D was associated with better glycemic control and greater treatment satisfaction. Long-term follow-up studies, extending the analysis to populations with diverse socioeconomic backgrounds, will help provide information on how to make AIDS systems available to all children with diabetes.

P177  |  Real life experiences of closed loop systems in children with type 1 diabetes mellitus

N. Punjabi¹, C. Shaw², K. Subburaj¹, M. Mesina³, A. Kshirsagar¹
¹West Middlesex University Hospital, Chelsea and Westminster Hospital NHS Foundation Trust, Pediatrics, London, United Kingdom

Introduction: Closed loop systems (CLS) are becoming more popular among the pediatric population with type 1 diabetes mellitus (T1DM), with the real time continuous glucose monitoring and insulin delivery providing improvements in maintaining optimal glucose control as well as being associated with psychological and physical benefits.

Objectives: This study aims to quantitatively assess the impact of CLS on diabetes control and qualitatively on quality of life of children with T1DM.

Methods: An observational single-center cohort study in the United Kingdom was conducted, with patients identified by the clinician in charge of their care. Quantitative assessment of diabetes control was collected from the electronic records and analyzed on Microsoft excel. An adapted structured questionnaire covering quality of life measures for children with T1DM, modified for relevance to CLS, was asked to patients and/or their guardians.

Results: Overall, 809 subjects were included in this analysis (48% females, 52% males), 30% treated with AID systems. All metrics were associated with better glycemic control when using AID compared to non-AID systems, except for TBR <54 mg/dl, which values were extremely low in both groups. Quality of life was significantly better in adolescents treated with the AID system, with significantly higher treatment satisfaction and the impact of diabetes significantly lower than in adolescents treated with non-AID systems (table 1).

Conclusions: The use of AID systems on a large unselected population of children and adolescents with T1D was associated with better glycemic control and greater treatment satisfaction. Long-term follow-up studies, extending the analysis to populations with diverse socioeconomic backgrounds, will help provide information on how to make AIDS systems available to all children with diabetes.

P178  |  Advanced hybrid closed loop MiniMed 780G system and its characteristics in achieving better glycemic outcome in children and adolescents with type 1 diabetes

G. Petrovski¹, J. Campbell¹, F. Al Khalaf¹, K. Hussain¹, E. Day¹
¹Sidra Medicine, Doha, Qatar
Introduction: The recent studies report that improved glycemic outcomes with Advanced Hybrid Closed Loop (AHCL) system are correlated with more stringent pump settings.

Objectives: The objective of this study was to evaluate initiation of Advanced Hybrid Closed Loop (AHCL) Minimed 780G system and its characteristics on glycemic control in children and adolescents with Type 1 Diabetes (T1D) previously treated with Multiple Daily Injections (MDI).

Methods: The observational single center study enrolled 67 individuals with T1D, aged 7–18 years, who initiated Minimed 780G system from October 2021 to December 2021 at Sidra Medicine in Qatar. Glycemic control (HbA1c and Time in Ranges) and AHCL characteristics (insulin u/kg, basal ratio, insulin to carb ratio (ICR), active insulin time (AIT), algorithm glucose targets, sensor wear and AutoMode use) were analyzed at baseline, 2 weeks and 3 months after the initiation of the AHCL system.

Results: 67 individuals (age 11.4 ± 2.9 years, female 39, diabetes duration 3.8 ± 1.8 years), where 77% of participants used Continuous Glucose monitoring (CGM) or flash glucose monitoring (FGM). HbA1c decreased from 8.3 ± 1.6% (67 ± 17.5 mmol/mol) at baseline, to 6.6 ± 0.6% (49 ± 6.6 mmol/mol) at 3 months ($p = 0.02$) of AHCL initiation, while TIR of 49.5 ± 15.8% increased to 77.1 ± 12.6% respectively. AHCL characteristics are shown in table 1. No episodes of severe hypoglycemia or DKA were reported.

Conclusions: MiniMed 780G system with both automated basal and bolus corrections, along with strengthening the ICR, shortening the AIT to 2–3 h and algorithm glucose target of 100 mg/dl and 110 mg/dl can improve glycemic control in a safe manner in children and adolescents previously treated with MDI.

Table 1. AHCL System Characteristics

<table>
<thead>
<tr>
<th></th>
<th>A Baseline</th>
<th>B First 2 weeks</th>
<th>A vs B, $P$</th>
<th>C Third Month</th>
<th>B vs C, $P$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensor wear, %</td>
<td>90.5±12.8*</td>
<td>93.9±10.9</td>
<td>/</td>
<td>94.7±25.1</td>
<td>/</td>
</tr>
<tr>
<td>AHCL usage, %</td>
<td>/</td>
<td>85.2±7.7</td>
<td>/</td>
<td>92.7±4.1</td>
<td>/</td>
</tr>
<tr>
<td>TDD, U/(kg/d)</td>
<td>1.0±0.4</td>
<td>1.1±0.3</td>
<td>1.1±0.3</td>
<td>1.1±0.3</td>
<td>/</td>
</tr>
<tr>
<td>Basal insulin, as % of TDD</td>
<td>41.6±9.8</td>
<td>33.1±5.9</td>
<td>31.1±2.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ICR, gr</td>
<td>15.2±8.2</td>
<td>12.1±7.1</td>
<td>8.8±3.2</td>
<td>2.5±0.6</td>
<td>/</td>
</tr>
<tr>
<td>AIT, h</td>
<td>3.4±0.5**</td>
<td>2.6±0.7</td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
</tbody>
</table>

Algorithm glucose target, % of users

- 100 mg/dl
  - 48 ***
  - 55 /
  - 59 /
- 110 mg/dl
  - 34 ***
  - 33 /
  - 37 /
- 120 mg/dl
  - 18 ***
  - 12 /
  - 4 /

All values are shown as mean±SD and %
AHCL, Advanced Hybrid Closed Loop System; TDD, total daily dose of insulin; ICR, Insulin To Carb Ratio; AIT, active insulin time
* Sensors wear in 52 participants, 90 days of CGM data on MDI
** as per manual bolus correction on MDI
*** algorithm glucose target on initiation of AHCL
median age at the last data download was 5.1 years (IQR 3.3–6.6), with a median duration of a-HCL treatment of 179 days (IQR 72;385). No ketoacidosis or severe hypoglycemia events were reported. Time above range (TAR) and mean glucose sensor significantly decreased since the beginning of a-HCL use and until the last download (p < 0.01), while time in range (TIR) significantly reduced (p < 0.01).

Conclusions: The use of a-HCL system Minimed 780G is safe and effective also in children below the age of 7 years and with a total daily insulin dose below 8 U.

P180 | Expanding access to automated insulin delivery (AID) within the Latinx pediatric type 1 diabetes (T1D) population

L. Geiser1, C. Berget1, G. Tellez1, G. Spiegel1, G. Forlenza2, A. Gerard-Gonzalez1
1Colorado University School of Medicine, Barbara Davis Center, Aurora, United States

Introduction: There are significant disparities in T1D care, with minority populations using insulin pumps and CGMs at a lower rate than non-Hispanic white patients. At the Barbara Davis Center (BDC) in Denver, Colorado, 72% of Non-Hispanic white youth with T1D use an insulin pump but only 43% of Latinx youth with T1D use pumps. Insulin pump therapies, especially AID, are associated with improved glycemic outcomes compared to multiple daily injections (MDI).

Objectives: The objective of this Quality Improvement (QI) project is to increase access to the t:slim Control IQ (CIQ) pump, an advanced AID system, among Latinx youth with T1D at the BDC.

Methods: A multidisciplinary team was formed, including the Latinx Clinic director, a bilingual nurse, and dietitian, and members of the clinical trial team experienced with the CIQ system. Barriers for pump use within the Latinx population were identified, including lack of Spanish training resources and low numeracy regarding carb counting. A query identified Latinx youth using multiple daily injections (MDI) to focus on (Table 1).

Results: To address barriers to CIQ use, the BDC QI team created three Spanish language resources to support training for CIQ: (1) Overview of the CIQ home screen, (2) guide to editing pump settings, and (3) guide to pairing the pump with the t:connect mobile app to facilitate pump uploads.

Additionally, a fixed dosing regimen for CIQ was developed to reduce the burden of carb counting for sliding scale insulin (SSI) patients. This regimen involves an assessment by our dietician to determine small, medium, and large meals to identify a fixed carb amount to use in the bolus calculator for each meal.

Conclusions: This QI project is essential to improve equity in diabetes care for the BDC Latinx population. Increasing the use of CIQ has the potential to lower burden of care and improve T1D outcomes. Data collection is ongoing to evaluate the impact of the program.

POSTER TOUR 20—MONOGENIC & OTHER FORMS OF DIABETES # 3

P181 | Off-label Liraglutide in 4 children with Wolfram syndrome type 1: Long-term follow-up of β-cell function and OCT parameters

R. Di Tonno1,2, G. Frontino1,2, A. Rigamonti1,2, V. Castorani1,2, E. Morotti1,2, F. Sandullo1,2, F. Scialabba1,2, F. Arrigoni1,2, R. Foglino1,2, B. Dionisi1,2, M.L. Cascavilla3, D. Canarutto4,5,6, F. Meschi1,2, R. Bonfanti1,2, L. Piemonti1,2
1IRCCS San Raffaele Hospital, Department of Pediatrics, Milano, Italy, 2IRCCS San Raffaele Hospital, Diabetes Research Institute, Milano,
Introduction: Wolfram syndrome type 1 (WS) is a rare orphan genetic disorder characterized by juvenile-onset of insulin-dependent diabetes mellitus and progressive neurodegeneration. Based on preclinical/clinical evidence we proposed liraglutide (LG), a glucagon-like peptide-1 receptor agonist (GLP-1R), as an off-label treatment in children with WS.

Objectives: To assess the effect of LG on β-cell function and retinal thickness of children with WS.

Methods: Four clinically and genetically confirmed WS patients, (age 10–14 years at baseline), were treated with LG for 15–36 months. LG was administered as a daily subcutaneously injection, starting at 0.3 mg/die and increased progressively up to the maximum dose of 1.8 mg/die. β-cell function was assessed by C-peptide AUC (CA) during mixed meal tolerance test. Retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) thickness were measured via optical coherence tomography (OCT, Carl Zeiss Meditec and 3D-Topcon).

Results: LG was well-tolerated. At the latest follow-up, CA ranged from 77 to 249% of baseline, suggesting overall stabilization of β-cell function during treatment (Table 1). Interestingly, also RNFL and GCC remained stable during follow-up even when taking into account potential differences between OCT devices by linear correlation (Figure 1). No adverse events were reported.

Conclusions: These are preliminary data of children affected by WS treated with LG with a long-term follow-up without significant overall worsening in both β-cell function and OCT parameters. LG has been shown to decrease ER stress and improve mitochondrial function in both β-cells and neurons and is the only GLP-1R approved for children older than age 10 years. Our data suggests that LG may represent a promising disease-modifying agent for WS. Longer and larger population RCT studies are warranted prior to it becoming used in routine care for WS.

Table 1

<table>
<thead>
<tr>
<th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
<th>Patient 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>F-U, months</td>
<td>0</td>
<td>7</td>
<td>16</td>
</tr>
<tr>
<td>C-AUC ng × min/ml</td>
<td>122</td>
<td>142</td>
<td>109</td>
</tr>
<tr>
<td>% variation from baseline</td>
<td>100</td>
<td>117</td>
<td>89</td>
</tr>
</tbody>
</table>
P182 | Hyper pigmented trichosis and diabetes: Common phenotype in two uncommon different monogenic diabetes!

S. Abourazzak1, C. Benghabrit1, S. Chaouki1, S. Ellard2, M. Hida1
1Faculty of Medicine and Pharmacy of Fez, Sidi Mohamed Ben Abdellah University, Pediatrics, Fez, Morocco, 2University of Exeter Medical School, Genomics Laboratory, Royal Devon and Exeter NHS Foundation Trust, Exeter, United Kingdom

Introduction: The type of diabetes assigned to a young person at diagnosis is typically based on their characteristics at presentation. Monogenic diabetes represents a heterogeneous group of disorders resulting from defects in single genes.

Objectives: This report describes a syndromic presentation of diabetes in whom a homozygous SLC29A3 mutation was identified in the first case with H syndrome; and an INSR mutation responsible of rare insulin resistance syndrome in the second case. Both patients presented pigmented hypertrichotic dermatosis.

Methods: Analysis of all the coding regions and exon/intron boundaries of the monogenic diabetes genes by targeted next generation sequencing at the Exeter genomics laboratory.

Results: Patient 1: A 4-year-old girl born to consanguineous parents, referred to the department of pediatrics for diabetes. She had a history of pigmented skin since in her neck and lower limbs, dysmorphic features, skeletal muscle hypertrophy, flexion contractures of fingers, hepatomegaly, hyperpigmented trichosis in her lower limbs generalized alopecia and severe hypertriglyceridemia. She was homozygous for a pathogenic SLC29A3 and diagnosed with H syndrome.

Patient 2: A 7 years old boy, born to consanguineous parents admitted for diabetes. He had developed progressive darkening of the skin involving the neck and axillae, with trichosis. Genetic studies revealed a homozygous missense mutation in the Insulin receptor gene confirming the diagnosis of Rabson Mendenhall syndrome.

Conclusions: The genetic diagnosis may inform medical management, gives insight into prognosis, and inform families of recurrence risk.

P183 | A novel GCK mutation requiring insulin therapy: Is it related to G6PD deficiency?

Y. Abdelmeguid1, E. Mowafy1, I. Marzouk1, S. Elsayed1
1Alexandria Faculty of Medicine, Department of Pediatrics, Alexandria, Egypt

Introduction: GCK-MODY is one of the most common MODY subtypes. GCK plays a major role in glucose metabolism, as it catalyzes the rate-limiting step of glucose phosphorylation. Most patients present with mild fasting hyperglycemia on routine screening. Glucose-6-phosphate dehydrogenase (G6PD) enzyme is an antioxidant. G6PD deficiency increases oxidative stress, so can lead to impaired insulin secretion by β-cells, and aggravation of diabetic injury.

Objectives: However, there are limited number of studies on the relationship between G6PD deficiency & DM.

Methods: We herein report a boy with a novel GCK mutation, and also diagnosed with G6PD deficiency which were not previously reported. Although patients with GCK-MODY receive no treatment, our patient required insulin; which could be related to G6PD deficiency.

Results: An 8-year-old boy born to consanguineous parents was diagnosed with G6PD deficiency at birth [G6PD assay 0.3 U/g (N > 7)]. He was screened as his 2 siblings had G6PD deficiency and did exchange transfusion during neonatal period. At age 14 months, he presented with DKA with HbA1c 8.24%, and low C-peptide. He was screened as his 2 siblings had G6PD deficiency and did exchange transfusion during neonatal period. At age 14 months, he presented with DKA with HbA1c 8.24%, and low C-peptide. He was started insulin 0.8 U/Kg/day. He had 2 grandparents, and 4 uncles diagnosed with DM. His genetic analysis revealed a heterozygous novel GCK missense variant [c.374A > G, p.(Tyr125Cys)] - not previously reported in gnomAD database. On follow up, fasting C-peptide improved and 2 h postprandial C-peptide was normal, denoting residual β-cell function. Although he had GCK mutation, trials to decrease insulin dose resulted in severe hyperglycemia & ketosis. His HbA1c ranged between 6.7% and 8.24% and required insulin therapy. The mother and elder sibling had impaired fasting hyperglycemia and were heterozygous for the same mutation, so they were advised to modify diet.

Conclusions: Further studies on the relationship between G6PD deficiency & DM are required. This also emphasizes the importance of genetic testing of suspected MODY patients, as it also helps in detecting family members with the same mutation.

P184 | Clinical and molecular characterization of neonatal diabetes mellitus (NDM): Single center experience from Western India

R. Keshwani1, S. Rao Chandrashekhar1, V. Dhawale1, R. Joshi1
1Bai Jerbai Wadia Hospital for Children, Division of Pediatric Endocrinology, Department of Pediatrics, Mumbai, India

Introduction: NDM is a rare genetic disease where comprehensive genetic testing allows for improved diagnosis and treatment.

Objectives: This study aims to characterize the clinical and molecular profile of NDM seen over last 10 years at B.J.Wadia Hospital for Children, Mumbai, India.

Methods: Retrospective study of records to derive demographic, clinical, and laboratory profile at presentation, the genetic mutation found and treatment given.

Results: 16 children (10 M, 6 F) presented with NDM at median age of 4 months (range: Day 1 to 7.5 months) with mean weight and height SDS of −1.7 and 0.67 respectively. DKA was the commonest presentation (n = 11/16). 9 (56%) had associated extra-pancreatic features. 3 (18.8%) were born of consanguineous union. Mutation studies were done in 13 cases from Exeter (UK). 2 (12%) children with transient NDM (1 ABCC8; 1 no mutation found) came off treatment by 3 months of age. 14 (88%) had permanent NDM and mutation studies were done in 11. Heterozygous KCNJ11 mutation was seen in 4 (29%) cases, of which one had DEND.
syndrome that died at 2.8 years of age and the other 3 are sulfonyl urea (SUR) responsive. A 1 child with heterozygous ABCC8 mutation is also SUR responsive. Three (21%) cases of Wolcott Rallison syndrome (WRS) had homozygous EIF2AK3 mutation of which 1 child died at 3 years of age. Another child with transient transaminitis had homozygous EIF2B1 mutation. Pancreatic agenesis with Arnold Chiari malformation was found in a child with homozygous PTF1A mutation. 3 (21%) children had Thiamine responsive diabetes and genetic study done in one showed homozygous SLC19A2.

Of the 14/16 (87.5%) children in follow up. Insulin therapy (n = 3), SUR (n = 4), Thiamine (n = 3) are the modalities of treatment ongoing with good metabolic control. Children with WRS also receive cofactors. A 2 children with TNDM are off therapy.

**Conclusions:** NDM has varied phenotype and some children have extra-pancreatic features. Genetic studies help in improved diagnosis and treatment.

**P185 An unusual diagnosis of monogenic diabetes in a 15-month old child**

A. Jacob¹, N. Thalance²

¹Al Jalila Childrens Specialty Hospital, General Pediatrics, Dubai, United Arab Emirates, ²Al Jalila Childrens Specialty Hospital, Pediatric Endocrinology, Dubai, United Arab Emirates

**Introduction:** Maturity Onset Diabetes of the Young (MODY) typically manifests in late childhood, adolescence, or young adulthood, with the highest rate between age 15 and 19 years of age. MODY comprises 1%–4% of childhood diabetes.

**Objectives:** -

**Methods:** -

**Results:** Case: We present a boy with new-onset diabetes who presented in diabetes ketoacidosis (DKA) at age of 15 months. He was presumed to have Type 1 diabetes given his age at onset, DKA at diagnosis and high presentation HbA1c (8.9%), however, initial auto-antibody testing for GAD-65, Insulin and IA2 were negative. Accordingly, we additionally checked ZnT8 and Islet-cell antibodies, which were also negative. Neither parent nor his 2 older siblings had diabetes, but paternal grandfather had a 64-year history of uncomplicated, very well-controlled insulin-dependent diabetes. The family chose to manage the child with a very strict low-carbohydrate diet, resulting in minimal insulin requirements, (<1u daily), with outstanding glucose control and follow-up HbA1c levels were below normal range (4.4%–4.8%). Additional antibody testing for Tetraspanin-7 was requested, (found in ~2% of otherwise antibody negative cases) but was not available.

Given his extremely low insulin requirement and negative antibody status, we proceeded to a MODY genetic panel. Genetic testing was suggestive for MODY 3 due to c.716C > T missense mutation in HNF1A (VUS), reported in 2 cases. Nonetheless, given the clinical picture and negative antibodies, we strongly suspect this mutation is causative.

For the time being, parents have decided to pursue his highly successful low-carbohydrate diet in preference to a trial of sulphonylurea (SU) therapy, as evaluating efficacy of SUs would be difficult given his negligible insulin requirement and likely significant β-cell reserve. Moreover, the family has concerns that SU therapy may accelerate β-cell demise, if in fact he truly has T1D. However, the family is willing to proceed to a trial of SUs if his exogenous insulin requirement rises.

**Conclusions:** Heterozygous pathogenic variants in the HNF1A gene cause 1–2% of all diabetes diagnoses overall and are characterized by early-onset diabetes in adolescence or young adulthood (<35 years) due to impaired β-cell function. One novel aspect of this case is the extremely young age of diagnosis. In conclusion, the use of molecular genetic testing to pursue a diagnosis in antibody-negative cases, particularly if diabetes is atypical.

**P186 Successful transfer of an adolescent with maturity onset diabetes of young (MODY) type 5, HNF1A mutation from insulin to once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) (Semaglutide) with a superior efficacy**

A. Al Mutair¹, B. Almulhem³

¹MNGHA-KASCH, Pediatric, Riyadh, Saudi Arabia

**Introduction:** Maturity onset diabetes of young (MODY) is a group of monogenic disorders characterized by AD inherited, accounting for approximately 1% to 6% of all pediatric diabetic patients. Sulfonylurea has been successfully used in MODY type 1 and 3; insulin therapy is needed for other types of MODY, including type 5. GLP-1RAs, Liraglutide daily injection, has been successfully used in one report, after which the patient was off insulin therapy.

**Objectives:** To present a case of MODY Type 5 that showed a great response to weekly treatment of GLP-1RAs (Semaglutide).

**Methods:** A case report. Consent were obtained. Results: In our case report, an 18-years old girl known to have MODY type 5 HNF1A1b mutation required both long and short-acting insulin (0.6 units/kg/ day). She had a history of high, low glucose readings and frequent hypoglycemia attacks. Therefore, once weekly, GLP-1RA (Semaglutide) was tried for 3 months. The dose was gradually increased from 0.25 mg to a maximum of 0.5 mg subcutaneously weekly. Insulin therapy was weaned, and then off insulin after the 6th dose; glucose readings were monitored via Dexcom CGM, which confirmed a significant improvement (Figure 1). Moreover, there was a disappearance of hypoglycemic attacks, a reduction of insulin doses approximately to zero, an improvement of time in range (TIR) to about 100%, enhanced glucose variability, and a reduction in the serum HbA1c from 6.1% to 5.6%, which was the lowest record since the diagnosis and finally injections number dropped from 28 per week to only one. However, the medication was stopped as the patient could not tolerate its gastric side effects after she was infected with COVID-19.

**Conclusions:** Semaglutide is effective and superior to insulin therapy for MODY type 5 and can be considered to replace insulin therapy. In
addition, CGM showed an excellent success that helped safely transfer the patient from intensive insulin therapy to the GLP-1RAs trial. Further studies are needed in MODY type 5.

P187  Modulation of antimony mediated therapy for an optimal insulin secretion during visceral leishmaniasis infection

S. Sinha
1Nehru Gram Bharati, Department of Zoology, Prayagraj, India

Introduction: Visceral Leishmaniasis is a macrophage associated disorder for the treatment of which antimony-based drug like Sodium Antimony Gluconate has been the first choice in the recent past. About 5 percent of the patients may develop insulin dependent diabetes mellitus. 

Objectives: It appears to have a direct action on pancreatic beta cells, resulting in initial insulin release followed by impaired insulin secretion. Within this context, we looked into alternate therapies of treatment along with SAG on triggering the CD2 epitope.

Methods: We have evaluated the effect of combining CD2 with conventional antimonial (sb) therapy in protection in BALB/c mice infected with either drug sensitive or resistant strain of Leishmania donovani with 3 million parasites via-intra-cardiac route. Mice were treated with anti CD2 adjunct SAG sub-cutaneously twice a week for 4 weeks. Assessment for measurement of weight, spleen size,
Conclusions: While limited by a small sample size, this pilot suggests NERDs may produce similar standard OGTT results to as an equivalent alternative to ODS. Interestingly, participants preferred ODS to NERDs candy. Future trials should be done with a larger sample size and age range to better understand the satisfaction level across a broader spectrum within this population.

P189 | Fifteen percent of fasting glycemia values in children and adolescents with GCK-MODY are outside the diagnostic range

J. Staník1,2, J. Hulin3, L. Barák1, E. Wallenfelsová4, S. Kyšková5, E. Jančová1, M. Hučková2, M. Škopková2, D. Gašperíková2
1Medical Faculty of the Comenius University, Department of Pediatrics, Bratislava, Slovakia, 2Institute of Experimental Endocrinology, Biomedical Research Center Slovak Academy of Science, Diabgene, Bratislava, Slovakia, 3Slovak Medical University and University Hospital in Bratislava, 1st Department of Internal Medicine, Bratislava, Slovakia, 4ENDO-EW Outpatient Department, Považská Bystrica, Slovakia, 5PENDIA Outpatient Department, Žilina, Slovakia

Introduction: Diagnostics of the GCK-MODY is based on the chronic stable fasting hyperglycemia between 5.5 and 8.0 mmol/L in majority of the patients. However, not all the glycemia values are ≥5.5 mmol/L.

Objectives: We aimed 1. to determine the percentage of fasting glycemia <5.5 or >8.0 mmol/L in children and adolescents with GCK-MODY, and 2. to determine the minimal number of fasting glycemia samples to find at least one glycemia ≥5.5 mmol/L with a probability of at least 95%.

Methods: We have performed a retrospective analysis of fasting glucose concentrations of people with GCK-MODY registered in Slovak nation-wide MODY registry. Children and adolescents <19 years of age with at least 5 fasting glycemia measurements available in hospital/outpatient departments were included.

Results: Out of >250 people with GCK-MODY in the registry, 54 children and adolescents with at least 5 fasting glycemia measurements were enrolled in this study. Out of 908 fasting glucose measurements, 136 (15%) were outside the diagnostic range for GCK-MODY; 108 (11.9%) were below 5.5 mmol/L and 28 (3.1%) were above 8.0 mmol/L. A 31 individuals (57.4%) had at least 5% (maximum 45%) of the fasting glucose values below 5.5 mmol/L and would thus need ≥2 measurements to determine a single blood glucose ≥5.5 mmol/L with a 95% probability.

Conclusions: Fasting glucose values outside the diagnostic range for children and adolescents with GCK-MODY are more frequent than previously assumed. More than 57% of people with GCK-MODY below 19 years of age may require at least 2 blood glucose measurements to find one ≥5.5 mmol/L with a probability of 95%. Therefore, a one-sample approach in the clinical diagnostics could fail to diagnose a significant number of individuals with GCK-MODY. Similarly, screening for individuals among family relatives of people with GCK-MODY could be influenced as well.
Lipoprotein Lipase (LPL) gene mutation as the cause of severe hypertriglyceridemia in a Libyan patient with type 1 diabetes mellitus

M. Ghawil1, I. Hadeed1, N. Algaziri1, O. Fathalla1, N. Ben Omar2, S. Omar2, O. Beheel2, M. Doggahi1, S. Absurewil1
1Pediatric Department, Tripoli University Hospital, Faculty of Medicine, University of Tripoli, Tripoli, Libya, 2Pediatric Department, Tripoli University Hospital, Tripoli, Libya

Introduction: Severe hypertriglyceridemia (HTG) is an uncommon complication of Type 1 diabetes mellitus (T1DM). LPL deficiency is a monogenic lipid metabolism disorder biochemically characterized by HTG inherited in an autosomal recessive manner. LPL gene located on chromosome 8p22, and more than 50 different mutations identified in patients with severe HTG >1000 mg/dl and it is associated with comorbidities, such as uncontrolled diabetes mellitus.

Objectives: Case report: A 21-years-old girl diagnosed at age of 4 years with T1DM. She carried to HLA-DRB1*03, -DRB1*04-DQB1*02,DQB1*03, was on short and intermediate acting insulin till 15 years old when she demonstrated a rising in triglyceride (TG) 301 mg/dl with normal total cholesterol(TC), HbA1c 10%,BMI 21.4 kg/m² where changed to flexible insulin regime with Long/Rapid-acting insulin and carb counting. She started treatment with Simvastatin.

At 17 years of age, BMI 18.7 kg/m², HbA1c was 12.5%, her TG 1120 mg/dl, TC 287 mg/dl, LDL128mg/dl, HDL 39 mg/dl, and the highest TG level was 1700 mg/dl. Blood pressure 110/65 mmHg, ECG, and Echocardiography done routinely and were normal.

Methods: Genetic analysis for hyperlipidemia showed a heterozygous LPL gene mutation. (c.809G > A,p.Arg270His,Chr8:19813385).

Results: Patient started treatment with Continuous Subcutaneous Insulin Infusion (CSII) pump in 2019.Currently with an intensive insulin therapy with CSII pump, HbA1c dropped to 7.7% within 6 months and TG decreased to 127 mg/dl and TC 133 mg/dl, LDL 82.9 mg/dl, HDL 31 mg/dl. Last investigation on March 2022: HbA1c6.8%,TG 52 mg/dl, TC 154 mg/dl, LDL116 mg/dl, HDL 50 mg/dl.

Recently, her other two sisters who diagnosed with T1DM also showed rising in triglyceride levels respectively 172 and 320 mg/dl.

Conclusions: We diagnosed for first time a heterozygous mutation of LPL gene in Libyan diabetic patient with severe hypertriglyceridemia. Currently with an intensive insulin therapy and correct metabolic control of T1DM, he maintains a normal lipid profile. Moreover genetic tests for immediate relatives should be performed.

POSTER TOUR 21—MONOGENIC & OTHER FORMS OF DIABETES # 1

P191 | Diabetes in children may very well be, in reality only a cloaked MODY 3. For patients with variants of uncertainty, give HNF1A the third degree

P. Svalastoga1, A. Kaci1, J. Molnes1,2, M. Solheim3, B.B. Johansson1, L. Krogvold1,2, T. Skrivarhaug1,2, S. Almven1,2, J.V. Sagen3,4, E. Søfteland3,4, L. Bjerkhaug5, E. Tjora3,11, I. Aukrust1,2, P.R. Njølstad1,11
1University of Bergen, Clinical Science, Bergen, Norway, 2University of Bergen, Department of Medical Genetics, Bergen, Norway, 3University of Bergen, Department of Clinical Science, Bergen, Norway, 4University of Oslo, Department of Clinical Medicine, Oslo, Norway, 5University of Oslo, Faculty of Dentistry, Oslo, Norway, 6Oslo University Hospital, Division of Childhood and Adolescent Medicine, Oslo, Norway, 7University of Bergen, Department of Pathology, Bergen, Norway, 8Haukeland University Hospital, Department of Medical Biochemistry and Pharmacology, Bergen, Norway, 9Western Norway University of Applied Sciences, Bergen, Norway, 10Haukeland University Hospital, Department of Pediatrics and Adolescents, Bergen, Norway

Introduction: Correctly, diagnosing HNF1A-MODY is important since subjects can be treated with sulfonylurea rather than insulin, improving metabolic control, and quality of life. Genetic testing can provide a precise diagnosis, but variants of uncertain significance pose an increasing challenge.

Objectives: We sought to identify MODY 3 by screening the national pediatric diabetes registry followed by thorough investigations in cases with unclear genetic results.

Methods: Autoantibody-negative subjects (n = 615) from The Norwegian Childhood Diabetes Registry was screened with exome sequencing, identifying 19 subjects with rare variants in HNF1A. Half of subjects had pathogenic mutations (n = 10), identifying MODY 3, and half were carriers of variants of uncertain significance (n = 9). Extra efforts were put forward to investigate this group, including functional investigations of the variants and a sulfonylurea switch trial, aiming to diagnose monogenic diabetes.

Results: Screening supplemented with refined diagnostics revealed a true prevalence of MODY 3 of 2.4%, permitting patients to stop insulin treatment. Genetics alone failed in providing definitive answers in half of cases, leaving the monogenic diagnosis hanging, but functional data predicted the clinical implications. Four variants (p.His143Pro, p.Lys222del, p.-Thr547Argfs*5, and p.Gln561*) displayed abnormal functional assays, aligning nicely with patients being able to switch to sulfonylurea. Patients unable to substitute insulin therapy (carrying p.Gly306Val, p.Gln175Glu, p.Ser451Gly and p.Pro580Leu) showed normal HNF-1A properties.

Conclusions: Uncloaking MODY in pediatric diabetes is important. The impact of setting the right diagnosis is considerable, permitting insulin-free treatment. Variant interpretation can pose a challenge. Here we show how functional investigations and thorough clinical
Assessments can aid the diagnostic process, leading to higher accuracy and representing a good example of precision medicine.

P192  |  Outcome in sq24-related transient neonatal diabetes
P. Cid Galache¹, L. Zamorano Bonilla¹
¹Hospital de Motril, UGC Pediatría y Neonatología, Motril, Spain

Introduction: 6q24-related transient neonatal diabetes mellitus (6q24-TNDM) is defined as transient neonatal diabetes mellitus caused by genetic aberrations of the imprinted locus at 6q24. The cardinal features are: severe intrauterine growth retardation, hyperglycemia that begins in the neonatal period in a term infant and resolves by age 18 months, dehydration, and absence of ketoacidosis.

Objectives: In this presentation, we want to show the evolution and outcome of a patient that was diagnosed in our unit 15 years ago.

Methods: The initial diagnosis was made using microsatellites looking for a paternal isodisomy or duplication. An isodisomy was found in our case. We have made a follow up throughout these years to see the evolution of our patient.

Results: The patient has been absolutely asymptomatic until she was 12 years old. Just 20 months ago (at the age of 13) she started to show abnormal HbA1C levels that has required insulin treatment. Nowadays she is having a perfect control of this new-onset diabetes using really low dose of Insulin glargine. Just 0.3 U/kg are being needed to keep the blood sugar levels in range in 90% of readings. The patient is not needing so far rapid acting insulin.
Conclusions: 6q24- related transient neonatal diabetes can have a relapse in the second or third decade of life in 50% of cases. It is important to know this is not a typical type 1 or 2 diabetes. The etiology of this hyperglycemia is related to this monogenic form of diabetes. So far this relapse is having a very good outcome using low doses of insulin glargine.

P193 | MODY2 presenting with post-prandial hyperglycemia, case report

H. Al Shaikh1
1Muscat Private Hospital, Pediatrics, Muscat, Oman

Introduction: Maturity Onset Diabetes of the Young is a non-insulin-dependent form of diabetes mellitus, diagnosed in mid childhood to young adulthood. It results from a single gene mutation and is divided into subtypes depending on the affected gene. MODY2 results from an autosomal dominant mutation in the GCK gene causing mild non-insulin-dependent fasting hyperglycemia, treated normally with diet control.

Objectives: To report a case of MODY2 with oligogeneity, and mainly post prandial hyperglycemia.

Methods: Medical information was retrieved from the computerized medical records.

Results: Case report:
A 9-year-old boy, presented at 8 years of age with dizziness and headache for 1 month and polyuria and polydipsia for 3 months. His random blood glucose was high, but fasting blood glucose was normal. Urine glucose was positive.

He was born at full-term, normal delivery with no complications. BW: 3.4 kg. The Parents are non-consanguineous. The paternal grandparents and maternal grandmother have T2DM. The mother had GDM. There is no family history of T1DM.


Physical Examination: No significant findings.

SBGM showed BG values in the pre-diabetic range before breakfast and the diabetic range post dinner. On OGTT: FG: 3.9 mmol/L, 2 h BG: 16.5 mmol/L. He was managed with diet control, daily exercise, and regular BG monitoring.

7 months later: It was noticed that the BG was going up, around 11 mmol/L fasting, and 20 mmol/L random. His BG got controlled with Glimepiride before lunch and Insulin Glargine HS.

Genetic analysis identified a mutation in the GCK gene c.146C > G (p.Thr49Ser). Interestingly, two other mutations were identified: c.1407C > T, GLIS3 gene, c.42_47del, SLC19A2 gene.

Conclusions: Oligogeneity may alter the clinical characteristics of MODY2, presenting mainly with post-prandial hyperglycemia.

P194 | A novel de novo likely pathogenic variant of WFS-1 gene in a Pakistani child

M. Hanif1, M. Ibrahim2, J. Raza3
1Misbah Hanif, Department of Pediatric Endocrinology and Diabetes, Karachi, Pakistan, 2National Institute of Child Health, Department of Pediatric Endocrinology and Diabetes, Karachi, Pakistan, 3Sindh Institute of Child Health and Neonatology, Endocrinology, Karachi, Pakistan

Introduction: Wolfram Syndrome is a rare genetic disorder caused by pathogenic alterations in WFS1 gene, resulting in neurodegeneration, pancreatic cell dysfunction, and apoptosis. Wolfram syndrome is associated with Diabetes Insipidus, Diabetes Mellitus, Optic Atrophy, and Deafness also known as DIDMOD. Though Wolfram syndrome is considered an autosomal recessive disorder, heterozygous pathogenic variants have been noted to cause Wolfram like syndrome (hearing impairment, diabetes mellitus, and optic atrophy).

Objectives: To highlight a novel de novo likely pathogenic variant of WFS1 in a Pakistani child causing Wolfram like syndrome.

Methods: Case Report.

Results: We report a novel de novo likely pathogenic variant in a Pakistani child in WFS1 gene who presented with clinical features consistent with wolfram like syndrome. A 7 years old boy visited our endocrine clinic for management of uncontrolled type 1 diabetes mellitus despite being on glargine and as part his HbA1c was high (14%), though other investigations were normal. A physical exam noted a short stature (−4.55 SDS for age 7 years), otherwise he appeared normal. Past history was significant for sensorineural deafness in his first year of life and had bilateral cataract surgery at the age of 5 years. Family history is only significant for type 2 diabetes on his paternal side. Based on these clinical findings diabetes with extra-pancreatic features was suspected and genetic testing was ordered. Original report noted c.2586G > T (p.Lys862Asn) as a variant of uncertain significance but subsequent parental testing led to the reclassification of variant as a likely pathogenic variant.

Conclusions: Based on the above findings eye exam was requested that showed bilateral optic atrophy, which further supported this diagnosis. Our report highlights the rare possibility of a heterozygous variant causing Wolfram like syndrome and identifies a novel likely pathogenic variant in WFS1 gene, supported by clinical features consistent with Wolfram like syndrome.

P195 | Transition from insulin to sulfonylurea in an infant with a novel ABCC8 mutation: A success story

M. Haider1, M. Arif2, F. Memon3, S. Kirmani1, K.N. Humayun1
1Aga Khan University, Pediatric Endocrinology, Karachi, Pakistan

Introduction: Neonatal diabetes mellitus (NDM) presenting within the first 6 months of life is an extremely rare condition, with an incidence of approximately 1 in 90,000–160,000 live births caused by 20 known
genetic mutations including both permanent and transient forms. In the past, most cases of NDM were being classically managed with lifelong insulin treatment but now it is known that heterozygous activating mutations in KCNJ11 and ABCC8 are responsive to oral sulfonylurea treatment restoring insulin secretion. In these patients, insulin can be effectively replaced by oral sulfonylureas, which improves glycemic control and quality of life. We report a case of NDM with a novel ABCC8 gene mutation, who was successfully transitioned from insulin to oral sulphonylurea therapy.

**Objectives:** To present our experience of transitioning a neonate with ABCC8 mutation from insulin to sulfonylurea.

**Methods:** Patients with clinical diagnosis of monogenic and syndromic diabetes were recruited and blood samples were sent for genetic analysis. We compared our results with different cohorts. The genetics of Pakistani, Arabic, and British cohort were tested in University of Exeter, Exeter, UK.

**Results:** A 39 patients from diabetic clinic (1064 Pts) of National Institute of Child Health were recruited for genetic testing who fulfilled the criteria for monogenic diabetes. We identified mutations in 18/27 cases with diabetes before 9 months of age. A 12 children presented after 9 months of age and had extra pancreatic features diagnosed with syndromic diabetes. We compared our cohort with Arabic, British, and Turkish cohorts. Consanguinity was highest in Pakistani population followed by Arab, British, and Turkish cohorts. EIF2AK3 (Wolcott Rallison syndrome) is commonest in 26.9% of Pakistani and Arab 22.7% cohort. British cohort had K$_{ATP}$ channel 29.9% mutation while Turkish Cohort has GCK mutation as 59% the commonest. In Pakistani children, 32.5% are of monogenic diabetes with extra pancreatic features while in Arab 37.5% and British 7.8% were reported.

**Conclusions:** Monogenic diabetes in Pakistani population has a similar spectrum as Ar, British and Turkish cohorts have different pattern of monogenic diabetes. Syndromic diabetes is more common in the Pakistani and Arab populations.

**Table 1:** Molecular genetic analysis for neonatal diabetes mellitus

<table>
<thead>
<tr>
<th>Gene</th>
<th>Parent</th>
<th>HGVS description</th>
<th>Location: GRCh37(hg19)</th>
<th>Zygosity</th>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZFP57</td>
<td>mother</td>
<td>NM_001109809.2:c806G &gt; A.p.(Arg269Gln)</td>
<td>Chr6: g.29641082</td>
<td>heterozygous</td>
<td>Pathogenic</td>
</tr>
<tr>
<td></td>
<td>father</td>
<td>NM_001109809.2:c806G &gt; A.p.(Arg269Gln)</td>
<td>Chr6: g.29641082</td>
<td>heterozygous</td>
<td>Pathogenic</td>
</tr>
</tbody>
</table>
**Objectives:** we report a case of Genetic Defect in 6q24 subtype ZFP57, which is pathognomonic of Transient Neonatal Diabetes Mellitus.

**Methods:** We report a case of TNDM with onset at first week of life & remission at 5 months of age registered at neonatal intensive care unit of university hospital of Sharjah. After exclusion of other causes of hyperglycemia, the case was diagnosed based on clinical criteria for transient diabetes: weight at birth, age when first hyperglycemia was detected, starting of insulin with progressive diminution, and definitive stop at the age of 5 months. Additionally, at the age of 3 month, the genetic confirmatory results were available to confirm transient neonatal diabetes.

**Results:** Genetic testing done at genomic laboratory, University of Exeter Medical School, UK showed loss of methylation at the 6q24 locus in Saeed's leukocyte DNA sample, which is a typical molecular feature of transient neonatal diabetes (MIM601410), likely due to maternal hypomethylation at the 6q24 locus. Parents were heterogenous carrier for the ZFP57 missense variant, p. [Arg269Gln] which is confirm diagnosis of transient neonatal diabetes, subtype ZFP57 (PP4_strong) & the risk that this couple's next pregnancy will be affected by transient neonatal diabetes is 1 in 4 (Table1).

**Conclusions:** NDM is rare disease needs High index of suspicion, early diagnosis. Insulin therapy is crucial to control hyperglycemia, obtain satisfactory weight gain and growth and to provide a better quality of life.

**P198 A case of de novo activating mutation in ABCC8 gene resulting in transient neonatal diabetes**

M. Ferreira Clemente1, H. Moore2, A. Onibere3

1Betsi Cadwaladr University Health Board - Glan Clwyd Hospital, Pediatrics and Neonatology, Bodelwyddan, United Kingdom, 2Betsi Cadwaladr University Health Board - Glan Clwyd Hospital, Pediatrics, Bodelwyddan, United Kingdom, 3Betsi Cadwaladr University Health Board - Glan Clwyd Hospital, Neonatology, Bodelwyddan, United Kingdom

**Introduction:** Neonatal diabetes Mellitus (NDM) is a rare monogenic diabetes, with an incidence ranging from 1 in 90,000 to 500,000 newborns in Europe.

**Based on the treatment duration, NDMis stratified as transient NDM (TNDM) and permanent NDM (PNDM). TNDM is linked to this disorder. It may be isolated or associated to other syndromic entities. Its etiopathogenesis is increasingly elucidated.**

**Objectives:** This work aims to study epidemiological, clinical, biochemical, genetic, therapeutic aspects, and outcome of NDM.

**Methods:** Descriptive Retrospective study from January 2006 to February 2016. We included all infants diagnosed with diabetes before 6 months of age, and followed at our department for diabetes mellitus.

**Results:** 15 infant with NDM were studied. Consanguinity was present in 53%, and a familial history of diabetes in 80%. 31% of these children had IUGR. Cardinal symptoms were dehydration, vomiting, diarrhea, osmotic polyuria. 66, 6% presented with diabetic ketoacidosis (DKA), and only 46, 6% had a diagnostic diagnosis of diabetes or DKA at first physician contact. Peptide C levels were generally low, and all patients tested were negative for autoimmune markers of diabetes.

F2AK3 and INS were found to be responsible for 42% of NDM cases.

**P199 Neonatal mellitus diabetes: Retrospective study in children's hospital of Rabat over 10 years**

Z. Imane1, A. Boulmane1, A. Balafrej1

1UM5R, Children's Hospital of Rabat, Rabat, Morocco

**Introduction:** Neonatal diabetes Mellitus (NDM) is a rare monogenic diabetes, with an incidence ranging from 1 in 90,000 to 500,000 newborns in Europe.

**Based on the treatment duration, NDMis stratified as transient NDM (TNDM) and permanent NDM (PNDM). TNDM is linked to this disorder. It may be isolated or associated to other syndromic entities. Its etiopathogenesis is increasingly elucidated.**

**Objectives:** This work aims to study epidemiological, clinical, biochemical, genetic, therapeutic aspects, and outcome of NDM.

**Methods:** Descriptive Retrospective study from January 2006 to February 2016. We included all infants diagnosed with diabetes before 6 months of age, and followed at our department for diabetes mellitus.

**Results:** 15 infant with NDM were studied. Consanguinity was present in 53%, and a familial history of diabetes in 80%. 31% of these children had IUGR. Cardinal symptoms were dehydration, vomiting, diarrhea, osmotic polyuria. 66, 6% presented with diabetic ketoacidosis (DKA), and only 46, 6% had a diagnostic diagnosis of diabetes or DKA at first physician contact. Peptide C levels were generally low, and all patients tested were negative for autoimmune markers of diabetes.

F2AK3 and INS were found to be responsible for 42% of NDM cases.
Mutations in ABCC8 gene were found in only two cases (15%), which one is candidate for DEND syndrome. Transfer from insulin to oral sulfonylurea was started in index patient.

Only 2 patients (14%) had a TNDM with ABCC8 mutation and abnormal 6q24.

**Conclusions:** In our study genetic etiology were different compared to Europeans and British patients, and it may due to the higher rate of consanguinity. However, KATP mutations (ABCC8, KCNJ11) should be systematically screened, in raison of their impact on the management and prognosis of NDM.

**POSTER TOUR 22—ASSOCIATED DISEASES # 2**

**P200 | Prevalence of parietal cell antibodies and iron deficiency in patients with type1 diabetes mellitus from north India**

S. Verma¹, K. Ahmed Bhat², V. Bhatia³, E. Bhatia⁴, S. Sudhanshu⁴

¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Endocrinology, Lucknow, India

**Introduction:** Type 1 diabetes mellitus (T1D) is associated with an increased prevalence of autoimmune disorders. Parietal cell antibody (PCA) mediated autoimmune gastritis increases the risk of iron-deficiency and pernicious anemia in adults with type 1 diabetes (T1DM). However, it is not known if these antibodies play a similar role in children and young adults with T1DM.

**Objectives:** We studied the prevalence of parietal cell antibody (PCA) and its clinical associations among T1D patients with onset below 30 years.

**Methods:** In a clinic-based cross-sectional study, 224 north Indian children and young adults with T1DM and 171 healthy controls were enrolled. We measured hemoglobin, serum ferritin, vitamin B12, PCA, thyroid peroxidase (TPO) and tissue-transglutaminase (TTG) antibodies in all patients.

**Results:** The prevalence of PCA was significantly higher in patients [22% (17%–28%)] than age and sex matched controls [10.2% (6%–6%); p = 0.002]. Patients with PCA had a higher frequency of anemia (60% vs. 30%, p < 0.001), lower hemoglobin [11.8 (2.5) g/dL vs. 12.5 (1.8) g/dL, p = 0.002] and lower serum ferritin [20.9 (31.5) μg/L vs. 29.4 (46.9) μg/L, p = 0.04], as compared to the T1D patients without PCA. Serum vitamin B12 did not differ between the two groups. On multivariate analysis, hemoglobin was associated with PCA (β = –0.174, p = 0.005), serum ferritin (β = 0.247, p < 0.001) and creatinine clearance (β = 0.160, p = 0.012). Patients with anemia had significantly low height Z-scores as compared to patients without anemia (–1.6 vs. –0.9, P = 0.004). The prevalence of anemia (31%), hemoglobin [median (IQR) 12.6 (1.8) g/dL] and ferritin levels [median (IQR) 28.9 (48.9) μg/L] in controls did not differ from that in T1D patients without PCA.

**Conclusions:** PCA was an independent risk factor for anemia and iron deficiency in children and young adults with T1DM.

**P201 | Management of diabetes in the context of a generalized congenital lipodystrophy**

M. Ben Lafqih¹, S. Ijdda², S. Rafi², G. El Mghari², N. El Ansari²

¹Management of Diabetes in the Context of a Generalized Congenital Lipodystrophy, Marrakech, Morocco, ²University Hospital Mohammed VI, Marrakech, Morocco

**Introduction:** Generalized congenital lipodystrophy, represents the most extreme phenotype of lipodystrophies with the loss of almost all body fat. It is a rare entity seen at birth or in the first months of life, predisposing to the early development of metabolic complications such as diabetes, hypertriglyceridemia, and fatty liver disease during childhood.

**Objectives:** We report the case of a patient in who generalized congenital with diabetes and different therapeutic options.

**Methods:** 28-year-old patient, the diagnosis of diabetes was revealed at the age of 14 years, and then she was put on 2 mixed insulins and rapid insulin with high doses at a rate of 2.2 IU / kg. At the age of 16, she presented with acute pancreatitis with revelation of major hypertriglyceridemia at 96 mg / L. On clinical examination, we found a adipose tissue atrophy involving the entire body and limbs with an appearance of pseudohypobemegaloy, muscle hypertrophy with clitoral hypertrophy, and mild hirsutism. The treatment of diabetes focused on hygiene and dietary measures, taking metformin and adjustment of his insulin doses.

**Results:** Lipodystrophic diabetes due to the presence of severe insulin resistance, both muscular and hepatic. Due to insulin resistance, some patients require high doses of insulin. It is important to limit the daily calorie intake in order to control blood sugar. Physical activity is strongly recommended. Recombinant leptin, effective on associated metabolic disorders but does not improve lipoatrophy. Regarding anti-diabetic treatments, metformin remains a first-line treatment due to its hepatic insulin sensitizing action, even if it has no action on the peripheral target tissues of insulin. Glucagon-like peptide-1 receptor agonists are often useful in treating hyperglycemia and overeating, as well as ultra-concentrated insulin.

**Conclusions:** The management of diabetes in the context of lipodystrophy is difficult and requires a multidisciplinary approach.

**P202 | Type 1 diabetes and myasthenia gravis**

C. Barcala¹, G. Krochik¹, C. Martinez Mateu¹, S. Monges², M. Prieto²

¹Garrahan Hospital, Pediatric Nutrition, Autonomous city of Buenos Aires, Argentina, ²Garrahan Hospital, Pediatric Neurology, Autonomous city of Buenos Aires, Argentina

**Introduction:** The development of immunological tolerance against self-antigens is called self-tolerance. The loss of it generates an abnormal regulation of autoreactive T lymphocytes or an alteration in the way in which the presentation of self-antigens is carried out and the development of autoimmune diseases. Type 1A Diabetes Mellitus (1ADM) is a metabolic disorder secondary to autoimmune destruction
of pancreatic beta cells and insulitis. It is the most common type of diabetes in childhood and youth. Myasthenia Gravis (MG) is an autoimmune disease caused by postsynaptic blockade of the myoneural plate by AAcs against Acetylcholine receptors (ACRA) or against molecules of the postsynaptic membrane. The association between DM1A and MG can be observed in type III polyglandular syndrome, characterized by autoimmune disease of the thyroid gland associated with other autoimmune entities.

**Objectives:** Describe the association of type 1 diabetes and myasthenia gravis.

**Methods:** Case Repost, three patients between 7 and 19 years old, with an association of MG and DM1A treated at the Garrahan Hospital.

**Results:** The association of autoimmune diseases related to DM1A is known. The most frequently Hashimoto’s Thyroiditis, Autoimmune Gastritis and Celiac Disease. In our group, the frequent association are hyroiditis and celiac disease. The autoimmune disease most frequently related to MG is thyroiditis. The coexistence of DM1A and MG is described in Polyglandular Syndrome III.

**Conclusions:** There is little published evidence on the association of DM1A and MG in children outside the Polyglandular Syndrome III. Two of the three patients have increased HbA1c compared to the mean of our follow-up population. There is no published evidence on the risk of complications in the long or medium term in these cases.

**P203 | Association of type 1 diabetes mellitus with autoimmune diseases in children in the department of endocrinology-diabetology and nutrition at Mohammed VI University Hospital Center Oujda**

H. Charif1, L. Yagoubi1, A. Ourdi1, I. Assarrar1, N. Messaoudi1, S. Rouf1,2, H. Latrech1,2

1Mohammed VI University Hospital Center, Faculty of Medicine and Pharmacy, Université Mohammed Premier Oujda, Endocrinology-Diabetology and Nutrition Department, Oujda, Morocco, 2University Mohammed Premier Oujda, Laboratories of Epidemiology, Clinical Research and Public Health, Faculty of Medicine and Pharmacy, Oujda, Morocco

**Introduction:** Type 1 diabetes is frequently accompanied by other autoimmune diseases that can sometimes be integrated into autoimmune polyendocrinopathies.

**Objectives:** Through this work, we sought to describe the association of autoimmune diseases with type 1 diabetes in children.

**Methods:** This is a retrospective and descriptive study, including 354 type 1 diabetic patients hospitalized in the Department of Endocrinology Diabetology and Nutrition at Mohammed VI University Hospital Center Oujda between 2016 and 2021. All our patients had benefited from a systematic search for autoimmune diseases. The statistical analysis was performed by SPSS version 21 software.

**Results:** The mean age of our patients was 16 ± 1.9 years. Our population was predominantly female with a sex ratio of 0.94. A family history of autoimmune diseases was noted in 6 cases. Anti-IA2 and anti-GAD antibodies were positive in 19% of cases.

Autoimmune diseases were noted in 23 patients, 34.7% of whom were men and 65.8% women. Autoimmune thyroïdism was the leading cause in 34% of cases. Type 1 diabetes mellitus preceded dysthyroidism in 65% of cases. Celiac disease was noted in 30% of cases. Autoimmune polyendocrinopathy was listed in 39.2% of cases and psoriasis in 0.28% of our patients.

**Conclusions:** The frequency of autoimmune diseases in type 1 diabetes, which can sometimes be part of autoimmune polyendocrinopathy, encourages screening for them when diabetes is discovered. The screening will allow an early management of these disorders and prevent further complications.

**P205 | Early insulin-induced lipoatrophies in a young child treated with topical tacrolimus**

E. Morotti1,2, G. Frontino1,2, A. Rigamonti1,2, R. Di Tonna1,2, V. Castorani1,2, F. Sandullo1,2, F. Scalalba1,2, F. Arrigoni1,2, R. Foglino1,2, B. Dionisi1,2, F. Meschi1,2, R. Bonfanti1,2,3

1IRCCS San Raffaele Hospital, Department of Pediatrics, Milano, Italy, 2IRCCS San Raffaele Hospital, Diabetes Research Institute, Milano, Italy, 3Università Vita-Salute San Raffaele, School of Medicine, Milano, Italy

**Introduction:** Insulin-induced lipoatrophies (IIIA) are rare but lead to detrimental effects on esthetics, glucose control, and quality of life. Causes are unclear, and there is no established treatment. There is a correlation with greater age (11.5 ± 3.8 years), disease duration (5.4 ± 3.6 years) and associated autoimmune diseases. Switching insulin preparations and mode of administration, local treatment cromolyn, low dose oral or topical corticosteroid are therapeutic options in IIIA with variable and often unsatisfying results. T is a macrolidecalcineurin inhibitor that inhibits T-cell activation and is approved in children with moderate–severe atopic dermatitis from 2 years of age.

**Objectives:** To assess the use of T on early IIIA in a young child with type 1 diabetes (T1D).

**Methods:** A 4-year-old boy with a 4-month history of T1D (sensor-augmented pump therapy with lispro) and no associated autoimmune diseases presented bilateral IIIA at the infusion set sites on the buttocks. At 8 months of follow-up, new IIIA appeared at the injection sites on the thighs bilaterally. The patient was switched to multiple injections of insulin as part and glargine. After 3 months and no improvement, local corticosteroid treatment was started. After another unsuccessful 3 months, and due to reported cases of T1D-related necrobiosis lipoidica successfully treated with T, local treatment was started. Primary endpoint was the increase of the subcutaneous fat thickness (SFT)at 6 months as measured by ultrasound (US). Measurements were recorded at baseline, 1 and 6 months.
Prevalence of coeliac disease in children with type 1 diabetes mellitus: a cross sectional study from a single tertiary center in Oman

M. Saleh1, M. Mustafa1, L. Al Marzooqi1, A. Rafakat2
1 Al Jalia Hospital, Pediatric Endocrinology, Dubai, United Arab Emirates, 2 Al Jalia Hospital, Pediatrics, Dubai, United Arab Emirates

Introduction: Coeliac disease (CD) is one of the autoimmune disorders that has been increasingly recognized to be associated with type 1 diabetes mellitus (T1DM). A 10 years ago, the prevalence of CD in T1DM patients was reported to be 5.5% in our center.

Objectives: To determine the prevalence of CD in T1DM in our cohort of patients who receive their medical care at Sultan Qaboos University Hospital.

Methods: Going through the electronic medical records of our patients and reviewing their immunology screen for CD that is performed routinely for all children diagnosed with T1DM.

Results: Out of 123 patients live with T1DM, currently aged between 4.3 to 18.8 years, whom received their medical care at pediatric diabetes unit in 2021; 20 patients (16.2%) had positive celiac screen at some point during their course of management. A 5 of them had further testing which ruled out coeliac disease, 2 other patients are currently under further work up by pediatric gastroenterology team. Therefore there is 13 patients confirmed having CD giving a prevalence of 10.5% which is double the prevalence of what was reported 10 years ago.

Conclusions: There is an alarming increase in the prevalence of Coeliac disease among patients live with Type 1 Diabetes Mellitus in our cohort of patients in a single tertiary center in Oman. Further studies are needed to explore the reasons for doubling the prevalence.

Clinical Profile and association of celiac disease in children with type 1 diabetes presenting in low middle income country

V. Rai1, D.D.K. Jokhio1, M. Riaz1, Z. Khoso1, D.T.M. Laghari1, S. Chachar2, P.M.N. Ibrahim1
1 National Institute of Child Health, Pediatric Endocrinology and Diabetes, Karachi, Pakistan

Introduction: Celiac disease (CD) is an immune-mediated enteropathy caused by permanent intolerance to gliadin & related proteins present in gluten part of diet in genetically susceptible individuals. CD was often thought to be a disease of western people, however current data in India, the North Africa & Middle East reveal that it affects 0.13% to 1.16% of lower risk of people & 2.3% to 4.3% of higher risk of people. CD, also termed as gluten-sensitive enteropathy, is a hereditary condition that affects both adults & children.

Objectives: To determine Clinical Profile and Association of Celiac Disease in Children With Type 1 Diabetes.
Methods: Study design: This cross-sectional study was conducted from 2 Jan 2019 to 2 Jul 2019 in NATIONAL INSTITUTE OF CHILD HEALTH (NICH).

Material and methods: Sample size is 126 cases of type 1 DM calculated on Open Epi software. By using prevalence 11.1%(19) of celiac disease in children with type 1 DM, Confidence interval of 95%, at margin of error 5.5%.

Patients with Type 1 diabetes mellitus (T1D) with age 1 to 18 years were included. Patients with diabetic ketoacidosis and evidence of pancreatic calcifications were excluded from the study.

Results: Out of 126 type 1 diabetes mellitus patients, 29(23.0%) were diagnosed to have celiac disease on the basis of positive serology. The mean age of the patients was 9.31 ± 4.40, 56(44.4%) patients were female and 70(55.6%) were male. A 30(23.8%) patients had diarrhea, 85(67.46%) patients were anemic, 26(20.6%) patients had abdominal pain.

Conclusions: Celiac disease is highly prevalent in patients with type 1 diabetes mellitus (23%). In this study, CD was diagnosed with the help of Anti tissue transglutaminas. IgA, IgG, and Anti-DGPs (IgG). These data imply that the frequency of CD in children with type 1 diabetes is larger, and diabetic children should be screened on a regular basis to ensure early detection and treatment of Celiac disease.

POSTER TOUR 23—EPIDEMIOLOGY & PATHOGENESIS # 3

P210 | Prevalence of C-peptide and antibody levels (anti GAD, Islet cell antibodies, insulin auto antibodies) in type 1 diabetic children at National Institute of Child Health Hospital Karachi, Pakistan

M. Riaz¹, T. Laghari¹, Z. Khoso¹, V. Rani¹, M.N. Ibrahim¹
¹National Institute of Child Health, Peads Endocrinology, Karachi, Pakistan

Introduction: Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by the loss of glycemic control. It is the autoimmune mechanism that has a latent period and results in destruction of pancreatic β-cells, which leads to the development of hyperglycemia and lifelong dependency on daily insulin injections. This autoimmune disorder develops as a consequence of a synergistic combination of genetic pre-disposition, largely unknown environmental triggers, and immunologic events.

As T1D remains the most common form of diabetes in children so this data would help in better understanding of the disease and its pathophysiology in our population.

Objectives: To determine the prevalence of C-peptide and antibody levels (anti GAD, Islet cell antibodies, insulin auto antibodies) in type 1 diabetic children at tertiary care hospital.

Methods: 98 children of both genders, at National Institute of Child Health, Karachi with type 1 DM for >1 month were included in the study. Children who did not give informed consent and whose GFR <30 ml/min were excluded.

In all these enrolled patients, C-peptide, human islet cell antibody (ICA), insulin auto antibodies (IAA) and antiglutamic acid decarboxylase (anti-GAD) were estimated. All demography, clinical history and laboratory data was recorded on a predesigned performa.

Results: In 77(78.3%) patients of Type 1 diabetes, C-peptide level was less than 0.8 and 47(48%) have positive anti-GAD level. There were 35(35.7%) patients who had positive IA2 level. Insulin auto antibodies were positive in 7(7.1%) patients and Islet Cell antibody level was negative in all 98(100%) of type 1 diabetic patients in this study.

Conclusions: Diabetic children had high levels of anti-GAD antibodies, insulin autoantibodies and islet cells antibodies but low level of C-peptide.

P212 | Analysis of the major histocompatibility complex (MHC) in type 1 diabetes patients from the United Arab Emirates using high-resolution family-phased haplotypes

H. Alnaqbi¹, S. Chehadeh¹, A. Deeb², A. Ahli³, D. Almalood³, H. Alsafar¹, G. Tay⁴
¹Khalifa University of Science and Technology, Center for Biotechnology, Abu Dhabi, United Arab Emirates, ²Mafraq Hospital, Department of Endocrinology, Abu Dhabi, United Arab Emirates, ³Khalifa University of Science and Technology, College of Medicine and Health Sciences,
DNA methyltransferase3A and ten eleven translocase: Impact of family history of diabetes on clinical features

Introduction: The Major Histocompatibility Complex (MHC) is a region containing major genetic risk factors for Type 1 Diabetes (T1D), a disease that is becoming more prevalent in the populations of the Arabian Peninsula. Family studies represent a robust method of disease association analysis, as they avoid a considerable source of ambiguity caused by un-detected population stratification biases that typically impact typical unrelated case-control studies.

Objectives: This study establishes a methodological example for future research on MHC-disease association and to improve our knowledge of the genetics of T1D in an understudied population.

Methods: In this study, Next Generation Sequencing (NGS) was used to genotype the Human leukocyte Antigens (HLA) class I and class II in 13 T1D patients from the United Arab Emirates (UAE), their unaffected family members (22 parents and 7 unaffected siblings), and 28 unrelated healthy UAE families (including one three-generations family). HLA haplotypes were assigned unequivocally by pedigree-based segregation analysis. A case-control analysis was conducted between pedigree-phased haplotypes of the patients and the control group using Bridging ImmunoGenomic Data-Analysis Workflow Gaps (BIGDAWG).

Results: Consistent with previous reports in Caucasian, North African, South Asian, and Middle Eastern populations, the MHC class II haplotype block marked by HLA- DRB1*03:01-DQA1*05:01-DQB1*02:01 and HLA-DQB1*03:02 showed significant associations with T1D. HLA-DQA1*01:02 was found to be negatively associated to T1D. Further, a high excess of HLA-DR3 or HLA-DR4 homozygosity was detected in patients, which could be due to consanguinity, a factor that could potentially increase the susceptibility of Arabian children to T1D.

Conclusions: The current study is important as it contributes to understanding the genetic mechanisms that ultimately lead to T1D incidence in an understudied population. Genetic markers may help identify individuals at high risk before clinical manifestations.

P213 DNA methyltransferase3A and ten eleven translocase: 2 in children with type 1 diabetes; role in disease pathogenesis and progression

N. Salah1, L. Salem1, S. Taha1, M. Youssef1, L. Annaka1, S. Hassan1, R. Mahmoud1

1Ain Shams University, Cairo, Egypt

Introduction: DNA methylation plays a pivotal role in autoimmunity and energy metabolism. However, its mechanistic role and clinical implications in type 1 diabetes (T1D) is still obscure.

Objectives: To assess the level of DNA methyl-transferase3A (DNMT3A) and ten-eleven translocase2 (TET2) in children with T1D compared to controls and to correlate them to disease duration, HbA1C and micro-vascular complications.

Methods: A 50 children with T1D and 50 matched controls were assessed for family history of T1D, diabetes duration, insulin therapy, anthropometric measures, fundus and the bedside neuropathy-disability score. TET2, DNMT3A, fasting lipids, glycated-hemoglobin (HbA1C) and urinary albumin-creatinine were measured.

Results: The mean TET2 of the studied children with T1D was 227.60 ng/ml and their mean DNMT3A was 2.59 ng/ml. Children with T1D had significantly higher TET2 (P = 0.015) and DNMT3A (P < 0.001) than controls. Children with T1D with diabetes duration ≤5 years had significantly higher TET2 than those with diabetes duration >5 years (P = 0.02) and controls (P < 0.001). TET2 was negatively correlated to diabetes duration (P < 0.001) and HbA1C (P < 0.001), while DNMT3A was positively correlated to diabetes duration (P < 0.001) and HbA1C (P = 0.001). TET2 was independently related to HbA1C (P = 0.001) and diabetes duration (P = 0.038), while DNMT3A was independently related to diabetes duration (P = 0.003) in children with T1D. Micro-vascular complications were not related to TET2 (P = 0.535) and DNMT3A (P = 0.310).

Conclusions: TET2 and DNMT3A are significantly higher in children with T1D than controls. Moreover, they are correlated with diabetes duration and HbA1C in children with T1D. Thus, they could serve as potential therapeutic targets for prevention and treatment of T1D.

Impact of family history of diabetes on clinical features at onset of type 1 diabetes—Data from a national, prospective Swedish cohort

E. Hedlund1,2, J. Tojjar1, L. Lilja3, H. Elding Larsson4,5, G. Forsander6,7, S.A. Ivarsson4, J. Ludvigsson4,5, C. Marcus10, F. Norström11, U. Samuelsson8,9, M. Persson12,13, A. Carlsson1,3

1Lund University, Department of Clinical Sciences, Lund, Sweden, 2Kristianstad Central Hospital, Kristianstad, Sweden, 3Skåne University Hospital, Lund, Sweden, 4Lund University, Department of Clinical Sciences, Malmö, Sweden, 5Skåne University Hospital, Malmö, Sweden, 6University of Gothenburg, Institute of Clinical Sciences, Gothenburg, Sweden, 7Sahlgrenska University Hospital, The Queen Silvia Children’s Hospital, Gothenburg, Sweden, 8Linköping University Hospital, Crown Princess Victoria Children’s Hospital, Linköping, Sweden, 9Linköping University, Division of Pediatrics, Dept of Biomedical and Clinical Sciences (BKV), Linköping, Sweden, 10Karolinska Institute, Department of Clinical Science Intervention and Technology, Division of Pediatrics, Stockholm, Sweden, 11Umeå University, Department of Epidemiology and Global Health, Umeå, Sweden, 12Karolinska Institute, Department of Medicine, Clinical Epidemiology, Stockholm, Sweden, 13Karolinska Institute, Södersjukhuset, Department of Clinical Science and Education, Stockholm, Sweden

Introduction: Increasing evidence suggest that type 1 diabetes (T1D) is a heterogenous disease.

Objectives: The aim of this study is to describe heredity for T1D or type 2 diabetes (T2D), both or none, in Swedish children with T1D.
and to examine whether family history of diabetes influences the clinical picture at disease onset.

**Methods:** Blood samples and data on diabetes heredity (first and second generation) were collected at diagnosis of T1D in 3647 children (<18 year-olds) from the national Better Diabetes Diagnosis (BDD) cohort in Sweden. Data was split into groups based on heredity, and analyzed for differences in autoantibodies (GADA, IAA, IA-2A, and ZnT8A), HLA-genotype, age, sex, BMI, and HbA1c at diagnosis. Parental diabetes was compared for 11 to 13-year-olds in the BDD-cohort (n = 811) and data from previously published data on healthy 12-year-old controls (n = 11,050).

**Results:** Compared with children with heredity for T2D, children with heredity for T1D were diagnosed at a lower age (p < 0.001) and had a lower mean HbA1c at diagnosis (p < 0.001), while children with a heredity of T2D had a higher BMI than those without heredity for diabetes (p < 0.001), but not those with heredity for T1D (p = 0.357). There were no differences in HLA or autoantibody profile between children with or without a T1D or T2D family history of diabetes. The relative risk of parental T1D among children with T1D was 3.88 (95% CI 2.99–5.05) and for T2D 1.85 (95% CI 1.26–2.73) compared with the healthy controls.

**Conclusions:** Heredity not only for T1D, but also T2D is more common in children developing T1D. This may suggest that, in addition to predisposition to autoimmunity, factors such as insulin resistance and obesity might play a role in the development of T1D. Also, the results indicate that family history of T1D is associated with a more rapid disease process.

**P215 | 3 Screen ICA ELISA—A new tool to identify pre-clinical diabetes in first-degree relatives of patients with type 1 diabetes (pre-d1abetes study)**


1Medical University in Białystok, Dep of Pediatric, Endocrinology and Diabetes with a Cardiology Division, Białystok, Poland, 2Medical University in Białystok, Białystok, Poland, 3University Children’s Hospital in Białystok, Białystok, Poland, 4Gdańsk Medical University, Gdańsk, Poland, 5Medical University in Łódź, Łódź, Poland, 6Rzeszów Medical University, Rzeszów, Poland, 7Medical University in Warszawa, Warsaw, Poland, 8Opole Medical University, Opole, Poland, 9Silesian Medical University, Katowice, Poland, 10Medical University in Wrocław, Wrocław, Poland, 11Jagiellon University Medical School in Krakow, Krakow, Poland, 12Pomeranian Medical University in Szczecin, Szczecin, Poland, 13Medical University in Lublin, Lublin, Poland, 14Memorial Institute of Healthy Children, Warsaw, Poland, 15Medicine University in Bydgoszcz, Bydgoszcz, Poland, 16Medical University in Poznan, Poznan, Poland, 17FIRS Laboratories, RSR Ltd, Cardiff, Cardiff, United Kingdom

**Introduction:** Overt clinical symptoms of type 1 diabetes (T1D) are often preceded by a pre-clinical stage of varying duration. Diagnosis of the pre-clinical stage is difficult and is based on the presence of specific islet autoantibodies in the subject’s blood.

**Objectives:** Apparently healthy first-degree relatives of patients with T1D were tested using the 3 Screen ICAELISA (RSR Ltd) for combined testing for autoantibodies to GAD65 (glutamic acid decarboxylase, 65 kDa isoform), ZnT8 (zinc transporter 8), and the islet antigen IA-2. A 3 Screen positives were subsequently tested for individual auto anti bodies. Potentially, approximately 70% of individuals with two or more types of diabetes associated auto anti bodies (including insulin auto anti bodies; IAA) will need insulin treatment over the next 10 years.

**Methods:** A total of 1056 subjects (age 1–18 years) were recruited from clinical Centers from Białystok (n = 237), Rzeszów (n = 80), Poznań (n = 74), Warsaw (n = 109), Warsaw (n = 42), Opole (n = 85), Wrocław (n = 90), Gdańsk (n = 55), Łódź (n = 118), Katowice (n = 46), Kraków (n = 14), Szczecin (n = 20), Bydgoszcz (n = 44), Lublin (n = 42). Serum samples collected by the coordinating clinics were tested by 3-Screen at FIRS Laboratories, RSR Ltd (Cardiff, UK). A 3 Screen positive serum samples were assayed by GAD65 Ab ELISA, IAA-2 Ab ELISA, ZnT8 Ab ELISA and the Insulin Ab RIA (www.rsrltd.com).

**Results:** Out of 1056 samples n = 85 (8.0%) were 3 Screen positive. Testing in individual autoantibody assays identified 59 children (5.6%) with multiple auto anti bodies who were diagnosed with pre-clinical diabetes. These children were followed-up with a noral glucose toler ance test and glycated hemoglobin determinations.

**Conclusions:** Early detection of islet autoantibodies by 3 Screen identifies pre-clinical T1D preceding development of carbohydrate abnormalities. This open sup opportunities for the racistve interventions in innovative clinical programs. Patient follow up with early education and multidirectional diabetes care should prevent occurrence of ketoacidosis associated with severe clinical manifestations.

**P216 | A retrospective study on diabetic ketoacidosis in children with newly diagnosed type 1 diabetes mellitus at Kantha Bopha Children’s Hospital Phnom Penh during 5 years from 1 January 2014 to 31 December 2018**

P. Laing1, M. Iv2, Y. Nguon3

1University of Health Sciences, Medicine, Phnom Penh, Cambodia, 2Kantha Bopha Children’s Hospital in Phnom Penh, Kantha Bopha II: Diabetic department, Phnom Penh, Cambodia, 3Kantha Bopha Children’s Hospital in Phnom Penh, Kantha Bopha IV, Phnom Penh, Cambodia

**Introduction:** Diabetic ketoacidosis (DKA) is a potentially severe and common condition in emergency rooms and pediatric intensive care units. It is one of the major complications in patients with type 1 diabetes mellitus (T1DM).

**Objectives:** To describe the prevalence, clinical characteristics at presentation, laboratory profiles, severity, and outcome of treatment as well as mortality rate of DKA with newly diagnosed T1DM in children.

**Methods:** It was a retrospective and descriptive study in 68 children presented as DKA with newly diagnosed T1DM treated at Kantha
Bopha Children’s Hospital in Phnom Penh from 1 January 2014 to 31 December 2018.

**Results:** Of 138 children presenting with new onset T1DM over the 5-year period, 68 cases had DKA of any severity (49.28%) with the sex ratio (M:F) of 1:1.52 and the mean age of 7.8 years old. Mostly, patients were from rural area (69.12%). Dyspnea was complaint frequently (39.71%). Among all chief complaints, there were 10.29% of altered level of consciousness and 5.88% of coma. The mean duration of the symptoms was 8.44 days, and of hospitalization was 24.56 days. Mean level of laboratory results were serum glucose (33.51 mmol/L), HbA1C (12.93%), pH (7.10), and HCO3 (7.45 mmol/L). The severity was divided into three categories like mild, moderate and severe (22.06%, 32.35%, and 45.59% respectively). During treatment, the mean time of DKA resolution was 21.09 h and complications were hypokalemia (29.41%), and hypoglycemia (22.06%). There were neither reported cases of cerebral edema nor mortality.

**Conclusions:** DKA at the time of T1DM diagnosis is accounted for almost half of all presented children and often severe. Children at admission mostly were from rural region and girls have high risk of DKA as well as those with the age of 10–15 years old. They had hypokalemia (29.41%) and hypoglycemia (22.06%) during the treatment, but no cases of cerebral edema or mortality.

**P217** | Ongoing increase in incidence of diabetes mellitus in Austrian children and adolescents <15 years (1999–2021)

B. Rami-Merhar¹, S. Hofer², E. Fröhlich-Reiterer², T. Waldhörm, M. Fritsch³, K. Nagl¹

¹Medical University of Vienna, Dept. of Pediatric and Adolescent Medicine, Vienna, Austria, ²Medical University of Innsbruck, Department of Pediatrics, Innsbruck, Austria, ³Medical University of Graz, Department of Pediatrics and Adolescent Medicine, Graz, Austria, ⁴Medical University of Vienna, Department of Epidemiology, Center of Public Health, Vienna, Austria

**Introduction:** Incidence trends for diabetes vary in different regions in the world and there is an ongoing discussion if the COVID-19 pandemic may have an influence in an increase in the diabetes incidence. **Objectives:** To analyze the time trends of nationwide diabetes incidence <15 years of age from 1999 until 2021 in Austria.

**Methods:** The Austrian Diabetes Incidence Study Group registers all newly diagnosed persons with diabetes mellitus <15 years of age in a prospective population-based study. The diabetes type was classified on the basis of clinical and laboratory findings according to American Diabetes Association criteria.

**Results:** In the time period 1999–2021 5888 persons were diagnosed with diabetes. Type 1 diabetes (T1D) accounted for the majority of cases: 5550 (94.3%), (female = 46.2%), 108 (1.8%) were classified as type 2 (T2D) (f = 59.3%) and 230 (3.90%) as other specific types of diabetes (f = 50.9%). After observing a constant increase in T1D incidence in the years 1999–2010, a plateau was reached in the years 2011–2020, while in 2021 a further increase was recorded, mainly driven by the age group 5–9 yrs. The standardized T1D incidence rate reached the highest number ever (28.6, 95%CI: 25.7–31.6) observed in this Austrian population based registry. This increase coincides with the global COVID-19 pandemic. The registry does not include data for infections or vaccinations. The rate of onset-DKA (pH <7.3) remains very high with 46.1% in 2021. No increase of T2D <15 years was detected and other forms of diabetes accounted for twice as many cases compared to T2D.

**Conclusions:** In Austria the T1D incidence <15 years is increasing with a peak in 2021, if this is related to infections within the COVID-19 pandemic remains still unclear. The rate of onset-DKA remains very high, indicating that the T1D diagnosis is delayed. Incidence of T2D did not increase and other specific types of diabetes were diagnosed more often compared to T2D.

**P218** | Partial remission in children with type 1 diabetes in Sweden: a retrospective, longitudinal study from 2007 to 2011 from the Swedish National Quality Register (SWEDIABKIDS)

A.-L. Fureman¹, M. Lilja², S. Särnblad², U. Samuelsson², M. Bladh³, T. Lind¹

¹Umeå University, Clinical sciences, Umeå, Sweden, ²Umeå University, Umeå, Sweden, ³Örebro University, Örebro, Sweden, ⁴Linköping University, Linköping, Sweden
Introduction: Metabolic control can be improved and the risk of acute and late complications be reduced if patients with type 1 diabetes go into partial remission (PREM).

Objectives: The study aimed to investigate what characterizes Swedish children with type 1 diabetes with PREM and whether method of insulin administration, that is, continuous subcutaneous insulin infusion (CSII) or multiple daily injections (MDI) affect the incidence and duration of the remission period.

Methods: Data on HbA1c, age at diagnosis, sex, duration of diabetes, and insulin administration method, total daily dose insulin (TDDI), and episodes of severe hypoglycemia and ketoacidosis were extracted from SWEDIABKIDS, a nation-wide register for diabetes care from 2007–2011. PREM was defined as TDDI <0.5 U/kg/day and HbA1c <57 mmol/mol (7.4%). Mean annual HbA1c and TDDI was calculated stratified for age groups 0–6, 7–12 and 13–17 years old and duration, 0–3, 3–12, 12–24, 24–36 months. Multivariate analysis with multiple logistic regression with remission as dependent variable and age at onset, insulin method, sex and duration of diabetes as independent variables was performed.

Results: Of 3887 patients were 56% boys. More boys (39%) than girls (34.3%) were in PREM at 3 months, p < 0.005. Fewer children 0–6 years old, had remission at 3 months (20.7%) and at 12 months (17.6%) compared to older age groups, both p < 0.001. A larger proportion of patients using CSII at 12 and 24 months remained in PREM compared to those with MDI (18% vs. 14%, p = 0.008 and 9% vs. 4.5%, p < 0.001). PREM was associated with CSII (OR:1.66 CI:1.29–2.12), shorter diabetes duration (OR:0.92 CI:0.87–0.98) and higher age at onset (OR:1.05 CI:1.03–1.08).

Conclusions: Young age, female sex, insulin through MDI, and longer duration of diabetes were associated with lower frequency of PREM. Use of CSII seem to contribute to longer PREM among Swedish children with type 1 diabetes, which in turn may affect acute and late complications.

P219 | Comparing inflammation and oxidative stress markers in adolescents with type 1 diabetes and healthy controls: Finding from the CARDEA study

M. Masse1, N. Silva Navarro2, V. McNealis1,2, S. Harnois-Leblanc1,3,4, J.-C. Lavoie1,5, M.G. Friedrich6, A. Van Hulst8, A.M. Nuyt1,9, J.-L. Bigras1,9, T.A Barnett1,10, A. Benedetti2, M.-È. Mathieu1,11, V. Drapeau12, M. Henderson1,3,9

1Research Center of CHU Sainte-Justine, Montréal, Canada, 2McGill University, Department of Epidemiology, Biostatistics and Occupational Health, Montréal, Canada, 3Université de Montréal, School of Public Health, Montréal, Canada, 4Research Center of Center Hospitalier Universitaire de Montréal, Montréal, Canada, 5Université de Montréal, Department of Nutrition, Montréal, Canada, 6McGill University Health Center, Montréal, Canada, 7McGill University, Department of Medicine and Diagnostic Radiology, Montréal, Canada, 8McGill University, Ingram School of Nursing, Montréal, Canada, 9Université de Montréal, 10McGill University, Department of Family Medicine, Montréal, Canada, 11Université de Montréal, School of Kinesiology and Physical Activity Sciences, Montréal, Canada, 12Université Laval, Department of Physical Activity, Québec, Canada

Introduction: Inflammation and oxidative stress contribute to cardiovascular disease (CVD) in adults, particularly those with type 1 diabetes (T1D), but their role in pediatric T1D is understudied.

Objectives: We verified disruptions in inflammation and oxidative stress markers in adolescents with T1D compared to healthy controls.

Methods: Cross-sectional study of 100 adolescents (14–18 years) with T1D from Sainte-Justine Hospital Diabetes Clinic (Montreal, Canada) and 97 age and sex-matched controls. Fasting leptin, adiponectin, tumor necrosis factor α (TNF-α), TNF receptor 1, TNF receptor 2, interleukin 6 (IL-6), and C-reactive protein (CRP) were measured by ELISA. Capillary electrophoresis assessed hydrogen peroxide metabolism using oxidized glutathione (GSSG), reduced glutathione (GSH), total glutathione (GSI), and redox potential. To evaluate differences between groups, we estimated linear regression models between T1D status (yes/no) and each marker adjusting for age, sex, and BMI z-score. Leptin, IL-6 and CRP were 100 log transformed to remedy skewness or nonlinearity (interpretation is % difference between groups).

Results: Adolescents with T1D had higher TNF-α (mean adjusted difference: 0.25 pg/ml [95% CI: 0.11; 0.39]), TNF receptor 2 [427 pg/ml [95% CI: 228; 625]], IL-6 [39.9% [95% CI: 20.1; 59.7]] and CRP [70.3% [95% CI: 38.5; 102.1]], but also higher adiponectin 2.77 ug/ml [95% CI: 1.40; 4.14] than controls. Lower levels of GSSG (−0.06 nmol/mg [95% CI: −0.11; −0.001]), GSH (−0.83 nmol/mg [95% CI: −1.42; −0.25]), GSI (−0.94 nmol/mg [95% CI: −1.59; −0.30]), and a less favorable redox potential (−3.46 E−mV [95% CI: −7.07; 0.15]) were also seen in adolescents with T1D. No differences were observed between groups for other markers.

Conclusions: Marked differences in markers of inflammation and oxidative stress are evident in pediatric T1D as early as adolescence, which could contribute to the early and aggressive CVD noted in individuals living with T1D.

POSTER TOUR 24—MONOCENIC OTHER FORMS OF DIABETES # 2

P220 | Neonatal diabetes mellitus due to monogenic defects in infants: Experience from a tertiary care center of a resource limited country

M. Arif1, F. Memon1, M. haider1, S. Kirmani1, K.N. Humayun1

1Aga Khan University, Pediatric Endocrinology, Karachi, Pakistan

Introduction: Neonatal diabetes mellitus (NDM) due to single gene defects, presenting within first 6 months of life mostly is extremely rare with >20 known mutations, including transient and permanent forms. Etiological heterogeneity exists, both dominant and recessive
forms are present. KCNJ11 and ABCC8 being most common. Genetic testing is challenging in Pakistan due to being resource limited but has implications on management, progression, and future pregnancies.

**Objectives:** To review the clinical and molecular genetics profile of infants with suspected monogenic diabetes who underwent genetic testing.

**Methods:** Infants with clinical diagnosis of monogenic and syndromic diabetes presenting to our center over last 10 years were recruited, blood samples were sent for molecular genetic testing for confirmation of diagnosis. We reviewed their clinical outcome, management challenges and long-term complications.

**Results:** Genetic testing was sent in overall 20 infants with clinical diagnosis of NDM, presenting at our center, with diabetic ketoacidosis in neonatal age. Mutations were identified in 12 patients. The most common genetic subtype was KCNJ11 identified in 4 infants followed by 3 infants with Wolcott Rallison syndrome caused by EIF2AK3. ABCC8 mutation was identified in 1 infant. All 4 infants with KCNJ11 and 1 with ABCC8 mutation were successfully transitioned from insulin to oral sulfonyurea with good glycemic control, no neurocognitive deficit except for one with KCNJ11 mutation. Out of 3 infants with EIF2AK3 mutation, 2 were lost to follow-up and later found to have expired due to hepatic failure with intercurrent illness, 3rd child is on regular follow-up and doing well. One infant with INS mutation was found and 2 with FOXP3 and LRBA gene were identified on subsequent testing. One infant had GCK mutation and has no insulin requirement. No mutation were identified in 7 patients after extensive testing.

**Conclusions:** Genetic testing is essential to confirm a diagnosis of monogenic diabetes, which guides clinical management and future counseling.

---

**P221 Clinical characteristics and genetics of Wolfram syndrome in a series of Sudanese children**

**A. Ahmed**

**1Jafar Ibn Auf Hospital, Pediatric Endocrinology, Khartoum, Sudan**

**Introduction:** Wolfram syndrome is a progressive hereditary multisystem disease, characterized by the acronym DIDMOAD (Diabetes Insipidus (DI), Diabetes Mellitus (DM), Optic Atrophy (OA) and Deafness). Its main clinical symptoms are early onset non-immune diabetes mellitus and optic atrophy. More than 300 mutations in Wolfram Syndrome 1 gene (WFS1) were detected. Homozygous and compound heterozygous mutations in WFS1 gene causes an autosomal recessive form. The genotype/phenotype relation is still not fully understood due to rarity of the disease. We hereby report a cases series of Wolfram syndrome, their characteristics, and genetic profile.

**Objectives:** We hereby report a cases series of Wolfram syndrome, their characteristics, and genetic profile.

**Methods:** Six patients from 3 different Sudanese families were enrolled. Clinical and biochemical features at presentation, biochemical tests, hearing and ophthalmological assessment were documented. Genetic testing was done in collaboration with Exeter genetics.

**Results:** Five had phenotypic features of diabetes mellitus, optical atrophy, hearing loss and WFS1 gene was sequenced. The sixth patient from the first family presented with only early onset non-immune diabetes mellitus, and showed the same mutation as her affected older siblings. All six patients harbored homozygous mutations in WFS1 gene, and a heterozygous mutation in WFS1 gene among all parents, and three different WFS1 mutations were identified.

**Conclusions:** Wolfram syndrome should be considered in every diabetic child with optic atrophy. Early diagnosis enables better and more comprehensive care for these patients.

---

**P222 Acquired generalized lipodystrophy associated with autoimmune hepatitis: A case report**


**1Faculty Hospital Brno, Pediatrics Department, Brno, Czech Republic, 2Faculty Hospital Brno, Department of Medical Genetics and Genomics, Brno, Czech Republic**

**Introduction:** Lipodystrophies (LD) are a heterogeneous group of rare diseases characterized by a deficit of adipose tissue, decreased leptin levels, and metabolic abnormalities such as insulin resistance and diabetes. Lipodystrophies are classified as genetic or acquired and according to the distribution of fat to partial or generalized.

**Objectives:** To describe a case of acquired generalized lipodystrophy (AGL).

**Methods:** AGL appears during childhood or adolescence and is more common in women than men. We present a case report of a 14 year old girl diagnosed with autoimmune hepatitis who developed severe generalized loss of subcutaneous fat and muscular appearance with prominent veins. Signs of acanthosis nigricans were visible on the neck, in the axillae and around the navel. The abdomen was with hepatomegaly. Hyperinsulinemia, hypertriglyceridemia, low leptin level have been recorded in the laboratory. Performed glucose tolerance test with finding impaired glucose tolerance. We also noted positive autoantibodies (GAD, ZnT8) and reduced C4 level. Cardiological examination showed hypertrophic cardiomyopathy. Liver biopsy with finding steatofibrosis.

**Results:** Based on these signs, we diagnosed AGL. The patient was started on diet therapy. She also required insulin treatment for AIH relapse and corticosteroid therapy.

**Conclusions:** AGL is associated with autoimmune diseases both organ-specific and systemic. A number of positive autoantibodies are reported in patients with AGL, but may not be associated with clinical manifestations of the disease. We consider that it is necessary to monitor these patients to see if the disease does not manifest itself in time.
Maturity-onset diabetes of the Young type 7 treated with the glucagon-like peptide-1 receptor agonist (Liraglutide)—First report

M. Al-Abdulsalam, S. Kuma, S. Al Gharabi, A. Al-Shidhani, S. Al-Yaarubi, A. Al-Futaisi, H. Alsaffar

Introduction: MODY is the most common form of monogenic diabetes and which usually manifests before 25 years of age. It accounts for 1%–2% of all diabetes. Liraglutide was reported to be effective in managing some types of MODY but never in patient with MODY-7.

Objectives: To describe the course of treatment in a patient diagnosed with MODY-7 stating the effect of Liraglutide during the management.

Methods: This is a case report of a 16-year-old girl diagnosed with diabetes at age of 8, when she presented with diabetic ketoacidosis and HbA1c of 12% (108 mmol/mol). Multiple daily injection regimen was commenced after diagnosis. Her glycemic control was challenging. We will explain her management.

Results: A strong family history of diabetes was noted and she had the same phenotypic features of her mother who is also on insulin therapy for her diabetes. Laboratory investigations revealed negative diabetes antibodies. Low C-peptide 0.73 ug/L (1.1–4.4). Insulin requirement was in the range of (1u/kg/day). Her obesity worsened reaching a BMI of 42 Kg/M2 after being 30 Kg/m2at diagnosis. Metformin was added with regular counseling about dietary intake and physical activity. Giving the course of management with going into a severe morbid obesity in presence of acanthosis nigricans, she underwent a genetic testing that revealed a heterozygous variant of the KLF11 gene which is known to cause MODY. Glibenclamide was tried at age of 14 during a hospital admission to monitor the glucose levels, but the trial failed as she ran severe and persistent hyperglycemia despite reaching a maximum dose. Later when Liraglutide became available, it was started on 0.6 mg subcutaneously, once daily, that was gradually increased reaching 1.8 mg daily. In response to that her weight reduced by 10Kg and the HBA1C improved to 7.5% (58 mmol/mol) over a 7-month period.

Conclusions: Improvement of BMI and glycemic control with Liraglutide in a patient with KLF11 gene mutation (MODY-7) was evident. This is first report to our knowledge.

Monogenic diabetes through a series of 35 cases and review of literature

Z. Imane, F. Radi, A. Boulmane, A. Balafrej

Introduction: Monogenic diabetes is a rare form of diabetes (<5%). Until now, more than 40 different genetic subtypes of monogenic diabetes have been identified, each having a typical phenotype and a specific pattern of inheritance. Molecular diagnostics is essential to improve the management of these patients.

Objectives: Our work consists of updating the epidemiological particularities, clinical, biological, and genetic therapy of monogenic diabetes in children through several cases collected in the unit of pediatric diabetology of the children’s hospital in Rabat.

Methods: We performed a retrospective descriptive study in the unit of pediatric diabetology of children’s hospital in Rabat. This study is based on a review of 35 cases of monogenic diabetes collected from January 2006 to February 2015 from clinical records and computer database. Genetic study was done in collaboration with molecular genetics laboratories from Exeter Hospital in England and INSERM in France Paris.

Results: In our study neonatal diabetes represents 37.14% (13 cases) of the patients, molecular genetic study has identified different mutations (EIF2AK3, FOXP3, ABCB, the insulin gene) in which 4 cases the genetic study found mutations. Wolfram syndrome accounted for 28.57% of the cases (10 cases). A 8 cases were genetically confirmed by the detection of the mutation W1F. Lipoatrophic-diabetes was found in two cases including one case corresponding to Berardinelli–Seip syndrome.

Our series also contained 28.57% (10 cases) of other monogenic diabetes whose genetic mutations have recently been reported (SLC19, SLC29), for the rest of the cases the genetic study is underway.

Conclusions: Monogenic diabetes is rare, but their frequency would be underestimated especially in Regions with the highest rate of consanguineous marriages. In addition, they are insufficiently sought because of the cost of genetic analysis and frequently misclassified as type 1 diabetes or type 2 diabetes.

Broadening the clinical spectrum of GLIS3-associated neonatal diabetes mellitus: Neuroblastoma as an associated feature

D. von Zezschwitz, S. Kummer, A. Meißner, A. Welters

Introduction: GLI-similar 3 (GLIS3) gene mutations cause a rare syndrome primarily characterized by permanent neonatal diabetes (ND) and congenital hypothyroidism (NDH-syndrome). Additional features include intrauterine growth retardation, facial dysmorphism, hepatic fibrosis, polycystic kidneys, congenital glaucoma, exocrine pancreatic insufficiency, and developmental delay.

Objectives: We here report an individual with NDH-syndrome caused by a homozygous GLIS3 mutation (c.1710 + 1), that additionally presented with inguinal hernia and neuroblastoma.

Methods: Case report.

Results: At 1 month of age, severe feeding difficulties prompted us to perform abdominal ultrasound that revealed a solid tumor in the
retroperitoneal space highly suspicious of neuroblastoma. However, no urinary excretion of catecholamine metabolites could be detected on multiple samples. Diagnosis was obtained by histopathological examination after tumor resection. Metastases were limited to skin, and the disease was hence classified as stage 4S according to INSS criteria. Genetic testing showed absence of MYCN amplification. The tumor was closely monitored without further treatment (watch-and-wait strategy) and did spontaneously regress over the next couple of months.

Conclusions: This report emphasizes the variable clinical spectrum of GLIS3-associated NDH-syndrome, since the mutation detected in our patient has previously been described in two individuals with differing clinical phenotype. Furthermore, a causative link between GLIS3 mutation and neuroblastoma cannot be excluded, particularly since GLIS3 acts as a transcription factor involved in the regulation of various cellular processes during embryonic development, including during neurulation. In view of the rather unusual tumor localization and absence of urinary catecholamine excretion, we therefore suggest to consider neuroblastoma screening in all infants with NDH-syndrome.

P226 | A case series of maturity onset diabetes of the young

A. Srivastava, N. K Bhat
Aster CMI Hospital, Pediatric Endocrinology, Bengaluru, India

Introduction: Maturity onset diabetes of young (MODY) is a collection of inherited disorders of non-immune-mediated diabetes mellitus that remains insufficiently diagnosed. It is important to diagnose these cases accurately given the clinical implications of syndromic features, cost-effective treatment regimen, and potential impact on multiple family members.

Objectives: Our objective is to describe the phenotype in patients with genetically confirmed MODY.

Methods: A retrospective, descriptive analysis of patients attending pediatric diabetes clinic in a tertiary level hospital, whose molecular studies were consistent with the diagnosis of MODY.

Results: Age at diagnosis ranged from 3 years to 21 years. Two patients had HNF1A gene mutation. One patient with HNF1A gene mutation was 11 years old girl, asymptomatic, the second patient was 21 years old girl with retinopathy and nephropathy. A 3 year old girl had heterozygous mutation in PDX1 gene and had asymptomatic hyperglycemia, with frequent episodes of spontaneous hypoglycemia. The fourth patient, 14 years old girl, had GCK mutation and mild, asymptomatic fasting hyperglycemia and the fifth patient, 17 years old girl presented with osmotic symptoms, not in diabetic ketoacidosis and a very high HbA1C.

Conclusions: The differentiation between type 1, type 2, monogenic, and other forms of diabetes have important implications for both therapeutic decisions and educational approaches. Diagnosis of MODY should be suspected in cases with family history of diabetes in one parent and in antibody negative patient with diabetes. Next generation sequencing provides an optimal approach for clinical care in such patients as it provides a genetic diagnosis that often precedes
development of additional clinical features, informs prognosis and guides clinical management.

**P227** | Blindness at initial presentation of new onset diabetes mellitus in a 13 year old girl

S.C. Lee1, J.C. Agwu3, C. Kallappa2, A.-J. Ghauri1

1Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom

**Introduction:** Bilateral cataracts are rarely the initial symptom of diabetes mellitus (DM). Patients with DM who developed cataracts usually have DM for many years. The prevalence of early cataracts in pediatric DM ranges between 0.7% and 3.4%.

**Objectives:** We report a case of DM diagnosis following onset of blindness due to new bilateral cataracts.

**Methods:** 13-year-old Caucasian girl presented with rapidly declining vision for 2 months. She was blind 2 weeks prior to presentation. Examination showed significant posterior subcapsular cataracts and visual acuity of 1/60 bilaterally. Urgent cataract surgery was scheduled. A 3 days before surgery, she attended emergency department with HbA1c of >146 mmol/mol and polydipsia for 7 weeks. Blood glucose was 27.8 mmol/L; ketone was raised at 1.9 mmol/L but she was not in diabetic ketoacidosis. She had no dysmorphic features and no acanthosis nigricans. Her BMI was 26.1. Anti-GAD, anti-IA2, and anti-ZnT8 were negative. C-peptide level was high at 813 pmol/L. There is family history of type 2 diabetes (T2D). Results of her genetic testing for monogenic diabetes are awaited. Child had cataract surgery with lens implant in two stages and her vision improved significantly.

**Results:** The etiology of early cataract in children with diabetes is unknown. Several theories include osmotic damage to lens structure, polyol pathway, and oxidative stress. It is currently unclear what type of diabetes our patient has. Though she was ketotic on presentation, the negative autoantibody profile suggests she may not have Type 1 diabetes. T2D is a possibility given her high HBA1c, family history and raised BMI. Monogenic diabetes is not typically associated with cataracts. HNF1B (MODYS) mutation was recently linked with bilateral cataracts. In 2 other cases, patients with bilateral cataracts and negative autoantibodies had PRRC2A gene mutation and a de novo INS gene mutation.

**Conclusions:** New onset bilateral cataracts are rare in children and should raise suspicion of DM or other metabolic conditions.

**POSTER TOUR 25—EPIDEMIOLOGY & PATHOGENESIS # 1**

**P228** | A novel de novo mutation in a baby with Dend syndrome

J. Padmanabhan1; S.S Bhattacharyya1; B. Banerjee2

1Manipal Hospital, Pediatric Endocrinology, Bengaluru, India; 2Manipal Hospital, Pediatric Neurology, Bengaluru, India

**Introduction:** We report a case of a 4 month old infant girl, first born of a non-consanguineous marriage, diagnosed with mild global developmental delay and infantile spasms at 3 months of age.

**Objectives:** We report a case of a 4 month old infant girl, first born of a non-consanguineous marriage, diagnosed with mild global developmental delay and infantile spasms at 3 months of age.

**Methods:** We conducted a retrospective cross-sectional study of diabetes mellitus in children under the age of 16 over a 4-year period from January 2015 to December 2018.

**Results:** Baby had failure to thrive, microcephaly, and hypertonia. Her MRI brain was normal. She was on vigabatrin with recent addition of prednisolone and clonazepam in view of refractory seizures. Antenatally she had IUGR, weighing 2.3 kg at birth and required hospital stay for asymptomatic hypoglycemia and feed intolerance. At 4 months of life, she developed drowsiness, lethargy, and vomiting. On examination, she had signs of dehydration and hyperglycemia with a blood glucose of 590 mg/dl. Intravenous fluids were started for correction of dehydration followed by insulin infusion at 0.04 U/kg/h. HbA1c was 12.8% and urine ketones were positive. A preliminary diagnosis of neonatal diabetes mellitus was made. Peripheral blood samples of baby and parents sent for genetic work-up. After 24 h, she was switched to subcutaneous insulin at 0.8 U/kg/day. Blood glucose levels were achieved in the range of 100-140 mg/dl. On 3rd of day hospital stay, baby was found pale, listless and unarousable in the morning. Immediately, CPR was initiated and during intubation milk was found in airway suggestive of aspiration. Despite best efforts, baby could not be revived. A novel heterozygous missense mutation in exon 1 of KCNJ11 gene resulting in amino acid substitution of alanine for threonine at codon 171 (p.Thr171Ala) was found. Segregation analysis showed that both parents did not have this variant indicating that the mutation is de novo in origin.

**Conclusions:** KCNJ11 gene encodes pore forming subunit (Kir6.2) of ATP-sensitive potassium channel. Only 20% of the mutations are associated with a triad of developmental delay, epilepsy and neonatal diabetes mellitus, collectively called as DEND syndrome. This rare and severe form of neonatal diabetes often responds to sulfonylurea therapy, which also helps in control of seizures.

**P229** | Epidemiological profile of type 1 diabetes in children: about 1000 patients in children’s hospital of Rabat over 4 years

Z. Imane1, A. Khlifi1, A. Balafrej1

1UM5R, Children’s Hospital of Rabat, Rabat, Morocco

**Introduction:** Diabetes is a chronic disease that is a public health problem. Its gravity is related to its acute and chronic complications. In children, this disease is becoming more and more common, with serious repercussions on the quality of life of the child, his family and his current and future health.

**Objectives:** The objective of this study is to define the epidemiological profile of the population of diabetic children identified in the endocrine-diabetology service at the Children’s Hospital - Ibn Sina.

**Methods:** We conducted a retrospective cross-sectional study of diabetes mellitus in children under the age of 16 over a 4-year period from January 2015 to December 2018.
Introduction: Type 1 diabetes (T1D) is the most common metabolic disease in children. Its incidence has recently increased, especially in children under the age of 5 years. The type of breastfeeding and the timing of introduction of gluten are included among the modifiable risk factors of T1D.

Objectives: The objective of this study is to assess the duration of breastfeeding, as well as to assess the early use of milk. Infant and gluten in children with type 1 diabetes.

Methods: This is a retrospective study including 117 patients aged between 1 year and 15 years with T1D, followed in the endocrinology-diabetology department of the Mohammed VI University Hospital Center of Oujda, Morocco. Data collection was compiled from the clinical patient diary and statistical analysis was performed by SPSS version 21 software.

Results: The median age during diagnosis was 10.18 ± 4 years, with a sex ratio M/F: 0:9. A family history of T1D was found in 13% of the patients. 98.2% of our children with type 1 diabetes were breastfed, 50.4% were weaned before the age of 3 months. Breastfeeding was continued for 3 to 6 months in 35.8% and for 6 to 12 months in 25.6%. Furthermore, exclusive breastfeeding for 3 months was only successful in 17.09% of cases. The early introduction of formula milk before the age of 3 months was found in 69.23% of patients. Gluten exposure before the age of 4 months was observed in 2.56% of cases, between 4-6 months in 81.19%, and beyond 7 months in 16.23% of patients.

Conclusions: Despite controversies in the results of current studies regarding the role of breast milk in the development of type 1 diabetes, the promotion of breastfeeding should be encouraged especially in the first year of life.
Introduction: Children’s type 1 diabetes is a rare entity, its prevalence is still poorly known, which makes its diagnosis-therapeutic-management and prognosis increasingly difficult and uncodified.

Objectives: The purpose of our study is to report the experience of the Endocrinology-Diabetology-Nutrition-Department in the management of diabetes-type 1 in children.

Methods: This is a retrospective-descriptive study including 12 children hospitalized in the Endocrinology-Diabetology-Nutrition-Department for the management of diabetes diagnosed before the age of 24 months. All patients underwent a clinical examination and a biological check-up. The statistical analysis was performed with SPSS-Version 21-software.

Results: The average age was 24 ± 9.6 months, and 12 ± 6 months at diagnosis, with a clear male predominance, (sex-ratio M/F: 2:1). Consanguinity was present in only one case, diabetes in the family was present in 83.8% of cases. Reasons of hospitalization were various: 8 cases for inaugural diabetes (66.7%), and 4 cases for unbalanced diabetes (33%). Diabetes was revealed by an episode of ketoacidosis in 66.7% of the cases. Cardio syndrome was present in 83.3% of cases before diagnosis. Mean HBA1C was 10% ± 1.2%. Anti-GAD antibodies were positive in 50% of cases, and Anti IA2 antibodies were positive in 41.6% of cases. Only 58.3% of cases benefited from the rest of autoimmunity biological-analysis, we found anti-TPO antibodies positive in 1 case, and anti-transglutaminase antibodies positive in 2 cases. In terms of therapy, 50% of our patients were under basal bolus insulin therapy with rapid and long acting insulin analogs, and 50% was treated with Rapid acting insulin plus NPH twice daily, afterwards 3 patients benefited from the insulin pump therapy.

Conclusions: Nowadays the incidence of diabetes in infant is clearly increasing, it is a diagnostic emergency that requires urgent and specialized management, hence the need for a global awareness of the medical staff on the different ways of discovery.

P233 | Have we identified all the autoantibodies associated with diabetes? Cases of the isolated positive presence of autoantibodies to islet cells (ICA) in children with type 1 diabetes

A. Ochocinska1, J. Świderska2
1Children’s Memorial Health Institute, Department of Biochemistry, Radioimmunochemistry and Experimental Medicine, Warsaw, Poland, 2Children’s Memorial Health Institute, Department of Endocrinology and Diabetology, Warsaw, Poland

Introduction: Autoantibodies to specific beta-cell antigens of the pancreatic islets are characteristic for pathogenesis of type 1 diabetes mellitus (T1D). ICA test that detects the presence of a group of polyclonal autoantibodies against all pancreatic beta cells (α, β, δ and PP cells). In recent years, there has been a tendency to replace the ICA test with the measurement of autoantibodies against biochemically defined pancreatic islet antigens: glutamic acid decarboxylase (GADA), protein tyrosine phosphatase (IA-2A), zinc transporter (ZnT8A) and insulin (IAA). The isolated positive presence of ICA despite negative results for GADA, IA2A, ZnT8A, and IAA suggests.

Objectives: Isolated positive presence of ICA despite negative results for GADA, IA2A, ZnT8A, and IAA was checked.

Methods: Laboratory results of 800 patients diagnosed for T1D in The Children’s Memorial Health Institute from January 2020 to April 2022 (460 girls, 340 boys) aged 3 to 18 (mean age 8 ± 2 years) who were to have a complete set of lab tests: glucose, c-peptide, ICA, GADA, IA2A, ZnT8A were analyzed retrospectively. Both ICA and specific autoantibodies were analyzed in all samples using manual tests (RIA or ELISA) by MedipanGMBH, Dahlewitz, Germany.

Results: Isolated positive results for ICA were observed in 38 cases (4.75%) of 800 analyzed patients. Most of the ICA screening positive patients were positive for multiple antibodies, with 624 children (78%) positive for both GADA and IA2A and 408 children (51%) positive for the three autoantibodies (GADA, IA-2A and ZnT8A). Insulin autoantibodies (IAA, measured by radioimmunoassay) were positive in 13 patients (1.6%).

Conclusions: The discovery of an isolated positive ICA result despite negative results for GADA, IA-2A, ZnT8A and IAA may suggest the existence of another, as yet unidentified, self-antigen or self-antigens. Therefore, ICA testing appears to be still important for children and adolescents diagnosed for T1D who would otherwise be negative for specific islet autoantibodies.

P234 | Combined SPINK1 mutations induce early onset severe chronic pancreatitis in a morbidly obese child

M. Abassi1, A. Al Shamsi2, A. Deeb3
1SSMC Pediatrics Residency Program/Pediatric Endocrinology Division, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates, 2Clinical Genetics Department, Tawam Hospital, Al Ain, United Arab Emirates, 3College of Medicine and Health Sciences, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates

Introduction: The most frequent causes of pancreatitis classically is gallstones or alcohol. Although underlying genetic mutation can have severe disease with high morbidity rate and frequent hospitalization.

Objectives: To illustrates the importance of diagnosing the underlying genetic mutation in the absence of other known causes of pancreatitis.

Methods: A14 years old female, presented with severe abdominal pain at the age of 7 years and was diagnosed with acute pancreatitis. She used to be admitted 3 times /year with severe epigastric, right hypochondriac pain radiating to the back with nausea and vomiting, receiving conservative management. She is obese since she was 2.5 years. At the age of 12 years was diagnosed with type 2 diabetes on metformin. Consanguineous parents but no family history of pancreatitis, diabetes, or obesity. Her younger sister has a global developmental delay with undiagnosed underlying etiology.
7-year incidence of diabetic ketoacidosis at type 1 diabetes onset in children

K. Dzięgat1, M. Dymierska1, E. Kowalczyk-Korzec1, A. Kowalska1
1Medical University of Warsaw, Department of Pediatrics, Warsaw, Poland

Introduction: The signs and symptoms of type 1 diabetes (T1D) in children usually develop quickly. The presence of diabetic ketoacidosis (DKA) is predominantly a consequence of delayed initiation of insulin therapy. Determining the incidence of DKA is important for further attempts to prevent this life-threatening complication.

Objectives: The aim of the study was to evaluate the frequency of DKA at the onset of T1D in children over a 7-year period in a large regional center.

Methods: We collected data of children with newly diagnosed T1D diagnosed in our department between 2015 and 2021. DKA was defined according to ISPAD 2018 guidelines. The study cohort comprised 1243 children (54.9% boys) with diabetes mellitus, but has several disadvantages as I.V. injection of insulin results in inactivation by proteolytic enzymes in liver, frequent hyperglycemia & hypoglycemia, local reactions like swelling, erythema.

Objectives: The aim of present work was to prepare a biodegradable system to deliver insulin through Concanavalin-A (Con-A) anchored PEGylated-PLGA nanoparticles, which would possibly, lead to enhance stability of system; prolong insulin fate in blood & enhance oral bioavailability of insulin by enhancing its lymphatic uptake using targeted approach.

Methods: PLGA Nanoparticles were prepared by Double Emulsification Method. Insulin loaded nanoparticles were characterized in-vitro for conjugation efficiency with ligand, entrapment efficiency, & stability. Studies like x-ray diffraction, differential scanning calorimetry, & integrity of entrapped insulin was assessed using circular dichroism spectrum & in-vitro lig & agglutination assay.

Results: Ex-vivo study was performed, which exhibited higher intestinal uptake of Con-A conjugated nanoparticles. System was found to be effective in protecting drug in GIT environment & with good release profile. In-vivo studies suggested that developed system lowered blood glucose levels within a safer limit over prolonged duration of action.

Conclusions: The developed nanoparticulate system can be a promising drug delivery carrier for oral insulin delivery in treatment of diabetes. Targeted approach led to better uptake of system & increasing oral bioavailability of drug as inferred from blood glucose profile, additionally it also prolongs circulation time due to PEG attachment. Thus the potential for use developed system as oral drug delivery system can be further investigated.

Characteristics and presentation at diagnosis of familial type 1 diabetes in Kuwait

D. Khalifa2, T. Alqaisi1, F. Othman1, F. Al-Juailla1, D. Al-Abdulrzaqa1,3, H. Al-Kandari1,4

1United Institute of Pharmacy, Pharmacy, Allahabad, India
Introduction: Research on familial type 1 diabetes (FT1D), which is divided into parent–child and sibling-pair subgroups, in comparison to sporadic T1D (ST1D), is limited globally and in Kuwait, considering the high incidence rate.

Objectives: To evaluate the baseline features at onset in FT1D vs ST1D in Kuwaiti children.

Methods: Children aged 14 years diagnosed with T1D between 2011 and 2021 were included. FT1D was defined as having an affected father and/or affected mother and/or affected sibling. ST1D was defined as having no first-degree relatives with T1D.

Results: Over the 10-year period, 1734 patients with T1D were included. 18.74% had FT1D, and 81.26% had ST1D. Around 3% (n = 65, 3.75%) had an affected father, 2.31% (n = 40) had an affected mother, 11.19% (n = 194) had an affected sibling, and 1.50% (n = 26) had two or more affected family members. ST1D presented with DKA at a higher rate compared to FT1D (39.0% vs. 23.4%; p-value < 0.001). Children with an affected father were more likely to present with DKA compared to the other groups, and were close to those diagnosed with ST1D (affected father 31.25%, affected mother 15.38%, affected sibling 22.92%, ≥2 affected family members 19.23%; ST1D 39%, p-value < 0.001). There was no significant difference between both groups regarding age at onset, gender distribution, and PICU admission. A statistical, but not clinical, significant difference was found between HbA1c values across the groups (ST1D 11.4%, affected father 10.6%, affected mother 9.65%, affected sibling 10.5%, ≥2 affected family members 10.3%; p-value = 0.001). FT1D group was at a lower risk of presenting with DKA at onset.

Conclusions: This is the first study in Kuwait to review the features of FT1D and ST1D among Kuwaiti children. FT1D is associated with a lower risk of DKA. Children with an affected father were more likely to present with DKA compared to other familial groups. Further studies are needed to better understand the role of family history of diabetes on the natural course, disease management, and outcomes.

P240 | The status of type 1 diabetes in children, UAE Eastern Region

W. Kaplan1, L. Al Oum2
1Tawam Hospital, Pediatrics, Al Ain, United Arab Emirates, 2Tawam Hospital, Al Ain, United Arab Emirates

Introduction: Type 1 diabetes mellitus (T1DM) accounts for the majority of newly diagnosed diabetes in children, and it is known to be globally under-controlled; several factors have been linked to diabetes control. No one has looked at this data in the UAE Eastern Region.

Objectives: Explore Patients’ demographic, level of diabetes control, associated comorbidities, and correlation between diabetes control and potential factors.

Methods: Data collection for patient ≤18 years with T1DM between January 2008 and June 2021. We analyzed patients’ demographics, DKA at presentation, insulin regimen, method of glucose monitoring, other autoimmune comorbidities and diabetes complications. HbA1c was compared across demographics, insulin regimen, and glucose monitoring.

Results: Out of the 243 eligible patients, 63% were Emiratis, 54% female, and 18% had positive history of T1DM in 1st degree relatives. Mean age at presentation was 6.6 ± 3.9 years, and the duration of diabetes was 5.2 ± 3.7 years. Autoantibodies were positive in 76% of patients, and 33% first presented with DKA.

HbA1c at presentation was 11.06 ± 2.30%, and the most recent was 8.64 ± 1.58%. HbA1c increased linearly from the end of 1st year to the last year. 65% of the patients were on MDI and 35% on CSII. Glucose monitoring was done by isCGM, SMBG, and CGM in 48%, 33%, and 19% of the patients, respectively. Autoimmune comorbidities and diabetes complications were found in 32% and 5.3% of the patients, respectively.

Males, prepubertal patients, and Non-UAE Nationals had lower Hba1c while no difference was seen between MDI and CSII or between SMBG, CGM, and isCGM groups. Frequency of glucose monitoring was associated with lower Hba1c. Finally, positive history of T1DM in 1st degree relatives correlated with a higher HbA1c.

Conclusions: T1DM is under-controlled in children in UAE Eastern Region. Age, gender, nationality, and presence of other household members with T1DM correlated with HbA1c level, while treatment regimen and method of glucose monitoring showed no correlation.

P241 | Plasma 25-Hydroxyvitamin D in children with celiac disease, type 1 diabetes, and with both celiac disease and type 1 diabetes compared with healthy subjects

M. Marino1, T. Galeazzi2, S. Gatti2, R. Gesuita3, V. Cherubini4, C. Catassi5, E. Lionetti2
1AOU Ospedali Riuniti, G. Salesi Hospital, Children and Motherhood Department, Pediatric Diabetology Unit, Ancona, Italy, 2Marche Polytechnic University, Department of Pediatrics, Ancona, Italy, 3Marche Polytechnic University, Interdepartmental Center of Epidemiology, Biostatistics and Medical Informatics (EBI Center), Ancona, Italy

Introduction: Vitamin D deficiency has been observed in celiac disease (CD) diagnosis and in type 1 diabetes (T1D) onset in previous studies.
**Objective**: To evaluate the vitamin D status of children with newly diagnosed CD, children with T1D at onset, and children with both CD and T1D.

**Methods**: In this cross-sectional study, we recruited 3 groups of children and adolescents with CD, T1D, both CD&T1D. Healthy school children screened during a prevention campaign for CD were enrolled as control group (CC). Plasma 25-hydroxyvitamin D was measured as the index of vitamin D nutritional status. Kruskal-Wallis test was used to compare the groups. The association of vitamin D levels with health conditions and the season of vitamin D measurement was analyzed by a multiple linear regression model.

**Results**: Overall, 393 children were included: 131 CG, 131 CD, 109 T1D, and 22 CD&T1D. The distributions of vitamin D levels in the four groups is shown in Figure 1. Children with CD, with T1D, or with both the diseases had significantly lower levels of vitamin D than controls. Vitamin D values were significantly higher in summer and in autumn than in winter and spring in healthy children, as expected, while no significant differences were observed in the presence of CD and/or T1D. Results of multiple regression analysis showed that T1D and CD&T1D groups on average had lower vitamin D levels than healthy children. Children with CD and with T1D also had significantly lower mean vitamin D values in summer and in autumn than CC in the same seasons (Table 1).

**Conclusions**: Our study shows that vitamin D is lower in children with CD or T1D as compared with healthy children, particularly in the most sun-exposed seasons. These findings support the hypothesis that vitamin D deficiency is associated with these both autoimmune diseases. Further studies are required to investigate if Vitamin D deficiency plays a role in the pathogenesis of these diseases.

**Table 2. Association of Vitamin D with health conditions and seasons**

<table>
<thead>
<tr>
<th></th>
<th>Regression coefficients</th>
<th>95% CI</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intercept</td>
<td>24.0</td>
<td>21.1;26.9</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Summer</td>
<td>14.4</td>
<td>9.7;19.1</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Autumn</td>
<td>16.5</td>
<td>12.5;20.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CD in summer</td>
<td>-14.6</td>
<td>-21.2;-8.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>T1D in summer</td>
<td>-11.1</td>
<td>18.0;-4.2</td>
<td>0.002</td>
</tr>
<tr>
<td>CD in autumn</td>
<td>-15.9</td>
<td>-21.6;-10.2</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>T1D in autumn</td>
<td>-9.9</td>
<td>-16.0;-3.8</td>
<td>0.002</td>
</tr>
</tbody>
</table>

Note: Multiple linear regression analysis. $R^2 = 0.43$.

Abbreviations: CC, controls; CD, celiac disease; T1D, Type 1 diabetes.

**P242 | Cases series: A description of clinical phenotypes and metreleptin effects in congenital generalized lipodystrophy**

L. Aletani¹, A. Alsaghir¹
¹King Faisal Specialist Hospital and Research Center, Pediatric Endocrine, Riyadh, Saudi Arabia

**Introduction**: Congenital generalized lipodystrophy (CGL) also known as berardinelli-seip congenital lipodystrophy, it is a rare genetic disorder characterized by the partial or total loss of adipose tissue and has a distinctive physical appearance of lipodystrophy, its classified into four types which are distinguished by their genetic cause. Most of the cases diagnosed at birth or soon thereafter, insulin resistant and hypertriglyceridemia is an associated metabolic complication related to CGL.

**Objectives**: A description of clinical phenotypes and metreleptin effects in Congenital generalized lipodystrophy.

**Methods**: Case series enrolled seven patients of pediatric age group.

**Results**: Case serious presentation: we report seven cases of pediatric age group with CGL all patients were presented with features of lipodystrophy (loss of subcutaneous tissue and Masculinization of body), we performed genetic analysis on all our patients, six was confirmed with genetic mutations and one has all the characteristics feature and complications without underlying genetic mutation. Five out of seven were diagnosed in first year of life, and the other two one after two year of age, and one after three year of age. All patients complicated with hypertriglyceridemia four of them at same year of diagnosis and two with diabetes mellitus which required insulin therapy, Four of them started on metreleptin were showed significant improvement in their clinical manifestations.

**Conclusions**: Loss of subcutaneous tissue is consistent and a key diagnostic feature of lipodystrophy so as reported cases are increased worldwide, more recognition and early detection are emphasized, in order to early initiation of treatment and prevent associated metabolic disturbance. While seems Metreleptin is the only medication has been effective treatment on CGL.
Introduction: Berardinelli-Seip congenital lipatrophy (BSCL) is characterized by near total fat atrophy since birth, associated with the progressive development of metabolic complications. The most common are diabetes, severe hypertriglyceridemia, acute pancreatitis, hepatic steatosis, and hepatomegaly, which are usually detected during infancy and adolescence; other features include muscle pseudo-hypertrophy and acromegaloïd appearance, umbilical hernia, polycystic ovary syndrome, cysts in the appendicular bones, cardiopathies, and cardiac rhythm disorders.

Objectives: We report a case of APS II that developed in a patient with sickle cell disease after allogeneic bone marrow transplant (BMT).

Methods: Our patient, presented in endocrine clinic at 8 years of age due to polyuria and polydipsia and not gaining weight, diagnosed as diabetes mellitus, started on insulin and oral hypoglycemics. At 12 years of age, presented with severe abdominal pain and vomiting and diagnosed as acute pancreatitis. At 22 years of age she again presented due to absence of menarche. On examination, she has coarse acromegaloïd facies, prominent supraorbital ridge, hollowing of cheeks, progonatism with dry thick hairs. She had large hands and feet with muscular hypertrophy in upper and lower limbs. She had acanthosis nigricans, umbilical hernia, hepatomegaly. SMR stage shows Breast stage I, pubic hair stage II, mild citoromegaly.

Results: Investigations show HbA1c 8%, deranged LFTs with hypercholesteremia and hypertriglyceridemia. USG abdomen shows Fatty hepatomegaly. Later on genetic test came out to be BSCL2 gene consistent with Berardinelli-Seip Syndrome. Treatment includes Insulin 8 U/kg/day and Poiglitazone, low fat diet, fish oil, statins.

Conclusions: Our diagnosis is Congenital lipatrophy syndrome, with associated consequences like diabetes mellitus, nonalcoholic steatohepatitis (NASH), delayed puberty and pancreatitis.

P245 Evolution and determinants of glycemic control in children and adolescents with type 1 diabetes in Belgium: A 10-year period observational real-world study

S. Chao1, D. Beckers2, K. Casteels3, M. Den Brinker4, S. Depoorter5, L. Doms6, D. Klink7, M.-C. Lebrethon8, K. Logghe9, J. Louis10, P. Lysy11, N. Seret12, G. Smeets13, T. Tenoutasse14, S. van Aken15, J. Vanbesien16, V. van Elshocht17, A.-S. van Herwegen1
1Sciensano, Belgian Scientific Institute of Public Health, Epidemiology and Public Health, Anderlecht, Belgium, 2CHU de Mont-Godinne, Yvoir, Belgium, 3UZ Leuven, Louvain, Belgium, 4UZ Antwerpen, Antwerp, Belgium, 5AZ Sint-Jan, Bruges, Belgium, 6ziekenhuis maas en Kempen, Maastricht, Belgium, 7ZNA Middelheim, Anvers, Belgium, 8CHR de la Citadelle, Liège, Belgium, 9AZ Delta, Roulers, Belgium, 10Grand Hôpital de Charleroi, Charleroi, Belgium, 11CHU Saint-Luc, Bruxelles, Belgium, 12Cliniques Saint-Joseph, Liège, Belgium, 13Jessa Ziekenhuis, Hasselt, Belgium, 14HUERF, Bruxelles, Belgium, 15UZ Gent, Gand, Belgium, 16UZ Brussel, Bruxelles, Belgium, 17INAMI, Bruxelles, Belgium

Introduction: Since 2008, all Belgian pediatric diabetes centers (PDCs) participate to a biennial audit/feedback, allowing to monitor the quality of care given in PDCs and to describe clinical and demographic characteristics of young patients with type 1 diabetes (T1D) on a national level.

Objectives: Here we present the evolution of the hemoglobin A1c (HbA1c) between 2008 and 2019 and investigate the determinants of HbA1c among children and adolescents with T1D.
Methods: Data were cross-sectionally and retrospectively collected between 2008 and 2019 from all Belgian PDCs (N = 16). The evolution over time of HbA1c was investigated on a continuous scale with generalized estimating equations (GEE). The association of HbA1c with age, gender, diabetes duration, presence of nuclear family, parent ethnicity, presence of a communication problem with the medical team, and insulin regimen were studied using GEE and Tukey–Kramer tests, as was the presence of psycho-social distress in the 2019 dataset.

Results: The number of patients with T1D (age 1–18 years) varied from 1948 in 2008 to 3777 in 2019. There was a linear decrease in HbA1c of 0.026 ± 0.008 percentage points per year on average: from 63 mmol/mol (7.9%) in 2008 to 60 mmol/mol (7.7%) in 2019 (P < 0.0001, adjusted for gender, age and diabetes duration). In 2019, the oldest patients (aged between 16–18 years), patients with the highest diabetes duration (>8.25 years), not living in a nuclear family, with two parents of non-Caucasian ethnicity (versus having at least one parent of Caucasian ethnicity) or having psychosocial distress had higher HbA1c compared to the other groups (P < 0.0001, adjusted for gender, age and diabetes duration). The presence of a communication problem was also associated with higher HbA1c, although less pronounced (P < 0.05, adjusted for gender, age and diabetes duration).

Conclusions: Our data shows that glycemic control improved over the past 11 years, but several subgroups still have high HbA1c levels. These subgroups may have a higher risk for developing long-term complications and deserve particular attention.

P246 | Predictive factors of good metabolic control in children with type 1 diabetes

Z. Imane¹, L. Saadaoui¹, A. Balafrej¹
¹UMSR, Children’s Hospital of Rabat, Rabat, Morocco

Introduction: The management of children with type 1 diabetes has been revolutionized first by the discovery of insulin and then by the development of new technologies. Nevertheless, the majority of patients still do not reach their glycemic target.

Objectives: The main objective of this study is to determine the predictive factors of good metabolic control in children with type 1 diabetes, in order to develop tailored approaches to improve the quality of management and prevent disease-related complications.

Methods: Prospective analytical and descriptive study spread over 6 years from January 2015 to January 2021 including type 1 diabetic children diagnosed between 2015 and 2019 and followed up at the “Maison du jeune diabétique” in collaboration with the diabetes department of the children’s hospital (P2). Clinical and epidemiological data were obtained from patient records and theFreediab database.

Results: The number of patients meeting the inclusion criteria was 542.A mean HbA1C in the target range was associated in bivariate analysis with patient age (p = 0.003), parental socioeconomic and academic level (p = 0.001), adhesion to health coverage (p = 0.001), initial HbA1C value (p = 0.001), number of self-monitoring of blood glucose (p = 0.001), and treatment regimen (p = 0.001). In multivariate analysis, the association was statistically significant for 5 parameters: socioeconomic level (β 0.10; 95%CI 0.10–0.26; p = 0.03), parents’ academic level (β 0.15; 95%CI 0.24–0.5; p = 0.002), adhesion to health coverage (β 0.12; 95%CI 0.18–0.46; p = 0.001), initial HbA1C level (β 0.16; 95%CI 0.15–0.38; p < 0.001) and number of self-monitoring of blood glucose (β 0.46; 95%CI 0.21–0.3; p < 0.001).

Conclusions: Our study demonstrates parameters related to good glycemic control that need to be taken into account to develop new management strategies for children with type 1 diabetes.

P247 | Rituximab role in preservation of pancreatic beta cells in patients newly diagnosed with type 1 diabetes mellitus: A report of 2 Palestinian cases

H. Eida¹, A. Mansour¹, T. Eleyan¹
¹Palestine Medical Complex, Ramallah, Palestine

Introduction: Type 1 diabetes mellitus (T1DM) is a condition caused by the clonal generation of autoantibodies by B cells. Rituximab, an immunosuppressive agent, has been shown in studies to protect pancreatic function in individuals newly diagnosed with type 1 diabetes mellitus (T1DM).

Objectives: We investigated the effects of rituximab in preserving beta cells function in two individuals with newly diagnosed T1DM.

Methods: For all cases, in order to be started on rituximab for the inhibition of the immune system and guard against pancreatic cell destruction, lab tests were done and were negative for both tuberculosis (TB) and Hepatitis B (Hep B). Premedications were given which included acetaminophen, antihistamine and corticosteroid, then 375 mg/m² of rituximab was administered four times at one-week intervals.

Results: In Case 1, HbA1c levels showed a significant drop on the same drugs and then steadily increased until returning to pre-rituximab levels 1 year later. In Case 2, however, HbA1c remained below 6.5% for 8 months following therapy and was below 7% after the second Rituximab dose. Both patients were administered a second Rituximab dose 1 year after the first one. While the second case remained on the same medications for maintenance of HbA1c, the first case was able to be maintained on just long-acting insulin without the need for the short-acting as before.

Conclusions: Rituximab as an immunosuppressive agent was able to protect pancreatic cells in patients with T1DM. However, the duration of effectiveness is variable.
POSTER TOUR 27—DIABETES NEW & ADJUNCTIVE TREATMENT AGENTS

P248 | Glycemic control with ultra-rapid lispro (URLi) versus lispro in children and adolescents with T1D: PRONTO-peds

1Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, United States, 2Joslin Diabetes Center, Harvard Medical School, Boston, United States, 3CPLIC/DASA Clinical Research Center, São Paulo, Brazil, 4Eli Lilly and Company, Indianapolis, United States

Introduction: URLi is a formulation developed to match physiological insulin secretion and improve PPG control. In a pooled analysis comparing pharmacokinetics and pharmacodynamics between URLi and lispro following subcutaneous injection, URLi showed better results compared with lispro.

Objectives: This phase 3, treat-to-target study evaluated efficacy and safety of URLi versus lispro in 716 pediatric patients (pts) with type 1 diabetes (T1D).

Methods: After 4-week lead-in to optimize basal insulin, pts were randomized to double-blind URLi (n = 280) or lispro (n = 298) injected 0–2 min prior to meals, or open-label URLi (n = 138) injected up to 20 min after meals (URLi+20). Pts remained on prestudy basal insulin (degludec, detemir, or glargine). Primary endpoint was HbA1c change from baseline after 26 weeks.

Results: Noninferiority was shown in HbA1c change with URLi vs lispro: estimated treatment difference (ETD) -0.02% (95% CI -0.17, 0.13) and with URLi+20 vs lispro: ETD -0.02% (95% CI -0.20, 0.17). Postprandial glucose (PPG) measured by self-monitored blood glucose (SMBG) was lower with URLi vs lispro 1 h after breakfast (p < 0.001) and dinner (p = 0.006). URLi significantly reduced 1 h postmeal glucose daily mean versus lispro.

Conclusions: In children and adolescents with T1D, URLi demonstrated similar overall glycemic control and greater PPG lowering with an acceptable safety and tolerability profile compared with lispro. When dosed at the start of meals, URLi showed noninferiority for HbA1c change from baseline versus lispro and lower PPG and 1 h postmeal glucose daily mean versus lispro.

P249 | Effect of BCG vaccination on immune-regulatory markers and glycemic control in children with new-onset type 1 diabetes mellitus (T1DM): A randomized double-blinded placebo-controlled pilot trial

A. Babbar1, R. Kumar2, A. Rawat1, N. Sachdeva2, B. Bharti1, S. Gupta1, J. Yadav1, D. Dayal1
1Postgraduate Institute of Medical Education and Research, Chandigarh, Department of Pediatrics, Advanced Pediatrics Center, Chandigarh, India, 2Postgraduate Institute of Medical Education and Research, Chandigarh, Department of Endocrinology, Chandigarh, India

Introduction: Upregulation of induced T-regs (iT-regs) and selective killing of the auto-reactive T cells has been postulated to occur after BCG vaccination. A few clinical trials have shown the effect of BCG on C-peptide secretion glycemic control.

Objectives: To study the effect of 2 doses of BCG vaccination on immune-regulatory markers and glycemic control in patients with Type 1 Diabetes (T1D).

Methods: A single-center, double-blinded, randomized placebo-controlled pilot trial was conducted over one-and-a-half-year on 40 children (2–12 years) with new-onset T1D. Children were randomized 1:1 into BCG and Placebo groups. In the BCG group, children received BCG vaccine 0.1 ml intradermally (2 doses, 1 month apart).

Table 1. Comparison of outcome parameters in the two groups at the end of 6 months (Per-Protocol Analysis)*

<table>
<thead>
<tr>
<th>Outcome parameters median (IQR)</th>
<th>BCG group (n = 17)</th>
<th>Placebo group (n = 17)</th>
</tr>
</thead>
<tbody>
<tr>
<td>iTregs (%) (CD3+ CD4+ CD25+ Foxp3+)</td>
<td>1.65 (0.93–2.81)</td>
<td>1.74 (1.2–2.35)</td>
</tr>
<tr>
<td>Plasma IL-17 (pg/ml)</td>
<td>14.3 (12.89–14.53)</td>
<td>13.79 (12.1–14.95)</td>
</tr>
<tr>
<td>Plasma TNF-Alpha (pg/ml)</td>
<td>16.21 (16.07–16.39)</td>
<td>16.18 (16.02–16.52)</td>
</tr>
<tr>
<td>Serum GAD 65 antibody (U/ml)</td>
<td>27.8 (15.8–30.19)</td>
<td>20.84 (15.3–27.72)</td>
</tr>
<tr>
<td>Serum IA 2 antibody (U/ml)</td>
<td>11.34 (11.2–6.52)</td>
<td>11.41 (11.29–8.94)</td>
</tr>
<tr>
<td>Serum IAA antibody (U/ml)</td>
<td>10.84 (7.04–13.4)</td>
<td>7.88 (6.56–9.57)</td>
</tr>
<tr>
<td>Plasma HbA1c (%)</td>
<td>7.5 (6.8–8.7)</td>
<td>7.5 (7.2–10)</td>
</tr>
<tr>
<td>Plasma HbA1c (mmol/mol)</td>
<td>58 (51–72)</td>
<td>58 (55–86)</td>
</tr>
<tr>
<td>Plasma C-peptide (mmol/L)</td>
<td>0.073 (0.026–0.122)</td>
<td>0.113 (0.050–0.334)</td>
</tr>
</tbody>
</table>

*BCG vaccination was administered to children with new-onset type 1 diabetes mellitus.
The placebo group received 0.1 ml of normal saline intradermally. The 2 groups were compared at the end of 6 months for the percentage of induced regulatory T cells (iT-regs) in blood, serum IL10, IL-17 and TNF-alpha levels, serum titres of pancreatic autoantibodies, and various glycemic control parameters.

**Results:** No significant difference was seen in the immune-regulatory markers in median (IQR) of IL-10, IL-17 and TNF-alpha and GAD-65, IA2 and IAA in the two groups at the end of 6 months. There was a higher reduction of HbA1c (p-value; 0.421) and lesser fall of C-peptide (p-value; 0.496) in the BCG group. The average fasting and random blood sugar and median total/basal/bolus insulin dose did not vary significantly between the two groups at 6 months.

**Conclusions:** BCG does not significantly improve immune-regulatory markers and glycemic control among children with new-onset T1DM who have been vaccinated at birth.

---

**Introduction:** Diabetes mellitus is an inherited, chronic disorder in the endocrine system that constitutes a main public health problem all over the worldwide.

**Objectives:** The present study investigated the impact of zinc oxide nanoparticles (ZnONPs) on serum parameters of renal function, on oxidative stress markers (malondialdehyde [MDA] and 8-isoprostane), and on expression level of insulin receptor, glucose transporter 2 (GLUT2), glucokinase genes and heat-shock proteins (HSPs) in rats.

**Methods:** Male Wistar rats (n = 64, 10 weeks old) were divided into four groups. Group 1 received a standard diet (12% of calories as fat). Group 2 received a standard diet, plus ZnONPs; received a single daily oral dose of ZnONPs of 100 mg/kg in suspension. Group 3 received a high-fat diet (40% of calories as fat) for 2 weeks, and was then injected with streptozotocin (STZ) on day 14 (STZ, 40 mg/kg intraperitoneally). Group 4 was treated in the same way as group 3 (HFD/STZ), but was supplemented with ZnONPs 100 mg/kg body weight/day. Oxidative stress in the kidneys of diabetic rats was evidenced by an elevation in levels of MDA and 8-isoprostane. Protein concentrations of insulin receptor, GLUT2, glucokinase genes and heat-shock proteins (HSP60 and HSP70) in renal tissue were determined by Western blot analyzes.

**Results:** ZnONPs supplementation lowered kidney concentrations of MDA, 8-isoprostane levels, serum urea-N, and creatinine, and reduced the severity of renal damage in the STZ-treated group (i.e., the
P251  |  Promoting adolescents' engagement in diabetes clinic encounters: Results from an RCT


1Trinity College Dublin, School of Nursing and Midwifery, Dublin, Ireland, 2University of North Carolina at Chapel Hill, Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, Chapel Hill, United States, 3Trinity College Dublin, School of Medicine, Dublin, Ireland

Introduction: This paper presents the results of a pilot randomized controlled trial of a co-designed intervention, which sought to empower adolescents’ understanding and successful management of their T1D.

Objectives: To conduct a pilot randomized controlled trial to test the effectiveness of a diabetes educational video with a question prompt list to increase adolescents’ question-asking and doctors’ education during clinic encounters.

Methods: Adolescents ages 11 to 17 with type 1 diabetes and their parents were enrolled from two urban pediatric clinics. Adolescents were randomized to the intervention or usual care groups. All participants completed surveys (Self-Efficacy for Diabetes Management Scale (SEDM), Self-Management of Diabetes – Adolescents Scale (SMOD-A), Participatory Decision-Making Scale (PDM)), their HbA1c recorded, and consultations audio-recorded at three clinic appointments. The intervention group also completed a QPL and watched an educational video on a tablet with their parents before meeting their doctor and completed a short evaluation after the consultation. Data were analyzed with SPSS (v 27). Ethical approval was obtained.

Results: A 35 doctors and 99 adolescents participated. The intervention group were significantly more likely to be engaged and ask more questions than the adolescents in the usual care group. Doctors were significantly more likely to educate the intervention adolescents group. There were no significant differences between the intervention and usual care group in relation to HbA1C, self-efficacy, self-management of diabetes, and participatory decision-making.

Conclusions: This pilot RCT demonstrated that the intervention influenced adolescents’ question asking and provider education in diabetes encounters. Adolescence is often a precarious period characterized by worsening HBA1c and disengagement with self-management; hence, it is essential that we find innovative ways to engage adolescents actively in healthcare encounters.

P252  |  Time limited eating in new-onset type 1 diabetes: Feasibility, acceptability, and effect on β-cell function

C. Berman1, A. Vidmar1, B. Miyazaki1, J. Raymond1

1Children’s Hospital Los Angeles, Endocrinology, Los Angeles, United States

Introduction: Time limited eating (TLE) improves β-cell responsiveness, decreases insulin resistance, lowers fasting glucose, and increases time in range on continuous glucose monitor (CGM) in adults with type 2 diabetes.

Objectives: The current study aims to evaluate TLE in pediatric type 1 diabetes (T1D), implemented within 6 months post-diagnosis. This period finds residual β-cell function, during which TLE may preserve and improve β-cell activity.

Aim (1) Assess feasibility, acceptability, and safety of TLE.

Aim (2) Test effectiveness of TLE on β-cell function, insulin sensitivity, and glucose utilization.

Aim (3) Test impact of TLE on glycemic control.

Methods: A randomized controlled trial of up to 40 youth aged 12–25 years with new-onset T1D will be conducted at an urban children’s hospital. Subjects will be randomized to either intervention (8-h feed/16-h fast) or control group (12-h feeding window) for an 8-week period. Feasibility and acceptability will be evaluated using questionnaires, weekly check-ins, and intervention adherence. Safety will be reviewed by frequency of hypoglycemia. β-cell function will be evaluated by mixed meal tolerance test (MMTT) with C-peptide levels. Glycemic control will be evaluated by percent of total time in range (TIR 70–180 mg/dl) on CGM and HbA1c. Mean change in data will be compared between baseline and post-intervention across study conditions.

<table>
<thead>
<tr>
<th></th>
<th>Without AGI (14 days)</th>
<th>With AGI (14 days)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean TIR (time in range)</td>
<td>48%</td>
<td>63%</td>
</tr>
<tr>
<td>Mean TBR (time below range)</td>
<td>20%</td>
<td>12%</td>
</tr>
<tr>
<td>Mean TAR (time above range)</td>
<td>32%</td>
<td>25%</td>
</tr>
</tbody>
</table>

Note: P value of TIR is <0.05; suggesting significant improvement.
groups. Two-sample t-tests will be used to compare (a) area under stimulated C-peptide curve, and (b) change in %TIR between groups. Multiple regression analysis using a linear mixed model will be utilized to account for covariates.

Results: Based on 2021 data, we anticipate 80 eligible youth with T1D. A 32% female, 74% English speaking, 62% public insurance, 40% Latin-X. This study has been approved by the institutional review board and recruitment is underway.

Conclusions: To our knowledge, this is the first study of TLE in youth with T1D and has the potential to change management of T1D by incorporating meal timing early in diagnosis.

P253  |  Effect of AGI on time in range (TIR) in T1D

T. Vyas1, B. Saboo2, K. Chennamsetti2, M. Saiyed2, N. Joshi3, J. Khedawala2, H. Nayak4, K. Patel5
1 Diacare-Diabetes Care and Hormone Clinic, Diabetology, Ahmedabad, India, 2 Diacare-Diabetes Care and Hormone Clinic, Ahmedabad, India, 3 GCS Medical College, Ahmedabad, India, 4 LG Hospital, Ahmedabad, India, 5 BJ Medical College, Ahmedabad, India

Introduction: AGIs lower the blood glucose levels by modifying the intestinal absorption of carbohydrates. AGI may play a role as a part of combination regimen in people who consume high carbohydrate diet and have high postprandial glucose levels as long as GI side effects are tolerated. Carbohydrates form a major portion of Indian meals.

Objectives: To study the effect of AGI (Acarbose) on glycemic variability by analyzing AGP (Libre pro) data of persons with T1D.

Methods: Consent from EC was taken.20 persons aged 12-18 years with Type 1 diabetes having post meal excursions and variability who developed hypoglycemia on increasing bolus doses were enrolled. These persons with put on AGP (Libre pro) twice consequently. In the first 14 days they are just on basal bolus insulin and in the next 14 days period they were also prescribed AGI (Acarbose) thrice a day (with breakfast, lunch and dinner). Both the AGP data was analyzed to compare the post meal sugar control offered by AGI.

Exclusion criteria:
- BMI < 18
- HBA1c > 10
- Persons having pre-existing GI issue, diabetic nephropathy

Conclusions: AGI significantly helps in controlling post meal sugars as analyzed from AGP data. Additionally, insulin bolus dose requirements also decreased.

P254  |  DKA with severe hypertriglyceridemia in a toddler boy: A rare presentation

F. Memon1, M. Arif2, M. Haider3, S. Kirmani3, K.N. Humayun1
1 Aga Khan University, Pediatric and Child Health, Karachi, Pakistan

Introduction: Diabetic ketoacidosis (DKA) is an acute metabolic complication occurring in patients with diabetes, especially in patients with type 1 diabetes (T1D) it can be life threatening. Moderate hypertriglyceridemia is commonly observed in DKA, but severe hypertriglyceridemia is rare, based on our review of the literature there are few cases reported previously of confirmed pediatric DKA with severe hypertriglyceridemia.

Objectives: none.

Methods: NA.

Results: Here we are presenting a case of a previously healthy 3-year-old toddler boy first time presented with diabetic ketoacidosis (DKA). Found to have grossly lipemic serum due to extremely high triglyceride (TG) levels observed without evidence of systemic complication, and cutaneous manifestation (e.g., xanthoma or xanthelasma). DKA was treated according to ISPAD guidelines, insulin was titrated according to blood sugar levels, and patients had an uneventful recovery with rapid resolving hypertriglyceridemia. Triglyceride levels were reduced from 10,749 mg/dl to 1431 mg/dl within 5 days after conventional treatment was commenced without plasmapheresis or anti-lipid medication. The patient had an uneventful recovery with rapid resolving hypertriglyceridemia.

Conclusions: In younger children, Diabetic ketoacidosis leads to a high risk of mortality, although severe hypertriglyceridemia is rare, it can increase this risk further. We suggest that lipid levels should be monitored in children who are presenting with DKA or uncontrolled diabetes regardless of age. Clinicians should be cautious while managing similar types of cases because of the possibility of associated acute pancreatitis which was absent in our case.

P255  |  Safety and effectiveness of insulin degludec in children with type 1 DM: Single center experience

A. Singh1, S. Bhattacharyya1
1 Manipal Hospital, Pediatric, Bengaluru, India

Introduction: Insulin Degludec is an ultra-long acting basal insulin approved for use in children above 1 year of age for Type 1 Diabetes. It has a flat peakless profile, which offers less intra-day and inter-day variability with once daily dosing and reduced risk of hypoglycemia.

Objectives: We aimed to evaluate the safety and efficacy of insulin Degludec as a part of basal-bolus regimen in type 1 Diabetic pediatric population at a single tertiary care center.

Methods: A total of 50 children with type 1 Diabetes Mellitus (20 boys and 30 girls) were observed over a period of 1 year after initiation of Degludec as basal insulin along with as part as bolus insulin. Baseline and post 1 year characteristics were analyzed including glycated hemoglobin (HbA1c), basal and total daily insulin requirements, and adverse events.

Results: Basal and bolus Insulin dose was titrated according to the SMBG profile of children. A significant fall in HbA1c level was seen from the baseline mean value of 10.4% to 7.7% (p < 0.05). The mean total daily dose (TDD) of insulin decreased from a 0.93 U/kg/day to
0.82 U/kg/day at the end of 1 year, but it was not significant (p = 0.66). The mean daily dose of insulin Degludec had significantly increased from 11.2 U/day to 12.6 U/day (p = 0.034); whereas the dose of insulin as part had reduced from 19 U/day to 18.5 U/day, but this difference was not statistically significant (p = 0.58). There were no episodes of diabetic ketoacidosis reported. No adverse events related to Degludec occurred over 1 year but 12% of children had mild asymptomatic hypoglycaemia (RBS between 50–70 mg/dl) following a higher bolus dose.

**Conclusions:** In our study, it was observed that insulin Degludec was well tolerated by pediatric population. Degludec improves glycemic control and compliance with reduced risk of symptomatic hypoglycemia and DKA.

P256 | Preparation and characterization of polymeric nanoparticles for sustained delivery of insulin

M. Bhargava1, S. Bhargava2
1Himalayan University, Pharmacy, Kanpur, India, 2United Institute of Pharmacy, Pharmacy, Allahabad, India

**Introduction:** Insulin is mainstay of drug therapy for patients with insulin-dependent diabetes mellitus, which is a syndrome of disordered metabolism, & resulting in abnormally high blood sugar levels. Oral insulin delivery has been major research issue, due to several advantages over other routes. However, this route poses several constraints for delivery of peptides & proteins, which are to be worked upon.

**Objectives:** Small intestine has been able to transport I-forms of amino acids against a concentration gradient and they compete for mechanism concerned. So, L-valine was used as a ligand for carrier-mediated transport of insulin-loaded polyactic-co-glycolic acid(PLGA) nanoparticles (NPs).

**Methods:** L-valine-conjugated-PLGA nanoparticles were prepared using double emulsion solvent evaporation method. Conjugated NPs were characterized for their surface morphology for shape & size by electron microscopy, drug entrapment efficiency, zeta potential, polydispersity index, in-vitro & in-vivo insulin release.

**Results:** Ex-vivo studies on intestine revealed that conjugated NPs showed greater insulin uptake as compared to non-conjugated NPs. In-vivo studies were performed on diabetic rabbits in which, Oral suspension of insulin-loaded PLGA-NPs reduced blood glucose level within 4 h which further decreased after 8 h. Ligand-conjugated formulation on oral administration produced hypoglycaemic effect within 4 h of administration, and this effect prolonged till 12 h of oral administration. Simultaneously, insulin concentration in withdrawn samples was also assessed & found that profile of insulin level is in compliance with blood glucose reduction profile.

**Conclusions:** L-valine NPs showed higher insulin uptake, as compared to NPs due to its relative high affinity for oligopeptide transporters present at intestine, which aids in increased bioavailability & better therapeutic response for orally administered insulin. Thus, L-valine NPs have potential for oral insulin delivery in effective management of Type-1 diabetes condition.

P257 | The association of vitamin D deficiency with poor glycemic control in children and adolescents with type 1 and type 2 diabetes

B. Zabeen1, B. Ahmed1, J. Nahar3, K. Azad1
1Princess Nourah bint Abdulrahman University, Pediatric, Riyadh, Saudi Arabia, 2King Saud University, Pediatric, Riyadh, Saudi Arabia, 3King Saud bin Abdulaziz University for Health Science, Pediatric, Riyadh, Saudi Arabia

**Introduction:** Multiple studies have previously shown that vitamin D deficiency is highly prevalent in type 1 and type 2 diabetes. Vitamin D (25(OH)D) effects on glycemic control are unclear in children and adolescents with type 1 diabetes.

**Objectives:** The study aimed to assess the vitamin D status and its relationship with the disease characteristics and glycemic status in children and adolescents with T1D and T2D.

**Methods:** A retrospective medical record review of children with T1DM and T2DM in Pediatric Diabetes Center in BIRDEM 2 hospital (Bangladesh Institute of Research and Rehabilitation of Diabetes Endocrine and Metabolic Disorders), was done over a 12-months period. The demographic and clinical data were collected through medical records with a structured questionnaire.

**Results:** Among 103 study participants, most had inadequate levels of vitamin D: deficiency76 (73.8%), and sufficiency27 (26.2%). The prevalence of vitamin D deficiency (VDD) was high in both types of diabetes: 55.3% were T1 D and 44.7% were T2 D. Majority female participants had vitamin D deficiency (VDD) compared to male participants. (p = 0.020). Most of the participants were from higher socioeconomic status (p = 0.013). Median BMI was significantly higher in Vitamin D deficiency compared to the sufficient group (p = 0.011). While comparing VDD with glycemic control, 60% of VDD patients had poor glycemic control: HbA1c > 9% compared to vitamin D sufficient (p = 0.017). On logistic regression. Univariate analysis revealed positive association between vitamin D deficiency and poor glycemic control along with age at diagnosis, median BMI and median LDL which remained significant in multivariate analysis (p = 0.003).

**Conclusions:** The present study revealed that the prevalence of vitamin D deficiency and among T1 and T2 diabetes children was very high. Future studies in large sample are required to assess hypovitaminosis D in youth with T1D and T2D and also the possible relating factors of vitamin D deficiency.

P258 | Initial home-based education and care for newly diagnosed T1DM children and adolescent: A health technology assessment

A. Alotaibi1, R. Al Khalifah2, H. Alfaradi3
1Princess Nourah bint Abdulrahman University, Pediatric, Riyadh, Saudi Arabia, 2King Saud University, Pediatric, Riyadh, Saudi Arabia, 3King Saud bin Abdulaziz University for Health Science, Pediatric, Riyadh, Saudi Arabia

**Introduction:** Multiple studies have previously shown that vitamin D deficiency is highly prevalent in type 1 and type 2 diabetes. Vitamin D (25(OH)D) effects on glycemic control are unclear in children and adolescents with type 1 diabetes.

**Objectives:** The study aimed to assess the vitamin D status and its relationship with the disease characteristics and glycemic status in children and adolescents with T1D and T2D.

**Methods:** A retrospective medical record review of children with T1DM and T2DM in Pediatric Diabetes Center in BIRDEM 2 hospital (Bangladesh Institute of Research and Rehabilitation of Diabetes Endocrine and Metabolic Disorders), was done over a 12-months period. The demographic and clinical data were collected through medical records with a structured questionnaire.

**Results:** Among 103 study participants, most had inadequate levels of vitamin D: deficiency76 (73.8%), and sufficiency27 (26.2%). The prevalence of vitamin D deficiency (VDD) was high in both types of diabetes: 55.3% were T1 D and 44.7% were T2 D. Majority female participants had vitamin D deficiency (VDD) compared to male participants. (p = 0.020). Most of the participants were from higher socioeconomic status (p = 0.013). Median BMI was significantly higher in Vitamin D deficiency compared to the sufficient group (p = 0.011). While comparing VDD with glycemic control, 60% of VDD patients had poor glycemic control: HbA1c > 9% compared to vitamin D sufficient (p = 0.017). On logistic regression. Univariate analysis revealed positive association between vitamin D deficiency and poor glycemic control along with age at diagnosis, median BMI and median LDL which remained significant in multivariate analysis (p = 0.003).

**Conclusions:** The present study revealed that the prevalence of vitamin D deficiency and among T1 and T2 diabetes children was very high. Future studies in large sample are required to assess hypovitaminosis D in youth with T1D and T2D and also the possible relating factors of vitamin D deficiency.

**POSTER TOUR 28—DIABETES IN DEVELOPING COUNTRIES & ACCESS TO CARE # 1**

P258 | Initial home-based education and care for newly diagnosed T1DM children and adolescent: A health technology assessment

A. Alotaibi1, R. Al Khalifah2, H. Alfaradi3
1Princess Nourah bint Abdulrahman University, Pediatric, Riyadh, Saudi Arabia, 2King Saud University, Pediatric, Riyadh, Saudi Arabia, 3King Saud bin Abdulaziz University for Health Science, Pediatric, Riyadh, Saudi Arabia

**Introduction:** Multiple studies have previously shown that vitamin D deficiency is highly prevalent in type 1 and type 2 diabetes. Vitamin D (25(OH)D) effects on glycemic control are unclear in children and adolescents with type 1 diabetes.

**Objectives:** The study aimed to assess the vitamin D status and its relationship with the disease characteristics and glycemic status in children and adolescents with T1D and T2D.

**Methods:** A retrospective medical record review of children with T1DM and T2DM in Pediatric Diabetes Center in BIRDEM 2 hospital (Bangladesh Institute of Research and Rehabilitation of Diabetes Endocrine and Metabolic Disorders), was done over a 12-months period. The demographic and clinical data were collected through medical records with a structured questionnaire.

**Results:** Among 103 study participants, most had inadequate levels of vitamin D: deficiency76 (73.8%), and sufficiency27 (26.2%). The prevalence of vitamin D deficiency (VDD) was high in both types of diabetes: 55.3% were T1 D and 44.7% were T2 D. Majority female participants had vitamin D deficiency (VDD) compared to male participants. (p = 0.020). Most of the participants were from higher socioeconomic status (p = 0.013). Median BMI was significantly higher in Vitamin D deficiency compared to the sufficient group (p = 0.011). While comparing VDD with glycemic control, 60% of VDD patients had poor glycemic control: HbA1c > 9% compared to vitamin D sufficient (p = 0.017). On logistic regression. Univariate analysis revealed positive association between vitamin D deficiency and poor glycemic control along with age at diagnosis, median BMI and median LDL which remained significant in multivariate analysis (p = 0.003).

**Conclusions:** The present study revealed that the prevalence of vitamin D deficiency and among T1 and T2 diabetes children was very high. Future studies in large sample are required to assess hypovitaminosis D in youth with T1D and T2D and also the possible relating factors of vitamin D deficiency.
Introduction: The initial education and care of newly diagnosed type 1 diabetes mellitus (T1DM) patients is critically important as it sets them on the right direction for managing chronic disease that needs intensive education and treatment.

Objectives: We aimed to evaluate effectiveness, safety, and cost-effectiveness of home-based education compared to hospital-based education for newly diagnosed children with T1DM.

Methods: We performed health technology assessment based on systematic review and meta-analysis of RCT. We searched Ovid/MEDLINE, Ovid/Embase, Cochrane Library, and other databases from 1995 to October 2021. We evaluated in duplicate and the title, abstract, and full text of relevant studies. The intervention was a home-based education and care (HBC) that is characterized by discharge on the same day of diagnosis followed by a series of educational outpatient sessions. The comparison is a hospital-based education and care (HOBC) that is characterized by admission to hospital after diagnosis of T1DM and include serial of in-patient educational sessions.

Results: We included four RCT with a total of 376 children. All the studies used hybrid intervention except one study in which the intervention was purely HBC. The control group in all the studies used HOBC. The overall risk of bias across studies is low. There was no significantly reported difference in DKA, severe hypoglycemia, pediatric quality of life and family impact at 6 and 12 months in both groups. HbA1c was lower at 12 months in the HBC, MD of 0.2%, CI (0.09, 0.34). Economic evaluation included two trials with a sample size of 263 participants. Both studies showed statistically significant lower cost favoring HBC with MD of (−2217 £) and (−1574 €). The incremental cost-effectiveness ratio for each mmol/mol reduction in HgA1c was 7434 £ / each mmol/mol reduction in HbA1c.

Conclusions: Home-based care is effective, safe, and cost-effective strategy for providing the initial diabetes care and education from a healthcare sector perspective.

Barriers/Inequities Contributors in Pump Uptake

| Tier 1 | Difficulty contacting patients for pump classes, visits, & shipment of device |
| Tier 2 | Language barrier/Lack of interpreter/materials not in other languages |
| Tier 3 | Lack of standardized screening tools to assess pump readiness |

| Tier 1 | Communication to & from pump vendors to clinic/patients |
| Tier 2 | Provider bias in offering pumps |
| Tier 3 | Provider concerns about pump safety |

| Tier 1 | Insurance issues/denials |
| Tier 2 | Multiple visits/travel cost/missed school/work |
| Tier 3 | Patient refusal/believes nothing attached to their body |

| Tier 1 | Stringent guidelines/multiple paperwork for patients on public insurance |
| Tier 2 | Staffing challenges/staff turnover |
| Tier 3 | Out of pocket cost for uninsured or underinsured patient |

Introduction: This work is done on behalf of the T1D Exchange QI Collaborative.

Objectives: Multiple studies have shown HbA1c and insulin pump use are significantly different in patients with type 1 diabetes (T1D), between racial and ethnic groups, with lower A1c and higher insulin pump use noted in non-Hispanic whites compared to Non-Hispanic Black patients (NHB) and Hispanics. We aimed to identify the barriers to the uptake of insulin pumps among NHB and Hispanics with type 1 diabetes.

Methods: The T1D Exchange Quality Improvement Collaborative (T1DX-QI) identified six endocrinology centers to pilot an equity-focused Quality Improvement mixed-method study to address disparities in insulin pump use among NHB and Hispanic patients. Participating sites used process maps and the Ishikawa diagram to identify pain points and barriers in the processes. Barriers were categorized into tiers based on the frequency of occurrence among participating centers.

Results: All participating centers (100%) reported tier 1 barriers as contributors to inequities. A majority of participating centers
identified tier 2 barriers (80%) and 40% of participating centers reported tier 3 barriers as contributors to inequities seen. (see Figure 1).

Conclusions: Identifying and addressing barriers to insulin pump uptake and use is fundamental to increasing use of insulin pumps and implementing meaningful changes in the process to improve equity. These concepts can be extended to use of technology in patients with T1D in general and adoption of these technologies and advanced automated closed loop systems may result in improvement in diabetes care.

P260  |  Food insecurity in pediatric type 1 and type 2 diabetes: The role for empathy and compassion

M. Desjardins1, Z. Boulil2, J. Parker2, C. Demeterco-Berggren1,2,3
1University of California, San Diego School of Medicine, La Jolla, United States, 2Rady Children's Hospital, San Diego, United States, 3UCSD Department of Pediatrics, Division of Pediatric Endocrinology, San Diego, United States

Introduction: Diet plays a critical role in type 1 (T1D) and type 2 diabetes (T2D) management. Healthcare providers and patients have reported discomfort discussing food insecurity due to the associated stigma.

Objectives: Here we aimed to evaluate the association between food insecurity status and glycemic management in pediatric diabetes. Furthermore, we aimed to evaluate compassion as a tool to improve the experience and perspective of patients regarding food insecurity screening.

Methods: This is a retrospective review of youth with T1D or T2D (age < 18 years) screened for food insecurity at RCHSD from July 2020 to June 2021 including data on sociodemographic variables and diabetes outcomes. Caregivers were surveyed on perspectives about food insecurity screening pre and post a 30 min compassion training session provided to medical assistants who administer the screening.

Results: Of 806 patients, 13% (80 with T1D and 23 with T2D) were positive for food insecurity. Among those, 83% were from minority racial/ethnic groups. Mean A1c (±SD) for the food insecure group was 9% (±3) and 8% ±2 for the food secure one. Logistic regression showed an association of positive food insecurity status with having public insurance (OR 1.4), speaking a language other than English (OR 1.2) and belonging to the Hispanic (OR 2.7) or the non-Hispanic Black race/ethnicity groups (OR 1.8). Caregivers (n = 50) reported feeling judged (9.6%), uncomfortable or very uncomfortable (7.9%) with the screening during the pre-intervention period. After intervention, 57 caregivers were surveyed with 3.5% feeling judged and 7.1% feeling uncomfortable or very uncomfortable with the screening.

Conclusions: This study highlights the impact of food insecurity in achieving equitable optimal glycemic management in youth with diabetes. Empathy and compassion interventions may have the potential to facilitate caregivers’ screening experience and help identify families who can receive appropriate resources.

P261  |  Injections site infections in a chart of diabetic children and young adults in northern Haiti

M.-M. Exavier1, W. Joseph1, M. Canarie2, N. Dunbar3
1Hopital Sacre-Coeur, North, Cap-Haitien, Haiti, 2Yale University School of Medicine, Pediatrics, New Heaven, United States, 3Connecticut Children's Hospital, Pediatrics, Hartford, United States

Introduction: None.

Objectives: There are many challenges to treating Type 1 Diabetes in resource limited settings beyond the provision of insulin. We sought to identify the frequency of injection site infections, describe these cases and possible consequences in children and young adults with Type 1 Diabetes in northern Haiti.

Methods: Chart review of children and young adults enrolled in the pediatric diabetes program at Hôpital Sacré Cœur in Milot, Haiti from 2019–2021. Data on age, gender, HbA1C, number and site of infection, and treatment required were noted.

Results: Charts of 86 children and young adults were reviewed. Twelve cases of wound infection in 10 (12%) patients were identified. There were 8 females and median age was 18 (IQR 16–19) years, with a mean duration of diabetes of 3 years. Mean HbA1c was 14.4% (SD 1.25) at the time of infection compared to 12.7% in the group. The most frequent location was the anterior thigh (6; 50%). All infections were treated with antibiotics, half of the patients were hospitalized (2 with concomitant DKA), and 25% of wounds were debrided. Factors thought to be associated with infections were aseptic practices, reuse of insulin syringes, lack of site rotation and poor access to small bore needles.

Conclusions: Injection site infection is common in children and young adults with Type 1 Diabetes in northern Haiti. Further study is needed to establish clear risk factors, but improved glycemic control, increased emphasis on asepsis, site rotation, and access to small bore needles may decrease these infections.

P262  |  An accidental pregnancy in type 1 diabetes mellitus

R. Gokalani1, H. Patel1, D. Panchal2, D. Chudasama3
1AHC Diabetes Clinic, Ahmedabad, India, 2Diacare Diabetes and Hormone Clinic Sabarmati, Ahmedabad, India, 3Hope Diabetes Clinic, Junagadh, India

Introduction: Pregnancy with diabetes is one of the important topics as it deals with two lives, so pre-conceptional counseling becomes essential. But accidental pregnancy is common condition where patient with pre-existing diabetes carries a huge risk of fetal and maternal complications. Optimal blood glucose control in type-1 diabetes itself is a challenge due to high variability, and accidental pregnancy in type-1 diabetes becomes a greater challenge.

Objectives: To study a case of accidental pregnancy in type1 diabetes.
Methods: A case of 29 years old lady with type-1 diabetes for last 16 years and hypothyroidism had an accidental pregnancy with gestational age of 2 weeks with Hb1C of 8.7%. When she consulted at our tertiary care center, she was on premixed insulin of Aspart- 30/70 and thyroxine 75 mcg. She was irregular with SMBG (self-monitoring of blood glucose) 2–3 times in week. She had erratic meal pattern and inconsistent exercise.

She was advised to terminate the pregnancy due to uncontrolled diabetes on first visit to the obstetrician. But she wanted to continue with the pregnancy. So obstetrician immediately advised to visit diabetologist.

She was shifted to basal-bolus treatment. She was advised to follow structured 6 point SMBG. She was taught carbohydrate counting and insulin correction factor according to insulin sensitivity. She was also asked to follow the regular exercise regimen permitted by obstetrician. She was provided one application in her mobile phone to upload SMBG data. She was also explained hypoglycemia prevention and treatment. She was asked to use continuous glucose monitoring intermittently. Her 1st anomaly scan at 12 weeks was done at 12 weeks which was absolutely normal. Her subsequent visits were planned every 45 days. She maintained her blood glucose with good SMBG, intermittent CGM and HbA1C.

Conclusions: Pregnancy and type1 diabetes needs the ultra-disciplinary care to have good outcome.

P263  |  Incidence and prevalence of type 1 diabetes in children and young adults in Burkina Faso

Y. Sagna1,2, W.P.A.H. Bagbila1,2, L. Zounggrana3,4, M.E. Saloukou5, S. Traoré6, N. Sawadogo7, C.G. Kyelen1,2, O. Guira3,4, M.S. Ouedraogo1,2, J.Y. Drabo3,4

1Université Nazi Boni, INSSA, Bobo-Dioulasso, Burkina Faso, 2CHU Souri Sanou, Médecine Interne, Bobo-Dioulasso, Burkina Faso, 3Université Joseph Ki-ZERBO, UFR/SDS, Ouagadougou, Burkina Faso, 4CHU Yalgado Ouedraogo, Médecine Interne, Ouagadougou, Burkina Faso, 5CHR de Koudougou, Médecine, Koudougou, Burkina Faso, 6CHR de Ziniaré, Médecine, Ziniaré, Burkina Faso, 7Université de Ouahigouya, Faculté de Médecine, Ouahigouya, Burkina Faso

Introduction: There are no data on type 1 diabetes (T1D) incidence and prevalence in Burkina Faso. The Life For A Child (LFAC) program is the main provider of diabetes care for the vast majority of youth with diabetes in Burkina Faso.

Objectives: We aimed to determine T1D incidence and prevalence in persons aged <25 years since the implementation of the LFAC program.

Methods: This study presents data on children and young people <25 years who prospectively received care from the Burkina Faso LFAC program between 2013 and 2021. Data were collected from the prospective program register. Diagnosis of T1D was clinical, based on presentation, abrupt onset of symptomatic hyperglycemia, need for insulin replacement therapy from diagnosis, and no suggestion of other diabetes types.

Results: Total of 265 cases were diagnosed with T1D <25 years in 2013–2021. Male-to-female ratio was 0.99. T1D incidence <25 years per 100,000 population/year increased from 0.06 in 2013 to 0.35 in 2021. Incidence <15 years rose from 0.02 to 0.15 per 100,000/year in 2013 and 2021, respectively. Prevalence <25 years was 0.19/100,000 in 2013 and 0.33/100,000 by 2021 (p < 0.001). Prevalence <15 years was 0.19/100,000 in 2013 and 0.33/100,000 by 2021 (p < 0.001).
Conclusions: Our report of known T1D cases shows lower incidence and prevalence rates in Burkina Faso. Known incidence and prevalence of T1D in Burkina Faso increased rapidly from 2013 to 2021, contemporaneous with the introduction and development of the LFAC. However, true incidence and prevalence may be underestimated with some missed cases due to death before diagnosis.

P264 | Bridging gaps for pediatric diabetics community: NGO initiatives in developing countries

S Pramod1, B Patil1
1HAOI, Community Medicine, Dhule, India

Introduction: Diabetes in children's brings mental-trauma/depression in family. Focused treatment for pediatric age-group is unavailable in developing-countries. 26% of diagnosed diabetics are children's. Adequately trained physicians/Nurses in issues of pediatric-diabetes needed to treat depression and smooth transition from diagnosis to treatment. Qualitative collaborative needed to make diabetic child's life bearable. Our NGO-project highlights these issues.

Retrospective analysis of past studies shows—counseling improves QOL & attitude toward diabetes-treatment.

Objectives: To describe care issues in diabetic-children's. Observe/modify nature of relationship between nurse and child. To evolve comprehensive Rx for patients and families.

Methods: A retrospective analysis of data base from 7 rural health-clinics. Specialized therapy/support to pediatric-age-group not available at any center. Total 117 children's [4–13 years] diagnosed with diabetes. 23 had additional endocrine/metabolic problems. Nursing/medical care plan analyzed. No specialized trained personal in rural/tribal India. Opinion/needs from patients families collected on feedback questionnaire. Trained 10 nurses & 2 physicians in pediatric cases [4 weeks training].

Results: Out of 117, 41 discontinued Rx due to improper counseling/guidance. 3 died. Patient/family's feedback highlights: Better access to newer drugs-delivery-systems, psychosocial support, follow-up-plan. Nurses/physician be sensitized in pediatric care-issues. Main issues of concern were:

[1] Illness and coping with their feelings.
[3] Concerns of cost of RX.

Conclusions: Multifaceted Relationship between nurse and Diabetic-child is crucial. We show concerns/difficulties while working in Asian set-up to international experts/seniors at ISPAD-2022-congress.

P265 | Adolescent diabetes management: Role of NGO’s in resource poor settings

S Pramod1, B Patil1
1HAOI, Community Medicine, Dhule, India

Introduction: Adolescent diabetes has social stigma in rural India. Such diabetes needs proper guidance/information/treatment-counseling outlets.

Objectives: This is burning issue in developing-nations. We all need to unite & form comprehensive diabetes care & counseling policy plan at ISPAD 2022. Treatment options must be suitable for developing-nations considering cost of Rx. Incorporating NGO’s in such efforts is very effective.

Methods: Our 15 year-old-NGO started Diabetes education-project in rural India from 2005. We started s education & surveillance project to analyze social & anthropological issues facing those affected by adolescent diabetes. Total 62adolescents subjects enrolled by Feed-back questionnaires to get their feedback on special needs, perceptions, social attitude on diagnosis of diabetes. Factors like community-inhibition, social-ostracism, economic-difficulties, marital discord, non-availability of treatment-guidance centers, lack of trained-staff analyzed & draft policy is recommended to Govt-agencies.

Results: Adolescent diabetes management must include care of nursing & psycho-social needs. Here role of NGO’s in diabetes education is very effective in terms of cost-management, better impact & better-compliance of young diabetics. Community mass intervention projects has proven useful in rural communities of resource poor-nations. ISPAD participants can collaborate with NGO-activists to address this issue. Uniform public health policy needed to implement & expand newer strategies to include broader range of diabetes care-issues.

Conclusions: Promoting dialog between Government-health-services &NGO’s accelerates diabetes education/awareness programs. NGO participation improves cost-efficacy of such initiatives in economically poor populations. This would reduce difficulties faced by young diabetics. WHO, ISPAD must form common guideline manual on this issue affecting developing-countries. We graphically present our NGO's project on diabetes education plan in four phases to participants.

P266 | Implementation of a diabetes management program to improve outcomes for young people with type 1 diabetes in Kazakhstan, India

C.M Lawrence1,2, S.R. Masoodi3, G.D Ogle4,5, B.R King1,2, K.A Vora1,2, C. Smart1,2, M. Paterson1, P.O. Ahmad3
1John Hunter Children's Hospital, Pediatric Endocrinology and Diabetes, New Lambton Heights, Australia, 2University of Newcastle, Callaghan, Australia, 3Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar, India, 4Life for a Child Program, Diabetes NSW and ACT, Glebe
Introduction: The John Hunter Children’s Hospital (JHCH) in Australia have developed a diabetes management program (Success With Intensive Insulin Management [SWIIM]). JHCH has achieved an average HbA1c of 7.0% with a population of over 400 young people. This program has been implemented at other regional centers in Australia where the average HbA1c has improved to 6.8%.

The Sher-I-Kashmir Institute of Medical Sciences (SKIMS) in Srinagar, India services 400 children with type 1 diabetes. The average HbA1c is 10.5% and the average life expectancy is 29 years. Access to blood glucose monitoring and diabetes education is limited.

Objectives: To demonstrate improvement in diabetes related outcomes through implementing a diabetes management program to a resource-limited population.

Methods: Medical, dietetic and patient education resources were developed as part of the SWIIM program and delivered to clinicians at SKIMS. Direct mentoring of SKIMS clinicians will be provided over the study period. Glucose monitors and strips were provided by the Life For A Child Foundation. Young people aged 0-18 years with type 1 diabetes attending SKIMS were recruited and baseline data was collected.

Results: 71 participants have been recruited to date (27 male, 44 female; 66 T1DM, 5 T2DM). At baseline, The average HbA1c was 9.9%; 13 participants (18%) had a HbA1c of 7.0% or less. Average number of blood glucose measurements per week was 8 (range 0–35). 1 patient had hypertension, 2 patients had cataracts, 1 patient had peripheral neuropathy. In the previous 12 months there have been 26 episodes of severe hypoglycemia (36.6%), 3 episodes of DKA (4.2%), and 21 diabetes related hospital admissions (29.6%).

Conclusions: We present a research plan for the implementation of a diabetes management program to improve type 1 diabetes related outcomes in a resource-limited population. Baseline data indicates most patients do not meet international targets for HbA1c and significant burden of diabetes related complications.

P267 | Outcomes of health care services provided to Egyptian patients with type 1 diabetes mellitus: A single center experience

S. Elhabsy, N. Elbarbary, A. Abdel-Hamid Hassan, R. Thabet
1Ain Shams University, Faculty of Medicine, Department of Pediatrics, Diabetes Unit, Cairo, Egypt

Introduction: Despite the existence of evidence-based guidelines for the care of children with diabetes, widespread gaps in knowledge, attitude, and practice remain.

Objectives: To evaluate the current health care services provided to patients with type 1 diabetes (T1D) registered in Pediatric and Adolescent Diabetology Unit (PADU) in terms of metabolic control and complications encountered.

Methods: From a developing country like Egypt, our center provided a description of the population of children with diabetes we serve according to benchmarking and data validation report that has been received from the international SWEET registry.

Results: Our center had contributed data for 672 patients (58.8% female). The mean age is 12.63 ± 3.41 years, mean BMI is 20.11 ± 4.03 (kg/m²) with a median diabetes duration of 5.54 ± 3.07 years. Mean HbA1c of all patients was 8.75 ± 1.94%, with 86.9% of patients having HbA1c >7%. The mean number of blood glucose monitoring is 2.43 ± 0.64 times/day and mean insulin dose is 1.17 ± 0.27 u/kg/day. In our population 30.5% of patients presented with DKA, 16.7% had severe hypoglycemia in the last year prior to enrollment.

Regarding microvascular complications 6.7% had nephropathy, 4.9% had peripheral neuropathy, no retinopathy and 10.85% had hyperlipidemia. Patients with more than 5-year-diabetes duration have significantly higher cholesterol level (167.58 ± 38.02 vs. 163.23 ± 35.54 mg/dl), higher LDL (100.23 ± 29.49 vs. 95.70 ± 28.11 mg/dl), and lower number of SMBG (2.24 ± 0.66 vs. 2.58 ± 0.57 times/day, p < 0.05 for all).

Conclusions: The results of our center are a testimony of the reality of managing diabetes by dynamic teams striving to achieve recommended standards of care for pediatric diabetes in an environment with limited resources. Dissemination of results and prospective projects serve as further motivation to improve outcome and more uniform care for patients with diabetes.

P268 | The effect of quality of care on Hba1c

M. Saiyed, B. Saboo, M. Pancholi, S. Shah
1Diacare-Diabetes Care and Hormone Clinic, Ahmedabad, India

Introduction: Quality of care is the care received by an individual from his family and that depends on their socioeconomic condition. As type 1 diabetes is a condition that demands constant care and support from the families.

Objectives: To evaluate the quality of care on average glucose value.

Methods: Patients were divided into three strata based on their annual income. The lower income group, middle income, and the higher income group. Inclusion: all patients visiting the clinic between Jan 2022 to March 2022. Exclusion: patients unwillingness. Mostly the lower and middle-income groups receive the benefits of diabetes essentials from our center. They are on NPN with regular insulin and use a glucose-monitoring device. The higher income group takes the benefits of basal-bolus therapy, use of AGP, and glucose meter. A structured questionnaire was prepared to achieve the objective. It had questions on Socio economic status and diabetes care.

Conclusions: The poor quality of care is directly proportionate to the average glucose level.

The poor quality of care is not always linked with the income of the family.
P269 | Longitudinal qualitative study of the experiences and effects of living in a Danish residential care facility for young people with diabetes

L.B. Johansen1, D. Grabowski1
1Steno Diabetes Center Copenhagen, Herlev, Denmark

Introduction: In Denmark, there is only one residential care home for children and young people with diabetes who, for various reasons, cannot stay at home and are unable to function and manage their diabetes on their own.

Objectives: The purpose of the study was to explore social identity variations over time and to conduct a sociological study of experiences and perceptions of everyday life in the context of a residential care facility for young people with diabetes.

Methods: The data consists of two sets of semi-structured interviews with residents (aged 15–21 years). We conducted nine interviews with residents in 2019 and 10 interviews 18 month later in 2021 (six repeats). The interview guide was focused on the individual experiences of living at the residential diabetes care facility as well as on the personal narratives. All interviews were transcribed verbatim and analyzed using the Pattern Oriented Analysis Approach (POLA) to identify groups of changes.

Results: The analysis produced three main themes:

1. Becoming more confident over time: The residents reported a high level of personal growth and maturity after moving to the residential care home,
2. Feeling different among peers: The residents reported a family-like community with diabetes as the common denominator - which enables new identity formations and,
3. Tacit knowledge of diabetes management and technology: The residents gained bodily knowledge of diabetes as it is not mentioned explicitly that often. The combined findings show that the residential care home is a potential way to normalcy, which enables new behaviors and new identities to be formed.

Conclusions: The results of our study are important steps toward understanding psychosocial challenges for diabetes management among children and young people without the traditional support from close relations. Furthermore, the results are also applicable to general clinical diabetes care of vulnerable or poorly regulated low-resource children and young people with diabetes.
Children’s DNT5 results were associated with children’s WHO-5 well-being test ($r = 0.17$, $p = 0.007$) but not with caregivers’ test results ($r = 0.05$, $p = 0.594$).

Center differences were strongest as to HbA1c ($p < 0.000001$), children’s DNT5 ($p < 0.000001$), as well as children’s WHO-5 test ($p < 0.000005$), and weaker but still significant, as to the mathematical tasks - wordless test ($p = 0.0061$).

Children’s responsibility/co-responsibility was significantly related to higher results in wordless and DNT5 test ($p = 0.003$, $p = 0.036$ respectively).

Conclusions: Numeracy skills in children with T1D seem to be an essential factor in successful glycemic control and the well-being of children and their caregivers.

P271 | Quality of type 1 diabetes care in pediatric cohort treated at Farwaniya Outpatient Clinic

F. Al-Juailla1, D. Alhomaidah1,2, A. Al-Tarrawah2, D. Mohammed2, A. Mohsen3, F. Othman4, D. Dalia Al-Abdulrazzaq1,2, H. Al-Kandari1,2
1Dasman Diabetes Institute, Population Health, Kuwait City, Kuwait, 2Farwaniya Hospital, Department of Pediatrics, Farwaniya, Kuwait, 3Kuwait University, Department of Pediatrics, Faculty of Medicine, Jabriya, Kuwait

Introduction: The prevalence of Type 1 diabetes (T1D) is growing as a major healthcare problem in Kuwait. Primary health care centers contribute crucially to diabetes care. Consequently, optimal care is critical for the management and prevention of risk factors and complications of T1D.

Objectives: To evaluate the quality of diabetes care in T1D patients treated at Outpatient Clinic compared to ISPAD guidelines published in 2018.

Methods: Patients (aged ≤16) diagnosed with T1D and followed up in the Outpatient Clinic at Farwaniya regional hospital with at least one visit in 2021 were included. A retrospective medical chart review was performed to obtain glycemic control, lipid profile, autoantibody screening, and treatment regimen. Clinical data were evaluated as per clinical goals set by ISPAD guidelines. Statistical analysis was performed.

Results: A total of 164 patients were enrolled (median age 9.76 years IQR 7.03–12.1, diabetes duration 2.4 years IQR 0.0–4.68). In 2021, testing rates for HbA1c levels and annual thyroid functions were very high (93.9% and 92.1%, respectively). From the cohort, 35.4% measured their blood pressure and more than half of patients evaluated their LDL-C levels (62.8%) and screened for celiac disease (62.8%). Around two-thirds of children diagnosed with T1D for >2 years performed urinary microalbumin tests (71.4%). Very few subjects (1.9%) met the recommended HbA1c target (<7.0%) compared to 35% met LDL-C target (<2.6 mmol/L). Moreover, 16.5% of children had LDL-C levels >3.4 mmol/L and only 5.9% were receiving lipid-lowering therapy. At the most recent clinical visit, 1.2% of patients were on Angiotensin-converting enzyme (ACE) inhibitors and 6.7% were prescribed Levothyroxine treatment.

Conclusions: Overall, outpatient T1D care in Farwaniya hospital provides high-quality services in terms of testing rates. However, achieving the recommended targets safely is a major challenge for the pediatric population. Further and closer investigations on a larger population are essential to reflect the quality of diabetes care provided for children with T1D.

P273 | Role of glucose variability on linear growth in children with type 1 diabetes

V. Castorani1, L. Matonti1, A. Blasetti1, N. Polidori1, F. Chiarelli1, C. Giannini1
1University of Chieti, Department of Pediatrics, Chieti, Italy

Introduction: Linear growth is impaired in children with type 1 diabetes (T1D) and poor metabolic control. A good metabolic control is a key therapeutic goal to prevent vascular complications but also for ensuring an appropriate anthropometric development during childhood.

Objectives: In this study, we aimed to identify and characterize the effects of glycemic variability on linear growth in children with T1D.

Methods: Data from 144 prepubertal children with T1D were evaluated. Anthropometric measurements (weight, weight-SDS, height, height-SDS, BMI, BMI-SDS) were collected and glycosylated hemoglobin (HbA1c) was measured at admission and every 4 months over a 2-year period. Glycemic variability indexes (glycemic coefficient of variation [CV], glycemic CV percentage [CV%] and the product between HbA1c-mean and HbA1c-SDS/100 [M*SDS-HbA1c/100]) were calculated. According to height-SDS changes after 2-years of follow up, the study population was divided into three tertiles groups and differences across groups were investigated for variables of interest.

Results: The three groups were similar in terms of age, gender and follow up period. After 2 years, all prepubertal children showed a significant positive trend of anthropometric growth. Across the three tertiles groups, HbA1c-SDS, CV, CV%, and M*SDS-HbA1c significantly decreased from the first to the third tertiles of height-SDS. During follow-up children with lower Δ height-SDS values, reported higher values of HbA1c-SDS, CV, CV%, and M*SDS-HbA1c than subjects with higher linear growth.

Conclusions: Glycemic variability correlates with the linear growth in children with T1D. Low glycemic variability indexes were reported in higher height-SDS tertile. Δheight-SDS is inversely correlated with glycemic CV, CV%, and M*SDS-HbA1c.
P274 | The trend of glycemic control among children with type 1 diabetes (T1D) who are followed at King Abdullah Specialist Children Hospital (KASCH) over 4 years period (January 2016 to December 2019)

N. Alissa¹, S. Al Humaidi¹, S. Alzaid¹, H. Al Faraldii¹, O. Al Dibasi², A. Al Mutair¹
¹MNGHA-KASCH, Pediatric, Riyadh, Saudi Arabia, ²KAMIRC, Riyadh, Saudi Arabia

Introduction: Children and caregivers of T1D need continuous education and involvement in diabetes care. A multi-disciplinary team approach is essential to empower management and problem-solving skills to improve glycemic control.

Objectives:
1. Assess the trend of glycemic control reflected by A1c, and ER visits for children with T1D over 4 years (yrs) in a specialized children’s hospital
2. Compare glycemic control and ER visits between patients on MDI with those on CSII
3. Evaluate the effect of expanding diabetic educators and nutrition services and a sub-specialized
4. children's hospital on glycemic control

Methods: Retrospective cohort study included children aged 1–16 yrs with T1D, diagnosed for at least 1 year. Were followed in KASCH in Riyadh, KSA. Those with social issues and other medical conditions were excluded. The study period was from Jan 2016 to 30 Dec 2019. Electronic charts were used. Descriptive statistics to explore the trend of A1c and total ER visits per patient per yr for 4 years for the two groups, CSII and MDI. Regression analyzes were conducted for A1c and ER visits. The significance level was declared at the alpha of 0.05, and SAS 9.4 was used.

Results: 499 patients with T1D were included in the study (49.9% Female). A 62 patients on CSII (12.42%) and 437 on MDI; their mean ages were (13.4 years in the CSII and 12.42 years in the MDI). A 3906 visits were reviewed (618 in the CSII, 3288 in the MDI). Mean A1c was 8.5% in CSII, 10.10% in the MDI (p < 0.0001), with a significant decline in the A1c trend in the MDI (0.63%, p < 0.0001). ER visits did not change but were significantly less in the CSII (Figure 1).

Conclusions: The trend of glycemic control in children with T1D showed improvement over 4 years, significantly so in the MDI. This can be explained by moving to a specialized children's hospital with an expansion in diabetes educators and a dedicated dietitian, which empower diabetes care. Glycemic control and ER visits were significantly lower in the CSII.

P275 | Perception of health care professionals and adolescents with type 1 diabetes regarding introduction of home-visits

P.-E. Kofoed¹, S. Lisbjerg², J. Thomsen³
¹Lillebælt Hospital, University Hospital of Southern Denmark, Department of Pediatrics and Adolescent Medicine, Kolding, Denmark, ²Nordjylland Hospital, Department of Pediatrics and Adolescent Medicine, Hillerød, Denmark

Introduction: Despite advancements in diabetes management, a subgroup of patients does not achieve an acceptable level of metabolic control. To achieve treatment goals for high-risk patients, a higher frequency of contact with health care professionals is essential. However, socioeconomic challenges often lead to nonattendance at the outpatient clinic.

Objectives: To uncover the perception of patients, mothers, and health care professionals regarding home-visits versus consultations at an outpatient clinic in order to being able to improve the services offered.

Methods: Semi-structured interviews with patients, mothers, and health care professionals were conducted to explore the experiences and perspectives of the concept at two pediatric diabetes clinics in Denmark. Paired t-tests were used to compare the HbA1c levels at the start of the intervention with HbA1c 1 year before and HbA1c at the end of the intervention.

Figure 1. A: HgbA1C Trend

Figure 1. B Total ER visits
**Results:** Both patients, mothers, and health care professionals found consultations in familiar surroundings to result in stronger relationships between health care professionals and families, creating greater opportunities to discuss personal issues aimed at improving the outcome of diabetes. Furthermore, home-visits facilitated finding alternative methods of helping patients and families integrating diabetes into everyday life.

The mean HbA1c level 1 year prior to the intervention (HbA1c-1) was: 76.4 mmol/mol (25%–75% percentiles: 61–87), and the mean HbA1c level at baseline (HbA1c-2) was: 71.8 mmol/mol (25%–75% percentiles: 57–80) (HbA1c-1 vs. HbA1c-2: p = 0.25). The mean HbA1c measured after the end of the intervention (HbA1c-3) was 83.9 mmol/mol (25%–75% percentiles: 73–89) (HbA1c-2 vs. HbA1c-3: p = 0.004).

**Conclusions:** Overall, home-visits were found to contribute toward creating a more constructive relationship. However, it was still a challenge to keep the scheduled appointments, and during this short study, no improvement in metabolic control could be observed.

**P277 | Predictive factors of optimal glycemic control over the first year follow-up of new onset type 1 diabetes in a pediatric population**

J.-B. Pons Del Rey1, M. Borel1, A. Daussac2, M. Talvard3, C. Munzer2, J. Pelicand1, C. Morin1

1Hôpital des Enfants, Diabétologie Pédiatrique, Toulouse, France, 2Hôpital des Enfants, Chef de Projet Statistiques, Toulouse, France

**Introduction:** Type 1 diabetes in the pediatric population corresponds to a serious pathology, potentially fatal, particularly in the event of delay or lack of appropriate care, resulting in a strong temptation on the way of life and whose incidence is in constant increase. The impact of early glycemic control, from the 1st year, has been demonstrated.

**Objectives:** To identify predictive factors of optimal glycemic control over the first year follow-up of new-onset type 1 diabetes (T1D) in children in our Center.

**Methods:** The primary variable was HbA1c at 1 year follow-up. Clinical, biological, social management and follow-up measures over the first year following diagnosis were analyzed for 104 participants (mean age 8.46 ± 4.09 year, 50% female) in the aim to identify associations with HbA1c. Optimal glycemic control was defined with ISPAD guidelines. The follow-up was divided into four three months periods, 0–3, 3–6, 6–9, 9–12.

**Results:** At the onset, the HbA1c was 11.42 ± 2.27% with 7.69% hospitalizations in Pediatric ICU. 73.08% children are with MDI treatment and 79.81% with isGCM. And 34 families raised the local precarity score.

During the first year, 10.58% had more than 4 follow-up and 11.45% were hospitalized for educational reinforcement or acute complications.

A 30.6% were hospitalized for installation of insulin pumps and CGM. The unique variable associated with optimal HbA1c at 1 year in the multiple analysis was TIR ≥ 60% at second follow up. Among patients with optimal control at 1 year, 90% had TIR ≥ 60% at follow-up 2. Of those who were not on target TIR at follow-up 2, 92% were also not on target Hba1c at the end of the first year (p = 0.0018).

**Conclusions:** Our study found that time in range at the 2nd follow-up (3 to 6 months) was predictive of glycemic control (HbA1c) at 1 year. It would allow us to propose a closer follow-up and an earlier intensification of the management, during the first year and especially during 3 to 6 months after the onset of T1D in children.

**P277 | Association of individual and parental factors in relation to glycemic control in adolescents with type 1 diabetes**

F. Memon1, M. Arif1, M. Haider2, S. Kirmani1, K.N. Humayun3

1Aga Khan University, Pediatric and Child Health, Karachi, Pakistan

2Aga Khan University, Pediatric and Child Health, Karachi, Pakistan

**Introduction:** Hyperglycemia is a major risk factor for the development of long-term complications in type 1 diabetes. Reasons for poor glycemic control in adolescents with type 1 diabetes are complex including poor adherence to diet and noncompliance with diabetes treatment regimens and parental involvement in diabetes management. This study aims to identify modifiable risk factors that influence glycemic control in adolescents with type 1 diabetes.

**Objectives:** To determine the association of individual and parental factors with glycemic control in adolescents with type 1 diabetes mellitus at the tertiary care center in Karachi.

**Methods:** This cross-sectional study included 139 participants aged 10–18 years with type 1 diabetes visiting the outpatient clinic, data was collected through face-to-face interviews after informed consent. Multiple variables linear regression models were applied to estimate the effect of the independent variables on the level of HbA1c.

**Results:** A 139 adolescents (mean age 13.7 years, range10-18 years) with type 1 diabetes were included. (55% female and 45% male), mean length of diagnosis was 5.2 years, range(1-15 years). All patients

<table>
<thead>
<tr>
<th>Variables</th>
<th>0–3 months</th>
<th>3–6 months</th>
<th>6–9 months</th>
<th>9–12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1c Mean ± SD</td>
<td>7.68 ± 1.09</td>
<td>7.05 ± 0.87</td>
<td>7.37 ± 0.89</td>
<td>7.62 ± 0.86</td>
</tr>
<tr>
<td>TIR ≥ 60%</td>
<td>73.8 ± 13</td>
<td>65.9 ± 15.6&lt;sup&gt;a&lt;/sup&gt;</td>
<td>57.6 ± 16.4</td>
<td>49.9 ± 16.8</td>
</tr>
</tbody>
</table>

<sup>a</sup> p = 0.0018 with fisher test
used basal/bolus injections (BBI). HbA1c levels reflecting poor glycemic control (HbA1c ≥ 9.5%) were found in 31% of the study population. Mean HbA1c level was high in adolescents >14 years as compared to <14 years 9% and 8.4% respectively (P-value 0.046) (CI - 1.17-0.0115). Our study revealed that less frequent blood glucose monitoring, fewer clinic visits per year, poor dietary compliance, less parental involvement in dietary management, glucose monitoring, and insulin administration were all independently associated with poor glycemic control P-value <0.05.

Conclusions: Inadequate glycemic control is common among adolescents with type 1 diabetes in our center. Adequate dietary compliance, frequency of blood glucose monitoring, regular clinic follow-ups, and parents’ involvement in child diabetes management will have a major impact on glycemic control.